{
 "nbformat": 4,
 "nbformat_minor": 0,
 "metadata": {
  "colab": {
   "provenance": [
    {
     "file_id": "1Ezff_nLlJHQ5jxaIQcmaQjxa6W_vrdKD",
     "timestamp": 1698117877933
    }
   ]
  },
  "kernelspec": {
   "name": "python3",
   "language": "python",
   "display_name": "Python 3 (ipykernel)"
  },
  "language_info": {
   "name": "python"
  }
 },
 "cells": [
  {
   "cell_type": "markdown",
   "source": [
    "# Natural Language Processing with Machine Learning Classifiers for Adverse Drug Effects"
   ],
   "metadata": {
    "id": "81G01biw-uRP"
   }
  },
  {
   "cell_type": "markdown",
   "source": [
    "### Set up the environment: "
   ],
   "metadata": {
    "id": "tzRknuSsJ-TP"
   }
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {
    "id": "18E-G3-A1XJO",
    "executionInfo": {
     "status": "ok",
     "timestamp": 1698160520219,
     "user_tz": -660,
     "elapsed": 644,
     "user": {
      "displayName": "Katarina Stankovic",
      "userId": "08589456312134700603"
     }
    },
    "ExecuteTime": {
     "end_time": "2023-10-31T11:14:54.160085100Z",
     "start_time": "2023-10-31T11:14:54.016719600Z"
    }
   },
   "outputs": [],
   "source": [
    "import root_config as rc\n",
    "\n",
    "rc.configure()\n",
    "\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "import sys\n",
    "\n",
    "from sklearn import metrics\n",
    "from sklearn.feature_extraction.text import CountVectorizer\n",
    "from sklearn.ensemble import RandomForestClassifier\n",
    "from sklearn.model_selection import GridSearchCV\n",
    "\n",
    "import warnings\n",
    "warnings.filterwarnings(\"ignore\")\n",
    "\n",
    "#Display maximum\n",
    "pd.set_option('display.max_columns', None)\n",
    "np.set_printoptions(threshold=sys.maxsize)"
   ]
  },
  {
   "cell_type": "markdown",
   "source": [
    "### **Data source:** \"ADE corpus\"\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\"ADE corpus\": annotated corpus freely available online by the works of Gurulingappa (2012). The corpus download link provided in the paper is now outdated, i.e. a dead link, so through [web archive](https://archive.org/web/) the corpus for download was obtained and validity checked against metrics given in published work. It is provided in the /data/nlp_model_training folder of this project.\n",
    "The corpus was created from annotating 3000 MEDLINE case reports for mentions of drugs, adverse effects, dosages, and the relationships between them. The annotations were created by 3 individuals.\n",
    "The corpus is spread into 3 files, DRUG-AE.rel and DRUG-DOSE.rel and ADE-NEG.txt.\n",
    "DRUG-AE.rel provides relations between drugs and adverse effects and has rows as:\n",
    "\n",
    "- Column-1: PubMed-ID\n",
    "\n",
    "- Column-2: Sentence\n",
    "\n",
    "- Column-3: Dose\n",
    "\n",
    "- Column-4: Begin offset of Dose at 'document level'\n",
    "\n",
    "- Column-5: End offset of Dose at 'document level'\n",
    "\n",
    "- Column-6: Drug\n",
    "\n",
    "- Column-7: Begin offset of Drug at 'document level'\n",
    "\n",
    "- Column-8: End offset of Drug at 'document level'\n",
    "delimited by a pipe delimiter.\n",
    "\n",
    "DRUG-DOSE.rel provides relations between drugs and dosages.\n",
    "ADE-NEG.txt provides all sentences in the ADE corpus that DO NOT contain any drug-related adverse effects and is of format:\n",
    "\n",
    "- PubMed-ID\\sNEG\\sSentence\n",
    "\n",
    "where 'NEG' is a fixed string.\n",
    "\n",
    "There are 6821 lines in DRUG-AE, i.e. 6821 annotations, but 4272 sentences. This is because some sentences have more than one relation mentioned. These sentences will be treated as positive for ADE labelled sentences.\n",
    "The sentences with drug-dosage relationships (i.e. 213 sentences) constitute a subset of 4272 sentences that contain drug-adverse effect relationships. There are 16695 sentences (and lines) in ADE-NEG and these will be treated as negative for ADE labelled sentences.\n",
    "\n",
    "Preprocessing is needed to reduce to unique sentences in DRUG-AE.rel, equalize the number of positive and negative labelled sentences, as well as to unify them into one dataframe and split into train and test."
   ],
   "metadata": {
    "id": "C1-hF8RA_LHb"
   }
  },
  {
   "cell_type": "markdown",
   "source": [
    "### Preprocessing: reduce to unique sentences in DRUG-AE.rel:"
   ],
   "metadata": {
    "id": "wQoFg-Ft_-Fh"
   }
  },
  {
   "cell_type": "code",
   "source": [
    "drugAE_path = r'../data/nlp_model_training/DRUG-AE.rel' \n",
    "drugAE = pd.read_csv(drugAE_path, sep=\"|\", names=['PubMed-ID',\\\n",
    "                                                 'Sentence',\\\n",
    "                                                 'Adverse-Effect',\\\n",
    "                                                 'Begin Adverse-Effect offset',\\\n",
    "                                                 'End Adverse-Effect offset',\\\n",
    "                                                 'Drug',\\\n",
    "                                                 'Begin Drug offset',\\\n",
    "                                                 'End Drug offset'])\n",
    "\n",
    "#Check how the first rows looks like:\n",
    "print(drugAE.head())\n",
    "drugAE_unique = drugAE.drop_duplicates(['PubMed-ID','Sentence'], keep='first')\n",
    "print(drugAE_unique.head())\n",
    "assert(drugAE_unique.shape[0] == 4272) #number of rows <-> unique sentences"
   ],
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "_vA2B98II9Gu",
    "executionInfo": {
     "status": "ok",
     "timestamp": 1698160513639,
     "user_tz": -660,
     "elapsed": 519,
     "user": {
      "displayName": "Katarina Stankovic",
      "userId": "08589456312134700603"
     }
    },
    "outputId": "18389194-2df4-4198-e823-72eb7ae21759",
    "ExecuteTime": {
     "end_time": "2023-10-31T11:14:54.317183800Z",
     "start_time": "2023-10-31T11:14:54.075935500Z"
    }
   },
   "execution_count": 5,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "   PubMed-ID                                           Sentence  \\\n",
      "0   10030778      Intravenous azithromycin-induced ototoxicity.   \n",
      "1   10048291  Immobilization, while Paget's bone disease was...   \n",
      "2   10048291  Unaccountable severe hypercalcemia in a patien...   \n",
      "3   10082597  METHODS: We report two cases of pseudoporphyri...   \n",
      "4   10082597  METHODS: We report two cases of pseudoporphyri...   \n",
      "\n",
      "              Adverse-Effect  Begin Adverse-Effect offset  \\\n",
      "0                ototoxicity                           43   \n",
      "1  increased calcium-release                          960   \n",
      "2              hypercalcemia                           31   \n",
      "3            pseudoporphyria                          620   \n",
      "4            pseudoporphyria                          620   \n",
      "\n",
      "   End Adverse-Effect offset                Drug  Begin Drug offset  \\\n",
      "0                         54        azithromycin                 22   \n",
      "1                        985  dihydrotachysterol                908   \n",
      "2                         44  dihydrotachysterol                 94   \n",
      "3                        635            naproxen                646   \n",
      "4                        635           oxaprozin                659   \n",
      "\n",
      "   End Drug offset  \n",
      "0               34  \n",
      "1              926  \n",
      "2              112  \n",
      "3              654  \n",
      "4              668  \n",
      "   PubMed-ID                                           Sentence  \\\n",
      "0   10030778      Intravenous azithromycin-induced ototoxicity.   \n",
      "1   10048291  Immobilization, while Paget's bone disease was...   \n",
      "2   10048291  Unaccountable severe hypercalcemia in a patien...   \n",
      "3   10082597  METHODS: We report two cases of pseudoporphyri...   \n",
      "5   10082597  Naproxen, the most common offender, has been a...   \n",
      "\n",
      "                  Adverse-Effect  Begin Adverse-Effect offset  \\\n",
      "0                    ototoxicity                           43   \n",
      "1      increased calcium-release                          960   \n",
      "2                  hypercalcemia                           31   \n",
      "3                pseudoporphyria                          620   \n",
      "5  erythropoietic protoporphyria                         1612   \n",
      "\n",
      "   End Adverse-Effect offset                Drug  Begin Drug offset  \\\n",
      "0                         54        azithromycin                 22   \n",
      "1                        985  dihydrotachysterol                908   \n",
      "2                         44  dihydrotachysterol                 94   \n",
      "3                        635            naproxen                646   \n",
      "5                       1641            Naproxen               1478   \n",
      "\n",
      "   End Drug offset  \n",
      "0               34  \n",
      "1              926  \n",
      "2              112  \n",
      "3              654  \n",
      "5             1486  \n"
     ]
    }
   ]
  },
  {
   "cell_type": "markdown",
   "source": [
    "### Preprocessing: equalize the number of positive and negative labelled sentences otherwise the model will be biased"
   ],
   "metadata": {
    "id": "WZB-vouqMw42"
   }
  },
  {
   "cell_type": "code",
   "source": [
    "adeNEG_path = r'../data/nlp_model_training/ADE-NEG.txt'  \n",
    "with open(adeNEG_path, 'r') as file:\n",
    "    lines = file.readlines()\n",
    "lines = [line.strip().split(' ', 2) for line in lines]\n",
    "adeNEG = pd.DataFrame(lines, columns=['PubMed-ID', 'NEG', 'Sentence'])\n",
    "\n",
    "print(adeNEG.head())\n",
    "assert(adeNEG.shape[0] == 16695)\n",
    "\n",
    "adeNEG = adeNEG.sample(n = drugAE_unique.shape[0], random_state = 0) \n",
    "assert(adeNEG.shape[0] == 4272)\n"
   ],
   "metadata": {
    "id": "jAYnPFYD2RLc",
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "executionInfo": {
     "status": "ok",
     "timestamp": 1698160527215,
     "user_tz": -660,
     "elapsed": 548,
     "user": {
      "displayName": "Katarina Stankovic",
      "userId": "08589456312134700603"
     }
    },
    "outputId": "5e8e0059-267d-4875-d94d-497dfa81e33f",
    "ExecuteTime": {
     "end_time": "2023-10-31T11:14:54.357976500Z",
     "start_time": "2023-10-31T11:14:54.127920900Z"
    }
   },
   "execution_count": 6,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "  PubMed-ID  NEG                                           Sentence\n",
      "0   6460590  NEG  Clioquinol intoxication occurring in the treat...\n",
      "1   8600337  NEG  \"Retinoic acid syndrome\" was prevented with sh...\n",
      "2   8402502  NEG  BACKGROUND: External beam radiation therapy of...\n",
      "3   8700794  NEG  Although the enuresis ceased, she developed th...\n",
      "4  17662448  NEG  A 42-year-old woman had uneventful bilateral l...\n"
     ]
    }
   ]
  },
  {
   "cell_type": "markdown",
   "source": [
    "### Preprocessing: unify into one dataframe"
   ],
   "metadata": {
    "id": "FHFquLZJO3mD"
   }
  },
  {
   "cell_type": "code",
   "source": [
    "adeNEG_inter = adeNEG.copy()\n",
    "adeNEG_inter['ADE'] = 0\n",
    "adeNEG_inter.drop(['PubMed-ID', 'NEG'], inplace=True, axis = 1)\n",
    "drugAE_inter = drugAE_unique.copy()\n",
    "drugAE_inter['ADE'] = 1\n",
    "drugAE_inter.drop(['PubMed-ID','Adverse-Effect',\\\n",
    "                                'Begin Adverse-Effect offset',\\\n",
    "                                'End Adverse-Effect offset',\\\n",
    "                                'Drug',\\\n",
    "                                'Begin Drug offset',\\\n",
    "                                'End Drug offset'], inplace=True, axis=1)\n",
    "unified = pd.concat([adeNEG_inter,drugAE_inter], ignore_index=True)\n",
    "unified.reset_index(drop=True, inplace=True)\n",
    "print(unified)"
   ],
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "H7pPHtU_PNiR",
    "executionInfo": {
     "status": "ok",
     "timestamp": 1698162517475,
     "user_tz": -660,
     "elapsed": 408,
     "user": {
      "displayName": "Katarina Stankovic",
      "userId": "08589456312134700603"
     }
    },
    "outputId": "c823196b-57cf-4fef-e9a6-4998bb856f93",
    "ExecuteTime": {
     "end_time": "2023-10-31T11:14:54.357976500Z",
     "start_time": "2023-10-31T11:14:54.192021500Z"
    }
   },
   "execution_count": 7,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                                               Sentence  ADE\n",
      "0     CONCLUSIONS: Our analysis of the published cas...    0\n",
      "1     A renal biopsy showed diffuse mesangial prolif...    0\n",
      "2     Analysis of the HLA system revealed the positi...    0\n",
      "3     Spontaneous intracerebral hemorrhage was diagn...    0\n",
      "4     Pulmonary thromboembolism after spinal instrum...    0\n",
      "...                                                 ...  ...\n",
      "8539  Reversible nonthrombocytopenic palpable purpur...    1\n",
      "8540  Lithium treatment was terminated in 1975 becau...    1\n",
      "8541  Eosinophilia caused by clozapine was observed ...    1\n",
      "8542  Eosinophilia has been encountered from 0.2 to ...    1\n",
      "8543  Successful challenge with clozapine in a histo...    1\n",
      "\n",
      "[8544 rows x 2 columns]\n"
     ]
    }
   ]
  },
  {
   "cell_type": "markdown",
   "source": [
    "### Preprocessing: split into train and test"
   ],
   "metadata": {
    "id": "JSR8AJAaUKmw"
   }
  },
  {
   "cell_type": "code",
   "source": [
    "from sklearn.model_selection import train_test_split\n",
    "train, test = train_test_split(unified, test_size=0.1, random_state = 0) \n"
   ],
   "metadata": {
    "id": "A_xmdQit7Go8",
    "executionInfo": {
     "status": "ok",
     "timestamp": 1698162276462,
     "user_tz": -660,
     "elapsed": 639,
     "user": {
      "displayName": "Katarina Stankovic",
      "userId": "08589456312134700603"
     }
    },
    "ExecuteTime": {
     "end_time": "2023-10-31T11:14:54.357976500Z",
     "start_time": "2023-10-31T11:14:54.223748Z"
    }
   },
   "execution_count": 8,
   "outputs": []
  },
  {
   "cell_type": "markdown",
   "source": [
    "### Text Analysis: Building Vectors (Tokens)\n"
   ],
   "metadata": {
    "id": "O9uZbwUn8ZqX"
   }
  },
  {
   "cell_type": "code",
   "source": [
    "#CountVectorizer: tokenizing strings and giving an integer id for each possible token, then counting the occurrences of each token in each sentence we're providing it with.\n",
    "count_vectorizer = CountVectorizer()\n",
    "\n",
    "#then return the document-term matrix\n",
    "train_vectors = count_vectorizer.fit_transform(train[\"Sentence\"])\n",
    "train_vectors"
   ],
   "metadata": {
    "id": "0xd4MSBp8ZM8",
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "executionInfo": {
     "status": "ok",
     "timestamp": 1698162720573,
     "user_tz": -660,
     "elapsed": 401,
     "user": {
      "displayName": "Katarina Stankovic",
      "userId": "08589456312134700603"
     }
    },
    "outputId": "05b1cb43-a0d1-45bd-b381-93fd0d84a0c6",
    "ExecuteTime": {
     "end_time": "2023-10-31T11:14:54.468928600Z",
     "start_time": "2023-10-31T11:14:54.242170100Z"
    }
   },
   "execution_count": 9,
   "outputs": [
    {
     "data": {
      "text/plain": "<7689x11029 sparse matrix of type '<class 'numpy.int64'>'\n\twith 126123 stored elements in Compressed Sparse Row format>"
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ]
  },
  {
   "cell_type": "code",
   "source": [
    "#Each term found by the analyzer during the fit is assigned a unique integer index corresponding to a column in the resulting matrix\n",
    "count_vectorizer.get_feature_names_out()\n"
   ],
   "metadata": {
    "id": "WzegwG4fMtX7",
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "executionInfo": {
     "status": "ok",
     "timestamp": 1698162725553,
     "user_tz": -660,
     "elapsed": 743,
     "user": {
      "displayName": "Katarina Stankovic",
      "userId": "08589456312134700603"
     }
    },
    "outputId": "acdc2677-1561-47ee-e14a-947c184e42de",
    "ExecuteTime": {
     "end_time": "2023-10-31T11:14:54.720206100Z",
     "start_time": "2023-10-31T11:14:54.437029Z"
    }
   },
   "execution_count": 10,
   "outputs": [
    {
     "data": {
      "text/plain": "array(['00', '000', '00001', '0001', '001', '005', '01', '02', '03',\n       '032', '04', '042', '0457', '05', '06', '07', '08', '09', '096',\n       '10', '100', '1000', '100bpm', '100mg', '101', '10172', '102',\n       '1021', '103', '104', '1050', '106', '1078', '108', '109', '11',\n       '110', '1100', '111', '1115', '114', '1159', '118', '119', '11q21',\n       '11q23', '12', '120', '1200', '122', '124', '1240', '125', '126',\n       '1270', '128', '13', '130', '131', '133', '134', '136', '137',\n       '1374', '138', '1392', '13th', '14', '140', '1400', '14225', '143',\n       '144', '1440', '144600', '1450', '149', '15', '150', '1500', '153',\n       '1543', '15th', '16', '160', '1600', '167', '168', '17', '171',\n       '173', '178', '17th', '18', '180', '1800', '186', '189', '19',\n       '190', '194', '195', '1952', '1955', '1960s', '1961', '1964',\n       '197', '1970', '1971', '1972', '1973', '1975', '1977', '1978',\n       '1979', '198', '1980', '1980s', '1983', '1985', '1989', '1990',\n       '1991', '1992', '1993', '1994', '1995', '1996', '1997', '1998',\n       '1999', '1a', '1a2', '1b', '1mm', '1st', '20', '200', '2000',\n       '2001', '2002', '2003', '2004', '2005', '2006', '2007', '200mg',\n       '201', '204', '205', '20fc01', '21', '213', '2149', '215', '22',\n       '225', '22nd', '22q11', '23', '230', '231', '2322', '234', '237',\n       '24', '240', '24559', '25', '250', '2500', '254', '255', '2582',\n       '25d', '26', '260', '261', '268', '27', '270', '277', '279', '28',\n       '283', '29', '296', '2982', '2a', '2a6', '2b', '2c8', '2d', '2d3',\n       '2d6', '2e1', '2nd', '30', '300', '3000', '3053', '306', '31',\n       '3151', '32', '320', '321', '322', '3250', '33', '3330', '337',\n       '34', '3400', '341', '342', '35', '355000', '356', '36', '362',\n       '368', '37', '371', '38', '39', '3908', '3a1', '3a2', '3a3', '3a4',\n       '3cps', '3d', '3rd', '40', '400', '4000', '4005', '41', '42', '43',\n       '430', '44', '448', '45', '450', '46', '460', '466', '47', '48',\n       '49', '494', '4th', '50', '500', '506', '51', '52', '528', '53',\n       '538', '54', '55', '550', '553', '55th', '56', '560', '569', '57',\n       '577', '58', '59', '5d', '5gy', '5ht2', '5q', '5th', '60', '600',\n       '61', '610', '62', '63', '64', '65', '66', '662', '67', '68',\n       '684', '69', '6mp', '6th', '70', '700', '704', '71', '7157', '72',\n       '722', '73', '7300', '74', '75', '750', '756', '75s', '76', '77',\n       '78', '79', '7952', '7th', '80', '800', '8062', '81', '82', '83',\n       '84', '85', '86', '87', '88', '8mop', '90', '900', '91', '92',\n       '93', '95', '957', '9589', '96', '960', '98', '99', '995', '99m',\n       '99tc', 'a140v', 'a1c', 'a594v', 'aa', 'abacavir', 'abandonment',\n       'abated', 'abdomen', 'abdominal', 'abdominocentesis', 'abdominus',\n       'abemayor', 'aberrant', 'abilities', 'ability', 'abl', 'ablation',\n       'ablc', 'able', 'abmt', 'abnormal', 'abnormalities', 'abnormality',\n       'abnormally', 'abo', 'abolish', 'abolished', 'aborted', 'abortion',\n       'abortions', 'about', 'above', 'abrogated', 'abrupt', 'abs',\n       'abscess', 'abscesses', 'abscessus', 'absence', 'absent',\n       'absorbed', 'absorption', 'abstained', 'abstainers', 'abstinence',\n       'abstinent', 'abundance', 'abundant', 'abuse', 'abuser', 'abusers',\n       'abvd', 'ac', 'acad', 'acanthamoeba', 'acanthamoebae', 'acarbose',\n       'acc', 'accelerate', 'accelerated', 'acceleration', 'accentuated',\n       'acceptable', 'acceptably', 'accepted', 'access', 'accessible',\n       'accessory', 'accident', 'accidental', 'accidentally', 'accolate',\n       'accompanied', 'accompanies', 'accompanying', 'accomplices',\n       'accordance', 'according', 'accordingly', 'account', 'accounted',\n       'accumulated', 'accumulation', 'accurate', 'accurately',\n       'accutane', 'ace', 'acenocoumarol', 'acepromazine', 'acetate',\n       'acetazolamide', 'acetic', 'acetoacetate', 'acetohexamide',\n       'acetonide', 'acetyl', 'acetylator', 'acetylators',\n       'acetylcholine', 'acetylcholinesterase', 'acetylsalicylic', 'ach',\n       'achieve', 'achieved', 'achieving', 'achilles', 'acid',\n       'acidification', 'acidosis', 'acids', 'acknowledge', 'acne',\n       'acneiform', 'aconitum', 'acoustic', 'acquired', 'acquisition',\n       'acral', 'acrodermatitis', 'acrogemaly', 'acromegalic',\n       'acromegaly', 'acryosyringium', 'acs', 'act', 'acted', 'acth',\n       'acting', 'actinomyces', 'actinomycin', 'actinomycosis', 'action',\n       'actions', 'activated', 'activating', 'activation', 'activator',\n       'active', 'actively', 'activity', 'acts', 'actual', 'actually',\n       'acuities', 'acuity', 'acute', 'acutely', 'acyclovir', 'ad169',\n       'adalimumab', 'adamts13', 'adaptable', 'adaptation', 'adapted',\n       'adaptive', 'adc', 'add', 'added', 'addict', 'addiction',\n       'addicts', 'adding', 'addison', 'addition', 'additional',\n       'additionally', 'additive', 'additives', 'address', 'addressed',\n       'adds', 'adducts', 'adefovir', 'adenine', 'adenocarcinoma',\n       'adenoma', 'adenomas', 'adenomatous', 'adenomectomy',\n       'adenomyosis', 'adenomyotic', 'adenosine', 'adenosquamous',\n       'adenovirus', 'adequate', 'adequately', 'adh', 'adhd', 'adherence',\n       'adherent', 'adhesion', 'adipocytes', 'adipose', 'adjacent',\n       'adjunct', 'adjunctive', 'adjusted', 'adjustment', 'adjustments',\n       'adjuvant', 'administer', 'administered', 'administering',\n       'administration', 'administrations', 'admission', 'admitted',\n       'admixed', 'admonishes', 'adnexal', 'adnexial', 'adolescence',\n       'adolescent', 'adolescents', 'adopted', 'adpkd', 'adr', 'adrenal',\n       'adrenaline', 'adrenals', 'adrenergic', 'adrenoceptor',\n       'adrenochrome', 'adrenocortical', 'adrenocorticotropic',\n       'adrenoleukodystrophy', 'adriamycin', 'adrs', 'adult', 'adulthood',\n       'adults', 'adv', 'advance', 'advanced', 'advancement', 'advances',\n       'advantage', 'advantages', 'adverse', 'adversely', 'advise',\n       'advised', 'advising', 'advocated', 'adynamic', 'aed',\n       'aeruginosa', 'aesthetic', 'aetiologic', 'aetiological',\n       'aetiologically', 'aetiology', 'af', 'af4p12', 'affect',\n       'affected', 'affecting', 'affective', 'affects', 'affinity',\n       'aflatoxicosis', 'aforementioned', 'africa', 'african', 'after',\n       'afterload', 'afternoon', 'afterward', 'again', 'against',\n       'agalactiae', 'agar', 'age', 'aged', 'agencies', 'agenesis',\n       'agent', 'agents', 'agep', 'ages', 'aggravate', 'aggravated',\n       'aggravation', 'aggregation', 'aggression', 'aggressive',\n       'aggressively', 'agitated', 'agitation', 'agno3', 'ago', 'agonist',\n       'agonists', 'agranulocytosis', 'agreement', 'agrees',\n       'agrobacterium', 'agvhd', 'ahc', 'ahmed', 'ahs', 'ai', 'aid',\n       'aids', 'aih', 'aiha', 'aild', 'aim', 'aimed', 'aiming', 'aims',\n       'ain', 'air', 'airway', 'ait', 'akathisia', 'akbr', 'akinesia',\n       'akinetic', 'al', 'alanine', 'alarming', 'albeit', 'albendazole',\n       'albicans', 'albumin', 'albuterol', 'alcohol', 'alcoholic',\n       'alcoholics', 'alcoholism', 'aldosterone', 'alemtuzumab',\n       'alendronate', 'alert', 'alfa', 'algorithm', 'alien', 'aliskiren',\n       'alive', 'alkali', 'alkaline', 'alkaloid', 'alkaloids',\n       'alkalosis', 'alkylating', 'all', 'allegations', 'allergen',\n       'allergic', 'allergies', 'allergologic', 'allergological',\n       'allergy', 'alleviate', 'alleviated', 'alleviation', 'allobmt',\n       'allogeneic', 'allograft', 'allografts', 'allopurinol', 'allow',\n       'allowed', 'allowing', 'allows', 'almost', 'alone', 'along',\n       'alopecia', 'alpers', 'alpha', 'alpha2a', 'alpha2b', 'alprazolam',\n       'already', 'also', 'alt', 'alteplase', 'alter', 'alteration',\n       'alterations', 'altered', 'alternaria', 'alternate', 'alternating',\n       'alternative', 'alternatives', 'alters', 'although', 'alum',\n       'aluminum', 'alveolar', 'alveolitis', 'always', 'alzheimer',\n       'amalgam', 'amantadine', 'amb', 'ambien', 'ambisome', 'amblyomma',\n       'amblyopia', 'ambulatory', 'amd', 'amebic', 'ameliorate',\n       'ameliorated', 'amelioration', 'amenable', 'amenorrhea',\n       'amenorrhoea', 'america', 'american', 'americanum', 'amifostine',\n       'amikacin', 'amiloride', 'amines', 'amino', 'aminobutyric',\n       'aminocaproic', 'aminoglutethimide', 'aminoglycoside',\n       'aminophylline', 'aminosalicylic', 'aminoterminal',\n       'aminotransferase', 'aminotransferases', 'aminotrasferase',\n       'amiodarone', 'amisulpride', 'amitriptyline', 'aml', 'ammonemia',\n       'ammonia', 'ammonium', 'amnesia', 'amnestic', 'amniocentesis',\n       'amniotic', 'amodiaquine', 'among', 'amount', 'amounts',\n       'amoxapine', 'amoxicillin', 'amphetamine', 'amphojel',\n       'amphojeloma', 'amphotercin', 'amphotericin', 'ampicillin',\n       'amplification', 'amplified', 'amplitude', 'ampoules',\n       'amprenavir', 'amputated', 'amputation', 'amputee', 'amsacrine',\n       'amsterdam', 'amygdala', 'amyloid', 'amyloidosis', 'amyotrophic',\n       'amyotrophy', 'an', 'ana', 'anabolic', 'anaemia', 'anaesthesia',\n       'anaesthesiologists', 'anaesthetic', 'anagen', 'anal', 'analeptic',\n       'analgesia', 'analgesic', 'analgesics', 'analog', 'analogs',\n       'analogue', 'analogues', 'analyse', 'analysed', 'analyses',\n       'analysis', 'analytic', 'analytical', 'analyze', 'analyzed',\n       'anamnesis', 'anamnestic', 'anaphylactic', 'anaphylactoid',\n       'anaphylaxis', 'anaplastic', 'anarchic', 'anasarca', 'anastomosis',\n       'anastrozole', 'anatomic', 'anc', 'anca', 'anchoring', 'and',\n       'androgen', 'androgenic', 'anecdotal', 'anecdotally', 'anecdotic',\n       'anemia', 'anemias', 'anephric', 'anesthesia', 'anesthesiologists',\n       'anesthetic', 'anesthetics', 'anesthetized', 'aneurysm',\n       'aneurysms', 'angel', 'angiitis', 'angina', 'angio',\n       'angiocentric', 'angiodestructive', 'angioedema', 'angiogenetic',\n       'angiogram', 'angiograms', 'angiographic', 'angiographically',\n       'angiography', 'angioimmunoblastic', 'angiolipomas',\n       'angiolipomatosis', 'angiomatous', 'angioneurotic', 'angiosarcoma',\n       'angiotensin', 'angle', 'angry', 'angulated', 'anhedonic',\n       'anhydrase', 'anicteric', 'aniline', 'animal', 'animals',\n       'anisocoria', 'ankle', 'ankylosing', 'anll', 'announced',\n       'anomalies', 'anomaly', 'anorexia', 'another', 'anoxic', 'antacid',\n       'antagonism', 'antagonist', 'antagonists', 'antecedent',\n       'antegrade', 'antenatal', 'anterior', 'anterograde', 'anthony',\n       'anthracostenosis', 'anthracycline', 'anti', 'antiadrenergic',\n       'antiandrogen', 'antiangiogenic', 'antiarrhythmic',\n       'antiarrhythmics', 'antibacterial', 'antibiotic', 'antibiotics',\n       'antibodies', 'antibody', 'anticancer', 'anticardiolipin',\n       'anticataplectic', 'anticholinergic', 'anticipated',\n       'anticlockwise', 'anticoagulant', 'anticoagulants',\n       'anticoagulation', 'anticonvulsant', 'anticonvulsants',\n       'antidepressant', 'antidepressants', 'antidepressive',\n       'antidiabetic', 'antidiabetics', 'antidiarrheal', 'antidiuresis',\n       'antidiuretic', 'antidouble', 'antiemetic', 'antiemetics',\n       'antiepileptic', 'antifungal', 'antifungals', 'antigen',\n       'antigenic', 'antigens', 'antiglaucoma', 'antiglobulin',\n       'antiglobulins', 'antigranulocyte', 'antihistamine',\n       'antihistaminic', 'antihistone', 'antihuman', 'antihypertensive',\n       'antiinflammatory', 'antileukotrienes', 'antilymphocyte',\n       'antimalarial', 'antimalarials', 'antimetabolite', 'antimicrobial',\n       'antimicrobials', 'antimonial', 'antimoniate', 'antimycotic',\n       'antineoplastic', 'antineutrophil', 'antinociceptive',\n       'antinuclear', 'antiparkinsonian', 'antiperspirant',\n       'antiphospholipid', 'antiplatelet', 'antipsoriatic',\n       'antipsychotic', 'antipsychotics', 'antiretroviral',\n       'antischistosomal', 'antispastic', 'antithrombin',\n       'antithrombotic', 'antithyroid', 'antitrypsin', 'antituberculosis',\n       'antituberculous', 'antitumor', 'antitumour', 'antivenin',\n       'antiviral', 'antizol', 'antral', 'anuria', 'anuric', 'anxiety',\n       'any', 'anywhere', 'ao', 'aorta', 'aortic', 'aorto',\n       'aortoarteritis', 'ap', 'apache', 'apart', 'apccs', 'apeced',\n       'aphasia', 'aphrodisiac', 'aphthous', 'apical', 'apl', 'aplasia',\n       'aplastic', 'apml', 'apnea', 'apneic', 'apnoea', 'apnoeas',\n       'apnoeic', 'apolipoprotein', 'apolt', 'apomorphine', 'apoptotic',\n       'aposafranine', 'apparent', 'apparently', 'appear', 'appearance',\n       'appeared', 'appearing', 'appears', 'appetite', 'apple',\n       'application', 'applied', 'apply', 'apportion', 'appreciated',\n       'approach', 'approaches', 'appropriate', 'appropriately',\n       'approval', 'approved', 'approximately', 'april', 'aprotinin',\n       'aptt', 'apv', 'aquagenic', 'aquaphor', 'aqueous', 'ara', 'arabia',\n       'arabinofuranosyl', 'arabinoside', 'arb', 'arborizing', 'arbour',\n       'architecture', 'arden', 'ards', 'are', 'area', 'areas', 'areata',\n       'areflexia', 'areolar', 'arf', 'argatroban', 'arginine', 'argues',\n       'argyria', 'aripiprazole', 'arise', 'arisen', 'arising', 'arm',\n       'arms', 'aromatase', 'aromatic', 'arose', 'around', 'array',\n       'arrest', 'arrested', 'arrests', 'arrhythmia', 'arrhythmias',\n       'arrhythmic', 'arrhythmogenic', 'arrival', 'arrived', 'arsenic',\n       'art', 'artecoll', 'arterial', 'arteries', 'arteriogram',\n       'arteriograms', 'arteriographic', 'arteriography',\n       'arteriosclerotic', 'arteriospasm', 'arteriosus',\n       'arteriothromboses', 'arteriovenous', 'arteritis', 'artery',\n       'artesunate', 'artherosclerosis', 'arthralgia', 'arthralgias',\n       'arthritic', 'arthritis', 'arthroplasty', 'arthroscopic',\n       'article', 'articular', 'articulating', 'artificial',\n       'artificially', 'as', 'asa', 'asbestos', 'ascending', 'ascites',\n       'ascitis', 'ascribe', 'ascribed', 'asct', 'aseptic', 'ashen',\n       'asian', 'ask', 'asked', 'asparaginase', 'aspartate', 'aspect',\n       'aspects', 'asperger', 'aspergillosis', 'aspergillus', 'aspirate',\n       'aspiration', 'aspirations', 'aspirin', 'asppc', 'assault',\n       'assay', 'assayed', 'assays', 'assess', 'assessed', 'assessing',\n       'assessment', 'assist', 'assistance', 'assisted', 'associated',\n       'association', 'associations', 'assume', 'assumed', 'assuming',\n       'assumption', 'ast', 'astatic', 'asterixis', 'asteroides',\n       'asthenia', 'asthenozoospermia', 'asthma', 'asthmatic',\n       'asthmaticus', 'astrocytoma', 'astute', 'asymmetric',\n       'asymptomatic', 'asystole', 'at', 'ataxia', 'ataxo', 'atazanavir',\n       'atenolol', 'atg', 'athelia', 'atheroembolic', 'atheroma',\n       'atherosclerosis', 'atherosclerotic', 'atin', 'atl', 'atomoxetine',\n       'atony', 'atopic', 'atovaquone', 'atra', 'atresia', 'atrial',\n       'atrio', 'atriopeptins', 'atrioventricular', 'atrophic', 'atrophy',\n       'atropine', 'att', 'attached', 'attachment', 'attack', 'attacks',\n       'attained', 'attainment', 'attempt', 'attempted', 'attempts',\n       'attendance', 'attendant', 'attending', 'attention', 'attenuation',\n       'attributable', 'attribute', 'attributed', 'atypia', 'atypical',\n       'audiometric', 'audiometry', 'auditory', 'augment', 'augmentation',\n       'august', 'aura', 'auranofin', 'aureus', 'aurothioglucose',\n       'aurothiomalate', 'australia', 'author', 'authors', 'autistic',\n       'auto', 'autoantibodies', 'autoantibody', 'autoimmune',\n       'autoimmunity', 'autologous', 'automated', 'autonomic',\n       'autopsies', 'autopsy', 'autosomal', 'autotransplantation',\n       'auxiliary', 'av', 'availability', 'available', 'avascular',\n       'avastin', 'average', 'avert', 'aviation', 'aviators', 'avidum',\n       'avium', 'avm', 'avoid', 'avoidance', 'avoided', 'avoiding',\n       'avoids', 'avp', 'avt', 'awaits', 'awaken', 'aware', 'awareness',\n       'away', 'axilla', 'axillae', 'axillary', 'axis', 'axonal',\n       'axoplasm', 'ayerst', 'ayurveda', 'az', 'aza', 'azacytidine',\n       'azar', 'azathioprine', 'azithromycin', 'azole', 'azotemia',\n       'azotemic', 'b12', 'b19', 'b27', 'b663', 'babies', 'baby', 'bac',\n       'bacilli', 'bacillus', 'bacitracin', 'back', 'background',\n       'backward', 'baclofen', 'bacteraemia', 'bacteraemic', 'bacteremia',\n       'bacteremic', 'bacteria', 'bacteriaemia', 'bacterial',\n       'bacteriological', 'bactrim', 'bag', 'bal', 'balance', 'balanced',\n       'bald', 'balint', 'baller', 'ballism', 'ballistic', 'balloon',\n       'ballooned', 'band', 'bands', 'bangkok', 'bank', 'bao',\n       'barbiturate', 'barbiturates', 'barcelona', 'barr', 'barracuda',\n       'barrier', 'bartter', 'basal', 'base', 'based', 'basedow',\n       'baseline', 'basement', 'basic', 'basilar', 'basis', 'batch',\n       'bayesian', 'bb', 'bccs', 'bcg', 'bcnu', 'bcr', 'bcva', 'be',\n       'beam', 'bearing', 'bears', 'beats', 'beau', 'became', 'because',\n       'beclomethasone', 'become', 'becomes', 'becoming', 'bed',\n       'bedridden', 'beds', 'bedside', 'bedtime', 'been', 'beer',\n       'before', 'beforehand', 'began', 'begin', 'beginning', 'begins',\n       'begun', 'behaving', 'behavior', 'behavioral', 'behaviors',\n       'behaviour', 'behavioural', 'behenoyl', 'behind', 'being',\n       'beliefs', 'believe', 'believed', 'belladonna', 'bellamine',\n       'belong', 'belonging', 'below', 'beneficial', 'benefit',\n       'benefited', 'benefits', 'benfluorex', 'benign', 'benzalkonium',\n       'benzarone', 'benzocaine', 'benzodiazepine', 'benzodiazepines',\n       'benzofuran', 'benzoin', 'benztropine', 'berlin', 'bertholletiae',\n       'best', 'beta', 'beta1', 'betalactam', 'betamethasone', 'bethesda',\n       'better', 'between', 'bevacizumab', 'beverages', 'beyond',\n       'bezoar', 'bfm', 'bfp', 'bh', 'bh4', 'bicalutamide', 'bicarbonate',\n       'bicornuate', 'bicytopenia', 'bid', 'biguanide', 'bilateral',\n       'bilaterally', 'bile', 'biliary', 'bilirubin', 'bimatoprost',\n       'bind', 'binding', 'bingeing', 'bioactive', 'bioavailability',\n       'biochemical', 'biochemistry', 'bioequivalency', 'biologic',\n       'biological', 'biomarkers', 'biomass', 'biomedicus',\n       'biomicroscopy', 'biophysiological', 'biopsies', 'biopsy',\n       'biopterin', 'biosynthesis', 'biperiden', 'biphenotypic',\n       'biphosphate', 'biphosphonate', 'bipolar', 'bipotent', 'birth',\n       'births', 'bis', 'bisabolol', 'bisegmentectomy', 'bisphosphonate',\n       'bisphosphonates', 'bisulfite', 'bite', 'bitemporal',\n       'bivalirudin', 'biventricular', 'bizarre', 'bkvn', 'bl', 'black',\n       'bladder', 'blame', 'blast', 'blasts', 'blebitis', 'blebs', 'bled',\n       'bleed', 'bleeding', 'bleomycin', 'blepharophimosis', 'blind',\n       'blindness', 'blistering', 'blisters', 'block', 'blockade',\n       'blockage', 'blocker', 'blockers', 'blocking', 'blocks', 'blood',\n       'bloodstream', 'bloody', 'blot', 'blotting', 'blue', 'blunt',\n       'blurred', 'bmt', 'bmtn', 'bo', 'bodies', 'body', 'boerhaave',\n       'bolus', 'bombay', 'bond', 'bone', 'bonnet', 'bony', 'boop',\n       'booster', 'boosts', 'border', 'borderline', 'bore', 'born',\n       'bortezomib', 'bos', 'bosentan', 'boston', 'both', 'bottle',\n       'botulinum', 'botulism', 'bound', 'bout', 'bowel', 'boxed', 'boy',\n       'boys', 'bp', 'bpd', 'bpm', 'brachycephaly', 'brachytherapy',\n       'bradycardia', 'bradykinins', 'bradypneic', 'brain', 'brainstem',\n       'branch', 'branching', 'break', 'breakdown', 'breaks',\n       'breakthrough', 'breast', 'breasts', 'breath', 'breathing',\n       'breaths', 'breck', 'bredinin', 'bretylium', 'bridge', 'bridging',\n       'brief', 'briefer', 'briefly', 'brigham', 'bright', 'brimonidine',\n       'bringing', 'brings', 'british', 'brittle', 'broad', 'broaden',\n       'broadened', 'broadening', 'bromide', 'bromocriptine',\n       'bromocryptine', 'brompheniramine', 'bronchial', 'bronchiectasis',\n       'bronchiolitis', 'bronchitis', 'bronchoalveolar',\n       'bronchoconstriction', 'bronchodilator', 'bronchodilators',\n       'bronchogenic', 'bronchopulmonary', 'bronchorrhoea',\n       'bronchoscopy', 'bronchospasm', 'bronchospastic', 'bronj',\n       'bronquiloalveolar', 'broth', 'brother', 'brothers', 'brought',\n       'broviacs', 'brown', 'brucella', 'brugada', 'bruisability',\n       'brushing', 'bs', 'btx', 'bubble', 'buccal', 'bucco',\n       'bucillamine', 'bucy', 'budd', 'budefat', 'budesonide', 'buffered',\n       'building', 'bulbar', 'bulking', 'bulky', 'bull', 'bullae',\n       'bullosum', 'bullous', 'bun', 'bundle', 'buphthalmos',\n       'bupivacaine', 'bupropion', 'burden', 'burkitt', 'burmese', 'burn',\n       'burning', 'burns', 'bursitis', 'burst', 'bursts', 'busulfan',\n       'busulphan', 'but', 'butorphanol', 'buttock', 'buttocks', 'butyl',\n       'bw', 'by', 'bypass', 'c1', 'c1q', 'c3', 'c3d', 'c4', 'c5',\n       'c677t', 'ca', 'cabergoline', 'cachectic', 'cad', 'cadaveric',\n       'cae', 'caedta', 'caesarean', 'caffeine', 'cake', 'calcaneus',\n       'calcification', 'calcifications', 'calcimimetics', 'calcineurin',\n       'calcinosis', 'calciphylaxis', 'calcipotriol', 'calcitonin',\n       'calcitriol', 'calcium', 'calculated', 'calculation', 'calculus',\n       'calgb', 'call', 'called', 'callosum', 'calmette', 'calotropis',\n       'calsynar', 'came', 'cameroon', 'camptocormia', 'campylobacter',\n       'can', 'canada', 'canal', 'canalicular', 'cancer', 'cancers',\n       'candida', 'candidate', 'candidates', 'candidial', 'candidiasis',\n       'cannabis', 'cannot', 'cannulation', 'canthus', 'cap', 'capable',\n       'capacity', 'capd', 'capecitabine', 'capillaritis', 'capillary',\n       'capsaicin', 'capsular', 'capsule', 'captopril', 'capture', 'car',\n       'carbachol', 'carbamazepine', 'carbamyl', 'carbapenem',\n       'carbethoxypsoralen', 'carbimazole', 'carbohydrate',\n       'carbohydrates', 'carbon', 'carbonate', 'carbonic', 'carboplatin',\n       'carboxypeptidase', 'carcinogenic', 'carcinoma', 'carcinomas',\n       'carcinomatosa', 'carcinostatic', 'cardama', 'cardiac', 'cardial',\n       'cardiobacterium', 'cardiocompressions', 'cardiogenic',\n       'cardiology', 'cardiomyopathy', 'cardiopulmonary',\n       'cardiorespiratory', 'cardiotoxic', 'cardiotoxicity',\n       'cardiotoxin', 'cardiovascular', 'cardioversion', 'cardioverter',\n       'cards', 'care', 'cared', 'careful', 'carefully', 'carers',\n       'carinii', 'carmeda', 'carmustine', 'carnitine', 'carotid',\n       'carotovora', 'carpentier', 'carpopedal', 'carried', 'carrier',\n       'carriers', 'carries', 'carry', 'cartilage', 'cascade', 'case',\n       'casei', 'cases', 'caspofungin', 'cast', 'castellanii',\n       'castleman', 'castration', 'casual', 'cat', 'catabolism',\n       'catabolized', 'catalyses', 'catalyst', 'catalysts', 'cataplexy',\n       'cataract', 'cataracts', 'catatonia', 'catatonic', 'catecholamine',\n       'catecholamines', 'categories', 'catheter', 'catheterisation',\n       'catheterization', 'catheters', 'caths', 'cation', 'cats',\n       'caucasian', 'caudal', 'caudate', 'causal', 'causalgic',\n       'causality', 'causation', 'causative', 'cause', 'caused', 'causes',\n       'causing', 'caustic', 'caution', 'cautionary', 'cautions',\n       'cautious', 'cautiously', 'cava', 'cavernosum', 'cavitary',\n       'cavity', 'cavus', 'cbdca', 'cbs', 'cbz', 'cc', 'ccnu', 'cd',\n       'cd2', 'cd20', 'cd3', 'cd30', 'cd33', 'cd34', 'cd4', 'cd45',\n       'cd45ro', 'cd5', 'cd56', 'cd7', 'cd8', 'cda', 'cddp', 'cdi',\n       'cdic', 'cdt', 'ce', 'ceased', 'cecal', 'cecum', 'cefazolin',\n       'cefmenoxime', 'cefotiam', 'cefoxitin', 'ceftazidime',\n       'ceftriaxone', 'cefuroxime', 'celiac', 'celiprolol', 'cell',\n       'cells', 'cellular', 'cellulitic', 'cellulitis', 'cement',\n       'cementation', 'cent', 'center', 'centers', 'central', 'centrally',\n       'centre', 'centrifugal', 'cephalexin', 'cephalosporin',\n       'cephalosporins', 'cerebellar', 'cerebellum', 'cerebral',\n       'cerebri', 'cerebrospinal', 'cerebrovascular', 'cerivastatin',\n       'ceroid', 'certain', 'certainly', 'certainty', 'ceruloplasmin',\n       'cervical', 'cervico', 'cervicothoracic', 'cervix', 'cesarean',\n       'cesium', 'cessation', 'cetirizine', 'cetrimide', 'cetuximab',\n       'cevimeline', 'cf', 'cfselow', 'cgi', 'ch3ch2ono', 'chain',\n       'chalazion', 'challenge', 'challenges', 'challenging', 'chamber',\n       'chance', 'change', 'changed', 'changes', 'changing', 'channel',\n       'channels', 'characterised', 'characteristic',\n       'characteristically', 'characteristics', 'characterize',\n       'characterized', 'charcoal', 'charcot', 'charlatans', 'charles',\n       'chart', 'chaud', 'chb', 'chc', 'cheap', 'check', 'checked',\n       'cheeks', 'chelation', 'chelonae', 'chemical', 'chemically',\n       'chemicals', 'chemistries', 'chemistry', 'chemoembolization',\n       'chemoirradiation', 'chemoprevention', 'chemoradiation',\n       'chemoradiotherapy', 'chemotactic', 'chemotherapeutic',\n       'chemotherapeutics', 'chemotherapies', 'chemotherapy', 'chest',\n       'chf', 'chiari', 'chiasm', 'chiasmal', 'chickenpox', 'child',\n       'childhood', 'children', 'chills', 'chilly', 'chimeric', 'chinese',\n       'chl', 'chloral', 'chlorambucil', 'chloramphenicol',\n       'chlorhexidine', 'chloride', 'chlormadinone', 'chloro',\n       'chlorodeoxyadenosine', 'chloroethyl', 'chloronitrosourea',\n       'chloroquine', 'chlorothiazide', 'chlorpromazine',\n       'chlorpropamide', 'choanal', 'chocolate', 'choice',\n       'cholangiography', 'cholangiopancreatography', 'cholangiopathy',\n       'cholangitis', 'cholecystectomy', 'cholecystitis', 'choledocus',\n       'cholelithiasis', 'cholestasis', 'cholestatic', 'cholestatis',\n       'cholesterol', 'cholestyramine', 'choline', 'cholinergic',\n       'cholinesterase', 'choosing', 'chop', 'chorea', 'choreiform',\n       'choreoballistic', 'chorioamnionitis', 'choriocarcinomic',\n       'chorioretinal', 'chorioretinitis', 'chorioretinopathy',\n       'choroidal', 'chose', 'chosen', 'chromatography', 'chromic',\n       'chromosomal', 'chromosome', 'chronic', 'chronically',\n       'chronological', 'chronology', 'chronotropic', 'chryseobacterium',\n       'churg', 'chymopapain', 'ci', 'cialis', 'cibenzoline',\n       'cicatrical', 'cicatricial', 'cicatrization', 'cicatrizing',\n       'ciclosporin', 'cidofovir', 'cigarette', 'cilastatin',\n       'ciliochoroidal', 'cimetidine', 'cincinnati', 'cinepazide',\n       'ciprofloxacin', 'cips', 'circuit', 'circulating', 'circulation',\n       'circumferential', 'circumoral', 'circumscribed', 'circumstances',\n       'circumstantial', 'circumvent', 'cirrhosis', 'cirrhotic', 'cis',\n       'cisapride', 'cisplatin', 'cisplatinum', 'citalopram', 'citation',\n       'citations', 'citb', 'cited', 'citrate', 'city', 'ciu', 'ck', 'cl',\n       'cladribine', 'claim', 'claimed', 'clarified', 'clarify',\n       'clarithromycin', 'clarity', 'class', 'classes', 'classic',\n       'classical', 'classically', 'classification', 'claudication',\n       'cleansing', 'clear', 'clearance', 'clearances', 'cleared',\n       'clearly', 'cleaves', 'cleaving', 'cleft', 'clemastine',\n       'clevudine', 'clexane', 'client', 'climacteric', 'clin',\n       'clindamycin', 'clinic', 'clinical', 'clinically', 'clinician',\n       'clinicians', 'clinico', 'clinicopathologic',\n       'clinicopathological', 'clinoril', 'clioquinol', 'clitoral', 'cll',\n       'clock', 'clofazamine', 'clofazimine', 'clofibrate', 'clomiphene',\n       'clomipramine', 'clonal', 'clonally', 'clonazepam', 'clonic',\n       'clonidine', 'clonus', 'clopidogrel', 'close', 'closed', 'closely',\n       'closer', 'clostridial', 'clostridium', 'closure', 'clot',\n       'clotrimazole', 'clots', 'clotting', 'cloxacillin', 'clozapine',\n       'clpd', 'cls', 'cluneal', 'cm', 'cmap', 'cml', 'cmo', 'cmv', 'cns',\n       'cnv', 'co', 'co2', 'coadministered', 'coadministration',\n       'coagulation', 'coagulopathy', 'coal', 'coalesce', 'coaptation',\n       'coarctation', 'coasting', 'coated', 'cobalt', 'cocaine',\n       'coccidioidal', 'coccidioidomycosis', 'cod', 'codeine',\n       'coefficient', 'coelomic', 'coenurosis', 'coenzyme', 'coexist',\n       'coexistent', 'coexisting', 'cognitive', 'cognizant', 'coherence',\n       'cohort', 'cohosh', 'coincided', 'coincidence', 'coincident',\n       'coincidental', 'coinciding', 'coinfection', 'colchicine', 'cold',\n       'coli', 'colic', 'colicky', 'colitis', 'collaborative', 'collagen',\n       'collagenase', 'collagenous', 'collapse', 'collapsed',\n       'collapsing', 'collateral', 'collaterals', 'collected',\n       'collection', 'colloidal', 'cologne', 'colon', 'colonic',\n       'colonies', 'colonoscopy', 'colony', 'color', 'colorectal',\n       'colored', 'colour', 'columbia', 'columbus', 'column', 'coma',\n       'comatose', 'combating', 'combativeness', 'combination',\n       'combinational', 'combinations', 'combined', 'combining', 'come',\n       'comedones', 'command', 'commenced', 'commencement', 'commencing',\n       'commentary', 'commercial', 'commiphora', 'common', 'commonly',\n       'communication', 'community', 'comorbidities', 'comorbidity',\n       'companies', 'company', 'comparable', 'comparatively', 'compare',\n       'compared', 'comparing', 'comparison', 'compartment',\n       'compassionate', 'compatible', 'compensated', 'compensatory',\n       'competitively', 'compiled', 'complain', 'complained',\n       'complaining', 'complaint', 'complaints', 'complement',\n       'complementary', 'complete', 'completed', 'completely',\n       'completing', 'completion', 'complex', 'complexes', 'compliance',\n       'compliant', 'complicate', 'complicated', 'complicates',\n       'complicating', 'complication', 'complications', 'component',\n       'components', 'composed', 'composition', 'compound', 'compounds',\n       'comprehensive', 'compresses', 'compression', 'compressive',\n       'comprise', 'comprising', 'compromise', 'compromised',\n       'compulsive', 'computed', 'computerized', 'concentrate',\n       'concentrated', 'concentrates', 'concentration', 'concentrations',\n       'concentric', 'concern', 'concerned', 'concerning', 'concerns',\n       'concise', 'conclude', 'concluded', 'concludes', 'conclusion',\n       'conclusions', 'concomitance', 'concomitant', 'concomitantly',\n       'concordant', 'concrete', 'concretions', 'concurrent',\n       'concurrently', 'condition', 'conditioned', 'conditioning',\n       'conditions', 'conducted', 'conducting', 'conduction',\n       'conductive', 'conduit', 'cone', 'confidence', 'confined',\n       'confirm', 'confirmation', 'confirmed', 'confirming', 'confirms',\n       'confocal', 'conforms', 'confounded', 'confounding', 'confused',\n       'confusing', 'confusion', 'confusional', 'congeners', 'congenita',\n       'congenital', 'congenitally', 'congestion', 'congestive', 'coning',\n       'conjectured', 'conjugated', 'conjunction', 'conjunctiva',\n       'conjunctival', 'conjunctivitis', 'connected', 'connection',\n       'connections', 'connective', 'conscious', 'consciousness',\n       'consecutive', 'consensus', 'consented', 'consequence',\n       'consequences', 'consequent', 'consequently', 'conservative',\n       'conservatively', 'consider', 'considerable', 'considerably',\n       'consideration', 'considerations', 'considered', 'considering',\n       'consist', 'consisted', 'consistent', 'consistently', 'consisting',\n       'consists', 'consolidation', 'constant', 'constantly',\n       'constellation', 'constipation', 'constitute', 'constitutes',\n       'constitutive', 'constriction', 'constrictive', 'construction',\n       'consultant', 'consultation', 'consulting', 'consumed',\n       'consumption', 'contact', 'contagiosa', 'contain', 'contained',\n       'containing', 'contains', 'contaminants', 'contaminated',\n       'contamination', 'contemplated', 'contemporary', 'contents',\n       'context', 'continence', 'continua', 'continuation', 'continue',\n       'continued', 'continues', 'continuous', 'continuously',\n       'contraceptive', 'contraceptives', 'contracted', 'contractile',\n       'contraction', 'contractions', 'contracture', 'contraindicated',\n       'contraindication', 'contralateral', 'contrary', 'contrast',\n       'contrasts', 'contribute', 'contributed', 'contributes',\n       'contributing', 'contribution', 'contributor', 'contributory',\n       'control', 'controlateral', 'controlled', 'controlling',\n       'controls', 'controversial', 'convalescent', 'conventional',\n       'conversely', 'conversion', 'convert', 'converted', 'converting',\n       'convincing', 'convoluted', 'convulsant', 'convulsions',\n       'convulsive', 'cool', 'coombs', 'cooperation', 'coordination',\n       'copaxone', 'copies', 'copper', 'cord', 'cordis', 'core', 'corn',\n       'cornea', 'corneal', 'corneoscleral', 'cornerstone', 'coronal',\n       'coronary', 'corporation', 'corporis', 'corpus', 'correct',\n       'corrected', 'correction', 'correlate', 'correlated', 'correlates',\n       'correlation', 'correlations', 'correspond', 'corresponding',\n       'corrosive', 'cortex', 'cortical', 'corticospinal',\n       'corticossteroids', 'corticosteroid', 'corticosteroids',\n       'corticotherapy', 'cortisol', 'corynebacterium', 'cosmetic',\n       'cost', 'costal', 'costly', 'costs', 'cotrimoxazole', 'cotton',\n       'cough', 'coughing', 'could', 'coumadin', 'coumarinic',\n       'counseled', 'count', 'counter', 'counterpart', 'countries',\n       'country', 'counts', 'coupled', 'course', 'courses', 'covalently',\n       'coved', 'coverage', 'covering', 'cox', 'cp', 'cpa', 'cpb',\n       'cph82', 'cpk', 'cpm', 'cpr', 'cps', 'cr', 'cra', 'cramping',\n       'cramps', 'cranial', 'craniocervical', 'craniofacial',\n       'craniosynostosis', 'craniotomy', 'craniovascular', 'crash',\n       'craving', 'cream', 'creams', 'create', 'created', 'creates',\n       'creatine', 'creatinine', 'credence', 'cremophor', 'creon',\n       'crescentic', 'crescents', 'cresol', 'crest', 'creutzfeldt',\n       'criminal', 'criminalization', 'crises', 'crisis', 'criteria',\n       'critical', 'critically', 'crohn', 'cromoglycate', 'crops',\n       'cross', 'crosslinking', 'crucial', 'crumley', 'crying',\n       'cryofibrinogenemia', 'cryopreserved', 'cryotherapy',\n       'cryptococcal', 'cryptococcosis', 'cryptococcus',\n       'cryptosporidiasis', 'crystal', 'crystalline', 'crystalluria',\n       'crystals', 'csa', 'csc', 'csd', 'csf', 'csfe', 'csfs', 'ct',\n       'ctc', 'ctla', 'ctpa', 'culprit', 'culprits', 'culture',\n       'cultured', 'cultures', 'culturing', 'cumulated', 'cumulative',\n       'cunninghamella', 'curariform', 'curative', 'cure', 'cured',\n       'curette', 'current', 'currently', 'curve', 'curvularia',\n       'cushing', 'cushions', 'cutanea', 'cutaneous', 'cutis', 'cutting',\n       'cvc', 'cvvhd', 'cy', 'cya', 'cyanamide', 'cyanocobalamin',\n       'cyanosed', 'cyanosis', 'cyclazocine', 'cycle', 'cycles', 'cyclic',\n       'cycling', 'cyclo', 'cyclofenil', 'cyclooxygenase',\n       'cyclophosphamide', 'cyclosporin', 'cyclosporine',\n       'cyclosposphamide', 'cylindruria', 'cyp', 'cyp1a1', 'cyp2b6',\n       'cyp2c19', 'cyp2c8', 'cyp2c9', 'cyp2d6', 'cyp3a', 'cyp3a4',\n       'cypher', 'cyproheptadine', 'cyproterone', 'cyst',\n       'cystadenocarcinoma', 'cysteamine', 'cystectomy', 'cystic',\n       'cysticerci', 'cysticercosis', 'cystitis', 'cystoid', 'cystoscopy',\n       'cysts', 'cytarabine', 'cytochrome', 'cytogenetic', 'cytokine',\n       'cytokines', 'cytologic', 'cytological', 'cytology', 'cytolytic',\n       'cytomegalic', 'cytomegalovirus', 'cytopenias', 'cytoplasm',\n       'cytoplasmic', 'cytosine', 'cytostatic', 'cytotoxic', 'cytoxan',\n       'd2', 'd3', 'da', 'dacarbazine', 'dacryolith', 'daily', 'daivonex',\n       'dalteparin', 'damage', 'damaged', 'damages', 'danaparoid',\n       'danazol', 'danger', 'dangerous', 'dantrolene', 'dap', 'dapsone',\n       'daptomycin', 'darbepoetin', 'darifenacin', 'dark', 'dartmouth',\n       'dasatanib', 'dasatinib', 'dat', 'data', 'date', 'daughter',\n       'daunomycin', 'dawley', 'day', 'days', 'daytime', 'dca', 'dcf',\n       'ddd', 'ddi', 'ddl', 'de', 'dead', 'deafness', 'dealer', 'dealing',\n       'deanol', 'death', 'deaths', 'debated', 'debilitating',\n       'debridement', 'debrisoquine', 'debulking', 'decade', 'decades',\n       'decadron', 'decanoate', 'decarboxylase', 'december',\n       'dechallenge', 'decided', 'deciding', 'decision', 'decisions',\n       'declared', 'decline', 'declined', 'decompensation',\n       'decompensations', 'decompression', 'decompressions',\n       'decongestant', 'decongestants', 'decoupling', 'decrease',\n       'decreased', 'decreases', 'decreasing', 'decrement', 'decrements',\n       'dedifferentiation', 'deducing', 'deemed', 'deep', 'deepening',\n       'defect', 'defective', 'defects', 'defences', 'defense',\n       'deferred', 'defibrillator', 'defibrillators', 'deficiencies',\n       'deficiency', 'deficient', 'deficit', 'deficits', 'define',\n       'defined', 'defines', 'defining', 'definite', 'definitely',\n       'definitive', 'definitively', 'deforming', 'deformities',\n       'deformity', 'degeneration', 'degradable', 'degradation',\n       'degraded', 'degranulation', 'degree', 'degrees', 'dehiscence',\n       'dehydrated', 'dehydration', 'dehydrogenase', 'del', 'delated',\n       'delay', 'delayed', 'deleterious', 'deletion', 'delirious',\n       'delirium', 'deliver', 'delivered', 'delivery', 'delusional',\n       'delusions', 'dem', 'demands', 'demarcated', 'demented',\n       'dementia', 'demethylation', 'demise', 'demodex', 'demonstrate',\n       'demonstrated', 'demonstrates', 'demonstrating', 'demonstration',\n       'demyelinating', 'demyelination', 'dendritic', 'dendrocytes',\n       'denervation', 'denied', 'denmark', 'densa', 'dense',\n       'densification', 'densities', 'density', 'dental', 'dentist',\n       'dentists', 'dentition', 'denture', 'dentures', 'deny',\n       'deodorants', 'deoxyadenosine', 'deoxycholate', 'deoxycoformycin',\n       'deoxyribonucleic', 'depakote', 'department', 'depend',\n       'dependence', 'dependency', 'dependent', 'depending', 'depends',\n       'depigmentation', 'depigmented', 'depleted', 'depletion', 'depo',\n       'deposit', 'deposition', 'deposits', 'depot', 'depressant',\n       'depressed', 'depression', 'depressive', 'deprivation', 'der',\n       'derivation', 'derivative', 'derivatives', 'derivatized',\n       'derived', 'dermal', 'dermatitis', 'dermatologic',\n       'dermatological', 'dermatology', 'dermatomal', 'dermatome',\n       'dermatomes', 'dermatomyositis', 'dermatopathology',\n       'dermatophyte', 'dermatoses', 'dermatosis', 'dermis',\n       'dermnatitis', 'dermotomy', 'desaturation', 'descemet',\n       'descemetocele', 'descending', 'describe', 'described',\n       'describes', 'describing', 'description', 'descriptions',\n       'descriptive', 'desensitization', 'desensitized', 'deserve',\n       'desferrioxamine', 'design', 'designed', 'desipramine',\n       'desirable', 'desired', 'desmethylclomipramine',\n       'desmethylsertraline', 'desmoid', 'desmoids', 'desmopressin',\n       'despite', 'desquamating', 'desquamation', 'desquamative',\n       'destabilize', 'destroyed', 'destruction', 'destructive',\n       'detachment', 'detail', 'detailed', 'details', 'detect',\n       'detectable', 'detected', 'detection', 'deteriorate',\n       'deteriorated', 'deterioration', 'deteriorations', 'determinants',\n       'determinations', 'determine', 'determined', 'detrimental',\n       'detrusor', 'devastating', 'develop', 'developed', 'developing',\n       'development', 'developmental', 'develops', 'device', 'devices',\n       'devoid', 'dexamethasone', 'dexmedetomidine', 'dextran',\n       'dextroamphetamine', 'dextromethorphan', 'dextrose', 'dhcc', 'di',\n       'diabetes', 'diabetic', 'diabetogenic', 'diagnose', 'diagnosed',\n       'diagnoses', 'diagnosing', 'diagnosis', 'diagnostic', 'dialysate',\n       'dialyses', 'dialysis', 'dialyzer', 'diameter', 'diameters',\n       'diamine', 'diaminopyridine', 'diamond', 'diamorphine', 'diamox',\n       'dian', 'diaphoresis', 'diaphoretic', 'diaphragm', 'diaphragmatic',\n       'diarrhea', 'diarrhoea', 'diazepam', 'diazoxide',\n       'dibenzothiazepine', 'dibenzoxazepine', 'dibucaine', 'dic',\n       'dichloroacetate', 'dichloroplatinum', 'diclofenac', 'dictated',\n       'did', 'didanosine', 'died', 'diet', 'dietary',\n       'diethylstilbestrol', 'differ', 'differences', 'different',\n       'differential', 'differentiate', 'differentiated',\n       'differentiation', 'differing', 'differs', 'difficile',\n       'difficult', 'difficulties', 'difficulty', 'diffuse', 'diffusion',\n       'digestive', 'digit', 'digital', 'digitalis', 'digits', 'digoxin',\n       'dihs', 'dihydropyrimidine', 'dihydrotachysterol',\n       'dihydroxybusulfan', 'dihydroxyvitamin', 'dilantin', 'dilatation',\n       'dilated', 'dilemma', 'diltiazem', 'diluting', 'dilution',\n       'dilutional', 'dilutions', 'dimension', 'dimercaprol',\n       'dimercaptosuccinic', 'dimers', 'dimethyl', 'diminished',\n       'diminishing', 'diminution', 'dimorphic', 'dinitrate', 'dioxide',\n       'diphasic', 'diphenhydramine', 'diphenylhydantoin', 'dipivefrin',\n       'dipivoxil', 'diplopia', 'dipropionate', 'diproprionate', 'dips',\n       'dipyridamole', 'dipyrone', 'direct', 'directed', 'directly',\n       'disability', 'disabling', 'disadvantage', 'disadvantages',\n       'disappearance', 'disappeared', 'disarticulation', 'disc',\n       'discarded', 'discharge', 'discharged', 'discharges', 'disciform',\n       'disclosed', 'discogram', 'discoid', 'discoloration',\n       'discolouration', 'discomfort', 'disconnection', 'discontinuance',\n       'discontinuation', 'discontinue', 'discontinued', 'discontinuing',\n       'discontinuous', 'discordant', 'discouraged', 'discovered',\n       'discovery', 'discrete', 'discuss', 'discussed', 'discusses',\n       'discussion', 'disease', 'diseases', 'disfiguring',\n       'disinhibition', 'disintegrating', 'disk', 'dislodgement',\n       'dismiss', 'disodium', 'disopyramide', 'disorder', 'disordered',\n       'disorders', 'disparities', 'dispersion', 'displacement',\n       'display', 'displayed', 'disqualification', 'disqualified',\n       'disregarded', 'disrupted', 'disruption', 'disruptive',\n       'dissecting', 'dissection', 'dissections', 'disseminated',\n       'dissemination', 'dissociation', 'dissolution', 'dissolved',\n       'distal', 'distally', 'distant', 'distension', 'distention',\n       'distinct', 'distinctions', 'distinctive', 'distinguish',\n       'distinguished', 'distortion', 'distraction', 'distress',\n       'distressing', 'distribution', 'distributions', 'disturbance',\n       'disturbances', 'disturbed', 'disturbing', 'disulfide',\n       'disulfiram', 'diuresis', 'diuretic', 'diuretics', 'diurnal',\n       'divalproex', 'diverse', 'diverticular', 'diverticulum', 'divided',\n       'diving', 'division', 'dizziness', 'dka', 'dl', 'dlb', 'dlk',\n       'dlst', 'dm', 'dme', 'dmso', 'dna', 'do', 'dobutamine',\n       'docetaxel', 'doctor', 'doctors', 'document', 'documentation',\n       'documented', 'documenting', 'docusate', 'does', 'dofetilide',\n       'dog', 'dogs', 'doing', 'domain', 'dominant', 'dominated', 'done',\n       'donepezil', 'donor', 'donors', 'dopa', 'dopamine', 'dopaminergic',\n       'doppler', 'dornase', 'dorsal', 'dorsiflexor', 'dorzolamide',\n       'dosage', 'dosages', 'dose', 'dosed', 'doses', 'dosing', 'double',\n       'doubled', 'doubling', 'down', 'downgrowth', 'doxetaxel',\n       'doxorubicin', 'doxorubicine', 'doxycycline', 'dpd', 'dpoaes',\n       'dr', 'dr5', 'drain', 'drainage', 'dramatic', 'dramatically',\n       'draw', 'drawn', 'draws', 'dress', 'dressing', 'dressings', 'drew',\n       'drink', 'drinking', 'drinks', 'driven', 'driving', 'drop',\n       'droplets', 'dropped', 'dropper', 'drops', 'drosophila',\n       'drowsiness', 'drowsy', 'drug', 'drugs', 'drusen', 'dry',\n       'dryness', 'dscg', 'dsp', 'dual', 'dubliniensis', 'duchenne',\n       'duct', 'ductal', 'ductopenia', 'ducts', 'ductus', 'due', 'duke',\n       'dumping', 'duodenal', 'duodenum', 'dura', 'durable', 'dural',\n       'duration', 'during', 'duties', 'duty', 'dvt', 'dwi', 'dying',\n       'dymelor', 'dynamic', 'dynamics', 'dysarthria', 'dysbarism',\n       'dyscrasias', 'dyserythropoiesis', 'dyserythropoietic',\n       'dysesthesia', 'dysfunction', 'dysfunctions', 'dysgenesis',\n       'dyskeratotic', 'dyskinesia', 'dyskinesias', 'dyskinetic',\n       'dyslipidemia', 'dysmaturation', 'dysmenorrhea', 'dysphagia',\n       'dysphoric', 'dysplasia', 'dyspnea', 'dyspnoea', 'dysproteinemia',\n       'dysreactive', 'dysrhythmia', 'dysthymia', 'dysthyroidism',\n       'dystonia', 'dystonias', 'dystonic', 'dystrophy', 'e1', 'e2',\n       'e390g', 'each', 'ear', 'earlier', 'earliest', 'early', 'ears',\n       'ease', 'easier', 'easily', 'east', 'easy', 'eat', 'eating',\n       'eaton', 'ebp', 'ebv', 'ec', 'ecchymoses', 'ecchymosis', 'eccrine',\n       'ecg', 'echocardiogram', 'echocardiographic',\n       'echocardiographically', 'echocardiography', 'echography',\n       'echoviral', 'echovirus', 'eclampsia', 'ecm', 'econazole',\n       'economic', 'economical', 'ecstasy', 'ect', 'ectasia',\n       'ectodermal', 'ectopic', 'ectropion', 'eczema', 'eczematous', 'ed',\n       'edema', 'edematous', 'edetate', 'edged', 'editor', 'edrf',\n       'education', 'edwards', 'eeg', 'efalizumab', 'efavirenz',\n       'effacement', 'effect', 'effective', 'effectively',\n       'effectiveness', 'effects', 'effectuated', 'efficacious',\n       'efficacy', 'efficient', 'effluvium', 'effort', 'efforts',\n       'effusion', 'effusions', 'eg', 'ege', 'egfr', 'ego',\n       'ehrlichiosis', 'eight', 'eighteen', 'eighth', 'eighty', 'either',\n       'ejaculation', 'el', 'elbow', 'elbows', 'elderly', 'elected',\n       'elective', 'electrical', 'electro', 'electrocardiogram',\n       'electrocardiographic', 'electrocardiographical',\n       'electroconvulsive', 'electroencephalograms',\n       'electroencephalographic', 'electroencephalography', 'electrolyte',\n       'electrolytes', 'electromyogram', 'electron',\n       'electroneuromyography', 'electrophysiologic',\n       'electrophysiological', 'electrophysiology',\n       'electroretinographic', 'electroretinography', 'electroshock',\n       'element', 'elements', 'elevated', 'elevation', 'elevations',\n       'eleven', 'eleventh', 'elicit', 'elicited', 'eliciting',\n       'eliminate', 'eliminated', 'eliminating', 'elimination', 'elonic',\n       'elp', 'elsewhere', 'elucidate', 'elucidating', 'eluting', 'em',\n       'emanating', 'emboli', 'embolia', 'embolic', 'embolism',\n       'embolization', 'embolized', 'embolus', 'embryonal', 'embryopathy',\n       'emegency', 'emepronium', 'emerged', 'emergence', 'emergency',\n       'emergent', 'emerging', 'emetic', 'emission', 'emollient',\n       'emotional', 'emphasis', 'emphasize', 'emphasized', 'emphasizes',\n       'emphasizing', 'emphysema', 'empirical', 'empirically', 'employed',\n       'employing', 'empty', 'emptying', 'empyema', 'emulsion', 'enabled',\n       'enabling', 'enalapril', 'enalaprilat', 'enamel', 'encephalitis',\n       'encephalomyelitis', 'encephalopathy', 'enciprazine', 'encounter',\n       'encountered', 'encouraged', 'encouraging', 'end', 'ended',\n       'endemic', 'endo', 'endocarditis', 'endocrine', 'endodermal',\n       'endodontic', 'endogeneous', 'endogenous', 'endoleaks',\n       'endometrial', 'endometrioid', 'endometriosis', 'endometriotic',\n       'endometrium', 'endomyocardial', 'endomysium', 'endophthalmitis',\n       'endoprostheses', 'endoprosthesis', 'endoscope', 'endoscopic',\n       'endoscopically', 'endoscopy', 'endothelial', 'endotheliitis',\n       'endothelin', 'endothelium', 'endotoxemia', 'endotracheal',\n       'endovascular', 'endozepines', 'enduring', 'enema', 'energy',\n       'enfuvirtide', 'engaged', 'engender', 'engl', 'english',\n       'engraftment', 'enhance', 'enhanced', 'enhancement', 'enhances',\n       'enhancing', 'enlarged', 'enlargement', 'enough', 'enoxaparin',\n       'enoxaparine', 'enrich', 'enriched', 'enrolled', 'ensued',\n       'ensuing', 'ensure', 'entamoeba', 'enteral', 'entered', 'enteric',\n       'entering', 'enteritis', 'enterobacter', 'enterobacteriaceae',\n       'enterococcal', 'enterococcus', 'enterocolitis', 'enterohepatic',\n       'enteropathic', 'enteropathica', 'enteropathy', 'entire',\n       'entirely', 'entities', 'entity', 'entrapment', 'entropion',\n       'entry', 'enuresis', 'environment', 'environmental', 'enzymatic',\n       'enzyme', 'enzymes', 'eo', 'eosin', 'eosinophil', 'eosinophilia',\n       'eosinophilic', 'eosinophils', 'ep', 'ependymoma', 'epicardial',\n       'epidemic', 'epidemiological', 'epidemiology', 'epidermal',\n       'epidermidis', 'epidermoid', 'epididymitis', 'epidural',\n       'epigallocatechin', 'epigastralgia', 'epigastric', 'epigenetic',\n       'epiglottitis', 'epilepsia', 'epilepsies', 'epilepsy', 'epileptic',\n       'epileptics', 'epilepticus', 'epileptiform', 'epileptogenic',\n       'epinephrine', 'epiphora', 'epirubicin', 'episode', 'episodes',\n       'episodic', 'epithelial', 'epithelioid', 'epithelioma',\n       'epithelium', 'epivodes', 'epo', 'epoch', 'epoetin',\n       'epoprostenol', 'epoxide', 'eps', 'epstein', 'equally', 'equi',\n       'equine', 'equivalent', 'equivocal', 'era', 'eradicated',\n       'eradication', 'erase', 'erectile', 'erection', 'erections',\n       'ergic', 'ergot', 'ergotamine', 'ergotism', 'erlotinib', 'eroded',\n       'erosion', 'erosions', 'erosive', 'erroneous', 'error', 'eruption',\n       'eruptions', 'eruptive', 'erwinia', 'erythema', 'erythemal',\n       'erythematosus', 'erythematous', 'erythrocyanosis', 'erythrocyte',\n       'erythroderma', 'erythrodermic', 'erythrodysaesthesia',\n       'erythroid', 'erythromycin', 'erythrophagocytosis',\n       'erythropoiesis', 'erythropoietic', 'erythropoietin', 'escalating',\n       'escape', 'escherichia', 'escitalopram', 'esmolol', 'esomeprazole',\n       'esophageal', 'esophagitis', 'esophago', 'esophagogastric',\n       'esophagogastroscopy', 'esophagogram', 'especially', 'esrd',\n       'esrf', 'essential', 'est', 'establish', 'established',\n       'establishes', 'establishing', 'establishment', 'ester',\n       'esterase', 'estimate', 'estimated', 'estradiol', 'estrogen',\n       'estrogens', 'et', 'etanercept', 'etc', 'ethambutol', 'ethanol',\n       'ethanolamine', 'ethical', 'ethmoid', 'ethmoidal', 'ethnically',\n       'ethyl', 'ethylene', 'ethylenediamine', 'etiologic', 'etiological',\n       'etiologies', 'etiology', 'etoglucid', 'etoposide', 'etretinate',\n       'eur', 'europe', 'european', 'euthyroid', 'evacuated',\n       'evacuation', 'evaluate', 'evaluated', 'evaluating', 'evaluation',\n       'evaluations', 'evans', 'even', 'evening', 'event', 'events',\n       'eventual', 'eventually', 'everolimus', 'every', 'evidence',\n       'evidenced', 'evidences', 'evident', 'evoked', 'evolution',\n       'evolutional', 'evolved', 'evolves', 'evolving', 'ewing',\n       'exacerbate', 'exacerbated', 'exacerbates', 'exacerbating',\n       'exacerbation', 'exacerbations', 'exact', 'exaggerated',\n       'exalbida', 'exam', 'examination', 'examinations', 'examine',\n       'examined', 'examiner', 'examines', 'example', 'examples',\n       'exanthem', 'exanthematous', 'exceeded', 'exceedingly',\n       'excellent', 'excellently', 'except', 'exception', 'exceptional',\n       'exceptionally', 'excess', 'excessive', 'exchange', 'exchanges',\n       'excimer', 'excised', 'excision', 'excitability', 'excitation',\n       'excitatory', 'excited', 'exclude', 'excluded', 'excluding',\n       'exclusion', 'exclusively', 'excrete', 'excreted', 'excretion',\n       'exemplifying', 'exercise', 'exercised', 'exercising', 'exerts',\n       'exfoliative', 'exhaustion', 'exhibit', 'exhibited', 'exhibiting',\n       'exhibits', 'exist', 'existence', 'existent', 'existing', 'exists',\n       'exocrine', 'exogenous', 'exophthalmos', 'expanding', 'expands',\n       'expect', 'expectations', 'expected', 'expensive', 'experience',\n       'experienced', 'experiences', 'experiencing', 'experiment',\n       'experimental', 'experimentally', 'experiments', 'expertise',\n       'expiratory', 'expired', 'explain', 'explained', 'explanation',\n       'explanations', 'explantation', 'exploration', 'exploratory',\n       'explore', 'explored', 'exposed', 'exposure', 'exposures',\n       'expressed', 'expressing', 'expression', 'expressly',\n       'extemporaneous', 'extended', 'extending', 'extends', 'extension',\n       'extensive', 'extensively', 'extensors', 'extent', 'external',\n       'externally', 'extra', 'extraarticular', 'extrabeam',\n       'extracapillary', 'extracellular', 'extracorporeal', 'extract',\n       'extraction', 'extrahepatic', 'extramedullary', 'extranodal',\n       'extraordinary', 'extrapyramidal', 'extrarenal', 'extraskeletal',\n       'extravasation', 'extravert', 'extreme', 'extremely',\n       'extremities', 'extremity', 'extremly', 'extrication', 'extrinsic',\n       'extrophy', 'extubated', 'extubation', 'exudate', 'exudates',\n       'exudative', 'eye', 'eyedrops', 'eyelid', 'eyes', 'ezetimibe',\n       'f1', 'fab', 'fabric', 'face', 'faced', 'facial', 'facilitate',\n       'facilitated', 'facilities', 'facility', 'facing', 'fact',\n       'factor', 'factors', 'factory', 'facts', 'faculty', 'fail',\n       'failed', 'failure', 'failures', 'falciparum', 'fall', 'falling',\n       'fallopian', 'falls', 'false', 'falsified', 'falx', 'familial',\n       'familiar', 'families', 'family', 'fanconi', 'far', 'fascicular',\n       'fasciitis', 'fasciotomy', 'fashion', 'fast', 'faster', 'fasting',\n       'fat', 'fatal', 'fatalities', 'fatality', 'father', 'fatigue',\n       'fatty', 'faultless', 'faulty', 'favor', 'favorable', 'favorably',\n       'favored', 'favors', 'favourable', 'fcc', 'fda', 'fde', 'feasible',\n       'feature', 'features', 'febrile', 'february', 'fecal', 'fed',\n       'federal', 'feeder', 'feeding', 'feedings', 'feeling', 'feelings',\n       'feet', 'feline', 'fell', 'felt', 'felty', 'female', 'females',\n       'femoral', 'femur', 'fenclofenac', 'fenoprofen', 'fentanyl',\n       'ferrets', 'ferritin', 'ferrous', 'fetal', 'fetotoxic', 'fetus',\n       'fever', 'fevers', 'few', 'fewer', 'ffp', 'fgs', 'fh', 'fiber',\n       'fibers', 'fibre', 'fibrillation', 'fibrils', 'fibrin',\n       'fibrinogen', 'fibrinolytic', 'fibrinous', 'fibroblast',\n       'fibrocystic', 'fibrogenesis', 'fibromatosis', 'fibroscopy',\n       'fibrosing', 'fibrosis', 'fibrotic', 'fibrous', 'fibula', 'field',\n       'fields', 'fifteen', 'fifth', 'fifty', 'fig', 'figo', 'figs',\n       'figures', 'filaments', 'file', 'filgastim', 'filgastrim',\n       'filgrastim', 'filled', 'filler', 'fillers', 'films', 'filter',\n       'filtering', 'filtration', 'final', 'finally', 'financial',\n       'finasteride', 'finding', 'findingd', 'findings', 'fine', 'finger',\n       'fingernails', 'fingers', 'fingertips', 'finished', 'fire',\n       'firmly', 'first', 'fish', 'fisher', 'fistula', 'fistulizing',\n       'fit', 'fits', 'five', 'fixation', 'fixed', 'fk', 'fk506',\n       'flaccid', 'flagellate', 'flank', 'flanks', 'flap', 'flare',\n       'flared', 'flashes', 'flat', 'flecainide', 'fleet', 'flexible',\n       'flexion', 'flexor', 'flexure', 'flicker', 'float', 'flora',\n       'floridly', 'flour', 'flow', 'flucloxacillin', 'fluconazole',\n       'fluctuating', 'fluctuation', 'fluctuations', 'flucytosine',\n       'fludarabine', 'fluid', 'fluids', 'flumazenil', 'flunitrazepam',\n       'fluorescein', 'fluorescence', 'fluorescent', 'fluoresone',\n       'fluoride', 'fluorine', 'fluorocytosine', 'fluoroquinolone',\n       'fluoroquinolones', 'fluoroscopy', 'fluorosis', 'fluorouracil',\n       'fluoxetine', 'fluphenazine', 'flupirtine', 'flurbiprofen',\n       'flush', 'flushing', 'flutamide', 'fluticasone', 'flutter',\n       'fluvoxamine', 'flux', 'fluxes', 'fmf', 'fna', 'foal', 'focal',\n       'foci', 'focus', 'focused', 'focuses', 'folate', 'fold', 'folds',\n       'foliaceus', 'folic', 'folinate', 'folinic', 'follicular',\n       'folliculorum', 'follow', 'followed', 'following', 'follows',\n       'followup', 'fomepizole', 'fondaparinux', 'food', 'foot', 'for',\n       'foramen', 'force', 'forced', 'forceps', 'forces', 'forearm',\n       'forearms', 'forefoot', 'forever', 'form', 'formalin', 'formation',\n       'former', 'formic', 'forming', 'forms', 'formulation', 'fortuitum',\n       'fortunately', 'forty', 'forward', 'foryears', 'fosamax',\n       'fosamprenavir', 'foscarnet', 'fosinopril', 'fossa', 'foul',\n       'found', 'foundation', 'four', 'fourteen', 'fourth', 'fourths',\n       'foveolar', 'fraction', 'fracture', 'fractured', 'fractures',\n       'fragile', 'fragility', 'fragment', 'fragments', 'fragmin',\n       'frail', 'frame', 'framework', 'frank', 'fraxiparin', 'freckles',\n       'free', 'french', 'frequencies', 'frequency', 'frequent',\n       'frequently', 'fresh', 'frg', 'friability', 'friction', 'from',\n       'frontal', 'fronto', 'frozen', 'fryl', 'fsgs', 'ft', 'fu', 'fudr',\n       'fulfilling', 'full', 'fully', 'fulminans', 'fulminant',\n       'fumigatus', 'function', 'functional', 'functioning', 'functions',\n       'fundamental', 'fundoscopic', 'fundus', 'fungal', 'fungemia',\n       'fungi', 'fungoides', 'fungus', 'fura', 'furazolidone',\n       'furosemide', 'furry', 'further', 'furthermore', 'fusarium',\n       'fusion', 'futher', 'future', 'fvs', 'g1691a', 'g2', 'g516t',\n       'g6pd', 'g874r', 'gaba', 'gabapentin', 'gabitril', 'gadolinium',\n       'gain', 'gained', 'gait', 'galactorrhea', 'gallate', 'gallbladder',\n       'gallium', 'gallstone', 'gallstones', 'gamble', 'gambling', 'game',\n       'gamete', 'gamma', 'gammaglobulin', 'gammaglobulinaemic',\n       'gammopathy', 'ganciclovir', 'ganglia', 'ganglion', 'gangrene',\n       'gap', 'gardner', 'garenoxacin', 'garlic', 'gas', 'gastaut',\n       'gastrectomy', 'gastric', 'gastrin', 'gastritis', 'gastro',\n       'gastroduodenitis', 'gastroenteritis', 'gastroenterological',\n       'gastroesophageal', 'gastrointestinal', 'gastroscopy',\n       'gastrostomy', 'gated', 'gatifloxacin', 'gaucher', 'gave', 'gaze',\n       'gazi', 'gbp', 'gc', 'gd', 'gee', 'gefitinib', 'gelatin',\n       'gelatine', 'gelatinous', 'gelofusine', 'gemcitabine',\n       'gemfibrozil', 'gemtuzumab', 'gender', 'gene', 'general',\n       'generalised', 'generalization', 'generalized', 'generally',\n       'generation', 'generations', 'generic', 'genes', 'genesis',\n       'genetic', 'genitourinary', 'genotoxic', 'genotype', 'genotypes',\n       'genotyping', 'gentamicin', 'gentamycin', 'geriatric', 'germ',\n       'german', 'germs', 'gerold', 'gestation', 'gestational',\n       'gestations', 'gh', 'ghb', 'ghd', 'gi', 'giant', 'gigantism',\n       'gilgor', 'gilles', 'ginger', 'gingiva', 'gingival',\n       'gingivectomy', 'girk', 'girl', 'girls', 'gist', 'gitelman',\n       'give', 'given', 'givers', 'giving', 'gl', 'gland', 'glands',\n       'glare', 'glass', 'glatiramer', 'glaucoma', 'gleason', 'gleevec',\n       'gliadel', 'glibenclamide', 'gliclazide', 'glioblastoma', 'glioma',\n       'gliomas', 'glipizide', 'global', 'globe', 'globulin', 'globus',\n       'glomerular', 'glomeruli', 'glomeruloesclerosis',\n       'glomerulonephritis', 'glomerulopathy', 'glomerulosclerosis',\n       'glomerulus', 'glostrup', 'glove', 'glucagon', 'glucocerebrosides',\n       'glucocorticoid', 'glucocorticoids', 'gluconate', 'glucosaminase',\n       'glucosaminidase', 'glucose', 'glucosidase', 'glucosuria',\n       'glucuronidation', 'glucuronide', 'glue', 'glutamic', 'glutamine',\n       'glutamyl', 'glutamyltranspeptidase', 'glutea', 'gluten',\n       'glyburide', 'glycemia', 'glycerine', 'glycine', 'glycol',\n       'glycopyrrolate', 'glycoside', 'glycosides', 'glycosuria',\n       'glycyrrhizin', 'glypressin', 'gm', 'gnrh', 'go', 'goal', 'goiter',\n       'gold', 'gonadal', 'gonioscopy', 'good', 'goose', 'goserelin',\n       'got', 'gout', 'gouty', 'gpp', 'gpt', 'grade', 'graded', 'grades',\n       'gradient', 'gradual', 'gradually', 'graft', 'grafting', 'grafts',\n       'gram', 'grams', 'grand', 'granular', 'granules', 'granulocyte',\n       'granulocytic', 'granulocytopenia', 'granuloma', 'granulomas',\n       'granulomatosis', 'granulomatous', 'graphic', 'grave', 'graves',\n       'gravis', 'gray', 'great', 'greater', 'greatly', 'green',\n       'greenlandic', 'grepafloxacin', 'grew', 'grey', 'grief',\n       'grindelia', 'griseofulvin', 'grocott', 'groin', 'groote',\n       'groshong', 'gross', 'grossly', 'ground', 'grounds', 'group',\n       'grouped', 'groups', 'grow', 'growing', 'grown', 'growth', 'gstm',\n       'gtbm', 'guanfacine', 'guarantee', 'guerin', 'guidance', 'guided',\n       'guideline', 'guidelines', 'guiding', 'gums', 'gumweed', 'gut',\n       'gutter', 'gvhd', 'gvo', 'gy', 'gynaecologist', 'gynaecomastia',\n       'gynecomastia', 'gyrase', 'h2', 'haart', 'habitual', 'hacking',\n       'had', 'haematologic', 'haematological', 'haematoma',\n       'haematopoietic', 'haemodialysis', 'haemoglobin', 'haemolysis',\n       'haemolytic', 'haemoperfusion', 'haemophagocytic', 'haemophilia',\n       'haemophiliacs', 'haemopoiesis', 'haemorrhage', 'haemorrhaged',\n       'haemorrhagic', 'haemosiderosis', 'haemostasis', 'haemostatic',\n       'hagedorn', 'hai', 'hair', 'hairy', 'hal', 'halcinonide', 'half',\n       'halfan', 'hallmark', 'hallmarks', 'hallopeau', 'hallucinations',\n       'hallucinatory', 'hallucinogenic', 'halofantrine', 'haloperidol',\n       'halothane', 'halt', 'halted', 'halting', 'halving', 'hand',\n       'handed', 'handling', 'hands', 'hansen', 'happen', 'hapten',\n       'haptens', 'haptoglobin', 'har', 'harada', 'harlequin', 'harm',\n       'harmful', 'harvest', 'harvesting', 'has', 'hashimoto', 'hasten',\n       'hastened', 'hasty', 'hat', 'have', 'having', 'hazard',\n       'hazardous', 'hazards', 'haze', 'hb', 'hbs', 'hbsab', 'hbsag',\n       'hbv', 'hc', 'hcc', 'hcl', 'hcm', 'hcq', 'hct', 'hcv', 'hd',\n       'hdarac', 'hdas', 'hdigg', 'hdl', 'hdmtx', 'he', 'head',\n       'headache', 'headaches', 'heads', 'healed', 'healer', 'healing',\n       'healon5', 'health', 'healthcare', 'healthy', 'hearing', 'heart',\n       'heartbeat', 'heat', 'heatstroke', 'heavy', 'height', 'heighten',\n       'heightened', 'held', 'helicobacter', 'heliox', 'help', 'helped',\n       'helpful', 'helping', 'hemagglutinin', 'hemangioma', 'hemangiomas',\n       'hematochezia', 'hematocrit', 'hematologic', 'hematological',\n       'hematoma', 'hematomas', 'hematopoiesis', 'hematopoietic',\n       'hematoxylin', 'hematuria', 'heme', 'hemianopsia', 'hemiparesis',\n       'hemiplegia', 'hemo', 'hemodiafiltration', 'hemodialyses',\n       'hemodialysis', 'hemodilution', 'hemodynamic', 'hemodynamically',\n       'hemoglobin', 'hemoglobinemia', 'hemoglobinopathies',\n       'hemoglobinuria', 'hemograms', 'hemolysis', 'hemolytic',\n       'hemoperfusion', 'hemophagocytic', 'hemophagocytosis',\n       'hemophilia', 'hemophiliac', 'hemophiliacs', 'hemopoietic',\n       'hemoptysis', 'hemorrhage', 'hemorrhages', 'hemorrhagic',\n       'hemostasis', 'hemostatic', 'hemothorax', 'hence', 'henna',\n       'heparin', 'heparinization', 'heparinoid', 'heparins', 'hepatic',\n       'hepatically', 'hepatis', 'hepatitis', 'hepato', 'hepatobiliary',\n       'hepatocanalicular', 'hepatocellular', 'hepatocytes',\n       'hepatolithiasis', 'hepatomegaly', 'hepatopathy',\n       'hepatosplenomegaly', 'hepatotoxic', 'hepatotoxicity',\n       'hepatoxicity', 'her', 'her2', 'herald', 'herbal', 'herbicides',\n       'here', 'hereby', 'hereditary', 'herein', 'heretofore',\n       'herniation', 'heroin', 'herpes', 'herpesvirus', 'herpetic',\n       'herpetiform', 'herpetiformis', 'herself', 'herxheimer',\n       'heterogeneity', 'heterogeneous', 'heterogenous', 'heterotopias',\n       'heterotopic', 'heterozygous', 'hexacetonide', 'hexane',\n       'hexoprenaline', 'hfn', 'hg', 'hgb', 'hgbs', 'hhv', 'hhv8',\n       'hiccupping', 'hiccups', 'hickman', 'hickmans', 'hidden',\n       'hidradenitis', 'high', 'higher', 'highest', 'highlight',\n       'highlighted', 'highlights', 'highly', 'hilar', 'him', 'himself',\n       'hind', 'hip', 'hipa', 'hippocampus', 'hips', 'his', 'histamine',\n       'histiocytes', 'histiocytic', 'histiocytoma', 'histogenesis',\n       'histologic', 'histological', 'histologically', 'histology',\n       'histolytica', 'histopathologic', 'histopathological',\n       'histopathologically', 'histopathology', 'histoplasma',\n       'histoplasmosis', 'historic', 'historical', 'historically',\n       'histories', 'history', 'hit', 'hitchcock', 'hitherto', 'hitts',\n       'hiv', 'hives', 'hla', 'hlh', 'hmsn', 'hncp', 'hncps', 'hodgkin',\n       'holter', 'home', 'homeostasis', 'hominis', 'homochlorcyclizine',\n       'homocysteine', 'homolog', 'homonymous', 'homosexual',\n       'homozygous', 'honeycombing', 'hong', 'hopa', 'hopantenate',\n       'hoped', 'hormonal', 'hormone', 'hormones', 'horn', 'horner',\n       'horrified', 'horses', 'hospital', 'hospitalization',\n       'hospitalizations', 'hospitalized', 'hospitals', 'host', 'hosts',\n       'hot', 'hour', 'hourly', 'hours', 'house', 'how', 'however',\n       'hpct', 'hpcts', 'hps', 'hpth', 'hr', 'hrct', 'hrg', 'hrs', 'hs',\n       'hsct', 'hsos', 'ht', 'ht2a', 'ht2c', 'ht4', 'hu', 'huge', 'human',\n       'humans', 'humeral', 'humor', 'humoral', 'hunter', 'hurler', 'hus',\n       'huttenlocher', 'hvf', 'hvod', 'hyaloid', 'hyaluronate',\n       'hyaluronic', 'hybrid', 'hybridization', 'hycanthone', 'hydatid',\n       'hydrate', 'hydration', 'hydroacy', 'hydrocarbon', 'hydrocephalus',\n       'hydrochloride', 'hydrochlorothiazide', 'hydrocloride',\n       'hydrocortisone', 'hydrogen', 'hydrolase', 'hydrops',\n       'hydroquinone', 'hydrotelluric', 'hydroxide', 'hydroxocobalamin',\n       'hydroxybutyrate', 'hydroxychloroquine', 'hydroxylapatite',\n       'hydroxylase', 'hydroxymethylglutaryl', 'hydroxytryptamine',\n       'hydroxyurea', 'hydroxyvitain', 'hydroxyzine', 'hygiene',\n       'hymenoptera', 'hyper', 'hyperactivity', 'hyperacute',\n       'hyperadrenergic', 'hyperalgesia', 'hyperalimentation',\n       'hyperammonemia', 'hyperandrogenism', 'hyperbaric',\n       'hypercalcemia', 'hypercalciuria', 'hypercellularity',\n       'hyperchloremic', 'hypercholesterolemia', 'hypercholestrerolaemic',\n       'hypercoagulability', 'hypercoagulable', 'hypercoagulopathy',\n       'hypercontractility', 'hypercortisolism', 'hypercytokinemia',\n       'hyperemia', 'hypereosinophilia', 'hyperexcitability',\n       'hyperextension', 'hyperferritinemia', 'hyperfractionated',\n       'hypergammaglobulinemia', 'hyperglycaemia', 'hyperglycemia',\n       'hyperglycemic', 'hypergranulosis', 'hyperhidrosis',\n       'hyperinfection', 'hyperinsulinaemia', 'hyperintense',\n       'hyperkalaemia', 'hyperkalaemic', 'hyperkalemia', 'hyperkalemic',\n       'hyperkeratosis', 'hyperkeratotic', 'hyperkinesias',\n       'hyperlactatemia', 'hyperleukocytosis', 'hyperlipidemia',\n       'hypermagnesemia', 'hypernatraemia', 'hypernatremia',\n       'hyperosmolar', 'hyperparathyroidism', 'hyperphenylalaninemia',\n       'hyperphosphataemia', 'hyperphosphatemia', 'hyperpigmentation',\n       'hyperpigmented', 'hyperplasia', 'hyperplasias', 'hyperpnea',\n       'hyperpolarizing', 'hyperproduction', 'hyperpyrexia',\n       'hyperrecruitment', 'hyperreflexia', 'hyperresponsive',\n       'hypersalivation', 'hypersecretion', 'hypersensitive',\n       'hypersensitivity', 'hypersexual', 'hyperstimulation',\n       'hypertension', 'hypertensive', 'hyperthermia', 'hyperthermic',\n       'hyperthryroidism', 'hyperthyroidism', 'hypertonia', 'hypertonic',\n       'hypertrichosis', 'hypertriglyceridaemia', 'hypertriglyceridemia',\n       'hypertrophic', 'hypertrophy', 'hyperuricemia', 'hyperventilation',\n       'hyphae', 'hyphema', 'hyphemas', 'hypnotic', 'hypo',\n       'hypoadrenalism', 'hypoalbuminaemia', 'hypoalbuminemia',\n       'hypocalcaemia', 'hypocalcemia', 'hypocalcemic',\n       'hypocontractility', 'hypofluorescence', 'hypofunctional',\n       'hypogammaglobulinemia', 'hypoglycaemia', 'hypoglycaemic',\n       'hypoglycemia', 'hypoglycemic', 'hypokalaemia', 'hypokalemia',\n       'hypokalemic', 'hypomagnesemia', 'hypomanic', 'hypomethylation',\n       'hyponatraemia', 'hyponatremia', 'hyponatremic', 'hypoosmolality',\n       'hypoparathyroidism', 'hypoperfused', 'hypoperfusion',\n       'hypopharynx', 'hypophosphatemia', 'hypophosphatemic',\n       'hypophysectomy', 'hypopituitarism', 'hypoplasia', 'hypoplastic',\n       'hypotension', 'hypotensive', 'hypothalamic', 'hypothermia',\n       'hypotheses', 'hypothesis', 'hypothesize', 'hypothesized',\n       'hypothyroid', 'hypothyroidism', 'hypotonia', 'hypotonic',\n       'hypouricemia', 'hypovolaemia', 'hypoxaemiant', 'hypoxemia',\n       'hypoxia', 'hysteresis', 'hysterosalpingograms', 'ia', 'ian',\n       'iat', 'iatrogenic', 'iatrogenically', 'ib', 'ibd', 'ibopamine',\n       'ibuprofen', 'ibzm', 'ic', 'icd', 'icds', 'icg', 'ichthyosis',\n       'icp', 'icsi', 'ictal', 'icteric', 'icterus', 'icu', 'idarubicin',\n       'iddm', 'ideal', 'ideally', 'ideas', 'idential', 'identical',\n       'identifiable', 'identification', 'identified', 'identifies',\n       'identify', 'identifying', 'idiopathic', 'idiopathically',\n       'idiosynactic', 'idiosyncratic', 'ie', 'if', 'ifn', 'ifnalpha',\n       'ifosfamide', 'ig', 'iga', 'ige', 'igf', 'igg', 'igg1', 'igiv',\n       'iha', 'ihc', 'ii', 'iib', 'iii', 'iiia', 'iir', 'il', 'ild',\n       'ilds', 'ile', 'ileal', 'ileocecal', 'iletin', 'ileum', 'ileus',\n       'iliac', 'iliocaval', 'ill', 'illicitly', 'illness', 'illnesses',\n       'illustrate', 'illustrated', 'illustrates', 'illustrating', 'im',\n       'image', 'images', 'imaging', 'imatinib', 'imbalance', 'imbibers',\n       'imidazoline', 'imipenem', 'imipramine', 'imiquimod', 'immediate',\n       'immediately', 'immersion', 'imminent', 'immobilization', 'immune',\n       'immunemediated', 'immunisation', 'immunity', 'immuno',\n       'immunoallergic', 'immunoassay', 'immunoblastic', 'immunoblasts',\n       'immunoblots', 'immunocompetent', 'immunocompromise',\n       'immunocompromised', 'immunodeficiency', 'immunodepressed',\n       'immunoelectron', 'immunofluorescence', 'immunofluorescent',\n       'immunoglobulin', 'immunoglobulins', 'immunohistochemical',\n       'immunohistochemistry', 'immunologic', 'immunological',\n       'immunologically', 'immunomodulating', 'immunomodulatory',\n       'immunopathogenesis', 'immunophenotyping', 'immunoreactive',\n       'immunoreconstitution', 'immunoregulation', 'immunosuppressant',\n       'immunosuppressants', 'immunosuppressed', 'immunosuppression',\n       'immunosuppressive', 'immunotherapy', 'impact', 'impaction',\n       'impair', 'impaired', 'impairing', 'impairment', 'impairments',\n       'impeded', 'impending', 'imperative', 'impetus', 'impingement',\n       'implant', 'implantable', 'implantation', 'implanted',\n       'implantology', 'implementation', 'implicate', 'implicated',\n       'implicates', 'implications', 'implies', 'importance', 'important',\n       'importantly', 'impossible', 'impregnated', 'impressive',\n       'improper', 'improve', 'improved', 'improvement', 'improvements',\n       'improves', 'improving', 'in', 'inability', 'inactivation',\n       'inactive', 'inadequate', 'inadvertent', 'inadvertently',\n       'inapparent', 'inappropriate', 'incapacitating', 'incessant',\n       'incidence', 'incident', 'incision', 'incisions', 'incite',\n       'include', 'included', 'includes', 'including', 'inclusion',\n       'incognito', 'incompatible', 'incomplete', 'inconclusive',\n       'incongruent', 'inconsistent', 'incontinence', 'incoordination',\n       'incorporate', 'incorporated', 'incorporation', 'incorrect',\n       'increase', 'increased', 'increases', 'increasing', 'increasingly',\n       'increlex', 'increments', 'incriminated', 'incurred', 'indapamide',\n       'indeed', 'independent', 'independently', 'index', 'indian',\n       'indicate', 'indicated', 'indicates', 'indicating', 'indication',\n       'indications', 'indicative', 'indicator', 'indices', 'indigent',\n       'indinavir', 'indirect', 'indisputably', 'indistinguishable',\n       'individual', 'individuals', 'indocyanine', 'indolent',\n       'indologenes', 'indometacin', 'indomethacin', 'induce', 'induced',\n       'inducer', 'inducers', 'induces', 'inducible', 'inducing',\n       'induction', 'indurated', 'industrial', 'indwelling',\n       'ineffective', 'inefficacious', 'inexpensive', 'infancy', 'infant',\n       'infantile', 'infants', 'infantum', 'infarct', 'infarcted',\n       'infarction', 'infarctions', 'infarcts', 'infecction', 'infected',\n       'infection', 'infections', 'infectious', 'inferior', 'infertile',\n       'infestation', 'infiltrate', 'infiltrates', 'infiltration',\n       'infiltrations', 'infiltrative', 'inflammation', 'inflammatory',\n       'infliximab', 'inflow', 'influence', 'influencing', 'influenza',\n       'information', 'informations', 'informed', 'infrequent',\n       'infrequently', 'infundibulum', 'infusaid', 'infused', 'infusion',\n       'infusional', 'infusions', 'infva', 'ingested', 'ingesting',\n       'ingestion', 'ingestions', 'ingredient', 'inguinal', 'inh',\n       'inhalation', 'inhalational', 'inhaled', 'inhaler', 'inhalers',\n       'inherited', 'inhibit', 'inhibited', 'inhibiting', 'inhibition',\n       'inhibitor', 'inhibitors', 'inhibitory', 'inhibits',\n       'inhomogeneity', 'initial', 'initially', 'initiate', 'initiated',\n       'initiating', 'initiation', 'initiative', 'injected', 'injecting',\n       'injection', 'injections', 'injector', 'injudiciously', 'injure',\n       'injured', 'injuries', 'injurious', 'injury', 'innate', 'inner',\n       'innocuous', 'innovative', 'inoperable', 'inorganic', 'inotropic',\n       'inpatient', 'inpatients', 'inr', 'inrs', 'insemination',\n       'insensitivity', 'insertion', 'insidious', 'insight', 'insipidus',\n       'insomnia', 'insomniac', 'inspiratory', 'inspite', 'instability',\n       'installation', 'instance', 'instances', 'instantly', 'instead',\n       'instill', 'instillation', 'instillations', 'institute',\n       'instituted', 'institution', 'institutional', 'instructed',\n       'instructions', 'instrument', 'instrumentation', 'instrumented',\n       'insufficiency', 'insufficient', 'insulin', 'insulins', 'insult',\n       'intact', 'intake', 'integral', 'integrating', 'integrin',\n       'intellect', 'intend', 'intended', 'intense', 'intensified',\n       'intensity', 'intensive', 'intensively', 'intent', 'intentional',\n       'inter', 'interact', 'interaction', 'interactions', 'interacts',\n       'interbody', 'intercellular', 'intercerebral', 'intercostal',\n       'interdisciplinary', 'interest', 'interesting', 'interestingly',\n       'interface', 'interfere', 'interfered', 'interference',\n       'interfering', 'interferon', 'interferons', 'interictal',\n       'interior', 'interlamellar', 'interleukin', 'interlobular',\n       'intermedia', 'intermediate', 'intermittent', 'intermittently',\n       'internal', 'international', 'interpret', 'interpretation',\n       'interpreted', 'interpreting', 'interrelationship',\n       'interrogation', 'interrupt', 'interrupted', 'interruption',\n       'interstices', 'interstitial', 'interstitium', 'intertriginous',\n       'intertrigo', 'interval', 'intervals', 'intervention',\n       'interventional', 'interventions', 'intestinal', 'intestinalis',\n       'intestine', 'intestines', 'intima', 'into', 'intolerable',\n       'intolerance', 'intoxication', 'intoxications', 'intra',\n       'intraarterial', 'intraarticular', 'intraatrial', 'intrabiliary',\n       'intracameral', 'intracardiac', 'intracavernous', 'intracellular',\n       'intracellulare', 'intracerebral', 'intracorneal', 'intracoronary',\n       'intracortical', 'intracranial', 'intractable', 'intradermal',\n       'intradiscal', 'intradural', 'intraepidermal', 'intraepithelial',\n       'intrahepatic', 'intralesional', 'intramural', 'intramuscular',\n       'intramuscularly', 'intranasal', 'intranuclear', 'intraocular',\n       'intraoperative', 'intraoral', 'intraorbital', 'intraparenchymal',\n       'intrapericardial', 'intraperitoneal', 'intrathecal',\n       'intrathecally', 'intrathoracic', 'intratubal', 'intratumoral',\n       'intrauterine', 'intravaginal', 'intravascular', 'intravenous',\n       'intravenously', 'intraventricular', 'intravesical',\n       'intravitreal', 'intravitreally', 'intravitreous', 'intrinsically',\n       'introduce', 'introduced', 'introduction', 'intrusive',\n       'intubated', 'intubation', 'invagination', 'invasion', 'invasive',\n       'inverse', 'inversion', 'investigate', 'investigated',\n       'investigation', 'investigations', 'investigators', 'invoking',\n       'involuntary', 'involution', 'involve', 'involved', 'involvement',\n       'involves', 'involving', 'inwardly', 'iodine', 'iol', 'ion',\n       'iontophoresis', 'iop', 'iothalamate', 'ipaa', 'iph', 'ipilimumab',\n       'ipsilateral', 'iraes', 'irbesartan', 'irinotecan', 'iris', 'iron',\n       'irradiated', 'irradiation', 'irregularities', 'irresectable',\n       'irrespective', 'irreversible', 'irreversibly', 'irrigation',\n       'irrigations', 'irritability', 'irritant', 'irritants',\n       'irritating', 'irritation', 'irritative', 'irvine', 'is',\n       'ischaemia', 'ischaemic', 'ischemia', 'ischemic', 'islet',\n       'isoelectric', 'isoenzyme', 'isoenzymes', 'isolate', 'isolated',\n       'isolates', 'isolation', 'isomer', 'isoniazid', 'isoproterenol',\n       'isosorbide', 'isotonic', 'isotretinoin', 'isozyme', 'isradipine',\n       'issue', 'issued', 'issues', 'it', 'itb', 'itch', 'itching', 'itp',\n       'itraconazole', 'its', 'itself', 'iu', 'iud', 'ius', 'iv', 'iva',\n       'ivb', 'ivc', 'ivermectin', 'ivf', 'ivig', 'ivpmp', 'ivs12nt1g',\n       'ivta', 'ixodes', 'jakob', 'january', 'japan', 'japanese',\n       'jarisch', 'jaundice', 'jaundiced', 'jaw', 'jehovah', 'jejunal',\n       'jejunitis', 'jejunum', 'jerks', 'jet', 'jewellery', 'jewish',\n       'jh', 'jhr', 'jiroveci', 'jitteriness', 'jk', 'john', 'johnson',\n       'joint', 'joints', 'joubert', 'joules', 'journals', 'jpn', 'jra',\n       'judged', 'judicious', 'jugular', 'july', 'junction', 'junctional',\n       'june', 'just', 'justice', 'justified', 'juvenile', 'juveniles',\n       'k1', 'k2', 'kala', 'kalimate', 'kampala', 'kansasii', 'kaposi',\n       'kappa', 'karyotype', 'karyotypic', 'kayexalate', 'kda', 'keep',\n       'keeping', 'keeshond', 'keloids', 'kennedy', 'kept', 'keratectomy',\n       'keratinization', 'keratitis', 'keratoacanthoma',\n       'keratoacanthomas', 'keratoderma', 'keratometry', 'keratomileusis',\n       'keratopathy', 'keratoplasty', 'ketamine', 'ketanserin',\n       'ketoacidosis', 'ketoacidotic', 'ketoconazole', 'ketone',\n       'ketonuria', 'ketoralac', 'ketorolac', 'ketosteroid', 'key',\n       'keys', 'kg', 'khz', 'ki', 'ki67', 'kidney', 'kidneys', 'killed',\n       'killing', 'kilogram', 'kinase', 'kinases', 'kind', 'kindred',\n       'kinetic', 'kinetics', 'kink', 'kiu', 'klebsiella', 'kleine',\n       'kluver', 'kluyvera', 'knee', 'knees', 'know', 'knowledge',\n       'knowledgeable', 'known', 'kogoj', 'kong', 'koyanagi', 'kpro',\n       'ks', 'kw', 'l5', 'la', 'lab', 'labaz', 'labd', 'label', 'labeled',\n       'labeling', 'labelled', 'labelling', 'labetalol', 'labia',\n       'labial', 'labor', 'laboratories', 'laboratory', 'labour', 'lack',\n       'lacking', 'lacosamide', 'lacrimal', 'lactam', 'lactamase',\n       'lactate', 'lactating', 'lactic', 'lactobacillus', 'lactogenesis',\n       'lad', 'laden', 'lady', 'lagophthalmos', 'lam', 'lambda',\n       'lambert', 'lamellar', 'lamina', 'lamivudine', 'lamotrigine',\n       'lamp', 'lamprene', 'language', 'lansoprazole', 'laparascopy',\n       'laparoscopic', 'laparoscopies', 'laparotomies', 'laparotomy',\n       'lapse', 'lar', 'large', 'largely', 'larger', 'larval',\n       'laryngeal', 'lasek', 'laser', 'lash', 'lasik', 'last', 'lasted',\n       'lasting', 'latanoprost', 'late', 'latency', 'latent', 'later',\n       'lateral', 'latest', 'latex', 'latinos', 'latter', 'lavage',\n       'laxative', 'layer', 'layers', 'lazarus', 'lca', 'ldlt', 'le',\n       'lead', 'leading', 'leads', 'leaflet', 'leak', 'leakage',\n       'learning', 'least', 'led', 'leflunomide', 'left', 'leg',\n       'legislation', 'legislative', 'legs', 'leiomyosarcoma',\n       'leishmania', 'leishmaniasis', 'lems', 'lenalidomide', 'lend',\n       'lends', 'length', 'lennox', 'lens', 'lenses', 'leo', 'leopard',\n       'lepirudin', 'leprechaunism', 'lepromatous', 'leprosum', 'leprosy',\n       'leptomeningeal', 'lesion', 'lesional', 'lesions', 'less',\n       'lessen', 'lesser', 'lethal', 'lethargic', 'lethargy', 'letters',\n       'letting', 'leucocytoclastic', 'leucocytopenia', 'leucocytosis',\n       'leuconostoc', 'leucopenia', 'leucovorin', 'leukaemia',\n       'leukaemic', 'leukaemoid', 'leukemia', 'leukemic', 'leukemogenic',\n       'leuko', 'leukocyte', 'leukocytes', 'leukocytoclastic',\n       'leukocytopenia', 'leukocytosis', 'leukoencephalopathy',\n       'leukopenia', 'leukoplakia', 'leukostasis', 'leukotriene',\n       'leukovorin', 'leuprolide', 'leuprorelin', 'levamisole', 'level',\n       'levels', 'levemepromazine', 'levetiracetam', 'levin', 'levo',\n       'levodopa', 'levofloxacin', 'levomepromazine', 'levonorgestrel',\n       'levothyroxine', 'lewy', 'lfts', 'lh', 'liberal', 'liberation',\n       'libido', 'libraries', 'library', 'licensed', 'lichen',\n       'lichenoid', 'licorice', 'lid', 'lidocaine', 'lids', 'lieu',\n       'life', 'lifesciences', 'lifestyle', 'lift', 'ligament', 'light',\n       'lightheadedness', 'like', 'likelihood', 'likely', 'likewise',\n       'limb', 'limbs', 'limbus', 'limit', 'limitation', 'limitations',\n       'limited', 'limiting', 'limits', 'lindane', 'line', 'lineage',\n       'linear', 'lines', 'linezolid', 'linguo', 'link', 'linkage',\n       'linked', 'links', 'liothyronine', 'lip', 'lipase', 'lipid',\n       'lipids', 'lipoatrophies', 'lipoatrophy', 'lipodystrophy',\n       'lipohypertrophy', 'lipoid', 'lipophilic', 'lipoproteinemia',\n       'liposomal', 'lips', 'liquid', 'lisinopril', 'lispro', 'list',\n       'listeria', 'lists', 'liter', 'literature', 'lithium', 'little',\n       'live', 'lived', 'livedo', 'liver', 'lives', 'living', 'lmw',\n       'lmwh', 'lng', 'loa', 'load', 'loading', 'lobe', 'lobenzarit',\n       'local', 'localization', 'localized', 'localizing', 'locally',\n       'located', 'lock', 'locus', 'lodged', 'long', 'longer', 'longest',\n       'longitudinal', 'longstanding', 'longterm', 'look', 'looking',\n       'loop', 'loops', 'loose', 'loperamide', 'lopinavir', 'lorazepam',\n       'lorcainide', 'losartan', 'losing', 'loss', 'losses', 'lost',\n       'lot', 'lotion', 'lovastatin', 'low', 'lower', 'lowered',\n       'lowering', 'lowest', 'lp', 'lpd', 'lph', 'ls', 'lt', 'ltg',\n       'lubrication', 'lucent', 'lucite', 'lugdunensis', 'lumbago',\n       'lumbar', 'lumbosacral', 'luminal', 'lunata', 'lung', 'lungs',\n       'lunulae', 'luprolide', 'lupron', 'lupus', 'lupuslike',\n       'luteinizing', 'lying', 'lyme', 'lymph', 'lymphadenitis',\n       'lymphadenomegaly', 'lymphadenopathy', 'lymphatic', 'lymphedema',\n       'lympho', 'lymphoblastic', 'lymphoblastoid', 'lymphocyte',\n       'lymphocytes', 'lymphocytic', 'lymphocytopenia', 'lymphocytosis',\n       'lymphohistiocytic', 'lymphohistiocytosis', 'lymphoid', 'lymphoma',\n       'lymphomas', 'lymphomatoid', 'lymphomatous', 'lymphopenia',\n       'lymphoproliferative', 'lynestrenol', 'lysis', 'lysosomal', 'm2',\n       'm4', 'ma', 'mac', 'macroangiopathies', 'macrocirculatory',\n       'macrodantin', 'macrolide', 'macrolides', 'macronodular',\n       'macrophage', 'macrophages', 'macrophagic', 'macroprolactinoma',\n       'macroscopic', 'macula', 'maculae', 'macular', 'macule',\n       'maculopapular', 'maculopathy', 'made', 'magnesium', 'magnetic',\n       'magnetocardiography', 'magnitude', 'main', 'mainly', 'mainstay',\n       'maintain', 'maintained', 'maintaining', 'maintenance', 'majocchi',\n       'major', 'majority', 'make', 'makes', 'making', 'mal', 'mala',\n       'malacoplakia', 'maladaptive', 'malaise', 'malar', 'malaria',\n       'malarial', 'malathion', 'malaysian', 'male', 'maleate', 'males',\n       'malformation', 'malformations', 'malfunctioning', 'malignancies',\n       'malignancy', 'malignant', 'maltose', 'mammaplasty', 'mammary',\n       'man', 'manage', 'managed', 'management', 'managing', 'mand',\n       'mandated', 'mandatory', 'mandible', 'manent', 'mania', 'manic',\n       'manifest', 'manifestation', 'manifestations', 'manifested',\n       'manifesting', 'manipulation', 'manner', 'mannitol', 'manual',\n       'manufacture', 'manufacturer', 'manufacturers', 'many', 'mao',\n       'maoi', 'maps', 'maqianzi', 'marantic', 'marcescens', 'march',\n       'mare', 'marginal', 'marie', 'marijuana', 'marinum', 'marked',\n       'markedly', 'marker', 'markers', 'market', 'marketed', 'marketing',\n       'markets', 'married', 'marrow', 'masculinization', 'mask',\n       'masked', 'masquerading', 'mass', 'masses', 'massive', 'massively',\n       'mast', 'mastectomy', 'master', 'masticatory', 'mastisol',\n       'matched', 'material', 'materials', 'maternal', 'matter',\n       'maturation', 'mature', 'maxilla', 'maxillary', 'maxim', 'maximal',\n       'maximum', 'may', 'mb', 'mbl', 'mcc', 'mcd', 'mcg', 'mcns', 'mds',\n       'meager', 'mean', 'means', 'measurable', 'measured', 'measurement',\n       'measures', 'measuring', 'mebendazole', 'mecamylamine',\n       'mechanical', 'mechanism', 'mechanisms', 'mechanistic',\n       'mechanistically', 'meckel', 'med', 'media', 'medial', 'median',\n       'mediastinal', 'mediastinitis', 'mediastinum', 'mediate',\n       'mediated', 'mediates', 'medical', 'medically', 'medicamentosa',\n       'medicating', 'medication', 'medications', 'medicine', 'medicines',\n       'mediterranean', 'medium', 'medline', 'medrol',\n       'medroxyprogesterone', 'medulloblastoma', 'mefloquine', 'mefv',\n       'megakaryocyte', 'megaloblastic', 'megavoltage', 'meglitinides',\n       'meglumine', 'meibomian', 'melanin', 'melanoma', 'melanonychia',\n       'meleate', 'mellitus', 'meloxicam', 'melphalan', 'melting',\n       'member', 'members', 'membrane', 'membranes',\n       'membranoproliferative', 'membranous', 'memory', 'men', 'menarche',\n       'meningeal', 'meninges', 'meningioma', 'meningiomas', 'meningitis',\n       'menopausal', 'menorrhagia', 'menstrual', 'menstruating', 'mental',\n       'mentally', 'mention', 'mentioned', 'meperidine', 'meq',\n       'mequitazine', 'mercaptopurine', 'mercury', 'merely', 'merits',\n       'merkel', 'meropenem', 'mesalamine', 'mesalazine', 'mesangial',\n       'mesenchymal', 'mesenteric', 'meshwork', 'mesilate', 'mesodermal',\n       'mesothelioma', 'mesylate', 'met', 'met843', 'meta', 'metabolic',\n       'metabolism', 'metabolite', 'metabolites', 'metabolized',\n       'metabolizer', 'metabolizers', 'metachromatic', 'metallo',\n       'metalloprotein', 'metamizole', 'metaphase', 'metaplasia',\n       'metaraminol', 'metastases', 'metastasis', 'metastasized',\n       'metastastic', 'metastatic', 'metered', 'metformin', 'methadone',\n       'methamphetamine', 'methanol', 'methazolamide',\n       'methemoglobinemia', 'methicillin', 'methimazole', 'methionine',\n       'method', 'methodologically', 'methodologies', 'methods',\n       'methotrexate', 'methotrimeprazine', 'methoxsalen',\n       'methoxypsoralen', 'methyl', 'methylation', 'methyldopa',\n       'methylene', 'methylenedioxymet', 'methylephedrine',\n       'methylmalonyl', 'methylphenidate', 'methylprednisolon',\n       'methylprednisolone', 'methylpyrazole', 'methyltransferase',\n       'methysergide', 'metipranolol', 'metoclopramide', 'metopic',\n       'metoprolol', 'metripranolol', 'metronidazole', 'mexico', 'mf',\n       'mferg', 'mg', 'mgso4', 'mh', 'mhz', 'mi', 'miacalcic',\n       'mianserin', 'mibg', 'michaelis', 'michigan', 'miconazole',\n       'micro', 'microabscesses', 'microanalytical', 'microangiopathic',\n       'microangiopathy', 'microbial', 'microbiologic', 'microbiological',\n       'microcalcifications', 'microcirculation', 'microcirculatory',\n       'microdissection', 'microemulsion', 'microg', 'micrograms',\n       'microgranulations', 'micrographic', 'microl', 'microliters',\n       'micromol', 'microperforations', 'microscopic', 'microscopy',\n       'microsomal', 'microsomes', 'microspheres', 'microtubule',\n       'microvessels', 'micturition', 'mid', 'midazalam', 'midazolam',\n       'midbrain', 'middle', 'midface', 'midoesophagus', 'mif', 'might',\n       'migraine', 'migrainosus', 'migration', 'migratory', 'mild',\n       'milder', 'milia', 'milieu', 'military', 'milk', 'milky',\n       'milliliters', 'million', 'milnacipran', 'mimic', 'mimicked',\n       'mimicking', 'min', 'mind', 'mineral', 'mini', 'minimal',\n       'minimize', 'minimum', 'minisatellite', 'minocycline', 'minor',\n       'minority', 'minoxidil', 'minute', 'minutes', 'mio', 'miosis',\n       'miotic', 'mirtazapine', 'misadventure', 'misapplication',\n       'misconceptions', 'misdiagnosed', 'misinterpreted', 'mismatched',\n       'misperceptions', 'missed', 'missing', 'mistake', 'mistaken',\n       'mistakenly', 'misuse', 'mite', 'mites', 'mithramycin', 'mitigate',\n       'mitigated', 'mitochondria', 'mitochondrial', 'mitomycin',\n       'mitotic', 'mitoxantrone', 'mitral', 'mixed', 'mixture',\n       'mixtures', 'mizoribin', 'mj', 'mk', 'ml', 'mll', 'mm', 'mm3',\n       'mmc', 'mmf', 'mmhg', 'mmi', 'mmol', 'mms', 'mo', 'mobilisation',\n       'mobilised', 'mobilization', 'mobitz', 'moclobemide', 'modalities',\n       'mode', 'model', 'models', 'moderate', 'moderately', 'modern',\n       'modest', 'modestly', 'modifications', 'modified', 'modifiers',\n       'modifying', 'modulating', 'modulator', 'mof', 'mofetil', 'mohs',\n       'moiety', 'molar', 'molded', 'molecular', 'molipaxin', 'mollusca',\n       'monitor', 'monitored', 'monitoring', 'mono', 'monoamine',\n       'monoarthritis', 'monoblastic', 'monoclonal', 'monocular',\n       'monocytic', 'monocytogenes', 'monocytosis', 'monohydrochloride',\n       'monomorphic', 'mononeuritis', 'mononuclear', 'mononucleosis',\n       'monooctanoin', 'monophasic', 'monosomy', 'monotherapy',\n       'monotonous', 'monovalent', 'monoxide', 'monozygotic', 'monsel',\n       'montelukast', 'month', 'monthly', 'months', 'mood', 'mooren',\n       'mop', 'morbid', 'morbidity', 'morbilliform', 'more', 'moreau',\n       'moreover', 'morning', 'morphea', 'morphine', 'morphologic',\n       'morphological', 'morphology', 'mortal', 'mortality', 'mosaic',\n       'mosm', 'most', 'mostly', 'mother', 'mothers', 'motile',\n       'motility', 'motion', 'motor', 'motorically', 'mouth', 'movement',\n       'movements', 'moving', 'moxalactam', 'moxifloxacin', 'mp', 'mpgn',\n       'mpp', 'mr', 'mra', 'mrcc', 'mri', 'mrs', 'mrsa', 'ms', 'msec',\n       'mslt', 'mt', 'mtbstfa', 'mthfr', 'mtor', 'mtorc1', 'mtx', 'much',\n       'mucinosis', 'mucociliary', 'mucocutaneous', 'mucoides',\n       'mucopurulent', 'mucosa', 'mucosae', 'mucosal', 'mucositis',\n       'mucous', 'muddy', 'mukul', 'mul', 'mullerian', 'multi',\n       'multiagent', 'multicentric', 'multiceps', 'multicycle',\n       'multidisciplinary', 'multifactorial', 'multifocal', 'multiform',\n       'multiforme', 'multihormonal', 'multimeric', 'multinodular',\n       'multiorgan', 'multiphasic', 'multiple', 'multiplex',\n       'multisystemic', 'multitargeted', 'multitrauma', 'multivessel',\n       'multivitamin', 'mumbai', 'munich', 'municipal', 'munro', 'murmur',\n       'muscarinic', 'muscle', 'muscles', 'muscular', 'musculature',\n       'musculoskeletal', 'must', 'mustard', 'mutagenic', 'mutant',\n       'mutation', 'mutations', 'mutilating', 'mutism', 'muzolimine',\n       'mvi', 'mxa', 'my', 'myalgia', 'myalgias', 'myasthenia',\n       'myasthenic', 'mycetoma', 'mycobacteria', 'mycobacterial',\n       'mycobacterium', 'mycologic', 'mycophenolate', 'mycoplasma',\n       'mycosis', 'mycotic', 'mydriasis', 'myelin', 'myelinolysis',\n       'myelinopathy', 'myelitis', 'myelo', 'myeloablative',\n       'myeloblastic', 'myelocytic', 'myelodysplasia', 'myelodysplastic',\n       'myelogenous', 'myelography', 'myeloid', 'myeloma',\n       'myelomonoblastic', 'myelomonocytic', 'myelopathy',\n       'myeloperoxidase', 'myeloproliferative', 'myelosclerosis',\n       'myelosuppression', 'myelotoxic', 'myelotoxicity', 'myocardial',\n       'myocarditis', 'myocloni', 'myoclonic', 'myoclonus', 'myocyte',\n       'myoglobin', 'myoglobinuria', 'myometrial', 'myonecrosis',\n       'myopathic', 'myopathy', 'myopericarditis', 'myopia', 'myopic',\n       'myosin', 'myositis', 'myotonia', 'myotonic', 'myxopapillary',\n       'n4', 'na', 'nabumetone', 'nadir', 'nafcillin', 'nail',\n       'nailplate', 'nails', 'nalbuphine', 'naloxone', 'naltrexone',\n       'named', 'naproxen', 'naranjo', 'narcolepsy', 'narcosis',\n       'narcotic', 'narcotics', 'narrow', 'narrowing', 'nasal', 'nash',\n       'nasogastric', 'nasolacrimal', 'nasopharyngeal', 'nasopharynx',\n       'nat2', 'natalizumab', 'national', 'native', 'natriuresis',\n       'natriuretic', 'nattermann', 'natural', 'naturally', 'nature',\n       'nausea', 'nbd', 'nc', 'ncph', 'ncse', 'ncvc', 'ndi', 'ne', 'near',\n       'nebulised', 'nebulization', 'nebulized', 'nebulizer', 'necessary',\n       'necessitate', 'necessitated', 'necessitates', 'necessitating',\n       'necessity', 'neck', 'necro', 'necrolysis', 'necropsy', 'necrosis',\n       'necrotic', 'necrotising', 'necrotizing', 'nedaplatin', 'need',\n       'needed', 'needle', 'needless', 'needs', 'nefazodone', 'negative',\n       'neglect', 'negligible', 'neh', 'neisseria', 'neither',\n       'nelfinavir', 'neoadjuvant', 'neodymium', 'neoformans', 'neonatal',\n       'neonate', 'neonates', 'neonatology', 'neoplasia', 'neoplasm',\n       'neoplasms', 'neoplastic', 'neostigmine', 'neothetazone',\n       'neovascularization', 'nephrectomy', 'nephritic', 'nephritis',\n       'nephrogenic', 'nephrolithiasis', 'nephropathy', 'nephrosis',\n       'nephrostomy', 'nephrotic', 'nephrotoxic', 'nephrotoxicity',\n       'nerve', 'nerves', 'nervous', 'nesiritide', 'net', 'netherlands',\n       'network', 'networks', 'neubulized', 'neural', 'neuralgia',\n       'neuralgic', 'neuraxial', 'neurilemmoma', 'neuritis',\n       'neuroblastoma', 'neurocysticercosis', 'neurodevelopmental',\n       'neuroendocrine', 'neurogenic', 'neuroglial', 'neurointensive',\n       'neurol', 'neuroleptic', 'neuroleptica', 'neuroleptics',\n       'neurologic', 'neurological', 'neurolysis', 'neurometabolic',\n       'neuromuscular', 'neuromyeloencephalopathy', 'neuron', 'neuronal',\n       'neurons', 'neuropathic', 'neuropathies', 'neuropathologic',\n       'neuropathological', 'neuropathologically', 'neuropathy',\n       'neuropharmacologic', 'neurophysiological', 'neuropsychiatric',\n       'neuropsychological', 'neuroretinitis', 'neurosyphilis',\n       'neurotic', 'neurotoxic', 'neurotoxicities', 'neurotoxicity',\n       'neurotoxin', 'neurotransmission', 'neurovascular', 'neutral',\n       'neutropenia', 'neutropenic', 'neutrophil', 'neutrophilia',\n       'neutrophilic', 'neutrophils', 'never', 'nevertheless',\n       'nevirapine', 'new', 'newborn', 'newborns', 'newer', 'newly',\n       'next', 'ng', 'nh', 'nhl', 'niacin', 'nic', 'nicotinic', 'niemann',\n       'nifedipine', 'niflumic', 'nifuroxime', 'nigerian', 'night',\n       'nighttime', 'nigra', 'nilotinib', 'nimesulide', 'nimodipine',\n       'nine', 'nineteen', 'nineteenth', 'ninth', 'nis', 'nisshin',\n       'nitidus', 'nitrate', 'nitrates', 'nitre', 'nitrendipine',\n       'nitrite', 'nitrites', 'nitritoid', 'nitrobenzofurazan',\n       'nitrofurantoin', 'nitrogen', 'nitroglycerin', 'nitrosourea',\n       'nitrous', 'nj', 'nm', 'nmda', 'nmo', 'nms', 'no', 'nocardia',\n       'nocardial', 'nocardiosis', 'nocere', 'nocturia', 'nocturnal',\n       'nodal', 'node', 'nodes', 'nodosa', 'nodosum', 'nodular', 'nodule',\n       'nodules', 'nodulosis', 'non', 'nonalcoholic', 'nonallergic',\n       'nonatopic', 'nonbenzodiazepine', 'noncardiogenic', 'noncirrhotic',\n       'noncompliance', 'noncompliant', 'nonconvulsive', 'nondetectable',\n       'nondiabetic', 'nondominant', 'nondural', 'none', 'nonexcisional',\n       'nonfunctional', 'nonhalogenated', 'nonhealing', 'nonhodgkin',\n       'noninvasive', 'nonketotic', 'nonmalignant', 'nonmethicillin',\n       'nonnucleoside', 'nonnutrient', 'nonoliguric', 'nonpenetrating',\n       'nonpigmenting', 'nonproductive', 'nonrandom', 'nonrapid',\n       'nonrhegmatogenous', 'nonselective', 'nonspecific', 'nonsteroidal',\n       'nonsurgical', 'nonsustained', 'nonthrombocytopenic', 'nontoothed',\n       'nonuse', 'nor', 'noradrenaline', 'noradrenergic', 'norcardia',\n       'norepinephrine', 'norethisterone', 'norfluoxetine', 'normal',\n       'normalisation', 'normalised', 'normalization', 'normalize',\n       'normalized', 'normally', 'normeperidine', 'normocellular',\n       'normokalemic', 'normotensive', 'normotensives', 'normovolemia',\n       'norpace', 'north', 'nortriptyline', 'norway', 'nose', 'not',\n       'notably', 'note', 'noted', 'noticed', 'notion', 'nourished',\n       'novel', 'november', 'novo', 'now', 'npd', 'nph', 'nrem', 'ns',\n       'nsaid', 'nsaids', 'nsc', 'nsclc', 'nsf', 'nste', 'ntx', 'nuchal',\n       'nuclear', 'nucleoside', 'nucleotide', 'nucleus', 'number',\n       'numbers', 'numbness', 'numerous', 'nursery', 'nurses', 'nursing',\n       'nutley', 'nutramigen', 'nutrition', 'nutritional', 'nyha',\n       'nystagmus', 'nystatin', 'nz', 'oak', 'obese', 'obesity',\n       'obidoxime', 'objective', 'objectives', 'obligations',\n       'obligatory', 'obliterans', 'obscure', 'obscured', 'observable',\n       'observation', 'observations', 'observe', 'observed',\n       'obsessional', 'obsessive', 'obstetrical', 'obstruction',\n       'obstructive', 'obtain', 'obtained', 'obtundation', 'obviate',\n       'obviating', 'obvious', 'occasion', 'occasional', 'occasionally',\n       'occasions', 'occipital', 'occlude', 'occlusion', 'occlusive',\n       'occult', 'occupancy', 'occupational', 'occupied', 'occupying',\n       'occur', 'occured', 'occuring', 'occurred', 'occurrence',\n       'occurrences', 'occurring', 'occurs', 'ocd', 'ochraceum', 'ocs',\n       'oct', 'octanoin', 'october', 'octreotide', 'ocular',\n       'oculobulbar', 'oculocardiac', 'oculography', 'oculogyric',\n       'oculomotor', 'oculoplastics', 'od', 'oddi', 'oddly', 'oedema',\n       'oedematous', 'oesophageal', 'oesophagoscopy', 'oesophagus',\n       'oestrogen', 'oestrogenic', 'of', 'off', 'offender', 'offending',\n       'offer', 'offered', 'offers', 'offspring', 'ofloxacin', 'often',\n       'ogc', 'oh', 'oh2', 'ohss', 'oil', 'oily', 'ointment', 'okt3',\n       'olanzapine', 'old', 'oleate', 'oleic', 'olfactory',\n       'oligodactyly', 'oligohidrosis', 'oliguria', 'oliguric', 'olp',\n       'omega', 'omental', 'omentectomy', 'omeprazole', 'omitted', 'on',\n       'onboard', 'once', 'oncol', 'oncologic', 'oncologists', 'oncology',\n       'one', 'ongoing', 'onj', 'only', 'ono', 'onset', 'onycholysis',\n       'onychomycosis', 'onychoschizia', 'oolong', 'oophorectomy',\n       'opacities', 'opacity', 'open', 'operated', 'operating',\n       'operation', 'operations', 'operative', 'operatively',\n       'ophthalmic', 'ophthalmicus', 'ophthalmol', 'ophthalmologic',\n       'ophthalmological', 'ophthalmologically', 'ophthalmologists',\n       'ophthalmology', 'ophthalmopathy', 'opiate', 'opioid', 'opioids',\n       'opisthotonus', 'opium', 'opportunistic', 'opportunity', 'optic',\n       'optical', 'optics', 'optimal', 'optimizing', 'optimum', 'option',\n       'options', 'optometrist', 'optometrists', 'or', 'oral', 'orally',\n       'orbit', 'orbital', 'order', 'orders', 'ordinately', 'org',\n       'organ', 'organic', 'organised', 'organism', 'organisms',\n       'organization', 'organized', 'organizing', 'organophosphate',\n       'organs', 'orgaran', 'orgasm', 'orientation', 'orifices', 'origin',\n       'original', 'originally', 'originate', 'originating', 'ornamental',\n       'oro', 'orofacial', 'orogastric', 'orthodromic', 'orthopaedic',\n       'orthopedic', 'orthopnea', 'orthostasis', 'orthostatic',\n       'orthotopic', 'os', 'oscillopsia', 'oseltamivir', 'oseophageal',\n       'osmolality', 'osmotic', 'osseous', 'ossicular', 'osteoarthritis',\n       'osteogenic', 'osteoid', 'osteomalacia', 'osteomuscular',\n       'osteomyelitis', 'osteonecrosis', 'osteonecrotic', 'osteopetrosis',\n       'osteoporosis', 'osteosarcoma', 'ostial', 'ostium', 'ot', 'other',\n       'others', 'otherwise', 'otitis', 'otologic', 'ototoxicity',\n       'ouabain', 'ounces', 'our', 'out', 'outbursts', 'outcome',\n       'outcomes', 'outer', 'outflow', 'outlet', 'outlined', 'outlines',\n       'outpatient', 'outpatients', 'output', 'outside', 'outstanding',\n       'oval', 'ovarian', 'ovaries', 'ovary', 'over', 'overall',\n       'overanticoagulation', 'overcome', 'overdosage', 'overdose',\n       'overdosed', 'overdoses', 'overdosing', 'overfilling',\n       'overgrowth', 'overhang', 'overhanging', 'overkill', 'overlap',\n       'overlapped', 'overlapping', 'overload', 'overloading',\n       'overlooked', 'overlying', 'overnight', 'overt', 'overuse',\n       'overusing', 'overview', 'overwhelming', 'ovulation', 'owing',\n       'own', 'oxacillin', 'oxalacetic', 'oxaliplatin', 'oxaliplatinum',\n       'oxaprozin', 'oxc', 'oxcarbazepine', 'oxidants', 'oxidase',\n       'oxidation', 'oxidative', 'oxide', 'oxpentifylline', 'oxybutynin',\n       'oxygen', 'oxygenase', 'oxymetalzoline', 'oxymetazoline',\n       'oxymetholone', 'p11', 'p12', 'p13', 'p36', 'p450', 'p450s', 'pa',\n       'pachymetry', 'pacing', 'package', 'packed', 'paclitaxel',\n       'paediatr', 'paediatric', 'paget', 'pah', 'paid', 'pain',\n       'painful', 'painless', 'paint', 'painter', 'pair', 'paired',\n       'palatal', 'palate', 'pale', 'palliation', 'palliative',\n       'pallidus', 'pallor', 'palm', 'palmar', 'palmitate',\n       'palmoplantar', 'palms', 'palpable', 'palpitations', 'palsy',\n       'pamidronate', 'pan', 'pancreas', 'pancrease', 'pancreatic',\n       'pancreaticoduodenal', 'pancreatin', 'pancreatitis',\n       'pancreatotoxic', 'pancreatotoxicity', 'pancytopenia', 'panel',\n       'panhypogammaglobulinaemia', 'panic', 'panniculitis',\n       'panreactive', 'pantoprazole', 'pantothenic', 'panuveitis', 'pap',\n       'papaverine', 'paper', 'papers', 'papillary', 'papilledema',\n       'papilloedema', 'papular', 'papules', 'para', 'paracetamol',\n       'paracolic', 'paracorporeal', 'paradoxical', 'paradoxically',\n       'paraesthesia', 'parakeratosis', 'parallel', 'paralleled',\n       'paralleling', 'paralysis', 'paralytic', 'parameters', 'paranoia',\n       'paranoid', 'paraparesis', 'paraplegia', 'parapsilosis',\n       'parasite', 'parasitic', 'parasitosis', 'paraspinal',\n       'parasympathetic', 'parathyroid', 'paratracheal', 'parenchyma',\n       'parenchymal', 'parent', 'parenteral', 'parents', 'paresthesia',\n       'paresthesias', 'parietal', 'parkinson', 'parkinsonian',\n       'parkinsonism', 'parolees', 'parotid', 'parotitis', 'paroxetine',\n       'paroxsymal', 'paroxysmal', 'part', 'partial', 'partialis',\n       'partially', 'participants', 'participated', 'particular',\n       'particularly', 'partly', 'parts', 'partum', 'parvovirus', 'pas',\n       'pass', 'passed', 'passes', 'past', 'patch', 'patchy', 'patellar',\n       'patency', 'patent', 'pathogen', 'pathogenesis', 'pathogenetic',\n       'pathogenic', 'pathogens', 'pathognomonic', 'pathologic',\n       'pathological', 'pathologically', 'pathologist', 'pathologists',\n       'pathology', 'pathophysiologic', 'pathophysiological',\n       'pathophysiology', 'pathway', 'pathways', 'patient', 'patients',\n       'pattern', 'patterns', 'paucity', 'pay', 'pazufloxacin', 'pbsc',\n       'pc', 'pcc', 'pccs', 'pci', 'pcna', 'pcnsl', 'pco', 'pcp', 'pcr',\n       'pct', 'pd', 'pdcs', 'pde5', 'pdes', 'pdgf', 'pdph', 'pdt', 'peak',\n       'pecoma', 'pecomas', 'pectoris', 'peculiar', 'pediatric',\n       'pediatricians', 'pedophilia', 'pedunculopontine', 'peep', 'peg',\n       'pegaptanib', 'pegfilgrastim', 'pegifnalpha', 'peginterferon',\n       'pegvisomant', 'pegylated', 'pei', 'peliosis', 'pellagra',\n       'pelvic', 'pelvis', 'pemetrexed', 'pemphigoid', 'pemphigus', 'pen',\n       'penetrating', 'penetration', 'penicillamine', 'penicillin',\n       'penicillins', 'penile', 'penis', 'pentacam', 'pentamidine',\n       'pentasa', 'pentavalent', 'pentazocine', 'pentobarbital',\n       'pentostatin', 'pentoxifylline', 'people', 'peptic', 'peptide',\n       'peptides', 'per', 'percent', 'percentage', 'percutaneous',\n       'perforated', 'perforates', 'perforating', 'perforation',\n       'perforations', 'perform', 'performance', 'performed',\n       'performing', 'perfume', 'perfusion', 'pergolide', 'perhaps',\n       'perhexiline', 'peri', 'periarticular', 'pericallosal',\n       'pericardial', 'pericarditis', 'pericardium', 'pericellular',\n       'pericystic', 'perilesional', 'perilymphatic', 'perimenopausal',\n       'perinatal', 'perinatally', 'perineal', 'periocular', 'period',\n       'periodic', 'periodically', 'periodontal', 'periods',\n       'perioperative', 'perioral', 'peripheral', 'periphlebitis',\n       'peritoneal', 'peritoneum', 'peritonitis', 'peritonsillar',\n       'peritransplant', 'periurethral', 'perivascular',\n       'periventricular', 'permanent', 'permanently', 'permeability',\n       'permeable', 'peroneal', 'perospirone', 'peroxidase', 'peroxisome',\n       'persimmon', 'persisent', 'persist', 'persisted', 'persistence',\n       'persistent', 'persistently', 'persisting', 'persists', 'person',\n       'personal', 'personality', 'persons', 'perspective',\n       'perspiration', 'pertaining', 'pertinent', 'peruvian', 'pes',\n       'pet', 'petit', 'pexid', 'peyronie', 'pfge', 'pfviii', 'pg',\n       'pge1', 'pge2', 'pglycoprotein', 'ph', 'phaeohyphomycosis',\n       'phakoemulsification', 'phantom', 'pharmaceutical',\n       'pharmaceuticals', 'pharmacia', 'pharmacist', 'pharmacists',\n       'pharmacodynamic', 'pharmacogenetic', 'pharmacogenetics',\n       'pharmacokinetic', 'pharmacokinetically', 'pharmacokinetics',\n       'pharmacologic', 'pharmacological', 'pharmacology',\n       'pharmacotherapy', 'pharmacovigilance', 'pharyngeal', 'phase',\n       'phases', 'phd', 'phenelzine', 'phenobarbital', 'phenobarbitone',\n       'phenol', 'phenolphthalein', 'phenomena', 'phenomenon',\n       'phenothiazine', 'phenothiazines', 'phenotype', 'phenotyped',\n       'phenotypes', 'phentolamine', 'phenylalanine', 'phenylbutazone',\n       'phenylbutyrate', 'phenylephrine', 'phenylpiperidine',\n       'phenylpropanolamine', 'phenytoin', 'pheochromocytoma',\n       'pheripheral', 'philadelphia', 'phosphatase', 'phosphate',\n       'phospho', 'phosphodiesterase', 'phosphokinase', 'phosphorus',\n       'photo', 'photoallergy', 'photocoagulation', 'photocontact',\n       'photodynamic', 'photography', 'photon', 'photopatch', 'photopic',\n       'photoreceptor', 'photoreceptors', 'photorefractive',\n       'photosensitive', 'photosensitivity', 'phototesting',\n       'phototherapeutic', 'phototoxic', 'phototoxicity', 'phrenal',\n       'phrenic', 'phs', 'pht', 'physical', 'physically', 'physician',\n       'physicians', 'physiological', 'physiotherapy', 'pi', 'pick',\n       'picture', 'pictures', 'piece', 'pigmementation', 'pigment',\n       'pigmentary', 'pigmentation', 'pigmented', 'pigtail', 'piiinp',\n       'pilocarpine', 'piloerection', 'pilot', 'pilsicainide', 'pimozide',\n       'pinchoff', 'pinhead', 'pinpoint', 'piperacillin', 'pipotiazine',\n       'piritrexim', 'pirmenol', 'piroxicam', 'pisa', 'pitfalls',\n       'pituitary', 'pivotal', 'pkp', 'pku', 'pla1', 'place', 'placebo',\n       'placebos', 'placed', 'placement', 'placental', 'places',\n       'placoid', 'plain', 'plan', 'planned', 'planning', 'plans',\n       'plant', 'plantar', 'plantaris', 'plants', 'planus', 'plaque',\n       'plaques', 'plasma', 'plasmacytoid', 'plasmaphereses',\n       'plasmapheresis', 'plasmatic', 'plasmid', 'plasminogen',\n       'plasmocytoma', 'plasmocytosis', 'plasmodium', 'plastic', 'plate',\n       'platelet', 'platelets', 'platinum', 'plavix', 'play', 'played',\n       'plays', 'pld', 'pleasure', 'pleiotropic', 'pleocytosis', 'pleura',\n       'pleural', 'pleurisy', 'pleuritic', 'pleuritis', 'pleurodesis',\n       'pleuropericarditis', 'pleuropulmonary', 'plms', 'plombage', 'plp',\n       'plugs', 'plural', 'pluripotent', 'plus', 'pml', 'pneumatic',\n       'pneumatoceles', 'pneumatosis', 'pneumococcal', 'pneumoconiosis',\n       'pneumocystis', 'pneumocytes', 'pneumomediastinum', 'pneumonia',\n       'pneumoniae', 'pneumonias', 'pneumonitis', 'pneumopathy',\n       'pneumothoraces', 'pneumothorax', 'pnh', 'pnm', 'po', 'podocyte',\n       'podocytes', 'point', 'pointe', 'pointes', 'points', 'poison',\n       'poisoning', 'polarization', 'pole', 'polg1', 'policlonal', 'poly',\n       'polyarteritis', 'polyarthralgia', 'polyarthritis',\n       'polyarticular', 'polychemotherapy', 'polyclonal', 'polycystic',\n       'polycythaemia', 'polyendocrinopathy', 'polyethylene',\n       'polygraphic', 'polyhexamethylene', 'polymerase',\n       'polymethylmethacrylate', 'polymorphic', 'polymorphism',\n       'polymorphisms', 'polymorphonuclear', 'polymorphous',\n       'polymyoclonus', 'polymyositis', 'polyneuropathy', 'polyp',\n       'polypeptide', 'polypharmacy', 'polyps', 'polyserositis',\n       'polysomnographic', 'polystryrene', 'polystyrene', 'polysulfone',\n       'polysynovitis', 'polyuria', 'pompholyx', 'pontine', 'pooled',\n       'poor', 'poorly', 'popliteal', 'popular', 'population',\n       'populations', 'porcine', 'porphyria', 'porphyric', 'porphyrin',\n       'porphyrinogens', 'port', 'portable', 'portal', 'portosplenic',\n       'posaconazole', 'pose', 'poses', 'positioning', 'positivation',\n       'positive', 'positivity', 'positron', 'possesses', 'possibility',\n       'possible', 'possibly', 'post', 'postacute', 'postcardiac',\n       'postchemotherapy', 'postdural', 'posterior', 'postexchange',\n       'postganglionic', 'posthypoglycemic', 'postictal',\n       'postirradiation', 'postmastectomy', 'postmenopausal',\n       'postmortem', 'postnecrotic', 'postoperative', 'postoperatively',\n       'postpartum', 'postprandial', 'postsurgically', 'postsynaptic',\n       'posttransplant', 'postulate', 'postulated', 'postural', 'posture',\n       'posturing', 'potassium', 'potent', 'potential', 'potentially',\n       'potentials', 'potentiate', 'potentiated', 'potentiates',\n       'potentiation', 'pounds', 'povidone', 'power', 'powerful', 'ppa',\n       'ppar', 'ppe', 'ppp', 'pr', 'practical', 'practically', 'practice',\n       'practitioners', 'practolol', 'pramipexole', 'pranlukast',\n       'pravastatin', 'praziquantel', 'prazosin', 'prca', 'pre',\n       'preadmission', 'precancerous', 'precautions', 'precede',\n       'preceded', 'preceding', 'precipitate', 'precipitated',\n       'precipitating', 'precipitation', 'precise', 'preclinical',\n       'preclude', 'precludes', 'precluding', 'preconception',\n       'precordial', 'precursor', 'precursors', 'predated',\n       'predecessors', 'prediabetes', 'predict', 'predicting',\n       'predictors', 'predispose', 'predisposed', 'predisposes',\n       'predisposing', 'predisposition', 'prednisolone', 'prednisone',\n       'predominance', 'predominant', 'predominantly', 'predominate',\n       'preeclampsia', 'preeclamptic', 'preexistent', 'preexisting',\n       'preference', 'preferential', 'preferentially', 'preferred',\n       'pregabalin', 'pregnancies', 'pregnancy', 'pregnant',\n       'preliminary', 'preloaded', 'premature', 'prematurely',\n       'premenopausal', 'premortem', 'prenatal', 'prenatally',\n       'preoperative', 'preoperatively', 'preparation', 'preparations',\n       'prepared', 'prepubertal', 'prerenal', 'pres', 'prescribed',\n       'prescribing', 'prescription', 'prescriptions', 'presence',\n       'present', 'presentation', 'presentations', 'presented',\n       'presenting', 'presently', 'presents', 'preservation',\n       'preservative', 'preserve', 'preserved', 'pressure', 'pressures',\n       'presumably', 'presume', 'presumed', 'pretense', 'preterm',\n       'pretransfusion', 'pretreated', 'pretreatment', 'prevalence',\n       'prevent', 'preventable', 'prevented', 'preventing', 'prevention',\n       'preventive', 'prevents', 'previous', 'previously', 'priapism',\n       'prick', 'prima', 'primarily', 'primary', 'primers', 'primidone',\n       'primigravid', 'primigravida', 'primum', 'principle', 'prior',\n       'prk', 'prl', 'pro', 'proarrhythmia', 'proarrhythmic',\n       'probability', 'probable', 'probably', 'probationers', 'probes',\n       'problem', 'problems', 'procainamide', 'procarbazine',\n       'procaterol', 'procedure', 'procedures', 'proceeding', 'procera',\n       'process', 'processed', 'processes', 'processing',\n       'prochlorperazine', 'procollagen', 'proconvulsant',\n       'proconvulsive', 'proctitis', 'proctor', 'proctoscopic', 'produce',\n       'produced', 'produces', 'producing', 'product', 'production',\n       'products', 'professionals', 'profile', 'profound', 'profoundly',\n       'profusely', 'progenitor', 'progestational', 'progestin',\n       'progestogens', 'prognosis', 'prognostic', 'program', 'programs',\n       'progress', 'progressed', 'progresses', 'progressing',\n       'progression', 'progressive', 'progressively', 'prohibited',\n       'projected', 'prokinetic', 'prolapse', 'proliferating',\n       'proliferation', 'proliferative', 'proliferator', 'prolong',\n       'prolongation', 'prolonged', 'promethazine', 'prominent',\n       'promising', 'promote', 'promoted', 'promotion', 'prompt',\n       'prompted', 'prompting', 'promptly', 'promyelocytic',\n       'promyleocytic', 'prone', 'proneness', 'pronounced', 'proof',\n       'propafenone', 'propanolamine', 'propecia', 'propensity',\n       'propeptide', 'proper', 'properly', 'properties', 'property',\n       'prophylactic', 'prophylactically', 'prophylaxis', 'propionate',\n       'propionic', 'propofol', 'proportion', 'propose', 'proposed',\n       'propoxyphene', 'propranolol', 'propria', 'proprioception',\n       'propylpentanoic', 'propylthiouracil', 'prospective',\n       'prospectively', 'prostacyclin', 'prostaglandin', 'prostate',\n       'prostatic', 'prostatism', 'prostheses', 'prosthesis',\n       'prosthetic', 'prostitute', 'protamine', 'protease', 'protect',\n       'protective', 'protein', 'proteinase', 'proteins', 'proteinuria',\n       'prothipendylhydrochloride', 'prothrombin', 'protocol',\n       'protocols', 'proton', 'protoporphyria', 'protracted', 'prove',\n       'proved', 'proven', 'provide', 'provided', 'provider', 'providers',\n       'provides', 'providing', 'province', 'provincial', 'proving',\n       'provocation', 'provoke', 'provoked', 'provoking', 'proximal',\n       'pruritic', 'pruritus', 'prystinamycin', 'psa', 'pseudo',\n       'pseudoallergic', 'pseudoaneurysm', 'pseudoaneurysms',\n       'pseudobulbar', 'pseudocholangitis', 'pseudocyst',\n       'pseudoephedrine', 'pseudolymphoma', 'pseudomembranous',\n       'pseudomonas', 'pseudophakic', 'pseudoporphyria',\n       'pseudoproteinuria', 'pseudotumor', 'psg', 'psl', 'psoralen',\n       'psoralens', 'psoriasiform', 'psoriasis', 'psoriatic',\n       'psoriatics', 'psvt', 'psychiatric', 'psychiatrically',\n       'psychiatrist', 'psychiatrists', 'psychiatry', 'psychoendocrine',\n       'psychogenic', 'psychomotor', 'psychomotoric',\n       'psychopharmacologic', 'psychopharmacological', 'psychosis',\n       'psychostimulants', 'psychotherapy', 'psychotic', 'psychotropic',\n       'psychotropics', 'pt', 'ptca', 'pte', 'pterygium', 'pth', 'ptld',\n       'ptosis', 'ptp', 'ptsd', 'ptt', 'ptu', 'ptx', 'puberty', 'public',\n       'publication', 'publications', 'publicly', 'published', 'pubmed',\n       'pulmonary', 'pulmonologist', 'pulse', 'pulsed', 'pulses', 'pump',\n       'pumping', 'pumps', 'punch', 'puncta', 'puncture', 'pupil',\n       'pupillary', 'pupils', 'pure', 'purging', 'purified', 'purine',\n       'purkinje', 'purple', 'purported', 'purpose', 'purposeless',\n       'purposes', 'purpura', 'purpuric', 'pursue', 'purulent',\n       'pustular', 'pustule', 'pustules', 'pustulosis', 'put', 'putamen',\n       'putaminal', 'putative', 'putting', 'puva', 'pv', 'pvb19', 'pve',\n       'pvt', 'pwo', 'pylori', 'pyloric', 'pyogenic', 'pyometra',\n       'pyramidal', 'pyrazinamid', 'pyrazinamide', 'pyrexia',\n       'pyridopsoralen', 'pyridostigmine', 'pyridoxine', 'pyrilamine',\n       'pyrimethamine', 'pyrimidine', 'q13', 'q23', 'q31', 'q578h', 'q6h',\n       'q8h', 'qrs', 'qt', 'qtc', 'quadrant', 'quadriparesis',\n       'quadriplegia', 'quadriplegic', 'quadruple', 'quality', 'quandary',\n       'quantitation', 'quantitative', 'quantities', 'queried',\n       'question', 'questioned', 'questioning', 'questionnaire',\n       'questionnaires', 'questions', 'quetiapine', 'quick', 'quickly',\n       'quiescent', 'quinacrine', 'quinapril', 'quinidine', 'quinine',\n       'quinolone', 'quinolones', 'quintas', 'quite', 'quoted', 'ra',\n       'rabbits', 'racial', 'radial', 'radiating', 'radiation', 'radical',\n       'radiculopathy', 'radioactive', 'radiochemotherapy',\n       'radiofrequency', 'radiograph', 'radiographic', 'radiographs',\n       'radioiodine', 'radioisotopic', 'radiologic', 'radiological',\n       'radiometric', 'radionuclide', 'radiopaque', 'radiosensitizing',\n       'radiotherapy', 'raise', 'raised', 'raises', 'raising', 'raiu',\n       'raloxifene', 'ramathibodi', 'ramipril', 'random', 'randomized',\n       'range', 'ranged', 'ranges', 'ranging', 'ranibizumab',\n       'ranitidine', 'rank', 'rapammune', 'rapamycin', 'rapid', 'rapidly',\n       'rar', 'rare', 'rarely', 'rarity', 'ras', 'rash', 'rashes', 'rat',\n       'rate', 'rates', 'rather', 'rating', 'ratio', 'rational', 'ratios',\n       'rats', 'ray', 'raynaud', 'razoxane', 'rbc', 'rbcs', 'rbd', 'rd',\n       're', 'rea', 'reabsorption', 'reaccumulation', 'reach', 'reached',\n       'reaching', 'reacted', 'reaction', 'reactions', 'reactivated',\n       'reactivation', 'reactivations', 'reactive', 'reactivity', 'read',\n       'readily', 'readings', 'readministered', 'readministration',\n       'readmitted', 'real', 'realignment', 'realized', 'reappear',\n       'reappearance', 'rearranged', 'rearrangement', 'reason',\n       'reasonable', 'reasons', 'rebiopsy', 'rebound', 'rebounds',\n       'recalcitrant', 'recall', 'recalled', 'receded', 'receive',\n       'received', 'receiver', 'receiving', 'recent', 'recently',\n       'receptor', 'receptors', 'recessive', 'rechallenge',\n       'rechallenged', 'recidivant', 'recipient', 'recipients', 'recluse',\n       'recognised', 'recognition', 'recognize', 'recognized',\n       'recognizing', 'recombinant', 'recommencement', 'recommend',\n       'recommendation', 'recommendations', 'recommended', 'recommending',\n       'recommends', 'reconstitution', 'reconstruction', 'record',\n       'recorded', 'recording', 'recordings', 'records', 'recourse',\n       'recover', 'recovered', 'recovery', 'recreational', 'rectal',\n       'rectifying', 'rectum', 'rectus', 'recur', 'recurred',\n       'recurrence', 'recurrences', 'recurrent', 'recurring', 'red',\n       'redistribution', 'redness', 'redo', 'redox', 'reduce', 'reduced',\n       'reduces', 'reducing', 'reductase', 'reduction', 'reductions',\n       'reestablished', 'reexamined', 'reference', 'referenced',\n       'references', 'referral', 'referred', 'refine', 'reflect',\n       'reflected', 'reflects', 'reflex', 'reflexes', 'reflux',\n       'refractive', 'refractoriness', 'refractory', 'refrain', 'refused',\n       'regained', 'regard', 'regarded', 'regarding', 'regardless',\n       'regards', 'regenerated', 'regeneration', 'regime', 'regimen',\n       'regimens', 'regimes', 'region', 'regional', 'registered',\n       'registry', 'reglan', 'regressed', 'regression', 'regular',\n       'regularly', 'regulate', 'regulated', 'regulating', 'regulation',\n       'regulatory', 'rehabilitation', 'reimplantation', 'reinfection',\n       'reinforcement', 'reinitiated', 'reinitiating', 'reinstated',\n       'reinstituted', 'reinstitution', 'reintroduced', 'reintroduction',\n       'reintubated', 'rejection', 'relapse', 'relapsed', 'relapses',\n       'relapsing', 'related', 'relating', 'relation', 'relationship',\n       'relative', 'relatively', 'relaxant', 'relaxants', 'release',\n       'released', 'releasing', 'relentless', 'relevant', 'reliability',\n       'reliable', 'relief', 'relieve', 'relieved', 'relieving',\n       'reluctant', 'rely', 'rem', 'remain', 'remainder', 'remained',\n       'remaining', 'remains', 'remarkable', 'remarkably', 'remarked',\n       'remedies', 'remedy', 'remember', 'remind', 'reminder', 'reminds',\n       'reminiscent', 'remission', 'remissions', 'remitted', 'remitting',\n       'remote', 'removal', 'removals', 'remove', 'removed', 'removing',\n       'remyelination', 'renal', 'render', 'rendered', 'renewed', 'renin',\n       'renoprival', 'renovascular', 'reopacification', 'repair',\n       'repeat', 'repeatable', 'repeated', 'repeatedly', 'reperfusion',\n       'repetitive', 'replace', 'replaced', 'replacement', 'replacing',\n       'repletion', 'replication', 'repo', 'report', 'reported',\n       'reportedly', 'reporting', 'reports', 'represent', 'represented',\n       'representing', 'represents', 'reproduce', 'reproduced',\n       'reproducible', 'reproducibly', 'reproductive', 'require',\n       'required', 'requirement', 'requirements', 'requires', 'requiring',\n       'rerated', 'rescue', 'research', 'researchers', 'resected',\n       'resection', 'resemble', 'resembled', 'resembles', 'resembling',\n       'reserpine', 'reserve', 'reserved', 'reserving', 'reservoir',\n       'residual', 'resin', 'resistance', 'resistant', 'resolution',\n       'resolve', 'resolved', 'resolves', 'resolving', 'resonance',\n       'resorption', 'resource', 'resources', 'respect', 'respectively',\n       'respiration', 'respiratory', 'respond', 'responded', 'responders',\n       'responding', 'responds', 'response', 'responses',\n       'responsibility', 'responsible', 'responsive', 'restart',\n       'restarted', 'restarting', 'restenosis', 'restitution', 'restless',\n       'restlessness', 'restoration', 'restore', 'restored', 'restoring',\n       'restricted', 'restricting', 'restriction', 'restrictive',\n       'result', 'resultant', 'resulted', 'resulting', 'results',\n       'resumed', 'resurgence', 'resuscitated', 'resuscitation',\n       'retained', 'retardation', 'retarded', 'retention', 'reticular',\n       'reticularis', 'reticulate', 'reticulin', 'reticulocytes',\n       'retina', 'retinae', 'retinal', 'retinitis', 'retinoblastoma',\n       'retinochoroiditis', 'retinoic', 'retinoids', 'retinopathy',\n       'retired', 'retreated', 'retreatment', 'retroauricular',\n       'retrogasserian', 'retrograde', 'retrogradely', 'retroperitoneal',\n       'retroperitoneum', 'retrospective', 'retrospectively',\n       'retrosternal', 'retroviral', 'rett', 'return', 'returned',\n       'returning', 'returns', 'reuptake', 'reveal', 'revealed',\n       'revealing', 'reveals', 'reversal', 'reverse', 'reversed',\n       'reversible', 'reversing', 'reversion', 'review', 'reviewed',\n       'reviews', 'revision', 'revisited', 'reye', 'rf', 'rfa', 'rfp',\n       'rfviia', 'rh', 'rhabdomylysis', 'rhabdomyolysis',\n       'rhabdomyosarcoma', 'rhe', 'rhegmatogenous', 'rhepo', 'rheumatic',\n       'rheumatism', 'rheumatoid', 'rheumatologic', 'rheumatological',\n       'rheumatologists', 'rheumatology', 'rhgh', 'rhinitis',\n       'rhodotorula', 'rhumgdf', 'rhythm', 'rhythmic', 'rhythms',\n       'ribavirin', 'riboflavin', 'rich', 'rickets', 'ridging', 'rif',\n       'rifabutin', 'rifampicin', 'rifampin', 'rifn', 'right', 'rigid',\n       'rigidity', 'rigorous', 'rigorously', 'rigors', 'riluzole', 'ring',\n       'ringer', 'rinsing', 'rippling', 'rise', 'risk', 'risks',\n       'risperidone', 'ritalin', 'ritodrine', 'ritonavir', 'rituximab',\n       'rls', 'rmd', 'rml', 'rna', 'robbed', 'robert', 'robust', 'roche',\n       'roden', 'roentgenograms', 'roentgenographic', 'rofecoxib',\n       'rolandic', 'role', 'roles', 'room', 'root', 'roots', 'rop',\n       'ropinirole', 'rosacea', 'rosaceiform', 'rose', 'rosiglitazone',\n       'rotational', 'roughly', 'round', 'roussel', 'route', 'routine',\n       'routinely', 'roxithromycin', 'rpe', 'rples', 'rpls', 'rrms', 'rs',\n       'rsd', 'rsds', 'rsv', 'rt', 'rta', 'rub', 'rubeosis', 'ruber',\n       'rubrum', 'rule', 'ruled', 'rules', 'ruling', 'runner', 'rupture',\n       'ruptured', 'rush', 'russell', 'russia', 's1', 's655l', 'sac',\n       'sachets', 'sacroiliac', 'sacrum', 'safe', 'safeguards', 'safely',\n       'safer', 'safest', 'safety', 'sagittal', 'sah', 'saharan',\n       'salazoslufapyridine', 'salazosulfapyridine', 'salbutamol',\n       'salicylate', 'saline', 'salivary', 'salmon', 'salmonella',\n       'salmonellosis', 'salpingo', 'salsalate', 'salt', 'salts',\n       'salutary', 'salvage', 'same', 'saml', 'sample', 'samples',\n       'sampling', 'sanding', 'sandoz', 'sanofi', 'sao2', 'saprophytic',\n       'sarcoidosis', 'sarcoma', 'sarcomas', 'sargramostim', 'sasp',\n       'saturation', 'saudi', 'saved', 'savings', 'saw', 'say', 'sc',\n       'scald', 'scale', 'scaled', 'scales', 'scaling', 'scalp', 'scan',\n       'scanning', 'scans', 'scaphoidectomy', 'scapularis', 'scarring',\n       'scars', 'scattered', 'scc', 'sce', 'scec', 'schedule',\n       'scheduled', 'schedules', 'schemes', 'schistocytes',\n       'schistocytosis', 'schizophrenia', 'schizophrenic', 'schlemm',\n       'schneiderian', 'school', 'schuur', 'schwann', 'sciatic',\n       'sciatica', 'scintigraphic', 'scintigraphy', 'scleral',\n       'scleritis', 'sclerodactyly', 'scleroderma', 'sclerodermatous',\n       'scleromyxedema', 'sclerosing', 'sclerosis', 'sclerotic',\n       'scolicidal', 'scope', 'scopolamine', 'score', 'scores', 'scoring',\n       'scr', 'scraping', 'screaming', 'screened', 'screening', 'scripta',\n       'scrofuloderma', 'scrotal', 'scrotum', 'sd', 'sda', 'sdas', 'sdc',\n       'sdcs', 'se', 'sea', 'seaman', 'search', 'seasonal', 'seated',\n       'seborrheic', 'sec', 'second', 'secondary', 'seconds', 'secretion',\n       'secretory', 'section', 'sectioning', 'sections', 'secure',\n       'secured', 'sedated', 'sedation', 'sedative', 'sediment',\n       'sedimentation', 'sedl', 'seeding', 'seeking', 'seem', 'seemed',\n       'seems', 'seen', 'seer', 'segment', 'segmental', 'segmentectomy',\n       'seizure', 'seizures', 'seldom', 'selected', 'selecting',\n       'selection', 'selective', 'selectively', 'selectivity', 'self',\n       'selfadministered', 'selfinjection', 'sella', 'semi',\n       'seminomatous', 'semiselective', 'semisynthetic', 'senile',\n       'senna', 'sensation', 'sensations', 'sense', 'sensitisation',\n       'sensitive', 'sensitivities', 'sensitivity', 'sensitization',\n       'sensitize', 'sensitizing', 'sensorimotor', 'sensorineural',\n       'sensory', 'sent', 'separate', 'separated', 'separately',\n       'separation', 'seps', 'sepsis', 'septal', 'september', 'septic',\n       'septicaemia', 'septicemia', 'septicum', 'septo', 'septra',\n       'septum', 'sequard', 'sequela', 'sequelae', 'sequels', 'sequence',\n       'sequences', 'sequencing', 'sequential', 'sequentially', 'sera',\n       'serial', 'series', 'serine', 'serious', 'seriously',\n       'seriousness', 'sero', 'serologic', 'serological', 'serologies',\n       'serology', 'seronegative', 'seropositive', 'serositis',\n       'serotonergic', 'serotonergically', 'serotonin', 'serotoninergic',\n       'serous', 'serratia', 'sertraline', 'serum', 'serumcholinesterase',\n       'serve', 'serves', 'session', 'sessions', 'set', 'sets', 'setting',\n       'settings', 'seven', 'seventeen', 'seventy', 'several', 'severe',\n       'severely', 'severity', 'sex', 'sexual', 'sgot', 'shadowing',\n       'shaking', 'shallow', 'shallowing', 'shape', 'shaped', 'shapes',\n       'share', 'shared', 'sharply', 'she', 'sheath', 'sheds', 'sheets',\n       'shepherd', 'shift', 'shifted', 'shining', 'ship', 'shivering',\n       'shock', 'shocks', 'short', 'shortage', 'shortened', 'shortening',\n       'shortens', 'shorter', 'shortly', 'shortness', 'shots', 'should',\n       'shoulder', 'show', 'showed', 'shower', 'showing', 'shown',\n       'shows', 'shunt', 'shunting', 'shunts', 'siadh', 'sibling',\n       'siblings', 'sibutramine', 'sicca', 'sickle', 'sickness', 'side',\n       'sided', 'sideroblastic', 'sigmoidoscopies', 'sigmoidovesical',\n       'sign', 'signaling', 'signed', 'significance', 'significant',\n       'significantly', 'signs', 'silastic', 'silent', 'silicone',\n       'silicosis', 'silodosin', 'silvadene', 'silver', 'similar',\n       'similarities', 'similarity', 'similarly', 'simple', 'simplex',\n       'simplifying', 'simulate', 'simulated', 'simulating',\n       'simultaneous', 'simultaneously', 'simvastatin', 'since', 'single',\n       'singular', 'sinoatrial', 'sins', 'sinus', 'sinuses', 'sinusitis',\n       'sinusoidal', 'sirolimus', 'sirs', 'sisters', 'sit', 'site',\n       'sites', 'situ', 'situation', 'situations', 'six', 'sixteen',\n       'sixth', 'sixty', 'size', 'sized', 'sizes', 'sjogren', 'sjs',\n       'skeletal', 'skin', 'skinned', 'skt', 'skull', 'sle', 'sleep',\n       'sleepiness', 'slides', 'slight', 'slightly', 'slit', 'slitlamp',\n       'slow', 'slowed', 'slowly', 'sludge', 'sm', 'small', 'smaller',\n       'smear', 'smears', 'smell', 'smoke', 'smoking', 'smon', 'smooth',\n       'sms', 'smx', 'snare', 'snellen', 'snhl', 'so', 'social',\n       'society', 'socio', 'soda', 'sodium', 'sodom', 'soft', 'soldier',\n       'sole', 'solely', 'soles', 'solid', 'solids', 'solitary',\n       'solution', 'solutions', 'solvent', 'solvents', 'somatic',\n       'somatostatin', 'some', 'sometimes', 'somewhat', 'somnolence',\n       'sonograms', 'sonographically', 'soon', 'sorafenib', 'sorbitol',\n       'sorbolene', 'sore', 'sotalol', 'sought', 'sound', 'source',\n       'sources', 'south', 'southern', 'sp', 'space', 'spacer', 'spacers',\n       'spaces', 'span', 'sparfloxacin', 'sparing', 'sparse', 'sparteine',\n       'spasm', 'spasmodic', 'spasms', 'spastic', 'spasticity', 'spayed',\n       'spb', 'spe', 'special', 'specialized', 'species', 'specific',\n       'specifically', 'specificity', 'specifics', 'specimen',\n       'specimens', 'spect', 'spectral', 'spectrometry', 'spectroscopic',\n       'spectroscopy', 'spectrum', 'speculate', 'speculated', 'speech',\n       'speed', 'sperm', 'sphenoidal', 'sphincter', 'spider', 'spike',\n       'spikes', 'spillage', 'spinal', 'spindle', 'spine',\n       'spinothalamic', 'spiral', 'spirits', 'spirography',\n       'spironolactone', 'spite', 'spleen', 'splenectomy', 'splenic',\n       'splenomegaly', 'splinter', 'spondylitis', 'spondyloarthropathy',\n       'spongiform', 'spongy', 'spontaneous', 'spontaneously', 'sporadic',\n       'sporadically', 'spots', 'spotting', 'spotty', 'spp', 'sprague',\n       'spray', 'sprays', 'spread', 'spreading', 'sprue', 'spt', 'sputum',\n       'sq', 'squamous', 'squeezed', 'sr', 'src', 'srl', 'ss', 'sseh',\n       'ssp', 'ssri', 'ssris', 'sstis', 'st', 'stability',\n       'stabilization', 'stabilized', 'stabilizer', 'stabilizing',\n       'stable', 'staff', 'stage', 'stages', 'staging', 'stain',\n       'stained', 'staining', 'stains', 'standard', 'standardized',\n       'standing', 'stanozolol', 'staphylococcal', 'staphylococcus',\n       'starch', 'start', 'started', 'starting', 'starts', 'stasis',\n       'state', 'stated', 'states', 'statin', 'statins', 'statistic',\n       'statistical', 'statistically', 'status', 'stavudine', 'stay',\n       'stearate', 'steatohepatitis', 'steatosis', 'stellate', 'stem',\n       'stenosis', 'stent', 'stenting', 'stentless', 'stents', 'step',\n       'stereotactic', 'sternal', 'steroid', 'steroidal', 'steroids',\n       'stevens', 'stibogluconate', 'stiff', 'still', 'stimulant',\n       'stimulants', 'stimulate', 'stimulates', 'stimulating',\n       'stimulation', 'stimulatory', 'stimuli', 'stimulus', 'sting',\n       'stn', 'stomach', 'stomatitis', 'stone', 'stones', 'stool',\n       'stools', 'stop', 'stoppage', 'stopped', 'stopping', 'storage',\n       'story', 'strabismus', 'strain', 'strains', 'stranded',\n       'strategies', 'strategy', 'stratified', 'strauss', 'streaking',\n       'streaks', 'strength', 'strengthened', 'strengthens',\n       'streptococcal', 'streptococci', 'streptococcus', 'streptokinase',\n       'stress', 'stressed', 'striatum', 'stricken', 'strict',\n       'stricture', 'stridor', 'strikes', 'striking', 'stringent',\n       'stroke', 'strokes', 'stromal', 'strong', 'strongly',\n       'strongyloides', 'structural', 'structure', 'structured',\n       'structures', 'strychnine', 'students', 'studied', 'studies',\n       'study', 'stump', 'stunted', 'stupor', 'stuporous', 'stutter',\n       'stuttering', 'sub', 'subacromial', 'subacute', 'subarachnoid',\n       'subcapsular', 'subcarinal', 'subclavian', 'subclinical',\n       'subconjunctival', 'subcortical', 'subcutaneous', 'subcutaneously',\n       'subcutis', 'subdural', 'subendocardial', 'subendothelial',\n       'subepithelial', 'subfamily', 'subfascial', 'subfebrile',\n       'subfulminant', 'subglottic', 'subgroup', 'subject', 'subjective',\n       'subjectively', 'subjects', 'sublamina', 'sublingual',\n       'submassive', 'submitted', 'submucosa', 'submucosal', 'subnormal',\n       'subsegmental', 'subsequent', 'subsequently', 'subset', 'subsided',\n       'substance', 'substances', 'substantia', 'substantial',\n       'substantiated', 'substernal', 'substitute', 'substituted',\n       'substitution', 'substitutional', 'substitutions', 'substrate',\n       'substrates', 'subthalamotomy', 'subtherapeutic', 'subtle',\n       'subtotal', 'subtypes', 'subungual', 'subunit', 'success',\n       'successful', 'successfully', 'succession', 'successive',\n       'successively', 'succinate', 'succinyl', 'succinylcholine',\n       'succumbed', 'such', 'sucralfate', 'sucrose', 'sudded', 'sudden',\n       'suddenly', 'suffer', 'suffered', 'suffering', 'sufficient',\n       'sufficiently', 'suflonylurea', 'sugar', 'suggest', 'suggested',\n       'suggesting', 'suggestive', 'suggests', 'suicidal', 'suicide',\n       'suitability', 'suitable', 'sulcus', 'sulfacetamide',\n       'sulfadiazine', 'sulfadoxine', 'sulfamethoxazole', 'sulfamylon',\n       'sulfasalazine', 'sulfate', 'sulfonamide', 'sulfonamides',\n       'sulfonate', 'sulfonylurea', 'sulfonylureas', 'sulfoxide',\n       'sulfur', 'sulindac', 'sulphasalazine', 'sulphate', 'sulphonamide',\n       'sulphonate', 'sulphonylurea', 'sulphureo', 'sulpiride',\n       'sulprostone', 'sumatriptan', 'summaries', 'summarize',\n       'summarized', 'summary', 'sun', 'sunburn', 'sunitinib',\n       'suntanning', 'superantigen', 'superficial', 'superimposed',\n       'superinfection', 'superior', 'supersensitivity', 'supervened',\n       'supervising', 'supervision', 'supplement', 'supplemental',\n       'supplementation', 'supplemented', 'supplements', 'supplies',\n       'supply', 'support', 'supported', 'supporting', 'supportive',\n       'supportively', 'supports', 'suppose', 'supposed', 'suppress',\n       'suppressed', 'suppresses', 'suppression', 'suppressive',\n       'suppressor', 'suppurative', 'supravenous', 'supraventricular',\n       'sural', 'suramin', 'surface', 'surfaces', 'surgeon', 'surgeons',\n       'surgery', 'surgical', 'surgically', 'surprising', 'surprisingly',\n       'surrounded', 'surveillance', 'survey', 'surveys', 'survival',\n       'survived', 'surviving', 'susceptibility', 'susceptible',\n       'suspect', 'suspected', 'suspecting', 'suspended', 'suspension',\n       'suspicion', 'sustained', 'sutures', 'suturing', 'suxamethonium',\n       'svt', 'swallowed', 'swallowing', 'sweat', 'sweating', 'sweats',\n       'sweet', 'swelling', 'switch', 'switched', 'switching',\n       'switzerland', 'swollen', 'sword', 'sws', 'sx', 'sydenham',\n       'sydney', 'symbolic', 'symmetric', 'symmetrically',\n       'sympathectomy', 'sympathetic', 'sympathomimetic', 'symphysitis',\n       'symptom', 'symptomatic', 'symptomatology', 'symptoms',\n       'synacthen', 'synaptic', 'syncopal', 'syncope', 'syncytial',\n       'syndrome', 'syndromes', 'synergeyes', 'synergistic',\n       'synergistically', 'synergy', 'syngeneic', 'synonymous',\n       'synostoses', 'synovectomy', 'synovial', 'synovitis', 'synthesis',\n       'synthetase', 'synthetic', 'syphilis', 'syphilitic', 'syringeal',\n       'syringosubarachnoid', 'syringotropic', 'system', 'systematic',\n       'systematically', 'systemic', 'systemically', 'systems',\n       'systolic', 't1', 't10', 't12', 't1c', 't1gr2nxm0', 't2', 't3',\n       't315i', 't4', 't7', 't8', 'ta', 'table', 'tablet', 'tablets',\n       'tacalcitol', 'tace', 'tachyarrhymias', 'tachyarrhythmia',\n       'tachyarrhythmias', 'tachycardia', 'tachycardic', 'tachypnea',\n       'tachypneic', 'tacrolimus', 'tadalafil', 'tae', 'taenia', 'tailed',\n       'take', 'taken', 'taking', 'tale', 'talus', 'tamoxifen',\n       'tamponade', 'tamponaded', 'tandem', 'tantrums', 'tap', 'tapered',\n       'tapering', 'tapping', 'tarda', 'tardive', 'target', 'targets',\n       'tarsal', 'task', 'taste', 'tathion', 'tattoos', 'taxane',\n       'taxanes', 'taxol', 'taxus', 'tazobactam', 'tb', 'tbii', 'tc',\n       'tca', 'td', 'tdf', 'tdm', 'tdp', 'tea', 'teachers', 'teaching',\n       'teams', 'tears', 'technetium', 'technical', 'technique',\n       'techniques', 'technologies', 'tee', 'teenage', 'teenager',\n       'teeth', 'tegaserod', 'tegretol', 'teicoplanin', 'telangiectasia',\n       'telemetry', 'telescoped', 'telmisartan', 'temozolomide', 'temper',\n       'temperature', 'temperatures', 'temporal', 'temporally',\n       'temporary', 'temporomandibular', 'tempting', 'temsirolimus',\n       'ten', 'tenckoff', 'tended', 'tendencies', 'tendency', 'tender',\n       'tenderness', 'tendon', 'tends', 'tenecteplase', 'tenofovir',\n       'tenosynovitis', 'tense', 'teratocarcinoma', 'teratogenic',\n       'teratogenicity', 'teratoma', 'terbinafine', 'terbutaline',\n       'terlipressin', 'term', 'termed', 'terminal', 'terminally',\n       'terminate', 'terminated', 'terminating', 'termination',\n       'terminations', 'terms', 'terreus', 'territory', 'tertiary',\n       'test', 'tested', 'testicle', 'testicular', 'testing',\n       'testosterone', 'tests', 'tetanic', 'tetany', 'tetrabenazine',\n       'tetracosactrin', 'tetracyclic', 'tetracycline', 'tetraparesia',\n       'tetraparesis', 'texts', 'tg', 'tga', 'tgf', 'th', 'thai',\n       'thalamic', 'thalassaemia', 'thalassemia', 'thalidomide', 'than',\n       'that', 'the', 'their', 'them', 'themselves', 'then', 'thenar',\n       'theophylline', 'theoretical', 'theoretically', 'theory',\n       'therapeutic', 'therapies', 'therapy', 'there', 'thereafter',\n       'thereby', 'therefore', 'thereon', 'thermoresistibile', 'these',\n       'they', 'thiabendazole', 'thiamine', 'thiazide',\n       'thiazolidinedione', 'thiazolidinediones', 'thickening',\n       'thickness', 'thigh', 'thighs', 'thin', 'think', 'thinning',\n       'thioamide', 'thioguanine', 'thiomalate', 'thionamide',\n       'thionamides', 'thiopurine', 'thiopurines', 'thioridazine',\n       'thiosulfate', 'thiotepa', 'thioxanthene', 'third', 'thirds',\n       'thirst', 'thirteen', 'thirty', 'this', 'thoracic',\n       'thoracoscopic', 'thorax', 'thorotrast', 'thorough', 'those',\n       'though', 'thought', 'thoughts', 'thr', 'threat', 'threaten',\n       'threatening', 'three', 'threshold', 'thresholds', 'thrive',\n       'throat', 'throbbing', 'thrombembolism', 'thrombi', 'thrombin',\n       'thrombo', 'thrombocyte', 'thrombocythaemia', 'thrombocythemia',\n       'thrombocytopenia', 'thrombocytopenic', 'thrombocytopoaenia',\n       'thrombocytoses', 'thrombocytosis', 'thromboembolic',\n       'thromboembolism', 'thrombolysis', 'thrombolytic', 'thrombolytics',\n       'thrombophilia', 'thrombophlebitis', 'thromboplastin',\n       'thrombopoietin', 'thrombosed', 'thrombosis', 'thrombotic',\n       'thrombus', 'through', 'throughout', 'thrust', 'thumbs', 'thus',\n       'thymectomy', 'thymic', 'thymidine', 'thymocyte', 'thymoma',\n       'thyrocytes', 'thyroglobulin', 'thyroid', 'thyroidectomy',\n       'thyroiditis', 'thyrotoxic', 'thyrotoxicosis', 'thyrotropin',\n       'thyroxin', 'thyroxine', 'tia', 'tiaa', 'tiacg', 'tiagabine',\n       'tibia', 'tibial', 'tic', 'tick', 'tickborne', 'ticlopidine',\n       'tics', 'tid', 'tigecycline', 'tightly', 'tightness', 'time',\n       'timely', 'times', 'timing', 'timolol', 'tincture', 'tine',\n       'tinea', 'tingling', 'tinnitus', 'tiny', 'tip', 'tipped', 'tips',\n       'tissue', 'tissues', 'titer', 'titers', 'titrated', 'titration',\n       'titres', 'tivd', 'tki', 'tkis', 'tlr', 'tlr7', 'tls', 'tma',\n       'tmj', 'tmp', 'tmz', 'tnf', 'tnfalpha', 'to', 'tobacco',\n       'tobramycin', 'tocainide', 'tocolysis', 'tocolytic', 'tocopherol',\n       'today', 'toddler', 'toenails', 'toes', 'together', 'tokyo',\n       'tolazoline', 'tolerability', 'tolerable', 'tolerance', 'tolerate',\n       'tolerated', 'tolerating', 'toll', 'tolmetin', 'tolterodine',\n       'toluene', 'tomographic', 'tomography', 'tone', 'tongue', 'tonic',\n       'tonicity', 'tonsil', 'tonsillectomy', 'tonsillitis', 'too',\n       'took', 'tool', 'tooth', 'toothache', 'tophaceous', 'topical',\n       'topically', 'topiramate', 'topographically', 'topography',\n       'torsade', 'torsades', 'torsemide', 'torsion', 'tos', 'tosylate',\n       'total', 'totally', 'tourette', 'tourniquet', 'towards', 'towne',\n       'toxemia', 'toxic', 'toxicities', 'toxicity', 'toxicokinetic',\n       'toxicological', 'toxicologiques', 'toxicology', 'toxicosis',\n       'toxin', 'toxoplasma', 'toxoplasmic', 'toxoplasmosis', 'tpa',\n       'tpmt', 'tpn', 'tpo', 'trab', 'trabecular', 'trabeculectomy',\n       'tracheal', 'tracing', 'track', 'tract', 'traction', 'tracts',\n       'trade', 'traditional', 'traditionally', 'tragedy', 'tragic',\n       'tram', 'tranexamic', 'tranquilizing', 'trans', 'transaminase',\n       'transaminasemia', 'transaminases', 'transaminitis',\n       'transbronchial', 'transcatheter', 'transcranial', 'transcriptase',\n       'transcutaneous', 'transderm', 'transdermal', 'transesophageal',\n       'transfer', 'transferred', 'transforaminal', 'transformation',\n       'transforming', 'transfused', 'transfusion', 'transfusions',\n       'transgraft', 'transhepatic', 'transient', 'transiently',\n       'transition', 'transitional', 'transitory', 'translocation',\n       'transluminal', 'transmission', 'transmitted', 'transmitter',\n       'transmitting', 'transnasal', 'transpeptidase', 'transplant',\n       'transplantation', 'transplanted', 'transplants', 'transport',\n       'transporters', 'transposition', 'transseptal', 'transsphenoidal',\n       'transtentorial', 'transtubular', 'transurethral', 'transvaginal',\n       'transvenous', 'transverse', 'trapezii', 'trastuzumab', 'trauma',\n       'traumatic', 'trazodone', 'treat', 'treatable', 'treated',\n       'treating', 'treatment', 'treatments', 'tree', 'tremens', 'tremor',\n       'tremors', 'tremulous', 'tremulousness', 'trends', 'treosulfan',\n       'trephine', 'treprostinil', 'tretinoin', 'trh', 'triad', 'trial',\n       'trials', 'triamcinolone', 'triazolam', 'trichiasis',\n       'trichomonas', 'trichophyton', 'trichosporon', 'trichosporonosis',\n       'trichotillomania', 'tricuspid', 'tricyclic', 'tried',\n       'trigeminal', 'trigger', 'triggered', 'triggering', 'triggers',\n       'triglyceride', 'triglycerides', 'trihexyphenidyl',\n       'triiodothyronine', 'trimester', 'trimethadione', 'trimethoprim',\n       'trimethoprime', 'trimethylangelicin', 'trimipramine', 'trimming',\n       'trimoxazole', 'trioxide', 'triple', 'triptan', 'triptans',\n       'trisalicylate', 'trisomy', 'tritherapy', 'troglitazone',\n       'trophic', 'tropicalis', 'troublesome', 'troubling', 'trough',\n       'trovafloxacin', 'true', 'trumpet', 'trunk', 'tryptase',\n       'tryptophan', 'ts', 'tsat', 'tsc1', 'tsc2', 'tsh', 'tshoma',\n       'ttkg', 'ttp', 'tts', 'tubal', 'tube', 'tubercular', 'tuberculin',\n       'tuberculoma', 'tuberculomas', 'tuberculosis', 'tuberculous',\n       'tubular', 'tubules', 'tubulin', 'tubulo', 'tubulointerstitial',\n       'tubulopathies', 'tularemia', 'tumor', 'tumoral', 'tumoricidal',\n       'tumors', 'tumour', 'tumours', 'tunisia', 'tunneling', 'tunnelled',\n       'turkish', 'turn', 'turned', 'turner', 'twelve', 'twenty', 'twice',\n       'twin', 'twins', 'twitch', 'twitches', 'two', 'type', 'types',\n       'typhimurium', 'typhlitis', 'typhoid', 'typical', 'typically',\n       'typing', 'tyr842', 'tyrosine', 'tzanck', 'tzds', 'uc', 'ucbt',\n       'ucva', 'ufh', 'uft', 'uganda', 'ui', 'uip', 'ukrain', 'ul54',\n       'ul97', 'ulcer', 'ulcerate', 'ulcerated', 'ulcerating',\n       'ulceration', 'ulcerations', 'ulcerative', 'ulcers', 'ulcus',\n       'ulnar', 'ultimately', 'ultrafiltration', 'ultrarapid',\n       'ultrasonic', 'ultrasonographic', 'ultrasonography', 'ultrasound',\n       'ultrastructural', 'ultrastructurally', 'ultrastructure',\n       'ultraviolet', 'umbilical', 'unable', 'unacceptable',\n       'unacceptably', 'unaccountable', 'unaware', 'unblocked',\n       'unbridled', 'uncertain', 'unchanged', 'uncharacteristic',\n       'unclear', 'uncommon', 'uncommonly', 'uncomplicated',\n       'unconscious', 'unconsciousness', 'uncontrollable', 'uncontrolled',\n       'uncorrected', 'under', 'underdosing', 'undergo', 'undergoes',\n       'undergoing', 'undergone', 'underlying', 'underreported',\n       'underscores', 'understand', 'understanding', 'understood',\n       'undertaken', 'undertaking', 'underway', 'underwent',\n       'undescribed', 'undesired', 'undetectable', 'undetermined',\n       'undiagnosed', 'undifferentiated', 'undoubtedly', 'undulating',\n       'uneventful', 'unexpected', 'unexplained', 'unfortunately',\n       'unfractionated', 'unidentified', 'uniform', 'unilateral',\n       'unilaterally', 'unintended', 'unintentional', 'unipolar',\n       'unique', 'uniquely', 'unit', 'united', 'units', 'universal',\n       'universalis', 'university', 'unknown', 'unless', 'unlicensed',\n       'unlike', 'unlikely', 'unmasked', 'unmasking', 'unnecessary',\n       'unopposed', 'unpredictable', 'unrecognized', 'unrelated',\n       'unremarkable', 'unreported', 'unresectable', 'unresponsive',\n       'unresponsiveness', 'unrevealing', 'unsatisfactory', 'unsolved',\n       'unsteady', 'unsuccessful', 'unsuccessfully', 'unsupervised',\n       'unsuspected', 'until', 'untoward', 'untreatable', 'untreated',\n       'unusual', 'unusually', 'unwanted', 'unwelcome', 'up', 'upbeating',\n       'updrs', 'upjohn', 'upon', 'upper', 'ups', 'upset', 'uptake',\n       'uraemic', 'urban', 'urea', 'urealyticum', 'ureaplasma', 'uremia',\n       'uremic', 'ureter', 'ureteral', 'ureterosigmoidostomy', 'urethane',\n       'urethral', 'urged', 'urgent', 'uric', 'uricaemia', 'urinary',\n       'urination', 'urine', 'urogenitalis', 'urokinase', 'urological',\n       'uroporphyrinogen', 'urosepsis', 'urothelial', 'urothelium',\n       'urticaria', 'urticarial', 'us', 'usa', 'usage', 'use', 'used',\n       'useful', 'usefulness', 'user', 'users', 'ushaar', 'using',\n       'usual', 'usually', 'uteri', 'uterine', 'utero', 'uterus',\n       'utility', 'utilization', 'utilized', 'utilizing', 'uv', 'uva',\n       'uvb', 'uveitis', 'v1', 'v11l', 'v3', 'va', 'vaccinated',\n       'vaccination', 'vaccine', 'vacuolar', 'vacuolated', 'vad', 'vads',\n       'vagina', 'vaginal', 'vaginalis', 'vaginosis', 'vagolytic',\n       'vague', 'valacyclovir', 'valerate', 'valid', 'valium',\n       'valproate', 'valproic', 'valuable', 'value', 'values', 'valve',\n       'valves', 'valvular', 'valvuloplasty', 'vanadium', 'vancomycin',\n       'vanished', 'vanishing', 'vapor', 'vaporub', 'vapour',\n       'vardenafil', 'varenicline', 'variable', 'variance', 'variant',\n       'variation', 'variations', 'variceal', 'varicella', 'varices',\n       'varicosities', 'varied', 'varies', 'varieties', 'variety',\n       'various', 'varix', 'vary', 'varying', 'vas', 'vascular',\n       'vasculature', 'vasculitis', 'vasculopathy', 'vasoactive',\n       'vasoconstrict', 'vasoconstriction', 'vasoconstrictive',\n       'vasoconstrictor', 'vasodilatation', 'vasodilatatory',\n       'vasodilation', 'vasodilator', 'vasomotor', 'vasopressin',\n       'vasospasm', 'vasospastic', 'vbds', 'vcr', 'vds', 've', 'vectors',\n       'vecuronium', 'vegetative', 'vegf', 'vehicle', 'vein', 'veins',\n       'velocities', 'velocity', 'vena', 'venlafaxine', 'veno', 'venous',\n       'venovenous', 'ventilation', 'ventilator', 'ventilatory',\n       'ventricle', 'ventricles', 'ventricular', 'ventriculitis',\n       'ventriculoperitoneal', 'venules', 'vera', 'verapamil', 'verba',\n       'verbal', 'verified', 'verify', 'vermian', 'vermis', 'verrucous',\n       'versa', 'versus', 'vertebral', 'vertical', 'vertigo', 'very',\n       'vesicle', 'vessel', 'vessels', 'veterans', 'veterinaires',\n       'veterinary', 'vfds', 'vgb', 'via', 'viable', 'vials', 'vibration',\n       'vice', 'vicks', 'victim', 'victims', 'video',\n       'videopolysomnographic', 'view', 'viewed', 'vigabatrin',\n       'vigilance', 'vigilant', 'vigorous', 'vigorously', 'vii', 'viia',\n       'viii', 'viloxazine', 'vinblastine', 'vinca', 'vincristine',\n       'vindesine', 'vinorelbine', 'vinyl', 'viokase', 'viraemia',\n       'viral', 'viramune', 'viremia', 'virilization', 'virulence',\n       'virus', 'viruses', 'virustaticum', 'visceral', 'viscoelastic',\n       'viscosity', 'viscosupplementation', 'visible', 'vision', 'visit',\n       'visited', 'visits', 'visual', 'visually', 'vital', 'vitamin',\n       'vitamins', 'vitiligo', 'vitrectomy', 'vitreous', 'vitritis',\n       'vitro', 'vivax', 'vivo', 'vm', 'vocal', 'vod', 'voglibose',\n       'vogt', 'volant', 'voltage', 'volume', 'volumes', 'voluntary',\n       'volunteer', 'volunteers', 'vomiting', 'von', 'voriconazole',\n       'vortex', 'vp', 'vpa', 'vrc', 'vs', 'vulgaris', 'vulnerability',\n       'vulnerable', 'vulval', 'vulvar', 'vvr', 'vwf', 'vzv', 'wafers',\n       'waiting', 'walked', 'walking', 'wall', 'walls', 'wallstent',\n       'wandering', 'ward', 'warfarin', 'warm', 'warned', 'warning',\n       'warranted', 'warrants', 'was', 'washout', 'wasting', 'water',\n       'watery', 'wave', 'waves', 'wax', 'way', 'ways', 'wbc', 'wd', 'we',\n       'weak', 'weakness', 'weaned', 'weaning', 'wear', 'wearer',\n       'wearing', 'wedge', 'week', 'weekly', 'weeks', 'wegener', 'weight',\n       'weighted', 'well', 'wenckebach', 'went', 'were', 'wes', 'west',\n       'western', 'wet', 'wg', 'what', 'wheat', 'wheezing', 'when',\n       'whenever', 'where', 'whereas', 'whereby', 'wherein', 'whether',\n       'which', 'while', 'whilst', 'white', 'who', 'whole', 'whom',\n       'whose', 'why', 'wide', 'widely', 'widen', 'widespread',\n       'wilcoxon', 'will', 'willebrand', 'wilmington', 'wilms', 'wilson',\n       'wish', 'wit', 'with', 'withdraw', 'withdrawal', 'withdrawing',\n       'withdrawn', 'withheld', 'withholding', 'within', 'without',\n       'witness', 'wk', 'wolff', 'woman', 'women', 'wood', 'wool', 'work',\n       'worker', 'workers', 'workup', 'world', 'worldwide', 'worn',\n       'worse', 'worsen', 'worsened', 'worsening', 'wort', 'would',\n       'wound', 'wounds', 'wpw', 'wrist', 'wrists', 'wyeth', 'x2', 'x3',\n       'xerostomia', 'xi', 'xiiia', 'xrt', 'xx', 'yag', 'year', 'yearly',\n       'years', 'yellow', 'yellowish', 'yet', 'yielded', 'yielding',\n       'ymdd', 'yohimbine', 'yolk', 'york', 'you', 'young', 'younger',\n       'youngest', 'yr', 'yrs', 'zafirlukast', 'zanamivir', 'zealand',\n       'zeneca', 'zephiran', 'zidovudine', 'zinc', 'ziprasidone',\n       'zoledronic', 'zolmitriptan', 'zolpidem', 'zomepirac', 'zone',\n       'zonisamide', 'zoonotic', 'zoster', 'zuclopenthixol', 'zurich',\n       'zygomycete', 'zygomycosis', 'zyprexa'], dtype=object)"
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ]
  },
  {
   "cell_type": "markdown",
   "source": [
    "### Create Vectors (Tokens) for the testing set"
   ],
   "metadata": {
    "id": "2yERiYlj9Z66"
   }
  },
  {
   "cell_type": "code",
   "source": [
    "# the train and test vectors use the same set of tokens:\n",
    "test_vectors = count_vectorizer.transform(test[\"Sentence\"])"
   ],
   "metadata": {
    "id": "s5b7Wxnp9ZKq",
    "executionInfo": {
     "status": "ok",
     "timestamp": 1698164777728,
     "user_tz": -660,
     "elapsed": 391,
     "user": {
      "displayName": "Katarina Stankovic",
      "userId": "08589456312134700603"
     }
    },
    "ExecuteTime": {
     "end_time": "2023-10-31T11:14:54.721699Z",
     "start_time": "2023-10-31T11:14:54.513996700Z"
    }
   },
   "execution_count": 11,
   "outputs": []
  },
  {
   "cell_type": "markdown",
   "source": [
    "### Machine Learning Model:\n",
    "\n",
    "* Random Forest [Classifier](https://scikit-learn.org/stable/modules/generated/sklearn.ensemble.RandomForestClassifier.html) applying [GridSearchCV](https://scikit-learn.org/stable/modules/generated/sklearn.model_selection.GridSearchCV.html) to find the best set of parameters."
   ],
   "metadata": {
    "id": "rEypbPKbVBZW"
   }
  },
  {
   "cell_type": "code",
   "source": [
    "#Initialise the Random Forest Classifier\n",
    "rfc = RandomForestClassifier(random_state=0) #used to get same output when reiterating the process\n",
    "\n",
    "param_grid = {\n",
    "    'n_estimators': [500, 700, 1000], \n",
    "    'max_features': ['auto', 'sqrt', 'log2'], \n",
    "    'max_depth' : [4,5,6,7,8],\n",
    "    'criterion' :['gini', 'entropy', 'log_loss'] #all it can be\n",
    "} \n",
    "\n",
    "#Call the GridSearchCV function to analyse each possible combination of parameters\n",
    "#split training data into 5 folds, train with 4 validate with the 5th, change the training 4\n",
    "CV_rfc = GridSearchCV(estimator = rfc, param_grid = param_grid, cv= 5)\n",
    "CV_rfc.fit(train_vectors, train[\"ADE\"])\n",
    "\n"
   ],
   "metadata": {
    "id": "brR02KcoDt2Y",
    "colab": {
     "base_uri": "https://localhost:8080/",
     "height": 116
    },
    "executionInfo": {
     "status": "ok",
     "timestamp": 1698164063152,
     "user_tz": -660,
     "elapsed": 1112542,
     "user": {
      "displayName": "Katarina Stankovic",
      "userId": "08589456312134700603"
     }
    },
    "outputId": "9fa213c6-4fe6-43c4-9d20-6dd5a0dc696c",
    "ExecuteTime": {
     "end_time": "2023-10-31T12:10:42.424817300Z",
     "start_time": "2023-10-31T11:14:54.545847400Z"
    }
   },
   "execution_count": 12,
   "outputs": [
    {
     "data": {
      "text/plain": "GridSearchCV(cv=5, estimator=RandomForestClassifier(random_state=0),\n             param_grid={'criterion': ['gini', 'entropy', 'log_loss'],\n                         'max_depth': [4, 5, 6, 7, 8],\n                         'max_features': ['auto', 'sqrt', 'log2'],\n                         'n_estimators': [500, 700, 1000]})",
      "text/html": "<style>#sk-container-id-1 {color: black;}#sk-container-id-1 pre{padding: 0;}#sk-container-id-1 div.sk-toggleable {background-color: white;}#sk-container-id-1 label.sk-toggleable__label {cursor: pointer;display: block;width: 100%;margin-bottom: 0;padding: 0.3em;box-sizing: border-box;text-align: center;}#sk-container-id-1 label.sk-toggleable__label-arrow:before {content: \"▸\";float: left;margin-right: 0.25em;color: #696969;}#sk-container-id-1 label.sk-toggleable__label-arrow:hover:before {color: black;}#sk-container-id-1 div.sk-estimator:hover label.sk-toggleable__label-arrow:before {color: black;}#sk-container-id-1 div.sk-toggleable__content {max-height: 0;max-width: 0;overflow: hidden;text-align: left;background-color: #f0f8ff;}#sk-container-id-1 div.sk-toggleable__content pre {margin: 0.2em;color: black;border-radius: 0.25em;background-color: #f0f8ff;}#sk-container-id-1 input.sk-toggleable__control:checked~div.sk-toggleable__content {max-height: 200px;max-width: 100%;overflow: auto;}#sk-container-id-1 input.sk-toggleable__control:checked~label.sk-toggleable__label-arrow:before {content: \"▾\";}#sk-container-id-1 div.sk-estimator input.sk-toggleable__control:checked~label.sk-toggleable__label {background-color: #d4ebff;}#sk-container-id-1 div.sk-label input.sk-toggleable__control:checked~label.sk-toggleable__label {background-color: #d4ebff;}#sk-container-id-1 input.sk-hidden--visually {border: 0;clip: rect(1px 1px 1px 1px);clip: rect(1px, 1px, 1px, 1px);height: 1px;margin: -1px;overflow: hidden;padding: 0;position: absolute;width: 1px;}#sk-container-id-1 div.sk-estimator {font-family: monospace;background-color: #f0f8ff;border: 1px dotted black;border-radius: 0.25em;box-sizing: border-box;margin-bottom: 0.5em;}#sk-container-id-1 div.sk-estimator:hover {background-color: #d4ebff;}#sk-container-id-1 div.sk-parallel-item::after {content: \"\";width: 100%;border-bottom: 1px solid gray;flex-grow: 1;}#sk-container-id-1 div.sk-label:hover label.sk-toggleable__label {background-color: #d4ebff;}#sk-container-id-1 div.sk-serial::before {content: \"\";position: absolute;border-left: 1px solid gray;box-sizing: border-box;top: 0;bottom: 0;left: 50%;z-index: 0;}#sk-container-id-1 div.sk-serial {display: flex;flex-direction: column;align-items: center;background-color: white;padding-right: 0.2em;padding-left: 0.2em;position: relative;}#sk-container-id-1 div.sk-item {position: relative;z-index: 1;}#sk-container-id-1 div.sk-parallel {display: flex;align-items: stretch;justify-content: center;background-color: white;position: relative;}#sk-container-id-1 div.sk-item::before, #sk-container-id-1 div.sk-parallel-item::before {content: \"\";position: absolute;border-left: 1px solid gray;box-sizing: border-box;top: 0;bottom: 0;left: 50%;z-index: -1;}#sk-container-id-1 div.sk-parallel-item {display: flex;flex-direction: column;z-index: 1;position: relative;background-color: white;}#sk-container-id-1 div.sk-parallel-item:first-child::after {align-self: flex-end;width: 50%;}#sk-container-id-1 div.sk-parallel-item:last-child::after {align-self: flex-start;width: 50%;}#sk-container-id-1 div.sk-parallel-item:only-child::after {width: 0;}#sk-container-id-1 div.sk-dashed-wrapped {border: 1px dashed gray;margin: 0 0.4em 0.5em 0.4em;box-sizing: border-box;padding-bottom: 0.4em;background-color: white;}#sk-container-id-1 div.sk-label label {font-family: monospace;font-weight: bold;display: inline-block;line-height: 1.2em;}#sk-container-id-1 div.sk-label-container {text-align: center;}#sk-container-id-1 div.sk-container {/* jupyter's `normalize.less` sets `[hidden] { display: none; }` but bootstrap.min.css set `[hidden] { display: none !important; }` so we also need the `!important` here to be able to override the default hidden behavior on the sphinx rendered scikit-learn.org. See: https://github.com/scikit-learn/scikit-learn/issues/21755 */display: inline-block !important;position: relative;}#sk-container-id-1 div.sk-text-repr-fallback {display: none;}</style><div id=\"sk-container-id-1\" class=\"sk-top-container\"><div class=\"sk-text-repr-fallback\"><pre>GridSearchCV(cv=5, estimator=RandomForestClassifier(random_state=0),\n             param_grid={&#x27;criterion&#x27;: [&#x27;gini&#x27;, &#x27;entropy&#x27;, &#x27;log_loss&#x27;],\n                         &#x27;max_depth&#x27;: [4, 5, 6, 7, 8],\n                         &#x27;max_features&#x27;: [&#x27;auto&#x27;, &#x27;sqrt&#x27;, &#x27;log2&#x27;],\n                         &#x27;n_estimators&#x27;: [500, 700, 1000]})</pre><b>In a Jupyter environment, please rerun this cell to show the HTML representation or trust the notebook. <br />On GitHub, the HTML representation is unable to render, please try loading this page with nbviewer.org.</b></div><div class=\"sk-container\" hidden><div class=\"sk-item sk-dashed-wrapped\"><div class=\"sk-label-container\"><div class=\"sk-label sk-toggleable\"><input class=\"sk-toggleable__control sk-hidden--visually\" id=\"sk-estimator-id-1\" type=\"checkbox\" ><label for=\"sk-estimator-id-1\" class=\"sk-toggleable__label sk-toggleable__label-arrow\">GridSearchCV</label><div class=\"sk-toggleable__content\"><pre>GridSearchCV(cv=5, estimator=RandomForestClassifier(random_state=0),\n             param_grid={&#x27;criterion&#x27;: [&#x27;gini&#x27;, &#x27;entropy&#x27;, &#x27;log_loss&#x27;],\n                         &#x27;max_depth&#x27;: [4, 5, 6, 7, 8],\n                         &#x27;max_features&#x27;: [&#x27;auto&#x27;, &#x27;sqrt&#x27;, &#x27;log2&#x27;],\n                         &#x27;n_estimators&#x27;: [500, 700, 1000]})</pre></div></div></div><div class=\"sk-parallel\"><div class=\"sk-parallel-item\"><div class=\"sk-item\"><div class=\"sk-label-container\"><div class=\"sk-label sk-toggleable\"><input class=\"sk-toggleable__control sk-hidden--visually\" id=\"sk-estimator-id-2\" type=\"checkbox\" ><label for=\"sk-estimator-id-2\" class=\"sk-toggleable__label sk-toggleable__label-arrow\">estimator: RandomForestClassifier</label><div class=\"sk-toggleable__content\"><pre>RandomForestClassifier(random_state=0)</pre></div></div></div><div class=\"sk-serial\"><div class=\"sk-item\"><div class=\"sk-estimator sk-toggleable\"><input class=\"sk-toggleable__control sk-hidden--visually\" id=\"sk-estimator-id-3\" type=\"checkbox\" ><label for=\"sk-estimator-id-3\" class=\"sk-toggleable__label sk-toggleable__label-arrow\">RandomForestClassifier</label><div class=\"sk-toggleable__content\"><pre>RandomForestClassifier(random_state=0)</pre></div></div></div></div></div></div></div></div></div></div>"
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ]
  },
  {
   "cell_type": "code",
   "source": [
    "CV_rfc.best_params_"
   ],
   "metadata": {
    "id": "PqmHpecPgWvd",
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "executionInfo": {
     "status": "ok",
     "timestamp": 1698164102011,
     "user_tz": -660,
     "elapsed": 447,
     "user": {
      "displayName": "Katarina Stankovic",
      "userId": "08589456312134700603"
     }
    },
    "outputId": "dea1b909-6c10-4b26-f97c-d356c659c8cc",
    "ExecuteTime": {
     "end_time": "2023-10-31T12:10:42.473432100Z",
     "start_time": "2023-10-31T12:10:42.409517500Z"
    }
   },
   "execution_count": 13,
   "outputs": [
    {
     "data": {
      "text/plain": "{'criterion': 'entropy',\n 'max_depth': 8,\n 'max_features': 'log2',\n 'n_estimators': 1000}"
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ]
  },
  {
   "cell_type": "markdown",
   "source": [
    "Using the best parameters, calling the classifier again"
   ],
   "metadata": {
    "id": "sIjFs1Wn6jhz"
   }
  },
  {
   "cell_type": "code",
   "source": [
    "rfc = RandomForestClassifier(criterion=CV_rfc.best_params_['criterion'],\\\n",
    "                             max_depth=CV_rfc.best_params_['max_depth'], \\\n",
    "                             max_features=CV_rfc.best_params_['max_features'], \\\n",
    "                             n_estimators=CV_rfc.best_params_['n_estimators'], \\\n",
    "                             random_state=0)\n"
   ],
   "metadata": {
    "id": "WMyUHTebgurh",
    "executionInfo": {
     "status": "ok",
     "timestamp": 1698164106550,
     "user_tz": -660,
     "elapsed": 432,
     "user": {
      "displayName": "Katarina Stankovic",
      "userId": "08589456312134700603"
     }
    },
    "ExecuteTime": {
     "end_time": "2023-10-31T12:10:42.474398100Z",
     "start_time": "2023-10-31T12:10:42.440638800Z"
    }
   },
   "execution_count": 14,
   "outputs": []
  },
  {
   "cell_type": "code",
   "source": [
    "rfc.fit(train_vectors, train[\"ADE\"])\n",
    "test[\"new_prediction\"] = rfc.predict(test_vectors)\n",
    "test.head()"
   ],
   "metadata": {
    "id": "KfU9EOV5VPXr",
    "colab": {
     "base_uri": "https://localhost:8080/",
     "height": 206
    },
    "executionInfo": {
     "status": "ok",
     "timestamp": 1698164790316,
     "user_tz": -660,
     "elapsed": 2900,
     "user": {
      "displayName": "Katarina Stankovic",
      "userId": "08589456312134700603"
     }
    },
    "outputId": "742d7671-f4b0-4f53-a404-a98c766b3bdc",
    "ExecuteTime": {
     "end_time": "2023-10-31T12:10:52.590041600Z",
     "start_time": "2023-10-31T12:10:42.471596500Z"
    }
   },
   "execution_count": 15,
   "outputs": [
    {
     "data": {
      "text/plain": "                                               Sentence  ADE  new_prediction\n4816  A case of polymyositis with dilated cardiomyop...    1               1\n722   Twenty-six patients with mycosis fungoides wer...    0               0\n3121  Dementia with Lewy bodies (DLB) has been assoc...    0               0\n3448  We should take dental treatment into account o...    0               0\n4429  Bronchiolitis obliterans organising pneumonia ...    1               1",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Sentence</th>\n      <th>ADE</th>\n      <th>new_prediction</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>4816</th>\n      <td>A case of polymyositis with dilated cardiomyop...</td>\n      <td>1</td>\n      <td>1</td>\n    </tr>\n    <tr>\n      <th>722</th>\n      <td>Twenty-six patients with mycosis fungoides wer...</td>\n      <td>0</td>\n      <td>0</td>\n    </tr>\n    <tr>\n      <th>3121</th>\n      <td>Dementia with Lewy bodies (DLB) has been assoc...</td>\n      <td>0</td>\n      <td>0</td>\n    </tr>\n    <tr>\n      <th>3448</th>\n      <td>We should take dental treatment into account o...</td>\n      <td>0</td>\n      <td>0</td>\n    </tr>\n    <tr>\n      <th>4429</th>\n      <td>Bronchiolitis obliterans organising pneumonia ...</td>\n      <td>1</td>\n      <td>1</td>\n    </tr>\n  </tbody>\n</table>\n</div>"
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ]
  },
  {
   "cell_type": "markdown",
   "source": [
    "### Evaluation of the model"
   ],
   "metadata": {
    "id": "jETaw6P36--j"
   }
  },
  {
   "cell_type": "code",
   "source": [
    "#accuraccy not such a good metric as mcc is\n",
    "\n",
    "acc_rfc = float(round(metrics.accuracy_score(test[\"ADE\"], test[\"new_prediction\"]),3))\n",
    "\n",
    "\n",
    "bacc_rfc = float(round(metrics.balanced_accuracy_score(test[\"ADE\"], test[\"new_prediction\"]),3))\n",
    "\n",
    "mcc_rfc = float(round(metrics.matthews_corrcoef(test[\"ADE\"], test[\"new_prediction\"]),3))\n",
    "\n",
    "f1_rfc = float(round(metrics.f1_score(test[\"ADE\"], test[\"new_prediction\"]),3))\n",
    "\n",
    "#Save results as a DataFrame:\n",
    "results_rfc = {'Accuracy' : [acc_rfc], 'Balanced Accuracy' : [bacc_rfc], 'MCC' : [mcc_rfc], 'F1-Score' : [f1_rfc]}\n",
    "rfc_results = pd.DataFrame.from_dict(data = results_rfc, orient='columns')\n",
    "print(rfc_results)"
   ],
   "metadata": {
    "id": "DJTtQl9LVr9Q",
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "executionInfo": {
     "status": "ok",
     "timestamp": 1698164862121,
     "user_tz": -660,
     "elapsed": 468,
     "user": {
      "displayName": "Katarina Stankovic",
      "userId": "08589456312134700603"
     }
    },
    "outputId": "9a81e8de-9725-444c-f43f-fa24e2ef31f1",
    "ExecuteTime": {
     "end_time": "2023-10-31T12:10:53.052467300Z",
     "start_time": "2023-10-31T12:10:52.618169100Z"
    }
   },
   "execution_count": 16,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "   Accuracy  Balanced Accuracy    MCC  F1-Score\n",
      "0     0.815              0.815  0.632     0.809\n"
     ]
    }
   ]
  },
  {
   "cell_type": "markdown",
   "source": [
    "## Setting up the data that should pass through the model"
   ],
   "metadata": {
    "collapsed": false
   }
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Loaded cohort from ..\\out\\total-drug-interactions.out\n"
     ]
    },
    {
     "data": {
      "text/plain": "    subject_id   hadm_id   stay_id drug_a_item_id drug_b_item_id  \\\n0     16796985  27317580  33550086         225798         225893   \n1     17007441  20790097  31504988         225798         225893   \n2     10118315  22138146  35949957         225798         225893   \n3     10267084  28933075  31922388         225798         225893   \n4     10413295  22438881  37973258         225798         225893   \n..         ...       ...       ...            ...            ...   \n95    17745537  25137618  31986786         225798         225893   \n96    17862236  26604678  30586056         225798         225893   \n97    18017363  28138354  37413388         225798         225893   \n98    18455402  26039491  34320919         225798         225893   \n99    18761260  26980143  31681715         225798         225893   \n\n           dose_b_time  event_count  \\\n0  2160-04-13 19:00:00           16   \n1  2138-06-12 00:00:00           28   \n2  2111-06-24 12:15:00           10   \n3  2147-12-03 04:10:00            4   \n4  2170-12-23 05:01:00           15   \n..                 ...          ...   \n95 2119-11-28 23:29:00            4   \n96 2127-09-29 15:30:00            4   \n97 2117-04-05 18:23:00            1   \n98 2193-08-17 10:06:00            8   \n99 2144-10-10 08:00:00           19   \n\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          text  \\\n0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 \\nName:  ___               Unit No:   ___\\n \\nAdmission Date:  ___              Discharge Date:   ___\\n \\nDate of Birth:  ___             Sex:   M\\n \\nService: CARDIOTHORACIC\\n \\nAllergies: \\nIV Dye, Iodine Containing Contrast Media / heparin\\n \\nAttending: ___.\\n \\nChief Complaint:\\nrecurrent pleural effusion\\n \\nMajor Surgical or Invasive Procedure:\\n___\\nTotal pulmonary decortication.\\n\\n___\\nRight AC PICC\\n\\n___\\nPEG tube placement\\n\\n___\\nPercutaneous tracheostomy (#8 Portex).\\n\\n___\\nLeft pleural pigtail placement\\n\\n \\nHistory of Present Illness:\\nMr ___ is a ___ recently evaluated while inpatient for a\\nloculated left pleural effusion and had a chest tube placed. He\\nnow presents to discuss treatment plan for his effusion. His \\n___\\nCT ___ noted increased left hydropneumothorax, stable LLL\\ncollapse, small right pleural effusion. Currently, he reports\\nincreased SOB at rest and with any activity. He also has\\noccasional cough productive of white phlegm, abd and left lower\\nthorax pain ___. Otherwise, he denies any fever, sweats or \\nother\\nnew sx. He presents now for decortication.\\n\\n \\nPast Medical History:\\n#CAD, status post CABGx3 (___)\\n#AAA\\n#Aortic stenosis s/p St. ___ AVR (___)\\n#Afib, on Coumadin \\n#Gout\\n#GERD\\n#HTN\\n#Hyperlipidemia\\n#Tonsillectomy and left knee surgery\\n#Hx of heavy ETOH use\\n#Lumbar disc disease\\n#BPH\\n#remote rectal bleeding, colonoscopy revealing polyps\\nPast Surgical History:\\n#Tonsillectomy\\n#Left knee arthroscopic surgery x2\\n \\nSocial History:\\n___\\nFamily History:\\nFather: died of CAD in ___\\nMother: died of PNA in ___\\nBrother: died age ___ of colon CA\\nBrother: died age ___ of CABG complications\\nSister: died age ___ lung CA\\nBrother: died of ___\\nSon: died of drug OD age ___\\nSon: age ___, healthy\\n \\nPhysical Exam:\\nBP: 92/66. Heart Rate: 72. Weight: # (refuse to ___ shoes off).\\nTemperature: 97.8. Resp. Rate: 16. Pain Score: 6. O2 \\nSaturation%:\\n100.\\n\\nGen: looks older than stated age, chronically ill appearing\\nNeck: no ___: diminished breath sounds LLL, few wheezes right\\nCor: RRR with click\\nExtrem: no CCE\\n\\n \\nPertinent Results:\\n                    WBC RBC   Hgb  Hct   MCV  MCH MCHC RDW Plt \\nCt \\n___ 06:50    8.7 2.61* 8.2* 26.9* 103* 31.3 30.4* 16.6* \\n169 \\nSource: Line-___ \\n___ 03:47    8.4 2.44* 7.8* 25.5* 105* 32.0 30.5* 16.8* \\n141* \\nSource: Line-___ \\n___ 04:09    9.8 2.62* 8.0* 27.3* 104* 30.6 29.5* 17.2* \\n136* \\nSource: Line-___ \\n___ 05:45    8.8 2.53* 8.0* 26.7* 105* 31.5 29.9* 17.7* \\n126* \\n___ 06:37    9.5 2.65* 8.2* 28.0* 106* 31.0 29.3* 17.9* \\n100* \\n___ 04:47    11.0 2.65* 8.6* 28.2* 107* 32.5* 30.5* 18.2* \\n98* \\nSource: Line-___ \\n___ 05:00    10.4 2.58* 8.3* 27.4* 106* 32.4* 30.5* 18.6* \\n71* \\nSource: Line-___ \\n___ 04:15    12.6* 2.70* 8.7* 28.7* 106* 32.3* 30.3* \\n19.5* 89* \\nSource: Line-___ \\n___ 02:07    9.4 2.62* 8.4* 27.3* 104* 32.1* 30.8* 20.2* \\n47* \\nSource: Line-___ \\n___ 02:54    8.5 2.38* 7.5* 25.9* 109* 31.6 29.1* 20.4* \\n66* \\nSource: Line-___ \\n___ 00:22    14.5* 2.68* 8.7* 29.3* 109* 32.2* 29.5* \\n20.6* 75* \\nSource: Line-___ \\n___ 23:37    15.5* 2.95* 9.2* 32.1* 109* 31.2 28.6* 20.6* \\n82*1 \\nSource: Line-a \\n___ 01:44    15.4* 2.65* 8.3* 28.9* 109* 31.5 28.9* 20.8* \\n110* \\n\\n  \\nSource: Line-___    PTT  Plt Ct       INR\\n___ 06:50    21.7*       2.0* \\nSource: Line-___ \\n___ 03:47          141*   \\nSource: Line-___ \\n___ 03:47    16.2*       1.5* \\nSource: Line-___ \\n___ 04:09          136*   \\nSource: Line-___ \\n___ 04:09    15.5* 32.2     1.4* \\nSource: Line-___ \\n___ 10:24    16.2*       1.5* \\nSource: Line-___ \\n___ 05:45          126*   \\n___ 05:45    16.8*       1.6* \\n___ 06:37          100*   \\n___ 06:37    19.9* 40.5*     1.9* \\n___ 04:47          98*   \\nSource: Line-___ \\n___ 04:47    19.9* 37.0*     1.9* \\n\\n                  Glucose UreaN Creat Na  K  Cl HCO3 AnGap \\n___ 06:50    127*1 72*   3.2* 141 4.4 98 30 17 \\nSource: Line-___ \\n___ 03:47    116*1 70*   3.3* 137 4.6 96 33* 13 \\nSource: Line-___ \\n___ 04:09    118*1 63*   3.4* 138 4.6 96 30 17 \\nSource: Line-picc \\n___ 09:10    133*1 59*   3.3* 137 4.7 97 29 16 \\nSource: Line-PICC \\n___ 05:45    109*1 47*   3.0* 136 4.3 95* 31 14 \\n___ 06:37    112*1 36*   2.5* 136 4.2 97 30 13 \\n___ 04:47    138*1 42*   2.9* 135 4.2 96 30 13 \\nSource: Line-PICC \\n___ 05:00    117*1 29*   2.4* 134 3.8 98 29 11 \\nSource: Line-PICC \\n___ 04:15    106*1 42*   3.2* 135 3.9 98 27 14 \\nSource: Line-PICC \\n___ 02:07    124*1 29*   2.3* 135 4.1 100 28 11 \\nSource: Line-aline \\n___ 02:54    991 18      1.5* 135 3.6 99 26 14 \\nSource: Line-aline \\n___ 17:55    101*1 13    1.2 136 3.8 100 27 13 \\nSource: Line-aline \\n___ 13:30    103*1 12    1.0 136 3.6 99 27 14 \\nSource: Line-aline \\n___ 06:06    113*1 14    1.1 134 3.8 100 25 13 \\nSource: Line-aline \\n___ 00:22    120*1 15    1.3* 132* ___ 15 \\nSource: Line-aline; MODERATELY HEMOLYZED SPECIMEN \\n___ 17:34    145*1 18    1.4* 133 ___ 15 \\nSource: Line-arterial; GROSSLY HEMOLYZED SPECIMEN \\n___ 07:51    112*1 20    1.3* 136 3.4 ___ \\nSource: Line-arterial \\n___ 23:37    129*1       1.5* 137 3.82 103 21* 17 \\nSource: Line-a; MODERATELY HEMOLYZED SPECIMEN \\n___ 19:34    141*1 27*    1.7* 135 4.22 ___ \\nSource: Line-a; MODERATELY HEMOLYZED SPECIMEN \\n___ 16:01    150*1 31*    2.0* 137 3.5 ___ \\nSource: Line-arterial \\n___ 08:05    133*1 33*    1.9* 137 3.5 ___ \\nSource: Line-arterial \\n___ 01:44    133*1 37*     2.3* 138 3.5 ___ \\nSource: Line-arterial \\n___ 19:30    134*1 44*    2.6* 137 3.8 ___ \\nSource: Line-arterial \\n___ 13:40    106*1 48*     2.9* 138 4.92 ___ \\nMODERATELY HEMOLYZED SPECIMEN \\n___ 07:14    106*1 57*     3.3* 139 4.5 100 22 22* \\n___ 01:40    122*1 66*     3.8* 138 4.6 ___ \\nADD ON \\n___ 19:53    121*1 79*     4.4* 141 5.1 ___ \\nSource: Line-arterial \\n___ 02:43    941 78*       4.5* 142 5.4* ___ \\nSource: Line-picc line \\n___ 14:00    801 74*       4.2* 142 5.3* ___ \\n___ 03:02    861 70*       3.8* 139 5.0 ___ \\nSource: Line-R ___ \\n___ 18:31    931 69*       3.6* 141 4.7 ___ \\nSource: Line-aline \\n___ 02:17    103*1 63*     3.4* 140 4.5 ___ \\nSource: Line-PICC \\n___ 17:55    104*1 59*     3.0* 139 4.6 ___ \\nSource: Line- aline \\n___ 03:07    921 57*        2.6* 140 4.5 ___ \\nSource: Line-arterial \\n___ 22:00    811 55*        2.5* 138 4.4 ___ \\nSource: Line-art \\n___ 14:40    135*1 56       2.5* 143 4.6 ___ \\nSource: Line-a line \\n___ 01:10    152*1 50*      2.1* 147* 4.2 ___ \\nSource: Line-arterial \\n___ 01:30    961 46*        1.7* 149* 4.1 110* 26 17 \\nSource: Line-art \\n___ 02:07    831 46*        1.7* 148* 4.1 ___ \\nSource: Line-A \\n___ 13:02    102*1 46*       1.6* 147* 3.9 ___ \\n___ 02:21    153*1 48*       1.5* 149* 3.4 108 32 12 \\nSource: Line-a line \\n___ 03:13    157*1 48*       1.3* 148* 3.6 ___ \\nSource: Line-a line \\n___ 04:29    112*1 46*       1.2 150* 3.6 113* 32 9 \\nSource: Line-art line \\n___ 20:00    175*1 47*      1.2 150* 4.2 111* 31 12 \\nSource: Line-art line \\n___ 05:31    199*1 47*      1.2 148* 3.6 106 34* 12 \\nSource: Line-PICC \\n___ 04:09    182*1 48*     1.2 149* 3.5 \\n\\n___ TTE\\nThe left atrium is moderately dilated. The estimated right \\natrial pressure is at least 15 mmHg. There is mild symmetric \\nleft ventricular hypertrophy with normal cavity size. Left \\nventricular systolic function is hyperdynamic (EF>75%). Right \\nventricular chamber size and free wall motion are normal. The \\nright ventricular free wall is hypertrophied. A bioprosthetic \\naortic valve prosthesis is present. The aortic valve prosthesis \\nappears well seated, with normal leaflet/disc motion and \\ntransvalvular gradients. Trace aortic regurgitation is seen. The \\nmitral valve leaflets are mildly thickened. There is mild \\nposterior leaflet mitral valve prolapse. Moderate to severe (3+) \\nmitral regurgitation is seen. Moderate [2+] tricuspid \\nregurgitation is seen. There is moderate pulmonary artery \\nsystolic hypertension. There is no pericardial effusion. \\n\\nCompared with the prior study (images reviewed) of ___, a \\nwell seated aortic valve bioprosthesis with normal gradients and \\ntrace aortic regurgitation is seen. Mild posterior mitral valve \\nprolapse is now appreciated. There is significantly more mitral \\nand tricuspid regurgitation. Pulmonary pressures are higher\\n\\n___ Chest CT :\\n1.  Persistent left lower lobe consolidation with decrease in \\nsize of the \\nleft-sided pneumothorax with chest tube in situ.   \\n2.  Increase in size of a right pleural effusion, now moderate.  \\n \\n3.  New left mildly displaced rib fracture. \\n4.  Intra-abdominal findings are better detailed on the CT \\nabdomen and pelvis. \\n\\n___ Liver US :\\n1.  Normal hepatic echotexture.  No focal lesions.  No biliary \\nduct dilation. \\n2.  Small amount of abdominal ascites. \\n3.  Gallbladder sludge and gallbladder wall edema, which in the \\nsetting of acute liver disease and ascites, is nonspecific. \\n4.  Enlarging abdominal aortic aneurysm, which now measures 7.8 \\nx 6.3 cm. \\n\\n___ Video swallow :\\n\\nOropharyngeal swallowing video fluoroscopy was \\nperformed in conjunction with the speech and swallow division.  \\nMultiple \\nconsistencies of barium were administered.  There is pre-spill \\nof contrast \\nonto the vallecula with a large amount of residue on the \\nvallecula.  \\nPenetration is seen with nectar and thin liquids \\n\\n___ Abd CT :\\n1.  Removal of left pleural tube since ___ with \\npersistent left lower lobe consolidation and probably empyema.  \\nLarge amount of air is present in the left pleural cavity, \\nincluding a 3.9 cm pocket of air which could be pleural or \\nintraparenchymal, and could be further evaluated with a \\ndedicated chest CT.  Interval enlargement of now large right \\npleural effusion with adjacent atelectasis.   \\n  \\n2.  Large subcutaneous gas tracks from the left thoracic soft \\ntissues to the left inguinal region and is likely related to \\nprior pleural tube placement.   \\n  \\n3.  New PEG tube within the stomach.  Moderate pneumoperitoneum, \\nno free \\ncontrast in the abdomen. \\n  \\n4.  Stable size of infrarenal abdominal aortic aneurysm with \\neccentric mural thrombus.   \\n  \\n5.  Moderate amount of intra-abdominal ascites, increased since \\nthe prior \\nexam \\n\\n___ Left pigtail placement:\\n1. Successful drainage of left upper hydropneumothorax with 8 \\n___ catheter. \\nCatheter attached to a Pleuravac device on suction.  No \\nperiprocedural \\ncomplications. \\n  \\n2. Pleural thickening/fluid identified along the left lateral \\nchest wall, with \\nnumerous locules of air.  Large consolidation with air \\nbronchograms identified \\nat the left lower lobe.  Loculated pleural effusion in the left \\nlower lung \\nwith numerous air locules and pleural thickening.  \\n  \\n3. Moderate sized right pleural effusion. \\n  \\n4. Moderate perihepatic fluid. \\n  \\n5. Multiple nonenlarged lymph nodes in the left axilla.  \\nMultiple prominent \\nsubcentimeter mediastinal lymph nodes, predominantly in the \\nparatracheal and \\nprevascular regions, likely reactive.  \\n  \\n6.  A 6.8 cm loculated collection identified along the \\nsubcutaneous tissues of \\nleft posterolateral chest wall containing locules of air.  \\n  \\n___ Bilat ___ duplex :\\nNo evidence of DVT in either lower extremity to the level of the \\n\\nknee.  Calf vein thrombus cannot be completely excluded.  \\nPulsatile femoral waveforms indicate elevated central venous \\npressure. \\n\\n___ Bilat UE duplex scan:\\nNo evidence of DVT in either upper extremity.  There is \\nsuperficial phlebitis involving the left upper arm cephalic \\nvein. \\n\\n___ 10:18 am Mini-BAL      BRONCHIAL LAVAGE. \\n\\n                            **FINAL REPORT ___\\n\\n   GRAM STAIN (Final ___: \\n      2+   ___ per 1000X FIELD):   POLYMORPHONUCLEAR \\nLEUKOCYTES. \\n      NO MICROORGANISMS SEEN. \\n\\n   RESPIRATORY CULTURE (Final ___: \\n      Commensal Respiratory Flora Absent. \\n      NON-FERMENTER, NOT PSEUDOMONAS AERUGINOSA. \\n         10,000-100,000 ORGANISMS/ML.. \\n         sensitivity testing performed by Microscan. \\n         MEROPENEM (<=1 MCG/ML). \\n\\n                              SENSITIVITIES: MIC expressed in \\nMCG/ML\\n                      \\n_________________________________________________________\\n                             NON-FERMENTER, NOT PSEUDOMONAS \\nAERUGINOSA\\n                             |   \\nAMIKACIN--------------  =>64 R\\nCEFEPIME--------------    16 I\\nCEFTAZIDIME-----------     2 S\\nCEFTRIAXONE-----------    32 I\\nCIPROFLOXACIN---------     2 I\\nGENTAMICIN------------  =>16 R\\nIMIPENEM--------------   <=1 S\\nLEVOFLOXACIN----------   <=1 S\\nMEROPENEM-------------       S\\nPIPERACILLIN/TAZO-----   <=8 S\\nTOBRAMYCIN------------  =>16 R\\nTRIMETHOPRIM/SULFA----   <=2 S\\n\\n \\nBrief Hospital Course:\\nMr. ___ was admitted to the hospital and taken to the \\nOperating Room where he underwent a  total pulmonary \\ndecortication.  He tolerated the procedure well and returned to \\nthe PACU intubated in stable condition. He had an epidural \\ncatheter placed for pain but it was capped and eventually \\nremoved  as he remained intubated. His chest tubes remained in \\nplace and were draining sanguinous fluid. The remainder of this \\nsummary will be done as a systems review for completeness.\\n\\nResp:  He was finally extubated on ___ after multiple other \\nproblems but required reintubation on 2 more occasions and \\neventually underwent a tracheostomy on ___.  Currently he \\nis doing well on a 35% trach collar and has his PMV in place \\nwhen supervised.  His trach tube was downsized to a #6 cuffless \\nportex on ___ and he continues to do well.  he has been \\ntreated for pneumonia on 2 occasions but currently is afebrile \\nwith a normal WBC and minimal sputum production.\\n\\nCV: He had problems with hypotension and septic shock on post op \\nday # 3.  He was on multiple pressors. During this work up an \\nabdominal CT revealed an enlarging infrarenal AAA 7.9x7.4 cm.  \\nThe Vascular surgery service was consulted and due to his \\nunstable hemodynamics, surgery could not be considered.  His \\nblood pressure was controlled and the vascular surgeons \\nrecommended follow up after he recovered from this \\nhospitalization.  He also has had problems with RAF and required \\nrate control with lopressor and diltiazem but unfortunately his \\nblood pressure would not tolerate.  He was digitalized and has \\nmaintained controlled atrial fibrillation.  His dig level needs \\nto be followed at least 3 times a week as his renal function \\nchanges.  Today his dig level is 1.9 on digoxin 0.125 mg twice a \\nweek. His blood pressure is in the 110-130 range.\\n\\nGI; During his initial post op sepsis his liver enzymes rose and \\na RUQ US had non specific findings.  Currently his transaminase \\nare normal and his last T bili is 1.9.  His nutritional status \\nhas been supported with tube feedings and a PEG tube was placed \\non ___.  He has been seen by the speech and swallow \\ntherapist but is too weak for oral trials.  He will need to be \\nre evaluated at rehab because he feels hungry and would love the \\nopportunity to swallow ice cream!  \\n\\nGU: His urinary catheter has been removed twice and he has \\nfailed 2 voiding trials.  The GU service needed to replace the \\ncatheter both times.  They recommend giving him a chance after \\nhe becomes more mobile and hopefully that will be successful.  \\nHe needs to make an appointment in the ___ clinic in ___ \\nweeks and he will have a voiding trial and/or a catheter \\nexchange.  His urine culture has been negative on many \\noccasions.  From a renal standpoint, he developed ___ on \\n___ when his urine output decreased and his blood pressure \\nwas 90-100.  He was evaluated by the renal service and \\neventually required dialysis until a week ago.  His Dialysis \\ncatheter was removed on ___.  Currently he will need blood \\nwork 3 times a week.  His creatinine is 3.2 and he's making \\nabout 1400 mls of urine daily.\\n\\nHeme: During his hospitalization his platelet count decreased to \\nas low as 47 and the hematology service was asked to consult to \\nrule out HIT.  He had a positive HIT antibody with optical \\ndenisty >1.0 indicating strong likelihood that result was a true \\npositve in the setting of therapeutic anticoagulation for afib \\nwith coumadin. However, his SRA came back negative.  In the \\ninterim he was treated with Coumadin alone but should his INR go \\n< 1.8 he should be bridged with Argatroban.  The \\ngeneral consensus is that it is a true HIT.  Currently his \\nplatelet count is normal but should be followed along with his \\nINR.\\n\\nID: not currently on any antibiotics and his only positive \\nculture from this admission was a mini BAL on ___ which \\ngrew pseudomonas and was treated. He has been afebrile and his \\nWBC is8K.\\n\\nAfter a long hospital stay he will be teransferred to rehab for \\nfurther management of his pulmonary issues and physical therapy \\nwith the hope of getting him home soon.\\n\\n \\nMedications on Admission:\\nThe Preadmission Medication list is accurate and complete.\\n1. Metoprolol Tartrate 75 mg PO BID \\n2. Diltiazem 60 mg PO BID \\n3. Docusate Sodium 100 mg PO BID \\n4. Warfarin 1 mg PO DAILY16 \\n5. Ranitidine 150 mg PO BID \\n6. Atorvastatin 80 mg PO DAILY \\n7. Oxycodone-Acetaminophen (5mg-325mg) 1 TAB PO DAILY:PRN pain \\n8. Aspirin 81 mg PO DAILY \\n9. Hydrochlorothiazide 25 mg PO DAILY \\n\\n \\nDischarge Medications:\\n1. Aspirin 81 mg PO DAILY \\n2. Docusate Sodium 100 mg PO BID \\n3. Acetaminophen 325-650 mg PO Q6H:PRN pain \\n4. Albuterol Inhaler ___ PUFF IH Q4H:PRN Wheeze \\n5. Bisacodyl 10 mg PO/PR DAILY \\n6. Chlorhexidine Gluconate 0.12% Oral Rinse 15 mL ORAL BID \\n7. Digoxin 0.125 mg PO 2X/WEEK (MO,FR) \\n8. Famotidine 20 mg PO DAILY \\n9. OxycoDONE Liquid ___ mg PO Q4H:PRN pain \\n10. Polyethylene Glycol 17 g PO DAILY:PRN constipation \\n11. QUEtiapine Fumarate 50 mg PO QHS:PRN insomnia \\n12. Sodium Chloride 0.9%  Flush ___ mL IV DAILY and PRN, line \\nflush \\n13. Ursodiol 250 mg PO TID \\n14. Ranitidine 150 mg PO BID \\n15. ___  MD to order daily dose PO DAILY16 \\n\\n \\nDischarge Disposition:\\nExtended Care\\n \\nFacility:\\n___\\n \\nDischarge Diagnosis:\\nLeft fibrothorax\\nSeptic shock\\nAcute blood loss anemia\\n___\\nAtrial fibrillation\\nLiver failure\\nPneumonia\\nHIT\\n\\n \\nDischarge Condition:\\nMental Status: Clear and coherent.\\nLevel of Consciousness: Alert and interactive.\\nActivity Status: Out of Bed with assistance to chair or \\nwheelchair.\\n\\n \\nDischarge Instructions:\\n* You were admitted to the hospital for surgery to correct your \\ntrapped lung and you developed multiple post op complications \\nrequiring a long, difficult hoapitalization. You are improving \\ndaily and should continue to do so.  We are transferring you to \\nrehab so that you can work on increasing your mobility and \\nstrength.\\n* Your trach tube will remain in place and gradually be \\ndownsized again.  It will eventually be removed once we are sure \\nyour secretions are under control.\\n* The Speech and swallow team will follow you and hopefully when \\nyou get stronger, you will be able to eat and eventually the \\nfeeding tube will be removed.\\n* Your bladder catheter should stay in and hopefully once you \\nare up and walking a bit, you will be able to void.  In the \\nmeantime, the catheter stays in and you will come back to the \\n___ clinic for a catheter exchange in ___ weeks.\\n* You will continue to see Dr. ___ in the ___ in a few \\nweeks.\\n+ If you have any new problems or concerns please call Dr. ___ \\nat ___.\\n \\nFollowup Instructions:\\n___\\n   \n1    \\nName:  ___                  Unit No:   ___\\n \\nAdmission Date:  ___              Discharge Date:   ___\\n \\nDate of Birth:  ___             Sex:   M\\n \\nService: MEDICINE\\n \\nAllergies: \\nNo Known Allergies / Adverse Drug Reactions\\n \\nAttending: ___.\\n \\nChief Complaint:\\nDOE \\n \\nMajor Surgical or Invasive Procedure:\\nIntubation\\nA-line \\nPICC line\\nTracheostomy\\nPEG\\n \\nHistory of Present Illness:\\n___ y/o M with h/o severe COPD, OSA and HTN who presented from \\n___ rehab with respiratory distress to ___ after \\ncomplaining of chest pain and dyspnea on exertion. Per notes, he \\nwas noted to have sudden onset SOB while walking in the hallway, \\nwent back to his room, put on his CPAP but this did not improve \\nhis breathing so went to ___. HR at ___ was 130s. \\nReceived nebs. At ___ he was wheezy, HR 120s (sinus), CXR \\nreportedly showed pulmonary edema and trop was indeterminate \\n(0.015, upper limit of normal 0.01), BNP 22. He was given lasix \\n40mg IV, SL NTG x3, solumedrol 125 IV, 25 PO metop and \\nlevalbuterol. ECG per per report with nonspecific ST changes. He \\nwas noted to become increasingly agitate and ABG showed CO2 of \\n82 so he was intubated at ___ for hypercarbic respiratory \\nfailure and started on a heparin gtt for ACS before transfer to \\n___. \\n\\nIn the ED here, initial vitals:  112 115/65 17 98% on unknown \\nvent settings, Exam showed wheezing, he was intubated, rate 18, \\nTV 400, PEEP 5 FiO2 60.  Initial ABG pH 7.17 / pCO2 112 /pO2 237 \\nHCO3 43. Additional labs showed PTT 61, WBC 13 ( 90% pmn, s/p \\nsolumedrol at OSH), Gluc 348, K 5.3 .  He continued sedation \\nwith versed/fentanyl, continued heparin gtt, and was given \\nazithromycin IV (no PO access), and CTA to rule out PE (read \\npending at time of arrival to MICU). \\n\\nRepeat ABG when RR increased to 25 pH 7.23 / pCO2 87 / pO2 78 / \\nHCO3 38 On transfer, vitals were:  114 121/63 22 92% vent \\n(unknown settings)\\n\\nOn arrival to the MICU, vitals are T:100.4 BP:102/54 P:117 R:19 \\nO2: 93% on pressure support ___ 60% FiO2, TV 500s. He is \\nintubated and sedated. \\n\\n \\nPast Medical History:\\nsevere COPD (AAT neg in the past) on home O2, FEV1 60%pred in \\n___  \\nStenotrophomonas colonization per AJ records (on ppx bactrim?)  \\nh/o pansens pseudomonas pneumonia  \\nHTN  \\nOSA uses CPAP  \\nObesity  \\nT2DM  \\n\\n \\nSocial History:\\n___\\nFamily History:\\nFather had COPD and died of an aneurysm. Mother died of a heart \\nattack in her ___. \\n \\nPhysical Exam:\\nADMISSION PHYSICAL EXAM:  \\nVitals- T:100.4 BP:102/54 P:117 R:19 O2: 93% on pressure support \\n___ 60% FiO2, TV 500s  \\nGENERAL: intubated sedated  \\nHEENT: Sclera anicteric, conjunctiva injectec, pupils 2mm \\nminimally reactive but equal,MMM, endotracheal tube and OGT in \\nplace  \\nNECK: supple, JVP not elevated, no LAD  \\nLUNGS: decreased air movement, expiratory wheezes difusely, \\nprolonged expiratory phase  \\nCV: tachycardic, regular normal S1 S2, no murmurs, rubs, gallops \\n \\nABD: MIldly distendedm, soft, +BS, no guarding or grimacing with \\ndeep palpation, no organomegaly  \\nEXT: Warm, well perfused, 2+ DP pulses, no clubbing, cyanosis or \\nedema  \\nSKIN: dry, warm, without rashes  \\nNEURO: sedated on fent/midaz, minimal spontaneous movement on \\narrival to ICU. \\n\\nDISCHARGE EXAM:\\nGen: eyes open, following commands, mouthing words\\n\\nHEENT: pupils small and reactive, equal, MMM, OP clear\\n\\nNECK: obese, trach in place\\n\\nCV: tachycardic, no MRG\\n\\nLUNGS: fair air movement, tachypneic, rare expiratory wheeze\\n\\nABD: soft and obese  + bowel sounds, mild RLQ tenderness\\n\\nGU: foley in place with light yellow urine\\n\\nGI: flexiseal out\\n\\nEXTR: warm, no edema, pitting edema in hands nearly resolved\\n\\nSKIN: R arm with several bullae ruptured and crusted over, mild \\nerythema but no pus or induration\\n\\n \\nPertinent Results:\\nADMISSION LABS:\\n========================\\n___ 11:30PM BLOOD WBC-13.8* RBC-4.37* Hgb-11.8* Hct-40.1 \\nMCV-92 MCH-27.0 MCHC-29.3* RDW-14.0 Plt ___\\n___ 11:30PM BLOOD Neuts-90.3* Lymphs-6.6* Monos-2.4 Eos-0.4 \\nBaso-0.3\\n___ 11:30PM BLOOD ___ PTT-61.7* ___\\n___ 11:30PM BLOOD Glucose-345* UreaN-23* Creat-1.1 Na-138 \\nK-5.5* Cl-93* HCO3-30 AnGap-21*\\n___ 11:30PM BLOOD cTropnT-0.02*\\n___ 11:30PM BLOOD CK-MB-4 proBNP-51\\n___ 03:45AM BLOOD Calcium-9.0 Phos-5.0* Mg-1.6\\n___ 11:16PM BLOOD Type-ART Rates-18/ Tidal V-400 PEEP-5 \\npO2-237* pCO2-112* pH-7.17* calTCO2-43* Base XS-8 -ASSIST/CON \\nIntubat-INTUBATED\\n___ 12:24AM BLOOD Lactate-2.3*\\n\\nIMAGING:\\n========================\\n___ TTE @AJ\\nThis is a technically difficult study. All cardiac chambers are \\nnormal in size.  Left ventricular systolic function is preserved \\nwith an estimated ejection fraction of 60%.  Abnormal septal \\nmotion is present. Right ventricular systolic  function is \\nnormal.  The aortic and mitral leaflets are minimally \\nthickenedwith no aortic and trace mitral regurgitation. There is \\ntrivial tricuspid regurgitation.  No pericardial effusion is \\nseen.  Compared to a prior study dated ___, there is no \\nsignificant change.   \\n       \\n\\n___ CTA chest\\nIMPRESSION: \\n1.  No pulmonary embolism. \\n2.  Faint ground-glass opacity in the right middle lobe and \\nlingula are non-specific, but could reflect infection or \\ninflammation. \\n3.  Background of centrilobular mild-to-moderate emphysema. \\n4.  Fatty liver. \\n\\n___ Upper extremity US w doppler\\nIMPRESSION:  No evidence of deep vein thrombosis in the right \\nupper extremity. \\n\\n___ Imaging PORTABLE ABDOMEN \\nThe enteric catheter passes below the level of the diaphragm, \\nending in the mid to upper stomach. The side-hole is near the \\nlevel of the gastroesophageal junction. There are no air-filled \\ndilated loops of bowel identified. The visualized aspects the \\nlungs are clear. IMPRESSION:    \\nEnteric catheter ends in the mid to upper stomach. The side-hole \\nis near the gastroesophageal junction. Advancement is \\nrecommended. \\n\\n___ Imaging LIVER OR GALLBLADDER US \\nThe study is severely limited secondary to poor acoustic windows \\nand overlying soft tissues.   \\nLIVER: The liver is severely echogenic resulting in poor \\nacoustic penetration. No focal lesions are identified in the \\nvisible portions of the liver parenchyma. Main portal vein and \\ncentral bile ducts cannot be assessed. There is no ascites.   \\nBILE DUCTS:  The common bile duct is not visualized.   \\nGALLBLADDER: Limited views of the gallbladder demonstrate no \\nevidence of \\nshadowing gallstones or gallbladder wall thickening.   \\nPANCREAS: The pancreas is not well visualized.  \\nSPLEEN: Normal echogenicity, measuring 11.8 cm.   \\nKIDNEYS: The right kidney is poorly assessed. The left kidney \\nmeasures 12.9 cm. Normal cortical echogenicity and \\ncorticomedullary differentiation is seen in the left kidney.  \\nThere is no evidence of masses, stones or hydronephrosis in the \\nleft kidney.   \\nRETROPERITONEUM: Visualized portions of aorta and IVC are within \\nnormal \\nlimits. IMPRESSION:  Severely echogenic liver consistent with \\nfatty infiltration, resulting in markedly decreased \\nvisualization of the majority of the liver including portal vein \\nand biliary structures. No definite evidence of gallstones or \\ngallbladder wall thickening.  Limited visualization of remaining \\nabdominal organs without focal abnormalities appreciated. \\n\\n___ Cardiovascular ECG \\nNormal sinus rhythm. Tracing is within normal limits. No \\ndiagnostic change \\nfrom ___. \\nIntervals Axes \\nRate PR QRS QT/QTc P QRS T \\n99  140 86 ___ 69\\n\\n___ Imaging CHEST (PORTABLE AP) \\nAs compared to the previous radiograph, the endotracheal tube \\nhas been removed and the patient has received an tracheostomy \\ntube. The left PICC line is in unchanged position.  Platelike \\natelectasis at the right lung bases is almost unchanged.  No new \\nfocal parenchymal opacities are visualized in the lung \\nparenchyma. Normal size of the cardiac silhouette. No \\npneumothorax. \\n\\nMICRO:\\n========================\\n___  BLOOD CULTURE ( MYCO/F LYTIC BOTTLE) PENDING _______\\n___  STOOL C. difficile DNA amplification assay-PENDING \\n_____\\n___  SPUTUM \\n   GRAM STAIN (Final ___: \\n      ___ PMNs and >10 epithelial cells/100X field. \\n      Gram stain indicates extensive contamination with upper \\nrespiratory\\n      secretions. Bacterial culture results are invalid. \\n      PLEASE SUBMIT ANOTHER SPECIMEN. \\n\\n   RESPIRATORY CULTURE (Final ___: \\n      TEST CANCELLED, PATIENT CREDITED. \\n\\n___  URINE URINE CULTURE-No growth\\n___  BLOOD CULTURE Blood Culture, Routine-No growth \\n___  BLOOD CULTURE Blood Culture, Routine-No growth\\n___  BLOOD CULTURE Blood Culture, Routine-No growth \\n___  SPUTUM\\nGRAM STAIN (Final ___: \\n      ___ PMNs and <10 epithelial cells/100X field. \\n      NO MICROORGANISMS SEEN. \\n\\n   RESPIRATORY CULTURE (Final ___: \\n      SPARSE GROWTH Commensal Respiratory Flora. \\n___  URINE URINE CULTURE-No growth\\n___  BLOOD CULTURE Blood Culture, Routine-No growth\\n___  BLOOD CULTURE Blood Culture, Routine-No growth\\n___  SPUTUM \\nGRAM STAIN (Final ___: \\n      >25 PMNs and <10 epithelial cells/100X field. \\n      3+  ___ per 1000X FIELD):   GRAM POSITIVE ROD(S). \\n      1+    (<1 per 1000X FIELD):   BUDDING YEAST. \\n\\n   RESPIRATORY CULTURE (Final ___: \\n      MODERATE GROWTH Commensal Respiratory Flora. \\n\\n___  URINE URINE CULTURE-No growth\\n___  BLOOD CULTURE Blood Culture, Routine-No growth\\n___  URINE URINE CULTURE-No growth \\n___  BLOOD CULTURE Blood Culture, Routine-No growth\\n___  BLOOD CULTURE Blood Culture, Routine-No growth \\n___  STOOL C. difficile DNA amplification assay-NEGATIVE\\n___  BAL\\nRespiratory Viral Culture (Final ___: \\n      TEST CANCELLED, PATIENT CREDITED. \\n      Refer to respiratory viral antigen screen and respiratory \\nvirus\\n      identification test results for further information. \\n\\n   Respiratory Viral Antigen Screen (Final ___: \\n      Positive for Respiratory viral antigens. \\n      Specimen screened for: Adeno, Parainfluenza 1, 2, 3, \\nInfluenza A, B,\\n      and RSV by immunofluorescence. \\n      Refer to Respiratory Virus Identification for further \\ninformation. \\n\\n   Respiratory Virus Identification (Final ___: \\n      Reported to and read back by ___ (___) ON \\n___ @\\n      12:39PM. \\n      POSITIVE FOR RESPIRATORY SYNCYTIAL VIRUS (RSV). \\n         Viral antigen identified by immunofluorescence. \\n\\n___  BLOOD CULTURE Blood Culture, Routine-No growth \\n___  BLOOD CULTURE Blood Culture, Routine-No growth\\n___  URINE URINE CULTURE-No growth \\n___  BLOOD CULTURE Blood Culture, Routine-No growth \\n___  BLOOD CULTURE Blood Culture, Routine-No growth\\n___  URINE URINE CULTURE-No growth\\n___  SPUTUM    GRAM STAIN (Final ___: \\n      >25 PMNs and <10 epithelial cells/100X field. \\n      2+   ___ per 1000X FIELD):   MULTIPLE ORGANISMS \\nCONSISTENT WITH     \\n                                    OROPHARYNGEAL FLORA. \\n\\n   RESPIRATORY CULTURE (Final ___: \\n      MODERATE GROWTH Commensal Respiratory Flora. \\n\\n___ Rapid Respiratory Viral Screen & Culture\\n___ 3:40 pm Rapid Respiratory Viral Screen & Culture\\n   Respiratory Viral Culture (Final ___: \\n      TEST CANCELLED, PATIENT CREDITED. \\n      Refer to respiratory viral antigen screen and respiratory \\nvirus\\n      identification test results for further information. \\n\\n   Respiratory Viral Antigen Screen (Final ___: \\n      Positive for Respiratory viral antigens. \\n      Specimen screened for: Adeno, Parainfluenza 1, 2, 3, \\nInfluenza A, B,\\n      and RSV by immunofluorescence. \\n      Refer to Respiratory Virus Identification for further \\ninformation. \\n\\n   Respiratory Virus Identification (Final ___: \\n      Reported to and read back by ___ ___ 1005. \\n      POSITIVE FOR RESPIRATORY SYNCYTIAL VIRUS (RSV). \\n         Viral antigen identified by immunofluorescence. \\n___ BLOOD CULTURE Blood Culture, Routine-No growth\\n___ BLOOD CULTURE Blood Culture, Routine-No growth\\n___ MRSA SCREEN MRSA SCREEN-Negative\\n\\nDISCHARGE LABS:\\n\\n___ 04:33AM BLOOD WBC-8.8 RBC-3.18* Hgb-9.4* Hct-29.8* \\nMCV-94 MCH-29.4 MCHC-31.4 RDW-18.0* Plt ___\\n___ 04:33AM BLOOD Glucose-167* UreaN-38* Creat-0.6 Na-138 \\nK-4.9 Cl-96 HCO3-32 AnGap-___ntibiotics:\\nOseltamivir ___\\nAzithromycin ___\\nVanc/zosyn ___\\nVanc/cefepime ___\\nLevofloxacin ___\\nBactrim ___\\n\\nSteroids:\\nMethylpred ___\\nPred ___\\n\\n___ with COPD, OSA, HTN presenting from rehab with acute onset \\ndyspnea on exertion found to have hypercarbic respiratory \\nfailure, RSV infection with course complicated by prolonged \\nrespiratory failure s/p trach/PEG and intermittent fevers. \\n\\n# COPD/Hypercarbic respiratory failure due to RSV: Patient \\npresented with respiratory failure from rehab to ___ where \\nhe was found to be hypercarbic and became more agitated, \\nrequiring intubation and transfer to ___ MICU. Viral panel \\nrevealed positive RSV and patient had reported some sick \\ncontacts at rehab, so this was felt to be the most likely \\ntrigger for his respiratory failure, with concommitant COPD \\nexacerbation. He was treated with high dose steroids, \\nazithromycin, and high dose albuterol and ipratropium. He \\nrecieved 5 days of oseltamivir. Broad spectrum antibiotics were \\ninitially stopped after 48 hours of negative blood, urine, and \\nsputum cultures, but broad spectrum antibiotics were reinitiated \\nmultiple times throughout course as below. CTPA on admission was \\nnegative for embolism, and imaging and BNP levels not consistent \\nwith pulmonary edema. Course was complicated by prolonged \\nrespiratory failure due to global muscle weakness and underwent \\ntrach/PEG on ___. Pt recieved prolonged steroid taper from \\n___ until ___.  To optimize pulmonary status, pt was diuresed \\nusing IV lasix bolus dosing from ___, discontinued for ___ \\nas below. At the time of discharge he was stable on the trach \\ntolerating trach mask intermittently throughout the day for up \\nto 1.5 hours. Mask limited by pt reporting feeling tired, but \\nABG monitoring indicated he was maintaining his respiratory \\nfunction and would likely tolerate longer periods. Recommend \\ntrying ativan with trach mask trials to reduce anxiety.\\n\\n# Fevers: Pt intermittently febrile to 103 throughout admission. \\nWas repeatedly cultured (blood, urine, sputum) and received \\nantibiotics intermittently (see abx course above). Bronchoscopy \\nwith trach/PEG ___ showed no secretions. Other non-infectious \\netiologies also possible such as drug fever, atelectasis, PE, or \\npost-procedural fevers were considered.  C diff was negative. CT \\ntorso was considered and was not pursued because pt defervesced \\nabout a week prior to d/c. He spiked a low fever to 100.6 on \\n___. Repeat cultures were negative including PICC which was \\nremoved. He was not given any antibiotics for this and he did \\nnot have any further fevers. Mycolitic blood culture and fungal \\nmarkers were negative. \\n\\n# Right arm edema: likely related to infiltrated IVs. Resolved \\nwith IV relocation and elevation. US was negative for DVT. \\n\\n# Hypernatremia: Elevated Na in the context of tube feeds. Free \\nwater flushes increased ___, FW deficit calculated to be 4 \\nliters on ___. Recieved 1L D5W and Na normalized.\\n\\n# ___: Cr  1.4 peak  from baseline 0.7 in the setting of \\ndiuresis, high fevers, stool loss. Improved with IVF, discharged \\nCr 0.6.\\n\\n# Tachycardia: Baseline HR prior to admission 110s sinus tach. \\nHR 110s-140s throughout ICU admissin. Restarted Metoprolol; \\ndischarged on metoprolol 12.5mg po q6h with HR IN LOW 100s.\\n\\n# Hyperglycemia: H/o DM, on high dose steroids in the setting of \\nCOPD exacerbation. Held metformin, hyperglycemic on home \\nglargine and SSI. Transitioned to insulin gtt then long acting \\nbut back to insulin gtt for difficult to control sugars. ___ \\nwas consulted and recommended NPH 25mg BID - pt was transitioned \\nto this from insulin gtt and sugars were well-controlled on this \\nregimen with sliding scale.\\n\\n# Hypokalemia/Hyperkalemia: Labile potassium (low with diuresis, \\nhigh when hyperglycemic). Adjusted tube feeds. Treated with \\nsliding scale K repletion; hyperglycemia was managed as above. \\n\\n# Transaminitis: ALT/AST 100s, RUQ US showed fatty liver, no \\ngallbladder disease. Resolving, only mild elevation ___. Home \\nstatin was discontinued on ___.\\n\\nCHRONIC INACTIVE ISSUES:\\n# HTN: held lisinopril \\n# Chronic pain: unclear location, held oxycodone, lyrica\\n# Constipation: continued home bowel regimen\\n# Nutrition: held iron to decrease risk of constipation while \\nhospitalized, continued Vit D, initiated tube feeds after PEG \\nplacement\\n# OSA: will likely continued to need nocturnal CPAP after weaned \\nfrom ventilator\\n# HL:  Discontinued simvastatin\\n# GERD: continued PPI\\n\\nTRANSITIONAL ISSUES:\\nHCP is Son ___ ___ \\nFull code\\nLong term resident at ___ prior to admission\\n- Trach can be downsized 2 weeks after placement (___)\\n- Iron deficiency anemia: patient missed outpatient EGD and ___ \\nfor work up of this. Will need to be rescheduled on discharge.\\n \\nMedications on Admission:\\nThe Preadmission Medication list is accurate and complete.\\n1. Ipratropium Bromide MDI 2 PUFF IH QID \\n2. MetFORMIN (Glucophage) 1000 mg PO BID \\n3. Simvastatin 20 mg PO DAILY \\n4. Ferrous Sulfate 325 mg PO DAILY \\n5. Lisinopril 5 mg PO DAILY \\n6. OxycoDONE (Immediate Release)  2.5 mg PO Q6H:PRN pain \\n7. OxycoDONE (Immediate Release)  5 mg PO QHS \\n8. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \\n9. Polyethylene Glycol 17 g PO DAILY \\n10. Fluticasone-Salmeterol Diskus (500/50)  1 INH IH BID \\n11. Vitamin D 1000 UNIT PO DAILY \\n12. Glargine 12 Units Bedtime\\nInsulin SC Sliding Scale using HUM Insulin\\n13. Senna 8.6 mg PO BID \\n14. Fluticasone Propionate NASAL 1 SPRY NU DAILY \\n15. Magnesium Oxide 200 mg PO EVERY OTHER DAY \\n16. Pregabalin 150 mg PO QHS \\n17. Pregabalin 75 mg PO QAM \\n18. Omeprazole 20 mg PO DAILY \\n19. Nystatin-Triamcinolone Ointment 1 Appl TP BID \\n20. Metoprolol Succinate XL 25 mg PO DAILY \\n\\n \\nDischarge Medications:\\n1. NPH 25 Units Breakfast\\nNPH 25 Units Dinner\\nInsulin SC Sliding Scale using REG Insulin\\n2. Ipratropium Bromide MDI 6 PUFF IH Q6H \\n3. Polyethylene Glycol 17 g PO DAILY:PRN contstipation \\n4. Senna 8.6 mg PO BID:PRN Constipation \\n5. Vitamin D 1000 UNIT PO DAILY \\n6. Acetaminophen 1000 mg PO Q8H:PRN fever or pain \\n7. Albuterol Inhaler ___ PUFF IH Q6H \\n8. Albuterol Inhaler ___ PUFF IH Q4H:PRN SOB/wheeze \\n9. Artificial Tears Preserv. Free ___ DROP BOTH EYES PRN dry \\neyes \\n10. Bisacodyl ___AILY:PRN constipation \\n11. Chlorhexidine Gluconate 0.12% Oral Rinse 15 mL ORAL BID \\n12. Docusate Sodium (Liquid) 100 mg PO TID:PRN constipation \\n13. Fluticasone Propionate 110mcg 6 PUFF IH BID \\n14. Heparin 5000 UNIT SC TID \\n15. Lansoprazole Oral Disintegrating Tab 30 mg PO DAILY \\n16. Lorazepam 0.5 mg IV BID:PRN anxiety on trach mask \\n17. Metoprolol Tartrate 12.5 mg PO Q6H \\n18. Ferrous Sulfate 325 mg PO DAILY \\n19. Magnesium Oxide 200 mg PO EVERY OTHER DAY \\n20. Simvastatin 20 mg PO DAILY \\n\\n \\nDischarge Disposition:\\nExtended Care\\n \\nFacility:\\n___\\n \\nDischarge Diagnosis:\\nhypercarbic respiratory failure\\nRSV infection\\nsevere COPD exacerbation\\nprolonged respiratory failure requiring trach and PEG\\n\\n \\nDischarge Condition:\\nLevel of Consciousness: Alert and nods to questions (unable to \\nspeak currently).\\nActivity Status: OOB to chair.\\n\\n \\nDischarge Instructions:\\nYou were admitted with respiratory failure and required \\nintubation. This was thought to be due to RSV viral infection. \\nYour course was complicated by exacerbation of your COPD, so you \\nwere treated with inhalers and steroids. You also developed \\nfevers and were treated with antibiotics and antivirals. You \\nwere unable to be extubated so a tracheostomy tube was placed so \\nyou could continue to receive mechanical ventilation and a PEG \\ntube was placed to give you tube feeds. You were then discharged \\nto rehab.\\n \\nFollowup Instructions:\\n___\\n   \n2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      \\nName:  ___                  Unit No:   ___\\n \\nAdmission Date:  ___              Discharge Date:   ___\\n \\nDate of Birth:  ___             Sex:   M\\n \\nService: CARDIOTHORACIC\\n \\nAllergies: \\nlatex / adhesive tape / IV Dye, Iodine Containing Contrast Media \\n/ morphine\\n \\nAttending: ___.\\n \\nChief Complaint:\\nSOB/tachypnea, increased WBC count, found to have new right \\npneumothorax, in context of minimally invasive esophagectomy on\\n___ \\n\\n \\nMajor Surgical or Invasive Procedure:\\n___\\n1. Esophagoscopy.\\n2. Bronchoscopy.\\n3. Right thoracotomy and partial decortication of lung.\\n4. Takedown of anastomosis and revision.\\n5. Repair of right mainstem bronchus.\\n6. Reinforcement of the bronchial suture line and the\\n    esophagogastric anastomosis with pleura.\\n\\n___\\n1. Esophagoscopy.\\n2. Flexible bronchoscopy.\\n \\nHistory of Present Illness:\\n___ s/p minimally invasive esophagectomy on ___, discharged \\nhome in good condition on ___, transferred from OSH today. \\nHe presented to OSH on\\n___ (POD#8) with complaint of increased SOB and tachypnea. \\nHe had been on tube feeds and taking clears PO, tolerating well. \\nHe had no vomiting or abdominal pain, no fevers or chills. CXR \\nat OSH showed 4-cm PTX on the R and a small pleural effusion. Of \\nnote, the patient was discharged with a known very small R PTX \\non ___. A CT was placed at OSH. He was also found to have \\nan\\nincreased WBC, but was afebrile, and hemodynamically stable. \\n\\nOf note, barium swallow study performed prior to discharge on \\n___ showed no leak. Upon transfer, he was hemodynamically \\nstable, not tachycardic\\nwith a normal blood pressure, with oxygen saturation of 98% on \\n4L NC. He had the chest tube in place. He denied any SOB/CP/N/V. \\nAn upper endoscopy was performed upon arrival in the ICU with \\nelective intubation, which revealed an approximately 3-4 cm \\nsegment of gastric tissue that appeared necrotic. The remainder \\nof the esophagus and stomach, including the anastamosis, \\nappeared\\nnormal. A bronchoscopy was also performed, which revealed a \\nsmall\\ndefect in the right mainstem bronchus.  \\n \\nPast Medical History:\\nHiatal hernia, PVD, h/o bronchitis, DJD, h/o bursitis, Barretts, \\nborderline DM, DVT, deviated septum, gastritis, allergic \\nrhinitis, asthma/COPD, hypercholesterolemia, HTN, depression, \\nanxiety, agoraphobia, LVH\\n\\n \\nSocial History:\\n___\\nFamily History:\\nMother\\nFather\\n___\\nOther: unknown cancer in both grandmothers\\n\\n \\nPhysical Exam:\\nUpon Discharge:\\n98.1  68  132/78 14 97%RA\\n\\nGENERAL        \\n[x] WN/WD  [x] NAD  [x] AAO  [ ] abnormal findings:\\n\\nHEENT          \\n[x] NC/AT   [x] EOMI   [x] PERRL/A   [x] Anicteric\\n[x] OP/NP mucosa normal     [x] Tongue midline\\n[x] Palate symmetric  [x] Neck supple/NT/without mass\\n[x] Trachea midline [x] Thyroid nl size/contour\\n[ ] Abnormal findings:\\n\\nRESPIRATORY    \\n[x] CTA/P     [x] Excursion normal     [x] No fremitus\\n[x] No egophony    [x] No spine/CVAT\\n[ ] Abnormal findings:\\n*incisions healing well, clean/dry/intact, steri strips in place \\n\\n\\nCARDIOVASCULAR \\n[x] RRR    [x] No m/r/g    [x] No JVD   [x] PMI nl  [x] No edema\\n[x] Peripheral pulses nl    [x] No abd/carotid bruit\\n[ ] Abnormal findings:\\n\\nGI             \\n[x] Soft    [x] NT   [x] ND  [x] No mass/HSM   [x] No hernia\\n[ ] Abnormal findings:\\n\\nGU             [x] Deferred  \\n[ ] Nl genitalia    [ ] Nl pelvic/testicular exam    [ ] Nl DRE\\n[ ] Abnormal findings:\\n\\nNEURO          \\n[x] Strength intact/symmetric    [x] Sensation intact/ symmetric\\n[x] Reflexes nl     [x] No facial asymmetry [x] Cognition intact\\n[x] Cranial nerves intact   [ ] Abnormal findings:\\n\\nMS         \\n[x] No clubbing   [x] No cyanosis   [x] No edema   [x] Gait nl\\n[x] No tenderness  [x] Tone/align/ROM nl   [x] Palpation nl\\n[x] Nails nl   [ ] Abnormal findings:\\n\\nLYMPH NODES   \\n[x] Cervical nl      [x] Supraclavicular nl     [ ] Axillary nl\\n[ ] Inguinal nl   [ ] Abnormal findings:\\n\\nSKIN           \\n[x] No rashes/lesions/ulcers\\n[x] No induration/nodules/tightening     [ ] Abnormal findings:\\n\\nPSYCHIATRIC    \\n[x] Nl judgment/insight    [x] Nl memory   [x] Nl mood/affect\\n[ ] Abnormal findings:\\n \\nPertinent Results:\\nCHEST X-RAY (___)\\n1.  Stable air-fluid level in the neo-esophagus. \\n2.  Stable right consolidation corresponding to the area of \\nmediastinal fat better evaluated on the recent CT. \\n3.  Improvement in right basilar atelectasis and edema. \\n4.  Stable small bilateral pleural effusions. \\n\\nCT TORSO (___):\\n1.  No evidence of anastomotic leak. \\n2.  8.1 cm collection of herniated mediastinal fat into the \\nright pleural \\nspace. \\n3.  Left upper and right middle lobe opacities compatible with \\npneumonia. \\n\\n___ 04:00AM BLOOD WBC-10.6 RBC-2.73* Hgb-8.2* Hct-26.3* \\nMCV-96 MCH-29.9 MCHC-31.1 RDW-15.7* Plt ___\\n___ 04:00AM BLOOD Plt ___\\n___ 04:00AM BLOOD Glucose-120* UreaN-16 Creat-1.0 Na-138 \\nK-4.6 Cl-99 HCO3-30 AnGap-14\\n___ 04:00AM BLOOD Calcium-8.7 Phos-3.8 Mg-2.2\\n \\nBrief Hospital Course:\\nMr. ___ was transferred to the Thoracic Surgery Service at \\n___ and underwent the following operation on ___: \\n1. Esophagoscopy.\\n2. Bronchoscopy.\\n3. Right thoracotomy and partial decortication of lung.\\n4. Takedown of anastomosis and revision.\\n5. Repair of right mainstem bronchus.\\n6. Reinforcement of the bronchial suture line and the\\n    esophagogastric anastomosis with pleura.\\n\\nPost-operatively, he was admitted to the ICU, where he was \\ninitially intubated, on antibiotics (vancomycin, zosyn, \\nfluconazole), with an NG tube, foley catheter, and 3 chest tubes \\nin place. On POD#2 he was successfully extubated. He was \\nmaintained on supplemental oxygen, with all tubes in place, and \\nantibiotics were continued. He was kept NPO, with tube feeds \\nrunning per his home regimen. Nutrition specialists were \\nconsulted and followed, along with Physical Therapists. \\n\\nUpon being deemed clinically stable and appropriate for transfer \\nto the general surgical floor, such was done. He remained NPO, \\nwith tube feeds, on IV pain medications, on antibiotics, being \\nseen by physical therapy, with regular daily chest x-ray and \\nlaboratory study check. \\n\\nOn ___ he underwent the following procedure:\\n1. Esophagoscopy.\\n2. Flexible bronchoscopy.\\nThe reader is referred to the Operative Note for details. In the \\nOR itself, his chest tubes were removed, with a confirmatory \\nchest x-ray thereafter. He was started on a clear liquid diet, \\nadvanced to full liquids as tolerated thereafter. All \\nantibiotics as above were continued in IV form through till the \\ntime of his discharge. He had good pain control with oral \\nmedications, was weaned off oxygen, and expressed feeling much \\nimproved in health. He was able to ambulate multiple times per \\nday independently. He continued on his tube feeds, in additional \\nto an improved oral intake daily. Once appropriate, he was \\nexplained and expressed agreement with the discharge plan, and \\ndischarged home in good condition. \\n \\nMedications on Admission:\\nThe Preadmission Medication list is accurate and complete.\\n1. Gabapentin 300 mg PO BID \\n2. Tiotropium Bromide 1 CAP IH DAILY \\n3. Clonazepam 0.5 mg PO BID \\n4. Verapamil SR 180 mg PO Q24H \\n5. Baclofen 10 mg PO TID \\n6. Omeprazole 20 mg PO DAILY \\n7. albuterol sulfate *NF* 90 mcg/actuation Inhalation q 4 hrs  \\nwheezing \\n8. Citalopram 40 mg PO DAILY \\n9. traZODONE 150 mg PO HS:PRN sleep \\n10. Acetaminophen 1000 mg PO Q6H \\n11. HYDROmorphone (Dilaudid) ___ mg PO Q4H:PRN pain \\n12. Docusate Sodium 100 mg PO BID \\n\\n \\nDischarge Medications:\\n1. Acetaminophen (Liquid) 650 mg PO Q6H \\nRX *acetaminophen 500 mg/5 mL 5 mL by mouth every six (6) hours \\nDisp #*1 Bottle Refills:*0\\n2. Citalopram 40 mg PO DAILY \\n3. Clonazepam 0.5 mg PO BID \\n4. Gabapentin 300 mg PO BID \\n5. HYDROmorphone (Dilaudid) ___ mg PO Q4H:PRN pain \\n6. traZODONE 150 mg PO HS:PRN sleep \\n7. albuterol sulfate *NF* 90 mcg/actuation Inhalation q 4 hrs  \\nwheezing \\n8. Baclofen 10 mg PO TID \\n9. Docusate Sodium 100 mg PO BID \\n10. Omeprazole 20 mg PO DAILY \\n11. Tiotropium Bromide 1 CAP IH DAILY \\n12. Verapamil SR 180 mg PO Q24H \\n13. TraMADOL (Ultram) 50 mg PO QID \\nRX *tramadol 50 mg 1 tablet(s) by mouth every six (6) hours Disp \\n#*40 Tablet Refills:*0\\n14. Metoprolol Tartrate 100 mg PO BID \\nRX *metoprolol tartrate 100 mg 1 tablet(s) by mouth twice a day \\nDisp #*40 Tablet Refills:*0\\n\\n \\nDischarge Disposition:\\nHome With Service\\n \\nFacility:\\n___\\n \\nDischarge Diagnosis:\\n1. Dehiscence of gastroesophageal anastomosis.\\n2. Fistula to right main stem bronchus.\\n\\n \\nDischarge Condition:\\nMental Status: Clear and coherent.\\nLevel of Consciousness: Alert and interactive.\\nActivity Status: Ambulatory - Independent.\\n\\n \\nDischarge Instructions:\\nCall Dr ___ ___ if you experience:\\n-Fevers greater than 101 or chills\\n-Increased shortness of breath, cough or chest pain\\n-Nausea, vomiting (take anti-nausea medication)\\n-Increased abdominal pain\\n-Incision develops drainage\\n\\nPain\\n-Dilaudid as needed for pain \\n-Take stool softners with narcotics\\n\\nActivity\\n-Shower daily. Wash incision with mild soap & water, rinse, pat \\ndry\\n-No tub bathing, swimming or hot tub until incision healed\\n-No driving while taking narcotics\\n-No lifting greater than 10 pounds until seen\\n-Walk ___ times a day for ___ minutes increase to a Goal of 30 \\nminutes daily\\n\\nDiet:\\n\\nTube feeds: Replete Full Strength 75cc/hr x 18 hrs \\n\\nFlush J-tube with water every 8 hours with 10 cc's of water, \\nbefore and after starting tube feeds and giving medications \\nthrough tube\\n\\nFull liquid diet, may increase to soft solids over the next few \\ndays as tolerated.\\nEat small frequent meals. Sit up in chair for all meals and \\nremain sitting for ___ minutes after meals\\n\\nDaily weights: keep a log bring with you to your appointment\\n\\nNO CARBONATED DRINKS\\n\\nDanger signs\\n\\nFevers > 101 or chills\\nIncreased shortness of breath, cough or chest pain\\nIncision develops drainage\\nNausea, vomiting (take anti-nausea medication)\\nIncreased abdominal pain\\n\\nCall if J-tube falls out (save the tube and bring with you to \\nthe hospital to be re-placed) or suture breaks\\n \\nFollowup Instructions:\\n___\\n   \n3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        \\nName:  ___                   Unit No:   ___\\n \\nAdmission Date:  ___              Discharge Date:   ___\\n \\nDate of Birth:  ___             Sex:   F\\n \\nService: CARDIOTHORACIC\\n \\nAllergies: \\nPercocet\\n \\nAttending: ___.\\n \\nChief Complaint:\\nDOE\\n \\nMajor Surgical or Invasive Procedure:\\n___\\nRight VATS RUL wedge\\n\\n \\nHistory of Present Illness:\\nMs ___ is a ___ with hep\\nC,cirrhosis and HCC had multiple lung nodules found on chest CT\\n___. The f/u CT ___ noted a new RUL 3.3mm nodule, while\\nall others were thought to be stable.Her PET ___ showed \\nmild\\nFDG avidity (SUV 1.4). ___ doesn't think ammenable to biopsy, so\\npt presents for eval for VATS wedge for biopsy. Pt reports\\noccasional DOE with usual activities, otherwise, denies\\nhemoptysis, cough, chest pain, HA, sweats, new bony pain.\\nShe presents now for biopsy.\\n \\nPast Medical History:\\nHep C\\ncirrhosis, decompensated\\nvarices\\n___ s/p RFA ___\\ns/p hyst\\ns/p cosmetic facial surg\\n\\n \\nSocial History:\\n___\\nFamily History:\\nson is deceased from ___ sarcoma.\\n\\n \\nPhysical Exam:\\nBP: 131/66. Heart Rate: 91. Weight: 134 (With Clothes; With\\nShoes). BMI: 25.3. Temperature: 98.1. O2 Saturation%: 99.\\n\\nGENERAL        \\n[x] WN/WD  [x] NAD  [x] AAO  [ ] abnormal findings:\\n\\nHEENT          \\n[x] NC/AT   [x] EOMI   [x] PERRL/A   [x] Anicteric\\n[x] OP/NP mucosa normal     [x] Tongue midline\\n[x] Palate symmetric  [x] Neck supple/NT/without mass\\n[x] Trachea midline [x] Thyroid nl size/contour\\n[ ] Abnormal findings:\\n\\nRESPIRATORY    \\n[x] CTA/P     [x] Excursion normal     [x] No fremitus\\n[x] No egophony    [x] No spine/CVAT\\n[ ] Abnormal findings:\\n\\nCARDIOVASCULAR \\n[x] RRR    [x] No m/r/g    [x] No JVD   [x] PMI nl  [x] No edema\\n[x] Peripheral pulses nl    [x] No abd/carotid bruit\\n[ ] Abnormal findings:\\n\\nGI             \\n[x] Soft    [] NT   [x] ND  [] No mass/HSM   [x] No hernia\\n[x ] Abnormal findings: tender RUQ w/ hepatomeg to ___ FB below\\nribs\\n\\nGU             [x] Deferred  \\n[ ] Nl genitalia    [ ] Nl pelvic/testicular exam    [ ] Nl DRE\\n[ ] Abnormal findings:\\n\\nNEURO          \\n[x] Strength intact/symmetric    [x] Sensation intact/ symmetric\\n[x] Reflexes nl     [x] No facial asymmetry [x] Cognition intact\\n[x] Cranial nerves intact   [ ] Abnormal findings:\\n\\nMS     \\n\\n        \\n[x] No clubbing   [x] No cyanosis   [x] No edema   [x] Gait nl\\n[x] No tenderness  [x] Tone/align/ROM nl   [x] Palpation nl\\n[x] Nails nl   [ ] Abnormal findings:\\n\\nLYMPH NODES   \\n[x] Cervical nl      [x] Supraclavicular nl     [x] Axillary nl\\n[x] Inguinal nl   [ ] Abnormal findings:\\n\\nSKIN           \\n[x] No rashes/lesions/ulcers\\n[x] No induration/nodules/tightening     [ ] Abnormal findings:\\n\\nPSYCHIATRIC    \\n[x] Nl judgment/insight    [x] Nl memory   [] Nl mood/affect\\n[x ] Abnormal findings: flat affect, very vague and slow to\\nprocess info\\n\\n \\nPertinent Results:\\n___ 05:34PM   HCT-34.2*\\n___ 05:34PM   PLT COUNT-88*\\n___ 05:34PM   ___\\n___ 07:05AM   GLUCOSE-89 UREA N-12 CREAT-0.9 SODIUM-135 \\nPOTASSIUM-4.3 CHLORIDE-104 TOTAL CO2-25 ANION GAP-10\\n\\n___ 9:57 pm Influenza A/B by ___\\n      Source: Nasopharyngeal swab. \\n\\n                            **FINAL REPORT ___\\n\\n   DIRECT INFLUENZA A ANTIGEN TEST (Final ___: \\n      Reported to and read back by ___ ___ ___. \\n      POSITIVE FOR INFLUENZA A VIRAL ANTIGEN. \\n\\n   DIRECT INFLUENZA B ANTIGEN TEST (Final ___: \\n      Negative for Influenza B. \\n\\n___ CT Torso :\\n1.  Large area of alveolar infiltrate which is patchy and \\nbilateral but \\ninvolving the right upper lobe more than the other lobes may \\nrepresent focal infectious process versus ARDS or drug reaction. \\n\\n2.  Right lower lobe airspace consolidation with air \\nbronchograms may also represent infectious process, small \\naspiration or atelectasis. \\n3.  Previously described lung nodules that were not resected are \\nnot seen and likely obscured by the ground-glass opacities. \\n4.  Cirrhotic morphology of the liver with evidence of portal \\nhypertension. \\n5.  Gallbladder sludge \\n\\n___ ___ scan :\\nNo sonographic evidence for right upper extremity deep vein \\nthrombosis.\\n\\n___ CXR :\\nAs compared to the previous radiograph from ___, \\nthere \\nis a mild decrease in severity and extent of the pre-existing \\nright upper lobe opacities.  Also improved is the retrocardiac \\natelectasis.  Otherwise, the radiograph is unchanged and the \\nappearance of the lung parenchyma is constant. \\nConstant size of the cardiac silhouette \\n\\n                    WBC RBC  Hgb   Hct  MCV MCH  MCHC  RDW Plt \\nCt \\n___ 06:30    4.6 3.31* 10.7* 31.8* 96 32.3* 33.6 14.5 94* \\n\\n\\n                 Glucose UreaN  Creat  Na   K    Cl  HCO3        \\n    \\n___ 07:15    94     15    0.8   136  3.8  105   25    \\n\\n \\nBrief Hospital Course:\\nMs. ___ was admitted to the hospital and taken to the \\nOperating Room where she underwent a right VATS RUL wedge \\nbiopsy.  She tolerated the procedure well and returned to the \\nPACU in stable condition.  She maintained stable hemodynamics \\nand had minimal chest tube drainage.\\n\\nFollowing transfer to the Surgical floor she had some problems \\nwith pain control and required vigorous pulmonary toilet to help \\nclear her secretions.  Following removal of her chest tube her \\npain lessened but she still required frequent Dilaudid to comply \\nwith incentive spirometry and chest ___.\\n\\nHer post pull CXR revealed a stable right apical space and her \\noxygen was weaned off without difficulty.  Her port sites were \\ndry.  She desaturated to the mid 70's on room air about 8 hours \\npost CT removal.  She was also tachycardic to 120 bpm.  Her ABG \\nwas 7.___.  Due to her hypoxia, she was transferred to \\nthe ICU for further management.  Her CXR revealed a RUL opacity \\nand she became more somnolent with an ABG of 7.___.  She \\nwas intubated, sedated and placed on full mechanical \\nventilation. Broad spectrum antibiotics were stared after she \\nwas pan cultured.  Her highest WBC was 12K.  Blood gases \\nimproved and bronchodilators were given on a standing basis.  \\nShe extubated herself the following day and was able to \\nventilate on her own and maintain adequate saturations. \\n\\nHer nasopharyngeal swab was positive for influenza A and she was \\nstarted on Tamiflu and her antibiotics were stopped.  She \\ncontinued to make good progress and was eventually transferred \\nback to the Surgical floor.  She initially was incontinent of \\nurine and stool and her lactulose was decreased to 15 ml BID.  \\nOnce her multiple bowel movements decreased she was continent \\nagain.  The lactulose was adjusted as needed based on her mental \\nstatus.  She had periods of confusion and some inattention and \\nthis resolved with lactulose 30 ml BID for her hepatic \\nencephalopathy.  \\n\\nShe still required oxygen at 2 liters to maintain an oxygen \\nsaturation of 94%.  She had periods where it was weaned down and \\noccasionally off but she couldn't sustain it with activity. She \\noccasionally has a productive cough and benefits from nebulizer \\ntherapy.  Her Tamiflu ends today after the last dose. \\n\\nThe Physical Therapy service worked with her and recommended a \\nshort term rehab placement prior to returning home to help \\nincrease her mobility, stamina and continue pulmonary toilet \\nwith the hope of sending her home off of oxygen.  She was \\ndischarged on ___ and will follow up in the Thoracic Clinic \\nin 2 weeks.\\n\\n \\nMedications on Admission:\\nThe Preadmission Medication list is accurate and complete.\\n1. Lactulose 30 mL PO TID \\n2. Zolpidem Tartrate 5 mg PO HS sleep \\n3. Furosemide 20 mg PO DAILY \\n4. Spironolactone 25 mg PO DAILY \\n5. Rifaximin 550 mg PO BID \\n6. Omeprazole 40 mg PO DAILY \\n7. albuterol sulfate *NF* 90 mcg/actuation Inhalation q 6 hrs \\nSOB \\n\\n \\nDischarge Medications:\\n1. Furosemide 20 mg PO DAILY \\n2. Omeprazole 40 mg PO DAILY \\n3. Rifaximin 550 mg PO BID \\n4. Spironolactone 25 mg PO DAILY \\n5. Zolpidem Tartrate 5 mg PO HS sleep \\n6. Calcium Carbonate 1250 mg PO BID \\n7. HYDROmorphone (Dilaudid) ___ mg PO Q4H:PRN pain \\nRX *hydromorphone 2 mg ___ tablet(s) by mouth every four (4) \\nhours Disp #*80 Tablet Refills:*0\\n8. albuterol sulfate *NF* 90 mcg/actuation INHALATION Q 6 HRS \\nSOB \\n9. Clonazepam 0.5 mg PO BID anxiety \\n10. Oseltamivir 75 mg PO Q12H \\nlast dose ___ \\n11. Ipratropium Bromide Neb 1 NEB IH Q6H \\n12. Senna 1 TAB PO BID constipation \\n13. Lactulose 30 mL PO BID \\n14. Guaifenesin ___ mL PO Q6H:PRN sputum \\n15. Heparin 5000 UNIT SC TID \\n\\n \\nDischarge Disposition:\\nExtended Care\\n \\nFacility:\\n___\\n \\n___ Diagnosis:\\nPulmonary nodule\\nInfluenza A\\nRespiratory insufficiency requiring re intubation\\n\\n \\nDischarge Condition:\\nMental Status: Clear and coherent.\\nLevel of Consciousness: Alert and interactive.\\nActivity Status: Ambulatory - Independent.\\n\\n \\nDischarge Instructions:\\n* You were admitted to the hospital for lung surgery and you've \\nrecovered well but still need some therapy prior to returning \\nhome. \\n* Continue to use your incentive spirometer 10 times an hour \\nwhile awake.\\n* Check your incisions daily and report any increased redness or \\ndrainage.   Cover the area with a gauze pad if it is draining.\\n* Your chest tube dressing may be removed in 48 hours.  \\n* You will continue to need pain medication once you are home \\nbut you can wean it over a few weeks as the discomfort resolves. \\n Make sure that you have regular bowel movements while on \\nnarcotic pain medications as they are constipating which can \\ncause more problems.  Use a stool softener or gentle laxative to \\nstay regular.\\n* No driving while taking narcotic pain medication.\\n* Take Tylenol  ___ mg every 6 hours in between your narcotic.  \\n* Continue to stay well hydrated and eat well to heal your \\nincisions\\n* Shower daily. Wash incision with mild soap & water, rinse, pat \\ndry\\n* No tub bathing, swimming or hot tubs until incision healed\\n* No lotions or creams to incision site\\n* Walk ___ times a day and gradually increase your activity as \\nyou can tolerate.\\n\\nCall Dr. ___ ___ if you experience:\\n-Fevers > 101 or chills\\n-Increased shortness of breath, chest pain or any other symptoms \\nthat concern you.\\n \\n \\n \\n \\nFollowup Instructions:\\n___\\n   \n4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      \\nName:  ___                  Unit No:   ___\\n \\nAdmission Date:  ___              Discharge Date:   ___\\n \\nDate of Birth:  ___             Sex:   M\\n \\nService: MEDICINE\\n \\nAllergies: \\nNo Known Allergies / Adverse Drug Reactions\\n \\nAttending: ___.\\n \\nChief Complaint:\\nUpper GI bleed\\n \\nMajor Surgical or Invasive Procedure:\\nnone\\n \\nHistory of Present Illness:\\nThis is a ___ gentleman with a pmhx. of alcohol \\ndependence who is transferred from ___ for \\nuncontrolled UGI bleed despite endoscopic intervention.  Per OSH \\nreport, patient was admitted on ___ for hematemesis and \\nmelanotic stools.  He underwent EGD on ___, which revealed \\nnon-bleeding grade II esophageal varicies and 2 duodenal ulcers, \\nwhich were thought to be the cause of patient's symptoms.  \\nUlcers were injected with epinepherine and patient remained \\nstable with hematocrits around 30 for about 72 hours.  On day of \\nadmission, hct dropped to 23 and patient had repeat endoscopy.  \\nDuodenal ulcers did not appear to be rebleeding, and five bands \\nwere placed around esophageal ulcers.  Patient was noted to have \\nBRBPR and colonoscopy was subsequently performed.  Scope was \\nadvanced to cecum however, only finding was copious bright red \\nblood.  Patient subsequently developed massive hematemesis and a \\nrepeat EGD was performed.  Four out of five bands were noted to \\nbe in place, but endoscopist did not advance further to avoid \\ndisloding bands or causing additional trauma.  Patient remained \\nintubated for airway protection.  There was question of \\naspiration during this episode of hematemesis.\\n.\\nOf note, patient was febrile to 103 on admission to OSH.  CXR \\nand urine cultures were reportedly unremarkable.  Patient was \\nstarted empirically on vanc/zosyn/flagyl for broad coverage.  \\nThere was also report of DTs during OSH admission.  Patient had \\nbeen placed on CIWA scale for withdrawal.  On ___ scored 20 \\nand 18, on ___ scored 7, 7, 5, and 4.\\n.\\nThe decision was made to transfer patient to facility with ___ \\ncapabilities.  Upon arrival to ___ MICU, HR was 80, BP 107/77, \\nSPO2 99% on CMV with FIO2 70%.  Patient was intubated and \\nsedated with propofol.  He has had no subsequent episodes of \\nhematemesis since EGD.\\n\\n \\nPast Medical History:\\n--Alcohol abuse\\n--HTN\\n \\nSocial History:\\n___\\nFamily History:\\nLung cancer in maternal uncle, mother with CHF.\\n \\nPhysical Exam:\\nUPON ADMISSION:\\nVS: Temp: BP: 92/68 / HR: 79 RR:  O2sat  \\nGEN: Intubated and sedated\\nHEENT: Pupils reactive, does not respond to commands\\nRESP: Coarse breath sounds throughout but with good air movement \\n\\nCV: RR, S1 and S2 wnl, no m/r/g  \\nABD: +BS, mildly distended, mild fluid wave\\nSKIN: Spider angiomas below neck and over clavicular area \\nNEURO: Sedated\\nRECTAL: Melena\\n.  \\nUPON DISCHARGE: pertinent changes only\\nOriented x3, no asterixis\\nAbdomen non-tender, no distention, no ascites\\nNo melena/hematochezia\\nNo wheezes/rhonchi/rales, respirations unlabored\\n \\nPertinent Results:\\nLabs upon admission:\\n\\n___ 08:54PM   PLT SMR-LOW PLT COUNT-81*\\n___ 08:54PM   HYPOCHROM-1+ ANISOCYT-2+ POIKILOCY-1+ \\nMACROCYT-3+ MICROCYT-NORMAL POLYCHROM-OCCASIONAL \\nOVALOCYT-OCCASIONAL TARGET-OCCASIONAL BURR-OCCASIONAL\\n___ 08:54PM   NEUTS-82* BANDS-0 LYMPHS-12* MONOS-5 EOS-0 \\nBASOS-0 ___ MYELOS-1*\\n___ 08:54PM   WBC-11.2* RBC-3.38* HGB-11.1* HCT-33.4* \\nMCV-99* MCH-32.7* MCHC-33.1 RDW-20.5*\\n___ 08:54PM   CALCIUM-7.0* PHOSPHATE-1.8* MAGNESIUM-1.9\\n___:54PM   CK-MB-2 cTropnT-<0.01\\n___ 08:54PM   CK(CPK)-114\\n___ 08:54PM   estGFR-Using this\\n___ 08:54PM   GLUCOSE-111* UREA N-16 CREAT-0.7 SODIUM-137 \\nPOTASSIUM-3.8 CHLORIDE-110* TOTAL CO2-25 ANION GAP-6*\\n___ 09:00PM   ___ 09:00PM   ___ PTT-28.6 ___\\n___ 09:00PM   PLT SMR-VERY LOW PLT COUNT-79*\\n___ 09:00PM   HYPOCHROM-NORMAL ANISOCYT-2+ POIKILOCY-1+ \\nMACROCYT-3+ MICROCYT-NORMAL POLYCHROM-1+ OVALOCYT-OCCASIONAL \\nTARGET-OCCASIONAL BURR-1+\\n___ 09:00PM   NEUTS-76* BANDS-2 LYMPHS-13* MONOS-9 EOS-0 \\nBASOS-0 ___ MYELOS-0\\n___ 09:00PM   WBC-10.6 RBC-3.11* HGB-10.8* HCT-30.4* MCV-98 \\nMCH-34.6* MCHC-35.4* RDW-20.3*\\n___ 09:00PM   ALBUMIN-2.2* CALCIUM-7.0* PHOSPHATE-1.8* \\nMAGNESIUM-1.9\\n___ 09:00PM   CK-MB-2 cTropnT-<0.01\\n___ 09:00PM   LIPASE-19\\n___ 09:00PM   ALT(SGPT)-31 AST(SGOT)-78* LD(LDH)-251* \\nCK(CPK)-110 ALK PHOS-74 TOT BILI-3.1*\\n___ 09:00PM   GLUCOSE-111* UREA N-15 CREAT-0.7 SODIUM-137 \\nPOTASSIUM-3.8 CHLORIDE-110* TOTAL CO2-25 ANION GAP-6*\\n___ 09:19PM   freeCa-0.96*\\n___ 09:19PM   ___ PH-7.44\\n___ 09:48PM URINE  ___ BACTERIA-OCC \\nYEAST-NONE ___ 09:48PM URINE  BLOOD-LG NITRITE-NEG PROTEIN-75 \\nGLUCOSE-NEG KETONE-TR BILIRUBIN-SM UROBILNGN-NEG PH-6.5 LEUK-SM\\n___ 09:48PM URINE  COLOR-Amber APPEAR-Hazy SP ___\\n.\\nLabs upon discharge: \\n.\\n___ 05:40AM BLOOD WBC-5.6 RBC-2.90* Hgb-9.5* Hct-29.2* \\nMCV-101* MCH-32.7* MCHC-32.4 RDW-18.4* Plt ___\\n___ 05:40AM BLOOD Neuts-54 Bands-0 ___ Monos-15* \\nEos-0 Baso-0 ___ Myelos-0\\n___ 05:40AM BLOOD ___\\n___ 05:40AM BLOOD Glucose-99 UreaN-20 Creat-0.7 Na-136 \\nK-3.9 Cl-105 HCO3-23 AnGap-12\\n___ 05:40AM BLOOD ALT-42* AST-84* AlkPhos-75 TotBili-0.9\\n___ 05:40AM BLOOD Calcium-9.4 Phos-3.0 Mg-1.8\\n___ 04:10AM BLOOD HBsAg-NEGATIVE HBsAb-POSITIVE \\nHBcAb-NEGATIVE HAV Ab-POSITIVE\\n___ 04:10AM BLOOD AFP-4.4\\n___ 04:10AM BLOOD HCV Ab-NEGATIVE\\n.\\nTTE:\\nThe left atrium is mildly dilated. No atrial septal defect is \\nseen by 2D or color Doppler. Left ventricular wall thickness, \\ncavity size and regional/global systolic function are normal \\n(LVEF >55%). Doppler parameters are indeterminate for left \\nventricular diastolic function. There is no ventricular septal \\ndefect. Right ventricular chamber size and free wall motion are \\nnormal. The ascending aorta is mildly dilated. The aortic valve \\nleaflets (3) are mildly thickened but aortic stenosis is not \\npresent. No aortic regurgitation is seen. The mitral valve \\nleaflets are mildly thickened. There is no mitral valve \\nprolapse. Physiologic mitral regurgitation is seen (within \\nnormal limits). There is borderline pulmonary artery systolic \\nhypertension. There is no pericardial effusion. \\n\\nIMPRESSION: Normal regional and global biventricular systolic \\nfunction. Indeterminate indices for diastolic function \\nassessment. No intra-cardiac shunt seen - cannot excluded \\nPFO/small ASD as bubble study not performed adequately. \\nBorderline pulmonary artery systolic hypertension.\\n.\\nAbdominal ultrasound with dopplers\\n1. Patent hepatic vasculature. \\n2. Echogenic and nodular hepatic architecture. An ill-defined \\nhypoechoic \\nstructure seen adjacent to the main portal vein could represent \\nfatty sparing, \\nhowever a lesion at this location cannot be excluded. A CT or \\nMRI is \\nsuggested to further evaluate for possible lesions. \\n3. Small amount of sludge within the gallbladder. \\n4. Trace of ascites in the perihepatic space \\n.\\nCXR ___:  \\nPrevious areas of pulmonary opacity, in the left suprahilar and \\nright \\njuxtahilar lung have cleared. A relatively small region of \\nperibronchial \\nopacification persists in the right lower lobe medially, but \\nthis is not a new finding. There is no pleural effusion. Stomach \\nis distended with fluid and retained material. Heart size is \\nnormal. Azygos remains distended. \\n.\\nUS abd limited ___: no ascites\\n.\\n___: ___: No evidence of DVT in right or left lower \\nextremity.\\n.\\nMicrobiology:\\nBlood cultures: ___: negative\\nUrine cultures: ___: negative\\nPeritoneal cultures: ___: negative\\nStool cultures/Cdiff: ___: negative\\n  \\n\\n \\nBrief Hospital Course:\\nMr. ___ is a ___ year old gentleman with ETOH abuse admitted \\nfor an UGIB with hospital course complicated by newly diagnosed \\ncirrhosis and hypoxemic respiratory failure. \\n.\\n# Hypoxemic respiratory failure: Initially thought to be \\nsecondary to pulmonary edema, possible PNA, restriction from \\nabdominal distention.  Was intubated while receiving diuresis \\ninitially with lasix gtt and received 8 day course of \\nvancomycin/zosyn for potential VAP.  Found to have one day of \\nhypotension thought to be secondary to overdiuresis of 3L in 24 \\nhours; pressures stabilized with small fluid boluses and \\nadministration of albumin.  Extubated successfully on ___.  \\nRespiratory status continued to improve with diuresis on floor, \\noxygen weaned, and repeat CXR showed improvement in pleural \\neffusions and no new consolidation.  \\n.\\n#  UGI BLEED:  Likely due to duodenal ulcer (injected with epi \\non ___ and esophageal varicies (5 bands placed on ___.  \\nHct stable since transfer from OSH.  Patient found to be \\nH.pylori positive, treated for 10 days (___) with \\namoxicillin/clarithromycin/PPI.  He was continued on \\npantoprazole 40mg BID, sucralafate, and nadolol upon discharge.  \\nHis heart rate remained in the ___, but nadolol could not be \\nfurther uptitrated because of SBP 90-100.  He received EGD \\n___ which showed one varix band in place, no new varices, no \\nbleeding.  Counseled to avoid heavy lifting.  He will need \\nrepeat EGD in 6 months for varices surveillance.\\n.\\n# Alcoholic cirrhosis:  His hepatic vasculature was patent, he \\nwas started on lactulose, rifaximin, furosemide.  He has a \\nhypoechoic lesion noticed on RUQ US, likely focal fatty sparing. \\n AFP 4.4, making hepatoma less likely, however MRI of liver \\nshould be completed as an outpatient.\\n.\\n# Hepatic encephalopathy: Likely due to GI bleed and sedation.  \\nIntermittently required haldol and seroquel for agitation.  Did \\nnot exhibit signs of withdrawl on the floor.  Mental status \\ncleared when GI bleed resolved. \\n.\\n# Fever: unclear source, presumed to be due to intra-abdominal \\ntranslocation of bacteria during  \\n.\\nHe was full code for this admission.\\n \\nMedications on Admission:\\n--Atenolol\\n \\nDischarge Medications:\\n1. thiamine HCl 100 mg Tablet Sig: One (1) Tablet PO DAILY \\n(Daily).\\nDisp:*30 Tablet(s)* Refills:*2*\\n2. pantoprazole 40 mg Tablet, Delayed Release (E.C.) Sig: One \\n(1) Tablet, Delayed Release (E.C.) PO Q12H (every 12 hours).\\nDisp:*60 Tablet, Delayed Release (E.C.)(s)* Refills:*2*\\n3. sucralfate 100 mg/mL Suspension Sig: Ten (10) ml PO four \\ntimes a day.\\nDisp:*300 mL* Refills:*2*\\n4. lactulose 10 gram/15 mL Solution Sig: Fifteen (15) ML PO \\nthree times a day: titrate for 3 bowel movements daily.\\nDisp:*1 bottle (960 mL)* Refills:*2*\\n5. furosemide 40 mg Tablet Sig: One (1) Tablet PO DAILY (Daily).\\nDisp:*30 Tablet(s)* Refills:*2*\\n6. rifaximin 550 mg Tablet Sig: One (1) Tablet PO BID (2 times a \\nday).\\nDisp:*60 Tablet(s)* Refills:*2*\\n7. nadolol 20 mg Tablet Sig: Two (2) Tablet PO HS (at bedtime).\\nDisp:*60 Tablet(s)* Refills:*2*\\n8. nadolol 20 mg Tablet Sig: One (1) Tablet PO QAM (once a day \\n(in the morning)).\\nDisp:*30 Tablet(s)* Refills:*2*\\n\\n \\nDischarge Disposition:\\nHome\\n \\nDischarge Diagnosis:\\nDuodenal ulcer\\nEsophageal varices\\nAcute blood loss anemia\\nHypoxemic respiratory Failure \\nVentilator-associated pneumonia \\nH. pylori infection\\nAlcoholic cirrhosis\\nHepatic encephalopathy\\nHypertension\\n\\n \\nDischarge Condition:\\nLevel of Consciousness: Alert and interactive.\\nActivity Status: Ambulatory - Independent.\\nMental Status: Clear and coherent.\\n\\n \\nDischarge Instructions:\\nYou were admitted to the hospital with GI bleeding from an ulcer \\nin the small intestine and abnormal blood vessels (varices) in \\nthe esophagus. Your blood counts remained stable after transfer \\nto ___ from ___, and you did not require \\nadditional blood transfusions. \\n\\nYou were treated for pneumonia, as well as for an infection in \\nthe stomach called H. pylori.\\n\\nYou likely have cirrhosis, scarring of the liver due to \\nexcessive alcohol use.  This underlying liver problem almost \\ncertainly contributed to the episodes of bleeding. It is \\nabsolutely necessary that you never drink alcohol again to avoid \\nfurther damage to the liver. Please make sure that you attend \\nall of your outpatient alcohol rehabilitation sessions. \\n\\nPlease follow up with one of our liver specialists, Dr. ___, \\non \\n___ at 3:40 ___.\\n\\nThe following medication changes were recommended:\\n- STOP Atenolol\\n- START thiamine 100mg daily\\n- START pantoprazole 40mg twice daily\\n- START sucralafate 100 mL four times daily\\n- START lactulose 15mL three times daily - you can increase or \\ndecrease this as need to have 3 bowel movements daily\\n- START furosemide 40mg daily\\n- START rifaximin 550mg twice daily\\n- START nadolol 20mg every morning and 40mg every evening\\n\\n \\nFollowup Instructions:\\n___\\n   \n..                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ...   \n95                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        \\nName:  ___                 Unit No:   ___\\n \\nAdmission Date:  ___              Discharge Date:   ___\\n \\nDate of Birth:  ___             Sex:   M\\n \\nService: MEDICINE\\n \\nAllergies: \\nheparin\\n \\nAttending: ___.\\n \\nChief Complaint:\\nhyperbilirubinemia, nausea, vomiting\\n \\nMajor Surgical or Invasive Procedure:\\n___: choledochoduodenostomy\\n \\nHistory of Present Illness:\\n___ year old M with mental retardation, s/p bioprosthetic MVR in \\n___ for mitral insufficiency, hypothyroidism, h/o PUD s/p \\nmassive bleed, and atrial fibrillation (not anticoagulated) who \\nwas recently diagnosed with pancreatic CA with liver mets. Pt \\nrecently discharged on ___ after undergoing EUS with FNA \\nconfirming diagnosis. Pt had some billiary obstruction from the \\nmass (Tbili 3.9 at discharge), but ERCP was unsuccessuful as the \\nscope could not be passed in the duodenum due to extrinsic \\ncompression. PTBD deferred as pt thought to be unlikely to \\ntolerate external drain maintenance. Pt seen in PCP's office \\nyesterday due to persistent nausea and vomiting. Labs show \\nrising bilirubin to 4.3, so admission has been arranged for \\nrepeat ERCP with rendezvous procedure. No fevers or chills. \\nNausea seems to have improved.  Prior to direct admission, \\npatient had persistent nausea and vomiting, so he was sent to \\nthe local hospital at ___, where a repeat CT scan \\nshowed enlarging liver lesions compared to prior CT scan at the \\nend of ___.  He was then transferred to the ___ ED.\\n\\nROS: unable to obtain\\n \\nPast Medical History:\\nMental retardation, moderate (I.Q. 35-49) \\nRectal prolapse / External hemorrhoids\\nMitral valve insufficiency, s/p bioprosthetic MVR ___\\nAnxiety\\nLumbar compression fracture\\natrial fibrillation\\nS/P colonoscopy \\nConstipation \\nHyperparathyroidism \\nPUD (peptic ulcer disease) \\nCerumen impaction\\nHeparin-induced thrombocytopenia\\nfibrous dysplasia\\nAspiration risk: mechanical soft ground diet with thin liquids.\\n\\nPAST MEDICAL HX REVIEW OF RECORDS-___ WEB:\\n___ valve prolapse with new regurgitation\\n___ valve prolapse with severe MR. ___ with LVH\\n___ with moderately dilated LV, LVEF 55-60%, Moderate LAE, \\nasymptomatic\\n___ echo with further dilated left ventricle (moderate \\nto severe) and preserved EF 55%. Severe mitral regurgitation and \\nmyxomatous degeneration of the bileaflets.\\nHx of rectal prolapse repair\\nObsessive-compulsive disorder with perservaration\\n___: mitral valve replacement with pericardial prosthesis \\nand ligation of left atrial appendage at Mass General: post op \\ncomplications included: atrial fibrillation requiring \\ncardioversion and amiodarone briefly\\nstarted on warfarin ___ after MVR x 6months more for HIT \\nthan for A. fib\\nAtrial fibrillation ___, on amiodarone briefly \\n___ sinus rhythm since cardioversion \\nin perioperative MVR period\\n\\nENDOCRINE:\\nOsteoporosis with a vertebral fracture of L1 in ___ and was \\nstarted on Fosamax in ___\\nHypercalcemia/Hyperparathyroidism with normal Sestamibi scan\\nElevated TSH in past with negative antibodies\\nHypothyroidism\\n \\nSocial History:\\n___\\nFamily History:\\nGiven his cognition the patient could not tell me what diseases \\nhis family members have or had.\\n\\n \\nPhysical Exam:\\nADMISSION PHYSICAL EXAM\\nVitals: 97.9 114/65 84 18 94%RA\\nGen: NAD, pleasant\\nHEENT: R facial droop/scarring, +icterus\\nCV: rrr, no r/m/g\\nPulm: clear b/l\\nAbd: soft, nontender, nondistended\\nExt: no edema\\nNeuro: alert, interactive, moves all extremities spontaneously, \\nconversant\\n \\nPertinent Results:\\nADMISSION LABS:\\n====================\\n___ 06:15AM BLOOD WBC-9.5 RBC-3.20* Hgb-11.5* Hct-35.1* \\nMCV-110* MCH-36.1* MCHC-32.8 RDW-14.7 Plt ___\\n___ 06:15AM BLOOD Glucose-118* UreaN-11 Creat-0.6 Na-143 \\nK-3.4 Cl-103 HCO3-34* AnGap-9\\n___ 06:15AM BLOOD Albumin-3.1*\\n___ 06:15AM BLOOD ALT-72* AST-101* AlkPhos-269* \\nTotBili-4.3*\\n___ 09:05AM BLOOD ___ PTT-31.7 ___\\n___ 06:33AM BLOOD Lactate-1.0\\n___ 03:30PM URINE Color-DkAmb Appear-Hazy Sp ___\\n___ 03:30PM URINE Blood-NEG Nitrite-NEG Protein-30 \\nGlucose-NEG Ketone-NEG Bilirub-SM  Urobiln-NEG pH-6.5 Leuks-NEG\\n___ 03:30PM URINE RBC-0 WBC-0 Bacteri-NONE Yeast-NONE Epi-0\\n\\nIMAGES\\n======\\n___: EUS and choledochoduodenostomy\\nImpression: EUS was performed using a linear echoendoscope at \\n___ MHz frequency: An ill-defined mass was noted in the head of \\nthe pancreas. The borders of the mass were irregular and poorly \\ndefined. CBD proximal to the mass was severely dilated At the \\nduodenum evaluation was made for a choledochoduodenostomy. The \\nextrahepatic bile duct was again visualized. A site for puncture \\nat D1/D2 was identified. \\nColor doppler was used to determine an avascular path for needle \\npuncture. \\nUnder EUS guidance, a 19-gauge needle was punctured through the \\nduodenal wall into CBD. \\nBilious fluid was aspirated confirming the location in CBD. \\nA cholangiogram was performed through the FNA needle revealing \\nmarked diffuse biliary dilation. \\nThere was no downstream drainage into the duodenum. \\nA 0.035 in guidewire was placed and reached the intrahepatic \\nducts. The needle was withdrawn. \\nAfter several methods were attempted to create a \\ncholedochoduodenostomy tract, an over the wire needle knife was \\nused to created a definitive tract under fluoroscopic \\nvisualization. \\nA hurricane balloon was then inserted to dilate the \\ncholedochoduodenostomy tract to 6 mm. \\nUpon attempting to advance the fully covered metal stent over \\nthe guidewire, the guidewire looped in the duodenum and wire \\naccess was temporarily lost. \\nThe EUS scope was then exchanged for a duodenoscope. Using a \\nsphincterotome, the guidewire was successfully advanced back \\ninto the CBD under fluoroscopic guidance. \\nA 10mm x 60mm WallFlex full-covered self expandable metal stent \\n(Ref: ___ ___: ___ was successfully placed in CBD \\nacross the duodenal wall, with resulting excellent bile flow. \\n \\nRecommendations: Return to ward for ongoing care. \\nIf any fever, worsening abdominal pain, or post procedure \\nsymptoms, please call the advanced endoscopy fellow on call \\n___/ pager ___. \\nNPO with IVF for hydration using RL. \\nCiprofloxacin and flagyl x 5 days\\n\\n___ KUB:\\nIMPRESSION: \\n1. No bowel obstruction or free air. \\n2. Bibasilar opacities incompletely characterized, likely \\natelectasis. \\n3. Mixed lytic and sclerotic left iliac lesion.  Comparison with \\nany older OSH studies recommended.\\n\\n___ PORTABLE CXR:\\nIMPRESSION:\\nNo previous images. Prosthetic valve is in place in a patient \\nwith intact \\nmidline sternal wires. There is enlargement cardiac silhouette \\nwith layering effusions, compressive basilar atelectasis, and \\ndiffuse parenchymal opacification consistent with pulmonary \\nedema. The possibility of superimposed pneumonia or even ARDS. \\nIV considered in the appropriate clinical setting. No evidence \\nof free intraperitoneal gas. However, this is not a true upright \\nview is rotated free air is AC is clinical concern, CT could be \\nobtained. \\n\\n \\n\\n \\n\\n \\nBrief Hospital Course:\\n___ year old male with PMH of mental retardation, bioprosthetic \\nMVR, A-fib and recently diagnosed metastatic pancreatic cancer \\npresenting with worsening biliary obstruction.\\n\\n1. Onc: Metastatic pancreatic cancer with worsening biliary \\nobstruction.  He underwent choledochoduodenostomy on ___.  \\nPlaced on ciprofloxacin and flagyl after the procedure.  \\nInitially tolerated a regular diet, had mild leukocytosis to 14 \\nthat resolved, bilirubin downtrending.  Developed bilious \\nvomiting on ___, KUB showed no evidence of free air or \\nobstruction.  Had increased abdominal distention on ___, CT \\nA/P orderered, while drinking contrast for CT scan developed \\nvomiting, worsening pain and distention, fevers and hypotension. \\n Transferred to ___ for further management. \\n\\n2. CV: Bioprosthetic MVR, atrial fibrillation not on \\nanticoagulation, hyperlipidemia. \\n-His home Toprol XL and lisinopril were held when he became \\nhypotensive.\\n-Continued simvastatin\\n\\n3. Thrombocytosis: Continue hydroxyurea\\n\\n4. History of HIT: Continue fondoparinux for DVT ppx\\n\\n5. Hypothyroidism: Continue Synthroid\\n\\n6. FEN/PPX: NPO, fondoparinux, PPI\\n\\nGuardian ___ ___ (all decisions made by\\nguardian)\\nFather: ___\\n___ (group home nurse) ___ with recently diagnosed pancreatic adenocarcinoma that \\npresented to the ___ with septic shock following recent GI \\nprocedure.\\n\\n#Septic shock: Patient with ___ SIRS criteria in setting of \\nlikely GI source of infection with hypotension unresponsive to \\nmultiple boluses of IVF consistent with septic shock. Given \\nperitoneal signs on exam there was concern that there might have \\nbeen leakage from perforation of small bowel in the setting of \\nrecent choledochoduodenostomy stent migration. Unfortunately, he \\nwas not a candidate for surgery or further endoscopic \\ninterventions with underlying co-morbidities and ongoing \\ncritical illness. Started vanc/zosyn and continue cipro/flagyl \\nfor double Pseudomonal and GNR, VRE, and C. diff coverage. \\nBolused with IVF PRN until CVP ___, maintained MAP >65 with \\nlevophed followed by vaso and epi, trended sVO2, lactate, and \\nABG q6h to help with hemodynamic monitoring. We were unable to \\nplace NGT ___ facial scarring and planned for CT w/contrast to \\nconfirm perforation if stabilized. \\n\\n#Hypoxic respiratory distress: Bilateral fluffy infiltrates on \\nCXR and new O2 requirement concerning for aspiration pneumonitis \\nvs. PNA vs. early ARDS. Initially satting well on ___ mask. \\nContinued to monitor oxygenation with IVF and titrated \\nsupplemental O2 to maintain SaO2 >90% Treatment of PNA with \\nabove abx\\n\\n#GOC: There was no chance of a meaningful recovery despite \\nmaximum medical therapy in the setting of abdominal perforation \\nwith no surgical option; as such, CPR was not indicated. His \\n___ agreed with this, and neither the medical \\nteam, nor ___ wished to intubate Mr. ___ as it would only \\nprolong suffering without offering a chance of survival. She \\nwanted to focus on comfort.\\n\\n#Metastatic pancreatic adenocarcinoma: Not a candidate for \\nchemo/XRT at time of presentation given critical illness. \\nInitial plan was that if the patient were to improve, we would \\nt/b with onc to discuss further management.\\n\\n#ET: Thrombocytopenic. Held hydroxyurea in setting of critical \\nillness.\\n\\n#Atrial fibrillation: Rate  well controlled. Held nodal agents \\nin setting of septic shock\\n\\n#Hypothyroidism: Continued synthroid\\n\\n#HTN: Held lisinopril in setting of shock\\n\\nUnfortunately, Mr. ___ began to deteriorate clinically \\nwith respect to increasing confusion and worsening mental \\nstatus. He was also somewhat more hypotensive, and given his \\ngoals of care, medical management was not to be escalated. This \\nincluded interventions like adding on pressors and intubation. \\nHe died suddenly in the setting of an arrhythmia, Torsades de \\npointes. He was DNR/DNI at that time, consistent with goals of \\ncare, and no resuscitation was attempted. \\n \\nMedications on Admission:\\nThe Preadmission Medication list is accurate and complete.\\n1. Zenpep (lipase-protease-amylase) 20,000-68,000 -109,000 unit \\noral tid \\n2. Ascorbic Acid ___ mg PO BID \\n3. Simvastatin 20 mg PO DAILY \\n4. Omeprazole 20 mg PO BID \\n5. Multivitamins 1 TAB PO DAILY \\n6. Polyethylene Glycol 17 g PO DAILY:PRN constipation \\n7. Metoprolol Succinate XL 25 mg PO DAILY \\n8. Psyllium 1 PKT PO TID:PRN constipation \\n9. Lisinopril 2.5 mg PO DAILY \\n10. Levothyroxine Sodium 50 mcg PO DAILY \\n11. Hydroxyurea 1000 mg PO DAILY \\n12. Docusate Sodium 100 mg PO BID \\n13. Fish Oil (Omega 3) 1000 mg PO BID \\n14. Citalopram 20 mg PO DAILY \\n15. Acidophilus (L.acidoph & \\n___ acidophilus) 175 mg oral \\nbid \\n16. Aspirin 81 mg PO DAILY \\n17. Acetaminophen 650 mg PO Q6H:PRN pain \\n\\n \\nDischarge Medications:\\nPatient passed away during hospitalization. \\n \\nDischarge Disposition:\\nExpired\\n \\nDischarge Diagnosis:\\nPancreatic adenocarcinoma with liver metastases\\nBile duct obstruction\\n\\n \\nDischarge Condition:\\nLevel of Consciousness: Alert and interactive.\\nActivity Status: Ambulatory - Independent.\\n\\n \\nDischarge Instructions:\\nThe patient expired during this hospitalization.\\n \\nFollowup Instructions:\\n___\\n   \n96                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                \\nName:  ___               Unit No:   ___\\n \\nAdmission Date:  ___              Discharge Date:   ___\\n \\nDate of Birth:  ___             Sex:   M\\n \\nService: MEDICINE\\n \\nAllergies: \\nSulfa (Sulfonamide Antibiotics) / ketamine\\n \\nAttending: ___.\\n \\nChief Complaint:\\nChest pain\\n \\nMajor Surgical or Invasive Procedure:\\nCardiac catheterization ___\\nCardiac catheterization ___ with drug eluting stent\\n\\n \\nHistory of Present Illness:\\nMr. ___ is a ___ y/o man with a PMH of CAD s/p \\nmultiple PCI, PVD s/p R BKA/L ___ toe amputation, stroke, HTN, \\nHLD, T2DM, chronic pain, who presents with chest pain. He \\npresented to the ED yesterday evening with three hours of \\ncrushing substernal chest pain, without radiation. He reported \\nthat it was similar to his prior MI pain but more sever. It was \\nworse with lying down and better when sitting up. Of note, he \\nhad also been experiencing erythema and pain of his left foot \\nand was febrile to ___ shortnly before arrival. \\n \\nIn the ED initial vitals were: T 99.8F BP 113/59 mmHg P ___ RR \\n20 O2 98% NC  \\nEKG: NSR, rate of 105, ST depressions in V4/V5, with TWI in \\nV1/V2, Q-wave in III\\nExam was notable for diaphoresis, tachycardia, and skin findings \\nconsistent with L foot cellulitis.\\nLabs/studies notable for normal Chem 7, including Cr of 1.2 \\n(though from a baseline of ~0.9), WBC 15,700, with 89.6%N, no \\nbands, H/H 13.9/42.9, PLT 273, trop-T of 0.02 rising to 0.40, \\nlactate 2.3, bland UA. CXR was notable for stable \\ncardiomediastinal silhouette, without evidence of pneumonia, \\nlarge effusion, or pneumothorax. A foot radiograph demonstrated \\nno evidence of erosion or radiographic evidence of \\nosteomyelitis.\\n\\nCardiology was consulted. He was treated with aspirin 243 mg, \\nvancomycin/Zosyn, heparin gtt, and nitroglycerin infusion. His \\nchest pain persisted, and therefore he was urgently taken to the \\ncardiac catheterization laboratory. Vitals on transfer: T 103.8F \\nBP 152/66 mmHg P ___ RR 18 O2 99% RA\\n\\nIn the cath lab, radial access was obtained, and he was found to \\nhave diffuse three vessel disease in a left dominant system with \\ncomplex lesions in the proximal LAD (bifurcation lesion with a \\ndiffusely disease restenotic diagonal), distal LAD, ostial ramus \\nintermedius and moderate disease in the dominant AV groove Cx \\ninto the LPDA. He was noted to have moderate-severe LV diastolic \\nheart failure, with an LVEDP of 23 mmHg. He continued to have \\nongoing chest pain despite IV NTG, heparin, and a high grade \\nfever, concerning for active infection with bacteremia/sepsis. \\nOverall, given his ongoing infection, the decision was made to \\ntreat the ongoing NSTEMI medically without PCI, with the option \\nto return for proximal LAD bifurcation stenting and distal LAD \\nstenting with PCI of the ramus intermedius after clearance of \\nthe infection. \\n\\nOn arrival to the CCU, he reported that he was continuing to \\nhave 4 of 10 chest pressure, though much improved from prior. He \\nactually reported that this pain is distinct from his prior \\nanginal pain. He also reported a headache; in fact, the headache \\nis bothering him more than the chest pain currently. He did \\nreport fevers, which started essentially shortly prior to his \\narrival in the ED. He reports pain and rash in his left foot, \\nwhich has improved since he arrived. Otherwise, he denied \\nnausea, vomiting, abdominal pain, dysuria, dyspnea, orthopnea, \\nedema, syncope, hematuria, hematochezia. \\n \\nREVIEW OF SYSTEMS:  \\n- as above, otherwise negative\\n \\nPast Medical History:\\n- CAD s/p PCIx8 reportedly (stents implanted at ___ in \\n___ info available. Last cath done at ___ in ___: nl LM. \\n80% mid LAD between prior stents, 70% apic LAD, D1 occluded at \\nprior stent, OM1 ___ 89%, 70% distal ramus at site of stent. \\nNondom small RCA. No intervention then)\\n- PVD s/p R BKA, L ___ toe amputation\\n- HTN\\n- T2DM c/b peripheral neuropathy\\n- HLD\\n- chronic pain\\n- stroke c/b L hemiparesis, now improved\\n- L sided humeral fracture (___), L patellar fracture, L \\ntibial plateau fracture\\n- depression\\n- pituitary adenoma \\n- laparoscopic appendectomy (___)\\n- angioplasty of LLE ___ ___ w/ Dr. ___\\n- multiple R heel debridement, free tissue transfer to R thigh \\nto R heel now s/p R BKA\\n\\n \\nSocial History:\\n___\\nFamily History:\\nFather died of esophageal cancer, was heavy smoker. Mother died \\nof unknown cancer type.\\n \\nPhysical Exam:\\nAdmission exam: \\nVS: T 98.0F BP 109/63 mmHg P 91 RR 14 O2 100%\\nGeneral: Uncomfortable appearing man, appearing his stated age.\\nHEENT: Anicteric sclerae, EOMs intact.\\nNeck: Supple, no JVD.\\nCV: RRR, no MRGs; normal S1/S2.\\nPulm: CTA b/l; no wheezes, rhonchi, or rales.\\nAbd: Soft, non-tender, non-distended, NABS.\\nExt: s/p R BKA. L toe lesions with mild erythema/tenderness, no \\nevidence ulceration or erosion. s/p L toe amputation. \\nDopplerable DP pulse.\\nNeuro: A&Ox3; CNs II-XII grossly intact. \\n\\nDischarge exam:\\nGeneral: Alert, awake, no acute distress\\nHEENT: anicteric sclera, MMM\\nNeck: No JVD appreciated\\nLungs: clear to auscultation bilaterally with good symmetric\\nairflow\\nCV: RRR with S1/S2, no murmurs, rubs, or gallops\\nAbdomen: soft, nontender\\nExtremities: warm, 2+ DP pulses, no edema\\n \\nPertinent Results:\\nAdmission and notable labs:\\n___ 06:00PM BLOOD WBC-15.7*# RBC-4.95 Hgb-13.9 Hct-42.9 \\nMCV-87 MCH-28.1 MCHC-32.4 RDW-13.3 RDWSD-42.1 Plt ___\\n___ 06:00PM BLOOD Neuts-89.6* Lymphs-3.9* Monos-5.4 \\nEos-0.2* Baso-0.2 Im ___ AbsNeut-14.08*# AbsLymp-0.61* \\nAbsMono-0.85* AbsEos-0.03* AbsBaso-0.03\\n___ 02:30AM BLOOD ___ PTT-49.2* ___\\n___ 06:00PM BLOOD Glucose-152* UreaN-17 Creat-1.2 Na-137 \\nK-4.6 Cl-101 HCO3-23 AnGap-18\\n___ 12:25PM BLOOD ALT-19 AST-45* LD(LDH)-162 AlkPhos-114 \\nTotBili-0.6\\n___ 06:00PM BLOOD cTropnT-0.02*\\n___ 09:26PM BLOOD cTropnT-0.06*\\n___ 12:54AM BLOOD cTropnT-0.13*\\n___ 04:15AM BLOOD cTropnT-0.21*\\n___ 08:00AM BLOOD CK-MB-21* cTropnT-0.40*\\n___ 12:25PM BLOOD CK-MB-21* cTropnT-0.48*\\n___ 06:09PM BLOOD CK-MB-20* cTropnT-0.52*\\n___ 04:30AM BLOOD CK-MB-22* cTropnT-0.72*\\n___ 06:00PM BLOOD Calcium-9.7 Phos-2.3* Mg-2.0\\n___ 12:25PM BLOOD Calcium-8.3* Phos-2.6* Mg-1.6 Cholest-103\\n___ 04:30AM BLOOD Calcium-8.7 Phos-2.8 Mg-1.9\\n___ 12:25PM BLOOD %HbA1c-7.7* eAG-174*\\n___ 12:25PM BLOOD Triglyc-85 HDL-33 CHOL/HD-3.1 LDLcalc-53\\n___ 06:21PM BLOOD Lactate-2.3*\\n___ 03:55AM URINE Blood-NEG Nitrite-NEG Protein-TR \\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-7.0 Leuks-NEG\\n___ 03:55AM URINE RBC-1 WBC-<1 Bacteri-NONE Yeast-NONE \\nEpi-0\\n___ 03:55AM URINE Color-Yellow Appear-Clear Sp ___\\n\\nMICROBIOLOGY\\n\\nIMAGING:\\nTTE ___\\nThe left atrium and right atrium are normal in cavity size. Left \\nventricular wall thicknesses are normal. The left ventricular \\ncavity size is normal. There is mild regional left ventricular \\nsystolic dysfunction with distal ___ of the LV showing \\nhypo-/akinesis. Doppler parameters are most consistent with \\nGrade I (mild) left ventricular diastolic dysfunction. Right \\nventricular chamber size and free wall motion are normal. The \\naortic root is mildly dilated at the sinus level. The ascending \\naorta is mildly dilated. The aortic valve leaflets (3) appear \\nstructurally normal with good leaflet excursion and no aortic \\nstenosis or aortic regurgitation. The mitral valve appears \\nstructurally normal with trivial mitral regurgitation. The \\nestimated pulmonary artery systolic pressure is normal. There is \\nan anterior space which most likely represents a prominent fat \\npad. \\n\\nIMPRESSION: Suboptimal image quality despite use of IV U/S \\ncontrast. \\n1) Mild regional left ventricular systolic dysfunction c/w CAD \\nin mid to distal LAD territory. \\n\\nCompared with the prior study (images reviewed) of ___, \\nregional wall motion abnormalities are new.\\n\\nCARDIAC CATH ___\\nDominance: Left\\nLMCA: The LMCA was short.\\nLAD: The proximal LAD had diffuse plaquing to 25% leading to an \\n85% bifurcation lesion extending to 75% at the ostium of the \\npreviously stented D1. D1 had diffuse in-stent and distal stent \\nedge restenosis to 80%. The mid LAD may have been \\nintramyocardial. The stent in the mid-distal LAD had hazy mild \\nin-stent restenosis. The distal LAD beyond the stent was of \\nsmall caliber and diffusely diseased to 85% before the\\nLAD wrapped well around the apex to the mid inferior septum. \\nFlow in the LAD was TIMI 2. \\nRamus intermedius: The stented ramus intermedius had a proximal \\nedge 70% stenosis at its ostium. There was also distal stent \\nedge restenosis to 80% in the lower basal pole of the ramus with \\nTIMI 2 flow beyond.\\nLCX: The CX supplied a tiny OM1. The large branching OM2/LPL1 \\nhad an origin 50% stenosis with more distal diffuse mild \\nplaquing to 40%. The distal AV groove CX had a 60% stenosis \\nbefore the prior stent. The other LPLs and the LPDA were all \\nsmall with diffuse disease to 45% in the mid LPDA. Flow in the \\nAV groove CX was pulsatile and delayed, consistent with \\nmicrovascular dysfunction.\\nRCA: The RCA was previously documented as non-dominant, small \\nand diffusely diseased and was not imaged today.\\nImpressions:\\n1. Diffuse three vessel disease in a left dominant system with \\ncomplex lesions in the proximal LAD (bifurcation lesion with a \\ndiffusely diseased restenotic diagonal), distal LAD, ostial \\nramus intermedius and moderate disease in the dominant AV groove \\nCX into the LPDA.\\n2. Moderate-severe left ventricular diastolic heart failure.\\n3. Ongoing chest pain despite IV TNG, IV heparin (with ACT only \\n181 secs), HR 95 and SBP <100 mm Hg.\\n4. High grade fever concerning for active infection with \\nbacteremia/sepsis.\\n\\nCXR ___\\nFINDINGS:    \\nAP portable upright view of the chest.  Mild linear atelectasis \\nin the lower lungs noted.  No focal consolidation is seen \\nconcerning for pneumonia.  No large effusion or pneumothorax \\nseen.  The left CP angle is partially excluded. \\nCardiomediastinal silhouette appears stable.  Bony structures \\nare intact. \\n\\n \\nBrief Hospital Course:\\nMr. ___ is a ___ y/o man with a PMH of CAD s/p \\nmultiple PCI, PVD s/p R BKA/L ___ toe amputation, stroke, HTN, \\nHLD, T2DM, chronic pain who has been admitted with NSTEMI in the \\nsetting of sepsis from skin and soft tissue infection. \\n\\n# CORONARIES: Diffuse 3VD, L dominant, complex lesions in ___ \\nLAD\\n(bifurcation lesion with a diffusely diseased restenotic diag), \\ndistal LAD, ostial ramus intermedius and moderate disease in the \\ndominant AV groove CX into the LPDA. Underwent PCA to LAD this \\nadmission (see below)\\n# PUMP: LVEF >55%\\n# RHYTHM: NSR\\n\\n# NSTEMI: Patient presented with chest pain in the setting of \\nsepsis. EKG showed NSR, rate of 105, ST depressions in V4/V5, \\nwith TWI in V1/V2, Q-wave in III. Trops initially 0.13 with CKMB \\n21. Patient initially underwent cardiac catheterization on \\nhospital day 1 which showed diffuse multivessel CAD. No \\nintervention was performed due to diffuse disease and ongoing \\nfevers (see below). He was planned for medical management with \\nnitro gtt for chest pain symptom relief as well as Plavix, \\nmetoprolol, aspirin 81, atorvastatin 80 mg qHS. ACEi was \\ninitially held due to hypotension (although ultimately resumed \\nover hospital course). However, troponins continued to rise and \\npatient again developed chest pain on ___ that was responsive \\nto SL nitro. He was placed on heparin gtt and isordil for chest \\npain control. He was taken back to the cath lab on ___, and \\nreceived a drug-eluting stent to proximal LAD, and balloon \\nangioplasty of D1 ostium and lower pole branch of ramus \\nintermedius. Please review OMR for the catheterization reports. \\n\\n# Severe sepsis secondary to cellulitis: Patient initially \\nfebrile, with leukocytosis, borderline hypotension and \\ntachycardia. Source appears to be left foot with warmth and \\nerythema. No evident ulceration or erosion. Dopplerable DP \\npulses. No evidence of trauma, though neuropathy and severe \\nperipheral vascular disease does place him at high risk for \\nSSTI. Given his recent hospitalizations and diabetes, patient \\nwas initially covered broadly, including with MRSA and \\nPseudomonal coverage. He does not have any cough or evidence of \\nPNA on CXR or evidence of UTI. He was initiated on vancomycin \\n1000 mg IV q8h and zosyn with panculture. Given concern for \\nosteomyelitis of foot, case discussed with vascular, podiatry, \\nand infectious diseases and decision was made that there was low \\nsuspicion for osteomyelitis, and no MRI was necessary. \\nUltimately, he defervesced and improved clinically in <24 hours \\nand it was felt that the source of infection was cellulitis. He \\nwas narrowed to cephalexin and will complete a course ending \\n___.\\n\\n#HEART FAILURE WITH PRESERVED EJECTION FRACTION. Noted to have \\nelevated LVEDP on catheterization. No dyspnea, PND, orthopnea at \\nthis time to suggest significant decompensation. Given concern \\nfor sepsis, he did not undergo diuresis initially. TTE this \\nadmission showed mild regional left ventricular systolic \\ndysfunction c/w CAD in mid to distal LAD territory. EF 45-50%.\\n\\nChronic issues:\\n# T2DM. Home glipizide and metformin were held, and he was \\nplaced on sliding scale insulin. \\n# CHRONIC PAIN. He was continued on home oxycodone 5 mg BID PRN \\nand breakthrough morphine ___ mg IV q4h PRN severe pain.\\n# PVD. He was continued on home aspirin, clopidogrel, and \\natorvastatin as above.\\n# DIABETIC NEUROPATHY. He was continued on home gabapentin 300 \\nmg TID.\\n# HLD. His home gemfibrozil was held, given interaction with \\natorvastatin 80 mg.\\n# ANXIETY. He was continued on home lorazepam 0.5 mg BID. \\n# DEPRESSION. He was continued on home sertraline 100 mg daily. \\n# IRON DEFICIENCY ANEMIA. He was continued on home ferrous \\nsulfate 325 mg daily.\\n# GERD. He was continued on home pantoprazole 40 mg q24h. \\n\\nTRANSITIONAL ISSUES:\\n- Given DES placed ___, patient should continue Plavix for \\nat least ___ year but likely lifelong given significant \\nmultivessel CAD and PVD\\n- Patient placed on long abx course for cellulitis with \\ncephalexin and should continue for 1 week after discharge \\n(started ___. \\n- home metoprolol tartrate 25mg was uptitrated to metoprolol \\ntartrate 50mg TID. ___ need to consider long acting metoprolol \\nsuccinate as HR and BP allows.\\n- Held home gemfibrozil during hospital course and discharge due \\nto interaction with atorvastatin 80 mg qHS.\\n- Please discuss cardiac clearance at upcoming cardiology \\nappointment so that patient can resume home ___\\n \\nMedications on Admission:\\nThe Preadmission Medication list is accurate and complete.\\n1. Ascorbic Acid ___ mg PO BID \\n2. Atorvastatin 80 mg PO QPM \\n3. Calcium Carbonate 500 mg PO BID \\n4. Clopidogrel 75 mg PO DAILY \\n5. Ferrous Sulfate 325 mg PO DAILY \\n6. GlipiZIDE 10 mg PO DAILY \\n7. Gemfibrozil 600 mg PO BID \\n8. Multivitamins 1 TAB PO DAILY \\n9. Senna 8.6 mg PO BID:PRN constipation \\n10. Sertraline 100 mg PO DAILY \\n11. Lisinopril 5 mg PO DAILY \\n12. LORazepam 0.5 mg PO Q12H:PRN anxiety \\n13. Zinc Sulfate 220 mg PO DAILY \\n14. MetFORMIN XR (Glucophage XR) 1000 mg PO BID \\n15. Vitamin D2 (ergocalciferol (vitamin D2)) 50,000 unit oral \\n1X/WEEK \\n16. Pantoprazole 40 mg PO Q24H \\n17. Polyethylene Glycol 17 g PO DAILY:PRN Constipation  \\n18. Sarna Lotion 1 Appl TP BID:PRN pruritis over back  \\n19. Gabapentin 300 mg PO TID \\n20. Docusate Sodium 100 mg PO BID \\n21. Aspirin 81 mg PO DAILY \\n22. OxyCODONE (Immediate Release) 5 mg PO BID:PRN Pain - \\nModerate \\n  Reason for PRN duplicate override: changing frequency of drug\\n23. Metoprolol Tartrate 25 mg PO DAILY \\n24. Nitroglycerin SL 0.3 mg SL Q5MIN:PRN chest pain \\n\\n \\nDischarge Medications:\\n1.  Cephalexin 500 mg PO Q6H \\nRX *cephalexin 500 mg 1 capsule(s) by mouth every six (6) hours \\nDisp #*28 Capsule Refills:*0 \\n2.  Metoprolol Tartrate 50 mg PO TID \\nRX *metoprolol tartrate 50 mg 1 tablet(s) by mouth three times a \\nday Disp #*28 Tablet Refills:*0 \\n3.  Ascorbic Acid ___ mg PO BID  \\n4.  Aspirin 81 mg PO DAILY  \\n5.  Atorvastatin 80 mg PO QPM  \\n6.  Calcium Carbonate 500 mg PO BID  \\n7.  Clopidogrel 75 mg PO DAILY  \\n8.  Docusate Sodium 100 mg PO BID  \\n9.  Ferrous Sulfate 325 mg PO DAILY  \\n10.  Gabapentin 300 mg PO TID  \\n11.  GlipiZIDE 10 mg PO DAILY  \\n12.  Lisinopril 5 mg PO DAILY  \\n13.  LORazepam 0.5 mg PO Q12H:PRN anxiety  \\n14.  MetFORMIN XR (Glucophage XR) 1000 mg PO BID  \\n15.  Multivitamins 1 TAB PO DAILY  \\n16.  Nitroglycerin SL 0.3 mg SL Q5MIN:PRN chest pain  \\n17.  OxyCODONE (Immediate Release) 5 mg PO BID:PRN Pain - \\nModerate \\n  Reason for PRN duplicate override: changing frequency of drug \\n18.  Pantoprazole 40 mg PO Q24H  \\n19.  Polyethylene Glycol 17 g PO DAILY:PRN Constipation   \\n20.  Sarna Lotion 1 Appl TP BID:PRN pruritis over back   \\n21.  Senna 8.6 mg PO BID:PRN constipation  \\n22.  Sertraline 100 mg PO DAILY  \\n23.  Vitamin D2 (ergocalciferol (vitamin D2)) 50,000 unit oral \\n1X/WEEK  \\n24.  Zinc Sulfate 220 mg PO DAILY  \\n25. HELD- Gemfibrozil 600 mg PO BID  This medication was held. \\nDo not restart Gemfibrozil until told to do so by your doctor\\n\\n \\nDischarge Disposition:\\nHome\\n \\nDischarge Diagnosis:\\nPrimary:\\nNon-ST elevation myocardial infarction requiring stent placement\\nSevere sepsis secondary to cellulitis\\n\\nSecondary:\\nCoronary artery disease\\nPeripheral vascular disease\\nDiabetes mellitus\\nHypertension\\nHyperlipidemia\\nChronic pain\\n\\n \\nDischarge Condition:\\nMental Status: Clear and coherent.\\nLevel of Consciousness: Alert and interactive.\\nActivity Status: Ambulatory - Independent.\\n\\n \\nDischarge Instructions:\\nDear Mr. ___,\\n\\nYou were seen at ___ for fevers \\nand for chest pain. Your fevers were ultimately felt to be due \\nto an infection of your skin/fat tissue (called \"cellulitis\"). \\nYou were initially treated with broad IV antibiotics but these \\nwere adjusted to oral antibiotics with the input of infectious \\ndisease. You will continue these antibiotics (cephalexin) for 7 \\ndays after you are discharged (end ___. \\n\\nFor your chest pain, you underwent a cardiac catheterization \\nearly in your admission to determine if there was a blockage in \\nthe arteries to your heart.\\n\\nWhat should you do when you leave the hospital?\\n- Please follow up with the appointments we have arranged.\\n- Please continue cephalexin (an antibiotic) until ___.\\n- Please discontinue your gemfibrozil due to the \\ndrug-interaction with atorvastatin. \\n- There were no other major medication changes. Please continue \\ntaking your Plavix.\\n\\nIt was a pleasure taking care of you at ___.\\n\\nSincerely, \\nYour ___ care team\\n \\nFollowup Instructions:\\n___\\n   \n97                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \\nName:  ___                   Unit No:   ___\\n \\nAdmission Date:  ___              Discharge Date:   ___\\n \\nDate of Birth:  ___             Sex:   F\\n \\nService: SURGERY\\n \\nAllergies: \\nPatient recorded as having No Known Allergies to Drugs\\n \\nAttending: ___.\\n \\nChief Complaint:\\n- colon cancer\\n \\nMajor Surgical or Invasive Procedure:\\n- exploratory laparotomy\\n- ileocecectomy\\n\\n \\nHistory of Present Illness:\\nOn admission:\\n___ yo female with history of iron deficiency anemia who was \\nevaluated by her primary care physician and found to have colon \\ncancer on colonoscopy. She now presents for ileocecectomy.  \\n \\nPast Medical History:\\n- paroxysmal atrial fibrillation\\n- hypertension\\n- hyperlipidemia\\n- arthritis\\n- vertigo\\n- spinal stenosis\\n- diabetes mellitus, type II\\n- anemia\\n.\\n- hysterectomy\\n- breast reduction\\n- repair for pelvic organ prolapse\\n- right rotator cuff repair\\n \\nSocial History:\\n___\\nFamily History:\\n- non-contributory\\n \\nPhysical Exam:\\nDay of Discharge:\\nVitals -  T:98.0  BP:141/60  HR:74  RR:16  O2sat:98% RA\\nGen: NAD, A&O x 3\\nCV: irregular, normal rate, no M/R/G\\nResp: CTAB, no respiratory distress\\nAbd: soft, not distended, no TTP, no rebound/guarding\\nIncision: C/D/I, no erythema or induration\\nExt: no C/C/E\\n \\nPertinent Results:\\n___ WBC-7.1 Hgb-9.5 Hct-29.6 Plt ___\\n___ WBC-11.2 Hgb-10.0 Hct-32.5 Plt ___\\n.\\n___ ___ PTT-25.5 ___\\n___ ___ PTT-19.4 ___\\n.\\n___ Glucose-118 UreaN-17 Creat-0.8 Na-141 K-4.2 Cl-104 \\nHCO3-27 \\n___ Glucose-105 UreaN-19 Creat-0.8 Na-137 K-4.8 Cl-102 \\nHCO3-25 \\n___ Albumin-3.2 Calcium-8.5 Phos-2.2 Mg-2.0\\n___ Calcium-9.0 Phos-3.7 Mg-2.0\\n.\\n___ ALT-17 AST-26 LD(LDH)-212 AlkPhos-49 TotBili-0.7\\n.\\n___ CK(CPK)-215\\n.\\n___ TSH-1.2\\n.\\n___ Digoxin-2.5\\n.\\nRAPID PLASMA REAGIN TEST (Final ___: NONREACTIVE. \\n.\\nUCX negative x ___\\nMRSA negative\\nBCX negative\\n.\\n___: CTA - No PE\\n___: LENIs - no DVT\\n___: ECHO - LVEF >55%, trace AR, mod MR\\n\\n      \\n\\n \\nBrief Hospital Course:\\n*)Colon Cancer\\nShe was taken to the operating room and underwent ileocecectomy; \\nplease see the operative report for full details. On POD#1 she \\ndeveloped intermittently low urine output and received \\nadditional IV fluids. Early in the morning on POD#2 she \\ndeveloped mild respiratory distress with a CXR consistent with \\nfluid overload. IV fluids were stopped and she was given Lasix \\nand nebulizer treatments, to which she responded. However, over \\nthe course of the day and into POD#3 she continued to have \\nissues with low urine output and respiratory distress, and was \\ntransferred to the MICU for closer monitoring.\\n.\\n*)MICU Course\\nMs. ___ was transferred to the medical ICU from the surgical \\nteam for hypoxia believed to be pulmonary edema.  On transfer \\nshe was fluid overloaded with evidence of pulmonary edema.  She \\nwas diuresed serially with lasix and her symptoms resolved.  She \\nwas transitioned from a high flow mask to decreasing oxygen \\nlevels, then finally to a nasal cannula. \\nHer ICU course was complicated by delirium on the night of \\nadmission that was controlled with IV haldol. In addition, while \\ndelerious she began to pass bright red bloody stools. Surgery \\nwas made aware and determined this to be consistent with her \\nsurgery. She was transfused one unit of pRBCs for a falling \\nhematocrit.  \\nThe patient's ICU course was prolonged by atrial fibrillation \\nwith a rapid rate that was difficult to control.  She was \\nstarted on metoprolol IV, trialed unsuccessfully on diltiazem \\nand amiodarone drips.  When her delirium resolved and she was \\nable to take PO medications, her home regimen with verapamil and \\nmetoprolol was adjusted with the assistance of cardiology to \\ncontrol her rate.\\n.\\n*)Post-operative Course (s/p MICU)\\nShe was transferred back to the floor and closely monitored, \\nwith no further episodes of respiratory distress. Her diet was \\nslowly advanced with the return of her bowel function, and on \\ndischarge she was tolerating a regular diet and her pain was \\nwell controlled on oral medications. \\n.\\n*)Atrial Fibrillation\\nHer heart rate was somewhat difficult to control initially, and \\nshe had some episodes of tachycardia after her return to the \\nfloor. Cardiology continued to follow her for the duration of \\nher hospital course. Medications were adjusted, with better \\ncontrol after the addition of digoxin. On discharge, her heart \\nrate was well controlled on digoxin and verapamil, and she was \\nto resume her home regimen of atenolol. Follow up with her \\nPCP/cardiologist was scheduled. Her Coumadin was held during her \\npost-operative recovery and was to be re-started on discharge. \\n \\nMedications on Admission:\\n- Tylenol\\n- warfarin (stopped ___\\n- vaginal cream\\n- simvastatin \\n- atenolol  \\n- verapamil \\n- alprazolam prn\\n- iron \\n- citracal\\n- MVI\\n- metformin \\n \\nDischarge Medications:\\n1. Atenolol 50 mg Tablet Sig: One (1) Tablet PO DAILY (Daily).  \\n2. Verapamil 120 mg Tablet Sig: One (1) Tablet PO Q12H (every 12 \\nhours).  \\n3. Percocet ___ mg Tablet Sig: ___ Tablets PO every six (6) \\nhours as needed for pain.\\nDisp:*40 Tablet(s)* Refills:*0*\\n4. Docusate Sodium 100 mg Capsule Sig: One (1) Capsule PO BID (2 \\ntimes a day) for 1 months: Take with pain meds.\\nDisp:*60 Capsule(s)* Refills:*0*\\n5. Metformin 500 mg Tablet Sig: One (1) Tablet PO BID (2 times a \\nday).  \\n6. Digoxin 250 mcg Tablet Sig: One (1) Tablet PO DAILY (Daily).\\nDisp:*30 Tablet(s)* Refills:*2*\\n7. Verapamil 120 mg Tablet Sig: One (1) Tablet PO Q12H (every 12 \\nhours).  \\n8. Atenolol 50 mg Tablet Sig: One (1) Tablet PO twice a day.  \\n9. Coumadin 5 mg Tablet Sig: One (1) Tablet PO once a day: \\nPlease take at 4pm.  \\n\\n \\nDischarge Disposition:\\nHome With Service\\n \\nFacility:\\n___ \\nhome\\n \\nDischarge Diagnosis:\\n- colon cancer\\n.\\n- paroxysmal atrial fibrillation\\n- hypertension\\n- arthritis\\n- hyperlipidemia\\n\\n \\nDischarge Condition:\\n- stable\\n- tolerating a regular diet\\n- pain controlled on oral medications\\n\\n \\nDischarge Instructions:\\nGeneral Instructions:\\nPlease call your doctor or return to the ER for any of the \\nfollowing:\\n* You experience new chest pain, pressure, squeezing or \\ntightness.\\n* New or worsening cough or wheezing.\\n* If you are vomiting and cannot keep in fluids or your \\nmedications.\\n* You are getting dehydrated due to continued vomiting, diarrhea \\nor other reasons. Signs of dehydration include dry mouth, rapid \\nheartbeat or feeling dizzy or faint when standing.\\n* You see blood or dark/black material when you vomit or have a \\nbowel movement.\\n* Your pain is not improving within ___ hours or not gone \\nwithin 24 hours. Call or return immediately if your pain is \\ngetting worse or is changing location or moving to your chest or \\nback.\\n*Avoid lifting objects > 5lbs until your follow-up appointment \\nwith the surgeon.\\n*Avoid driving or operating heavy machinery while taking pain \\nmedications.\\n* You have shaking chills, or a fever greater than 101.5 (F) \\ndegrees or 38(C) degrees.\\n* Any serious change in your symptoms, or any new symptoms that \\nconcern you. \\n* Please resume all regular home medications and take any new \\nmeds \\nas ordered. \\n* Continue to ambulate several times per day.\\n.\\nIncision Care:\\n-Your steri-strips will fall off on their own. Please remove any \\nremaining strips ___ days after surgery.\\n-You may shower, and wash surgical incisions.\\n-Avoid swimming and baths until your follow-up appointment.\\n-Please call the doctor if you have increased pain, swelling, \\nredness, or drainage from the incision sites.\\n.\\nMedications: \\n1. Coumadin: please restart your home does of coumadin 5 mg \\ndaily.\\n-You need to have lab work done on ___ and have the \\nresults faxed to your cardiologist. \\n2. Digoxin 0.25 mg by mouth daily. Please hold for HR ___ \\n-You should take this medication once a day.\\n-A handout was provided regarding this medication. \\n\\n \\nFollowup Instructions:\\n___\\n   \n98                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \\nName:  ___                 Unit No:   ___\\n \\nAdmission Date:  ___              Discharge Date:   ___\\n \\nDate of Birth:  ___             Sex:   M\\n \\nService: CARDIOTHORACIC\\n \\nAllergies: \\nAmiodarone / Monosodium Glutamate\\n \\nAttending: ___.\\n \\nChief Complaint:\\nAsymptomatic ascending aortic aneurysm\\n \\nMajor Surgical or Invasive Procedure:\\n___ - Redo Sternotomy, Replacement of ascending aorta and \\ntotal arch. \\ntracheostomy ___\\ngastrojejunostomy ___\\n\\n \\nHistory of Present Illness:\\nThis ___ year old white male underwent repair of a Type A aortic \\ndissection and coronary artery bypass in ___. The aorta was \\nnoted to be dissected to both iliacs at that time and he \\nsubsequently had coil embolization of left\\ninternal iliac aneurysm ___. Recent CTA shows increase in \\nascending aortic diameter to 6.3 cm. He was referred for \\nsurgical evaluation.\\n\\n \\nPast Medical History:\\nPeripheral vascular disease\\nascending aortic aneurysm\\nType A aortic dissection\\nHypertension\\nCongestive heart failure\\nAtrial fibrillation s/p ablation ___\\nTachybrady syndrome s/p pacemaker\\nVentral Hernia\\nCholelithiasis\\nDiverticulosis\\nBenign Prostatic Hypertrophy\\nSpinal stenosis \\ns/p Replacement of Ascending aorta (26mm Gelweave \\ngraft)/resuspension of Aortic Valve /Coronary Artery Bypass \\nGraft x1 (SVG to ___\\ns/p Coil embolization of left internal iliac ___\\ns/p Tonsillectomy\\ns/p left trigger finger release\\nhyperlipidemia\\n \\nSocial History:\\n___\\nFamily History:\\nnoncontributory\\n \\nPhysical Exam:\\nAdmission:\\n\\nPulse:  Resp:  O2 sat: \\nB/P  Right: 132/76  Left: 128/80\\nHeight: ___    Weight: 203 lbs\\n\\nGeneral:\\nSkin: Dry [X] intact [X]\\nHEENT: PERRLA [X] EOMI [X]\\nNeck:  Supple [X] Full ROM [X]\\nChest: Lungs clear bilaterally [X]\\nHeart: RRR [X]  Irregular []  Murmur\\nAbdomen: Soft [X] non-distended [X] non-tender [X] bowel sounds \\n+\\n[X] ventral hernia\\nExtremities: Warm [X], well-perfused [X]  Edema Varicosities:\\nNone [X] left thigh saph. vein harvest site incision well-healed\\nNeuro: Grossly intact [X],nonfocal exam, MAE ___ strengths\\nPulses:\\nFemoral      Right/Left: 2+\\nDP           Right/Left: 2+\\n___           Right/Left: 2+\\nRadial       Right/Left: 2+\\n\\nCarotid Bruit    Right/Left: none\\n\\n \\nPertinent Results:\\n___ Head CT\\nThere is no evidence of hemorrhage, edema, mass or mass effect.  \\n\\nThere is no evidence of acute vascular territorial infarct. The \\npreviously \\nseen hypoattenuating focus within the left frontal lobe is again \\ndemonstrated, most likely representing partial volume-averaging \\neffect.The ventricles and sulci are normal in caliber and \\nconfiguration, unchanged in size in comparison to prior studies. \\nNo fracture identified. \\n  \\n___ Chest CT without contrast\\nThere is complete resolution of the pre-existing left \\npneumothorax with \\ncomplete reexpansion of the left lung. \\nIn the mediastinum, the aortic graft continues to be barely \\nvisualized. The parts of the superior pericardial recess that \\nbulge into the aortopulmonary window are of unchanged \\n___. Also unchanged are the diffuse calcifications of the \\naortic valve and the coronary arteries. The pre-described \\nretrosternal fluid collection is of unchanged apical basal \\nextent, however, its overall thickness has minimally decreased. \\nIn unchanged manner, the fluid collection does not contain gas \\nand shows as far as an assessment without contrast is possible. \\nUnchanged moderate cardiomegaly. Minimal increase of the \\npre-existing bilateral pleural effusions. Newly occurred \\nbilateral dependent areas of atelectasis with air bronchograms. \\nThe symmetry and the bilateral nature of the changes favor \\natelectasis over pneumonia. Newly appeared are minimal \\nuncharacteristic peribronchial nodular opacities in the right \\nlower lung that are too small to represent substantial \\ninfectious changes that could cause the clinical symptoms of the \\npatient. Unchanged suspicion of bronchomalacia. No atrial septal \\ndefect is seen by 2D or color Doppler. Overall left ventricular \\nsystolic function is normal (LVEF>55%). Right ventricular \\nchamber size and free wall motion are normal. A mobile density \\nis seen in the descending aorta consistent with an intimal \\nflap/aortic dissection with likely thrombus. The aortic valve \\nleaflets (3) are mildly thickened. No masses or vegetations are \\nseen on the aortic valve. Mild (1+) aortic regurgitation is \\nseen. The mitral valve leaflets are mildly thickened. No mass or \\nvegetation is seen on the mitral valve. Trivial mitral \\nregurgitation is seen. No masses or vegetations are seen on the \\npulmonic valve, but cannot be fully excluded due to suboptimal \\nimage quality. There is no pericardial effusion. \\n\\n___ Echo:\\nIMPRESSION: No evidence of endocarditis. Normal bi-ventricular \\nfunction. Mild aortic regurgitation. Extensive descending aortic \\ndissection with thrombus in the false lumen.   \\n\\nHematology \\nCOMPLETE BLOOD COUNT WBC RBC Hgb Hct MCV MCH MCHC RDW Plt Ct \\n___  6.0 3.34* 10.1* 31.2* 93 30.2 32.4 17.0* \\n224 \\nSource: Line-PICC \\nBASIC COAGULATION ___, PTT, PLT, INR) ___ PTT Plt Smr Plt Ct \\n___ \\n___          224   \\nSource: Line-PICC \\n___ 15.4* 26.8     1.3* \\nChemistry \\nRENAL & GLUCOSE    Glucose UreaN Creat Na K Cl HCO3 AnGap \\n___  95    42*    1.1 145 4.2 109* 27 13 \\nSource: Line-PICC \\nENZYMES & BILIRUBIN ALT AST LD(LDH) CK(CPK) AlkPhos Amylase \\nTotBili DirBili \\n___    65* 44* 265*   88 18 0.6   \\n \\nOTHER ENZYMES & BILIRUBINS Lipase \\n___         179* \\n \\nCHEMISTRY TotProt Albumin Globuln Calcium Phos Mg UricAcd Iron \\n___                   8.7 3.5 2.3     \\n\\nNEUROPSYCHIATRIC     Phenoba Phenyto Valproa Phenyfr %Phenyf \\n___    12.2         \\n   \\n___  ART 37.1  CPAP  40   86 33* 7.49* 26 \\n \\n \\n  \\n\\n \\nBrief Hospital Course:\\nMr. ___ was admitted to the ___ on ___ for surgical \\nmanagement of his ascending aortic aneurysm. He was taken to the \\noperating room where he underwent a redo sternotomy with \\nreplacement of his ascending aorta and arch. Please see \\noperative note for details. Postoperatively he was taken to the \\nintensive care unit for monitoring. He remained intubated and \\nsedated following surgery. \\n\\nLeft shoulder and right thigh twitching was noted and a \\nneurology consult was obtained. A head CT was performed which \\nwas negative. Repeat scan 2 days later also negative. He \\ncontinued to have seizure activity and was started on dilantin, \\nKeppra, and ultimately phenobarbital over more than a week with \\ncontinued frequent seizures whenever Propofol was off. Propofol \\nwas turned off to continue to evaluate his neurological status \\nwith continued neurology evaluations and continuous EEG \\nmonitoring. He had persistent fevers with no source for many \\ndays.  Eventually he developed a LLL pneumonia with enterococcus \\nin his sputum and positive blood cultures. Ampicillin and \\ngentamicin were started and he defervesced.\\n\\nHe eventually was off Propofol without seizures (although still \\nunresponsive) and the phenobarbital was weaned by levels.  He re \\nspiked fevers and cultures of sputum on ___ grew Serratia for \\nwhich a two week course of Cipro and Vancomycin were given. \\nLines were changed multiple times during these times. Of note, \\nthe patient has a right IJ thrombosis discovered during a line \\nplacement. \\n\\nNeurology continued to follow the patient with multiple EEG's \\nperformed to evaluate seizure activity.  He was weaned off of \\ndilantin, briefly taken off phenobarbital and then restarted on \\na standing dose. He was weaned down on Keppra with improving \\nmental status but EEG performed on ___ showed increased \\nseizure activity.  His Keppra was increased to 750 mg nightly \\nand he was kept on his maintenance phenobarbital dose per \\nneurology recommendations. CT of the head on ___ showed \\nhypodensity of the right frontal lobe. Repeat head CT on ___ \\nshowed no acute process. The patient's mental status improved \\ngradually and he was following simple commands, answering \\nquestions and moving all extremities at the time of discharge.  \\nPer neurology, the patient is to maintain his standing doses of \\nphenobarbital and Keppra and follow up with neurology after \\ndischarge from rehab. Multiple discussions were had with his \\nwife and family throughout the course.\\n\\nThe patient developed atrial fibrillation during his hospital \\ncourse and was started on Lopressor for rate control. He was on \\nand off Neo-Synephrine intermittently.  He was anticoagulated \\nwith Coumadin for afib (which was briefly held due to \\nhematuria).  At the time of discharge, he had restarted Coumadin \\nand INR was slowly increasing.  He was no longer in atrial \\nfibrillation but being paced with his intrinsic permanent \\npacemaker at a rate in the 60's alternating with sinus rhythm in \\nthe 70's.  He was on a maintenance dose of beta blockers.\\n\\nThe patient was slowly weaned on the ventilator and on ___ he \\nunderwent a percutaneous tracheostomy at the bedside.  See \\noperative note for full details.  He was treated for a full two \\nweek course for enterococcus pneumonia.  He was thought to be \\ncolonized with serratia and required no further antibiotic \\ntreatment.  He did have a left sided chest tube placed for \\neffusion. CXR on ___ showed small left effusion, left \\nbasilar atelectasis.  He was tolerating CPAP with a pressure \\nsupport of 10, becoming tachypneic with lower pressure support \\ntrials.  CXR on ___ showed small left effusion and left \\nbasilar atelectasis. He was restarted on a 7 day course of Lasix \\nfor the effusion.\\n\\nMr. ___ underwent a minilaparotomy and transgastric jejunal \\ntube placement on ___.  See operative report for full \\ndetails.  He was tolerating tube feeds at goal.  Stools were \\nbeing guiaced and were negative.\\n\\nThe patient had hypernatremia and increased BUN throughout his \\nhospital course.  He was thought to be intravascularly dry and \\nLasix was discontinued.  He was given free water and sodium \\nreturned to a normal range.  Creatinine peaked at 1.9 but was \\nback to baseline (1.1) at the time of discharge.  He did have \\nhematuria after foley trauma while on Coumadin.  He was seen by \\nurology and started on continuous bladder irrigation.  His urine \\nbecame clear and foley was pulled ___. He failed to void and \\nfoley was reinserted later that night with small old blood clots \\nevacuated.  He was able to be easily manually irrigated and \\nurine was clear at discharge.  Per urology recommendations, the \\npatient was started on Flomax and he is to have a repeat voiding \\ntrial in 2 weeks.  No further urology follow up is needed unless \\nhematuria recurs.\\n\\nInterventional pulmonology was consulted for a question of \\nbronchomalacia after a bronchoscopy. They determined he needed \\nno intervention at this time.\\n\\nMr ___ received multiple units of red blood cells throughout \\nhis hospital course.  He had iron studies done which showed \\nnormal iron levels, low TIBC and low transferrin levels.  It was \\ndetermined that the patient has anemia of chronic disease.  He \\nwas restarted on Coumadin on ___ and had a goal INR ___ for \\natrial fibrillation and right internal jugular thrombosis.  \\nLength of anticoagulation to be determined by the patient's \\ncardiologist and neurologist.\\n\\nAt the time of discharge, Mr. ___ was afebrile, white blood \\ncount was normal, he was being Hoyer lifted into a chair and \\ntolerating the settings of CPAP 40% PEEP 5 PS 12.  His mental \\nstatus continued to improve. It was felt that he was safe for \\ntransfer to a rehabilitation facility at this time. \\n\\n \\nMedications on Admission:\\nNorvasc 5', Lipitor 20', Lasix 20', Lopressor 150\", KCl 20', \\nFlomax 0.4', ASA 81', Colace 200', MVI, Multag 400', Lorazepam \\n0.5', Naproxen prn \\n \\nDischarge Medications:\\n1. Acetaminophen 650 mg Tablet Sig: ___ Tablets PO Q4H (every 4 \\nhours) as needed for temperature >38.0.  \\n2. Aspirin 81 mg Tablet, Chewable Sig: One (1) Tablet, Chewable \\nPO DAILY (Daily).  \\n3. Docusate Sodium 50 mg/5 mL Liquid Sig: 10 ml  PO BID (2 times \\na day).  \\n4. Magnesium Hydroxide 400 mg/5 mL Suspension Sig: Thirty (30) \\nML PO DAILY (Daily) as needed for constipation.  \\n5. Dronedarone  Oral\\n6. Ranitidine HCl 15 mg/mL Syrup Sig: 10 ml  PO DAILY (Daily).  \\n7. Bisacodyl 10 mg Suppository Sig: One (1) Suppository Rectal \\nDAILY (Daily) as needed for constipation.  \\n8. Polyvinyl Alcohol-Povidone 1.4-0.6 % Dropperette Sig: ___ \\nDrops Ophthalmic Q6H (every 6 hours).  \\n9. Ipratropium-Albuterol ___ mcg/Actuation Aerosol Sig: ___ \\nPuffs Inhalation Q6H (every 6 hours).  \\n10. Simvastatin 10 mg Tablet Sig: Two (2) Tablet PO DAILY \\n(Daily).  \\n11. Phenobarbital 20 mg/5 mL Elixir Sig: 7.5 ml  PO TID (3 times \\na day).  \\n12. Metoprolol Tartrate 25 mg Tablet Sig: 0.5 Tablet PO TID (3 \\ntimes a day).  \\n13. Senna 8.6 mg Tablet Sig: One (1) Tablet PO BID (2 times a \\nday).  \\n14. Nystatin 100,000 unit/mL Suspension Sig: Five (5) ML PO QID \\n(4 times a day).  \\n15. Levetiracetam 100 mg/mL Solution Sig: Five (5) ML PO QAM \\n(once a day (in the morning)).  \\n16. Levetiracetam 100 mg/mL Solution Sig: 7.5 ML PO QPM (once a \\nday (in the evening)).  \\n17. Tamsulosin 0.4 mg Capsule, Sust. Release 24 hr Sig: One (1) \\nCapsule, Sust. Release 24 hr PO HS (at bedtime).  \\n18. Warfarin 2.5 mg Tablet Sig: One (1) Tablet PO ONCE (Once): \\nDose for Goal INR ___ ___.  \\n19. Sodium Chloride 0.9%  Flush 10 mL IV PRN line flush \\nTemporary Central Access-ICU: Flush with 10mL Normal Saline \\ndaily and PRN. \\n20. Potassium Chloride 10 mEq Capsule, Sustained Release Sig: \\nTwo (2) Capsule, Sustained Release PO twice a day for 7 days.  \\n21. Lasix 40 mg Tablet Sig: One (1) Tablet PO twice a day for 7 \\ndays.  \\n\\n \\nDischarge Disposition:\\nExtended Care\\n \\nFacility:\\n___\\n \\nDischarge Diagnosis:\\nDilated ascending aorta\\ns/p replacement of ascending aorta and arch\\npostoperative seizures\\nPeripheral vascular disease\\ns/p Type A aortic dissection\\nHypertension\\nCongestive heart failure\\nAtrial fibrillation s/p ablation ___\\nTachybrady syndrome s/p pacemaker\\nVentral Hernia\\nCholelithiasis\\nDiverticulosis\\nBenign Prostatic Hypertrophy\\nSpinal stenosis \\ns/p Replacement of Ascending aorta (26mm Gelweave \\ngraft)/resuspension\\nof Aortic Valve /Coronary Artery Bypass Graft x1 (SVG to PDA)\\n___\\ns/p Coil embolization of left internal iliac ___\\ns/p Tonsillectomy\\ns/p left trigger finger release\\ns/p tracheostomy\\ns/p gastrojejunostomy\\n\\n \\nDischarge Condition:\\ngood\\n\\n \\nDischarge Instructions:\\n1) Monitor wounds for signs of infection. These include redness, \\ndrainage or increased pain. Please contact you surgeon at ___ with all wound issues. \\n2) Report any fever greater then 100.5\\n3) Flush double lumen PICC with 10 cc NS q shift\\n3) Report any weight gain of 2 pounds in 24 hours or 5 pounds in \\n1 week.\\n4) Wash incision daily with soap and water. No lotions, creams \\nor powders to incision until it has healed (6 weeks).\\n5) No lifting greater then 10 pounds for 10 weeks from date of \\nsurgery.\\n6) No driving for 1 month.\\n7) Check lytes, BUN/Cre, Hct, coags daily until stable - Goal \\nINR ___ Call with any questions or concerns.\\n \\nFollowup Instructions:\\n___\\n   \n99                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       \\nName:  ___                    Unit No:   ___\\n \\nAdmission Date:  ___              Discharge Date:   ___\\n \\nDate of Birth:  ___             Sex:   M\\n \\nService: SURGERY\\n \\nAllergies: \\nNo Known Allergies / Adverse Drug Reactions\\n \\nAttending: ___.\\n \\nChief Complaint:\\nMVC, b/l ankle fractures\\n \\nMajor Surgical or Invasive Procedure:\\n___ - ex-fix L ankle; closure scalp lac\\n___ - ORIF R ankle, washout L ankle\\n___ - Trach\\n___ - PEG\\n___ - Debridement L foot/heel. Longer trach \\n \\nHistory of Present Illness:\\n___ s/p MVC vs guard rail as unrestrained driver, swerved with \\nsignificant intrusion and prolonged extrication of 45-minutes. \\nPatient was GCS at scene with significant bleeding from scalp \\nnoted and large blood loss at scene. Patient was brought to \\n___ by medflight with ancef given en route, hemodynamically \\nstable. GCS was 15 on arrival to ED. Surveys and radiographic \\nworkup revealed a right closed ankle fracture, left open ankle \\nfracture\\nwith significant deformity, and large scalp laceration actively \\nbleeding. Patient's left foot was mildly cooler than the right \\nwith only a DP doppler signal (baseline exam unknown).\\n \\nPast Medical History:\\nPMH: HTN, HL, ? OSA\\nPSH: Umbilical hernia repair\\n\\n \\nSocial History:\\n___\\nFamily History:\\nNC\\n \\nPhysical Exam:\\nAdmission Physical:\\nT 99.1  P 98  BP 118/44  RR 18  O2 94% 4L\\nanxious, in pain, AOx3\\nairway intact, breathing stable, HD stable\\nsuperficial scalp laceration\\ntrachea midline without crepitus\\nchest wall stable, no crepitus\\nabdomen soft/nontender/nondistended\\npelvis stable\\nno gross deformity upper extremities\\n\\nSevere deformity of left ankle, with foot angled ~90 degrees\\nmedially with respect to leg. Extensive open area on lateral\\naspect with exposed muscles and tendons. DP by Doppler. Unable \\nto\\nassess ___ due to deformity.  Deformity of right ankle, closed. \\nDP\\nand ___ by Doppler.  Remainder of extremities nontender and with\\nfull ROM.\\n\\nDischarge Physical:\\nInteractive, usually following commands\\ntracheostomy in place, on trach mask\\nlungs CTAB\\nRRR, no r/m/g\\nabd \\n \\nPertinent Results:\\nImaging:\\n-___ Trauma CXR and Pelvic XR: No abn  \\n-___ Bilateral ankle fx: Dislocation of the right ankle with \\nlateral displacement of the talus in relation to the tibia. \\nThere is a distal fibular fracture with a distal fragment \\ndisplaced posteriorly. There is a talonavicular dislocation and \\nmild widening at the calcaneocuboid joint. There is also likely \\na medial malleolus fracture. There is a displaced proximal fifth \\nmetatarsal fracture. The left ankle is dislocated with the talus \\ndisplaced medially compared to the tibia. There is also \\ndisplaced fracture of the medial malleolus. There is likely \\nless-well visualized fracture of the lateral malleolus as well \\nas the distal fibula. There are proximal and distal fifth \\nmetatarsal fractures.  \\n-___ CT Head: Small right vertex subgaleal hematoma  \\n-___ CT Cspine: No fracture  \\n-___ CTA chest/abd/pelvis: no PE, no obvious abnormality  \\n-___ TTE: unremarkable, LVEF>55%, RV wnl  \\n-___ CXR: Lsided opacities  \\n-___ CT Head: No acute intracranial process  \\n-___ MRI/MRA: 1. Few small white matter infarcts seen \\nbilaterally, suggestive of embolic disease. No evidence of \\nanoxic brain injury. 2. Patent carotid and vertebral arteries.  \\n-___. Multiple peripheral pulmonary opacities could \\nrepresent septic emboli. Aggressive search for a source of \\ninfection is recommended. 2. Increased bibasilar consolidation \\nof the dependent lungs, most likely representing atelectasis, \\nthough an infectious process is possible. 3. New small bilateral \\npleural effusions.  \\n-___ TEE: No valvular vegetation, abscess, or intracardiac \\nmass/thrombus visualized  \\n-___ ___: negative for DVT  \\n-___ Bilateral ankle xrays: Hardware well aligned, no \\ndislocations  \\n-___ Overall appearance is similar. Possible very slight \\ninterval improvement in the CHF findings.  \\n\\nAdmission Labs - \\n___ 12:55PM   WBC-23.0* RBC-3.91* HGB-11.9* HCT-36.3* \\nMCV-93 MCH-30.5 MCHC-32.9 RDW-13.0\\n___ 06:00PM   GLUCOSE-192* UREA N-27* CREAT-1.5* SODIUM-143 \\nPOTASSIUM-4.2 CHLORIDE-109* TOTAL CO2-20* ANION GAP-18\\n___ 12:55PM   LIPASE-___ M s/p MCV with bilateral ankle fractures admitted to the TICU \\nintubated. In brief, he made steady improvements over his 24 day \\nstay and was discharged to a ventilator rehabilitation on \\n___. Below is his hospital course through his stay in the \\nTrauma ICU:\\n\\nHe was taken emergently to the OR for wash out and splinting of \\nhis fractures and repair of his scalp laceration. Intraop, he \\nrequired phenylephrine with 3L crystalloid and 3U PRBC given to \\nwean off. In PACU, he was noted to be very agitated with mild \\nhypotension. On arrival to ___, he was hemodynamically stable \\nbut confused. Subsequently, had hypoxic event leading to PEA s/p \\nCPR and epi x 2, difficult intubation. \\n\\nN:  Following intubation the pt was kept sedated on fentanyl and \\npropofol. He was administered PRN haldol due to agitation. It \\nwas difficult to establish an adequate neuro exam because of \\nsedation and agitation and on HD 4 a continuous EEG was ordered. \\nThe EEG was significant for periodic epileptiform discharges, \\nconcernign for seizure activity. A neurology consult was \\nobtained and the patient was started on keppra. An MRI was \\nobtained which was significant for a few small white matter \\ninfarcts seen bilaterally, suggestive of embolic disease. There \\nwas no evidence of anoxic brain injury and the carotid and \\nvertebral arteries were patent. Final read on EEG was \\nencephalopathy with no focal or epileptiform features. It was \\nfelt that the Keppra was adequately treating previously recorded \\nepileptiform activity and it was recommended he stay on Keppra \\nuntil follow-up in one month with Dr ___. He continued to \\nbe agitated and over the course of the remaider of his ICU stay \\nhe was tried on various regimens of haldol, ativan, precedex, \\nativan, clonidine, and seroquel for his agitation. Ultimately \\nthe patient's mental improved by the end of his first week and \\nhe was kept on a stable dose of seroquel and clonidine for \\nintermitent agitation. He continued to improve and by discharge \\nwas interactive, following commands though still mildly \\nagitated. He requires Trazodone to sleep some nights. \\n\\nCV: He had a brief PEA arrest post-op. Due to continued fevers a \\nCTA Chest was done on HD 9. The read was concerning for septic \\nemboli. A formal TEE was obtained and was significant for no \\nvalvular vegetation, abscess, or intracardiac mass/thrombus \\nvisualized. He otherwise had no cardiovascular issues.\\n\\nPulm: Following PEA arrest immediately post op the patient was \\nintubated. The patient was initially weaned to CPAP but due to \\nrespiratory distress he was placed on APRV and CMV through \\nvarious portions of his initial hospitalization. He was placed \\non a prolonged course of vancomycin and inhaled tobramycin. \\nGiven his inability to wean from the vent he had a tracheostomy \\nperformed on ___. Following the procedure he was slowly \\nweaned to CPAP and then to trach color which he was tolerating \\nwell at the time of discharge. \\n\\nGI: On HD 5 tube feeds were initiated through an OGT. The \\npatient was able to tolerate full feeds and they were only \\ndiscontinued prior to procedures. On ___ the patient \\nunderwent a percutaneous gastrostomy tube placement as a more \\npermanent solution to long term feeding. He was able to tolerate \\nfull feeds via the PEG through the rest of his hopitalization. \\nHe will be discharged on Isosource 1.5 Cal Full strength; \\nAdditives: Beneprotein, 35 gm/day, Goal rate: 45 ml/hr.\\n\\nGU: No active issues. His urine output was adequate throughout \\nhospitalization. He was on a Lasix drip HD ___ as he mobilized \\nthe fluid from his admission resuscitation. He then was given \\nintermittent lasix for several days and transitioned to \\nlisinopril. His Foley catheter was removed ___.  \\n\\nHeme: He had a persistent mild anemia. This was believed to be \\ndue to anemia of chronic disease. He was transfused a total of \\n14 units PRBC: 11 units ___, and a subsequent 3 \\nunits over the following 3 weeks. He was started on iron \\nsupplementation.\\n\\nID: He was treated for two weeks with broad spectrum antibiotics \\nas he was spiking fevers and had a rising WBC. His BAL from \\n___ showed \\nESCHERICHIA COLI.    10,000-100,000 ORGANISMS/ML.\\nMORGANELLA ___. 10,000-100,000 ORGANISMS/ML.\\nIt was unclear if he was spiking fevers from this pneumonia or \\nfrom his left leg, which had shown signs of worsening necrosis. \\nFollowing debridement of his left leg on ___, his fevers \\nsubsided and he was narrowed to Ancef for coverage. \\n\\nExtrem:\\nHe presented with bilateral lower extremity fractures. His right \\nlower extremity underwent ORIF on admission and has done well. \\nHis left leg had significantly more soft tissue damage and a \\nmore impressive fracture pattern. He was placed in an an \\nexternal fixator on that side and underwent several debridements \\nduring his stay. His final debridement was ___ by Dr ___ at \\nwhich time he was left with an exposed gastroc tendon and \\ncalcaneous. The prospect of a BKA was discussed with his family, \\nand the decision was made to continue dressing changes and have \\nhim see Dr ___ in follow-up for consideration of flap coverage. \\nPer orthopedic surgery, he is to be non-weight bearing on both \\nlower extremities.  \\n \\nMedications on Admission:\\nLisinopril 40', Simvastatin 20' HS, Metoprolol tartrate 150'', \\nDiltiazem ER 240\\n\\n \\nDischarge Medications:\\n1. bisacodyl 5 mg Tablet, Delayed Release (E.C.) Sig: Two (2) \\nTablet, Delayed Release (E.C.) PO DAILY (Daily) as needed for \\nConstipation.  \\n2. senna 8.8 mg/5 mL Syrup Sig: One (1) Tablet PO BID (2 times a \\nday).  \\n3. insulin regular human 100 unit/mL Solution Sig: One (1)  \\nInjection ASDIR (AS DIRECTED).  \\n4. heparin (porcine) 5,000 unit/mL Solution Sig: One (1)  \\nInjection TID (3 times a day).  \\n5. albuterol sulfate 90 mcg/actuation HFA Aerosol Inhaler Sig: \\nSix (6) Puff Inhalation Q4H (every 4 hours) as needed for \\nwheezing.  \\n6. ipratropium bromide 17 mcg/actuation HFA Aerosol Inhaler Sig: \\nSix (6) Puff Inhalation QID (4 times a day).  \\n7. acetaminophen 650 mg/20.3 mL Solution Sig: One (1)  PO Q6H \\n(every 6 hours) as needed for pain/fever.  \\n8. miconazole nitrate 2 % Powder Sig: One (1) Appl Topical BID \\n(2 times a day) as needed for rash.  \\n9. docusate sodium 50 mg/5 mL Liquid Sig: One (1)  PO BID (2 \\ntimes a day).  \\n10. camphor-menthol 0.5-0.5 % Lotion Sig: One (1) Appl Topical \\nQID (4 times a day) as needed for itching.  \\n11. diltiazem HCl 60 mg Tablet Sig: One (1) Tablet PO QID (4 \\ntimes a day).  \\n12. levetiracetam 100 mg/mL Solution Sig: One (1)  PO BID (2 \\ntimes a day): Continue until follow-up with neurology.  \\n13. metoprolol tartrate 50 mg Tablet Sig: Three (3) Tablet PO \\nTID (3 times a day).  \\n14. trazodone 50 mg Tablet Sig: 0.5 Tablet PO HS (at bedtime) as \\nneeded for insomnia .  \\n15. lisinopril 20 mg Tablet Sig: One (1) Tablet PO DAILY \\n(Daily).  \\n16. clonidine 0.2 mg Tablet Sig: One (1) Tablet PO TID (3 times \\na day).  \\n17. ferrous sulfate 300 mg (60 mg iron)/5 mL Liquid Sig: One (1) \\n PO DAILY (Daily).  \\n18. cefazolin 10 gram Recon Soln Sig: One (1) Recon Soln \\nInjection Q8H (every 8 hours).  \\n\\n \\nDischarge Disposition:\\nExtended Care\\n \\nFacility:\\n___\\n \\nDischarge Diagnosis:\\nRespiratory failure\\nTraumatic brain injury with delerium\\nBilateral lower extremity fractures\\n\\n \\nDischarge Condition:\\nMental Status: Confused - sometimes.\\nLevel of Consciousness: Alert and interactive.\\nActivity Status: Out of bed with assistance. NWB bilateral lower \\nextremities.\\n\\n \\nDischarge Instructions:\\nPlease call your doctor or nurse practitioner if you experience \\nthe following:\\n*New chest pain, pressure, squeezing or tightness.\\n*New or worsening cough, shortness of breath, or wheeze.\\n*Vomiting and cannot keep down fluids or your medications.\\n*Dehydration due to continued vomiting, diarrhea, or other \\nreasons. Signs of dehydration include dry mouth, rapid \\nheartbeat, or feeling dizzy or faint when standing.\\n*Blood or dark/black material when you vomit or have a bowel \\nmovement.\\n*Burning when you urinate, blood in your urine, or urinary \\ndischarge.\\n*Your pain doesn't improve in ___ hours or is not gone within \\n24 hours. Call or return immediately if your pain becomes \\nsevere, changes location or moves to your chest or back.\\n*Shaking chills or fever greater than 101.5F or 38C.\\n*An acute change in your symptoms, or new symptoms that concern \\nyou.\\n*Increased pain, swelling, redness, or drainage from any \\nincisions you may have.\\n*Any of the warning signs listed below.\\n\\n \\nFollowup Instructions:\\n___\\n   \n\n    nlp_result  \n0            0  \n1            0  \n2            0  \n3            0  \n4            0  \n..         ...  \n95           0  \n96           0  \n97           0  \n98           0  \n99           0  \n\n[100 rows x 9 columns]",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>subject_id</th>\n      <th>hadm_id</th>\n      <th>stay_id</th>\n      <th>drug_a_item_id</th>\n      <th>drug_b_item_id</th>\n      <th>dose_b_time</th>\n      <th>event_count</th>\n      <th>text</th>\n      <th>nlp_result</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>16796985</td>\n      <td>27317580</td>\n      <td>33550086</td>\n      <td>225798</td>\n      <td>225893</td>\n      <td>2160-04-13 19:00:00</td>\n      <td>16</td>\n      <td>\\nName:  ___               Unit No:   ___\\n \\nAdmission Date:  ___              Discharge Date:   ___\\n \\nDate of Birth:  ___             Sex:   M\\n \\nService: CARDIOTHORACIC\\n \\nAllergies: \\nIV Dye, Iodine Containing Contrast Media / heparin\\n \\nAttending: ___.\\n \\nChief Complaint:\\nrecurrent pleural effusion\\n \\nMajor Surgical or Invasive Procedure:\\n___\\nTotal pulmonary decortication.\\n\\n___\\nRight AC PICC\\n\\n___\\nPEG tube placement\\n\\n___\\nPercutaneous tracheostomy (#8 Portex).\\n\\n___\\nLeft pleural pigtail placement\\n\\n \\nHistory of Present Illness:\\nMr ___ is a ___ recently evaluated while inpatient for a\\nloculated left pleural effusion and had a chest tube placed. He\\nnow presents to discuss treatment plan for his effusion. His \\n___\\nCT ___ noted increased left hydropneumothorax, stable LLL\\ncollapse, small right pleural effusion. Currently, he reports\\nincreased SOB at rest and with any activity. He also has\\noccasional cough productive of white phlegm, abd and left lower\\nthorax pain ___. Otherwise, he denies any fever, sweats or \\nother\\nnew sx. He presents now for decortication.\\n\\n \\nPast Medical History:\\n#CAD, status post CABGx3 (___)\\n#AAA\\n#Aortic stenosis s/p St. ___ AVR (___)\\n#Afib, on Coumadin \\n#Gout\\n#GERD\\n#HTN\\n#Hyperlipidemia\\n#Tonsillectomy and left knee surgery\\n#Hx of heavy ETOH use\\n#Lumbar disc disease\\n#BPH\\n#remote rectal bleeding, colonoscopy revealing polyps\\nPast Surgical History:\\n#Tonsillectomy\\n#Left knee arthroscopic surgery x2\\n \\nSocial History:\\n___\\nFamily History:\\nFather: died of CAD in ___\\nMother: died of PNA in ___\\nBrother: died age ___ of colon CA\\nBrother: died age ___ of CABG complications\\nSister: died age ___ lung CA\\nBrother: died of ___\\nSon: died of drug OD age ___\\nSon: age ___, healthy\\n \\nPhysical Exam:\\nBP: 92/66. Heart Rate: 72. Weight: # (refuse to ___ shoes off).\\nTemperature: 97.8. Resp. Rate: 16. Pain Score: 6. O2 \\nSaturation%:\\n100.\\n\\nGen: looks older than stated age, chronically ill appearing\\nNeck: no ___: diminished breath sounds LLL, few wheezes right\\nCor: RRR with click\\nExtrem: no CCE\\n\\n \\nPertinent Results:\\n                    WBC RBC   Hgb  Hct   MCV  MCH MCHC RDW Plt \\nCt \\n___ 06:50    8.7 2.61* 8.2* 26.9* 103* 31.3 30.4* 16.6* \\n169 \\nSource: Line-___ \\n___ 03:47    8.4 2.44* 7.8* 25.5* 105* 32.0 30.5* 16.8* \\n141* \\nSource: Line-___ \\n___ 04:09    9.8 2.62* 8.0* 27.3* 104* 30.6 29.5* 17.2* \\n136* \\nSource: Line-___ \\n___ 05:45    8.8 2.53* 8.0* 26.7* 105* 31.5 29.9* 17.7* \\n126* \\n___ 06:37    9.5 2.65* 8.2* 28.0* 106* 31.0 29.3* 17.9* \\n100* \\n___ 04:47    11.0 2.65* 8.6* 28.2* 107* 32.5* 30.5* 18.2* \\n98* \\nSource: Line-___ \\n___ 05:00    10.4 2.58* 8.3* 27.4* 106* 32.4* 30.5* 18.6* \\n71* \\nSource: Line-___ \\n___ 04:15    12.6* 2.70* 8.7* 28.7* 106* 32.3* 30.3* \\n19.5* 89* \\nSource: Line-___ \\n___ 02:07    9.4 2.62* 8.4* 27.3* 104* 32.1* 30.8* 20.2* \\n47* \\nSource: Line-___ \\n___ 02:54    8.5 2.38* 7.5* 25.9* 109* 31.6 29.1* 20.4* \\n66* \\nSource: Line-___ \\n___ 00:22    14.5* 2.68* 8.7* 29.3* 109* 32.2* 29.5* \\n20.6* 75* \\nSource: Line-___ \\n___ 23:37    15.5* 2.95* 9.2* 32.1* 109* 31.2 28.6* 20.6* \\n82*1 \\nSource: Line-a \\n___ 01:44    15.4* 2.65* 8.3* 28.9* 109* 31.5 28.9* 20.8* \\n110* \\n\\n  \\nSource: Line-___    PTT  Plt Ct       INR\\n___ 06:50    21.7*       2.0* \\nSource: Line-___ \\n___ 03:47          141*   \\nSource: Line-___ \\n___ 03:47    16.2*       1.5* \\nSource: Line-___ \\n___ 04:09          136*   \\nSource: Line-___ \\n___ 04:09    15.5* 32.2     1.4* \\nSource: Line-___ \\n___ 10:24    16.2*       1.5* \\nSource: Line-___ \\n___ 05:45          126*   \\n___ 05:45    16.8*       1.6* \\n___ 06:37          100*   \\n___ 06:37    19.9* 40.5*     1.9* \\n___ 04:47          98*   \\nSource: Line-___ \\n___ 04:47    19.9* 37.0*     1.9* \\n\\n                  Glucose UreaN Creat Na  K  Cl HCO3 AnGap \\n___ 06:50    127*1 72*   3.2* 141 4.4 98 30 17 \\nSource: Line-___ \\n___ 03:47    116*1 70*   3.3* 137 4.6 96 33* 13 \\nSource: Line-___ \\n___ 04:09    118*1 63*   3.4* 138 4.6 96 30 17 \\nSource: Line-picc \\n___ 09:10    133*1 59*   3.3* 137 4.7 97 29 16 \\nSource: Line-PICC \\n___ 05:45    109*1 47*   3.0* 136 4.3 95* 31 14 \\n___ 06:37    112*1 36*   2.5* 136 4.2 97 30 13 \\n___ 04:47    138*1 42*   2.9* 135 4.2 96 30 13 \\nSource: Line-PICC \\n___ 05:00    117*1 29*   2.4* 134 3.8 98 29 11 \\nSource: Line-PICC \\n___ 04:15    106*1 42*   3.2* 135 3.9 98 27 14 \\nSource: Line-PICC \\n___ 02:07    124*1 29*   2.3* 135 4.1 100 28 11 \\nSource: Line-aline \\n___ 02:54    991 18      1.5* 135 3.6 99 26 14 \\nSource: Line-aline \\n___ 17:55    101*1 13    1.2 136 3.8 100 27 13 \\nSource: Line-aline \\n___ 13:30    103*1 12    1.0 136 3.6 99 27 14 \\nSource: Line-aline \\n___ 06:06    113*1 14    1.1 134 3.8 100 25 13 \\nSource: Line-aline \\n___ 00:22    120*1 15    1.3* 132* ___ 15 \\nSource: Line-aline; MODERATELY HEMOLYZED SPECIMEN \\n___ 17:34    145*1 18    1.4* 133 ___ 15 \\nSource: Line-arterial; GROSSLY HEMOLYZED SPECIMEN \\n___ 07:51    112*1 20    1.3* 136 3.4 ___ \\nSource: Line-arterial \\n___ 23:37    129*1       1.5* 137 3.82 103 21* 17 \\nSource: Line-a; MODERATELY HEMOLYZED SPECIMEN \\n___ 19:34    141*1 27*    1.7* 135 4.22 ___ \\nSource: Line-a; MODERATELY HEMOLYZED SPECIMEN \\n___ 16:01    150*1 31*    2.0* 137 3.5 ___ \\nSource: Line-arterial \\n___ 08:05    133*1 33*    1.9* 137 3.5 ___ \\nSource: Line-arterial \\n___ 01:44    133*1 37*     2.3* 138 3.5 ___ \\nSource: Line-arterial \\n___ 19:30    134*1 44*    2.6* 137 3.8 ___ \\nSource: Line-arterial \\n___ 13:40    106*1 48*     2.9* 138 4.92 ___ \\nMODERATELY HEMOLYZED SPECIMEN \\n___ 07:14    106*1 57*     3.3* 139 4.5 100 22 22* \\n___ 01:40    122*1 66*     3.8* 138 4.6 ___ \\nADD ON \\n___ 19:53    121*1 79*     4.4* 141 5.1 ___ \\nSource: Line-arterial \\n___ 02:43    941 78*       4.5* 142 5.4* ___ \\nSource: Line-picc line \\n___ 14:00    801 74*       4.2* 142 5.3* ___ \\n___ 03:02    861 70*       3.8* 139 5.0 ___ \\nSource: Line-R ___ \\n___ 18:31    931 69*       3.6* 141 4.7 ___ \\nSource: Line-aline \\n___ 02:17    103*1 63*     3.4* 140 4.5 ___ \\nSource: Line-PICC \\n___ 17:55    104*1 59*     3.0* 139 4.6 ___ \\nSource: Line- aline \\n___ 03:07    921 57*        2.6* 140 4.5 ___ \\nSource: Line-arterial \\n___ 22:00    811 55*        2.5* 138 4.4 ___ \\nSource: Line-art \\n___ 14:40    135*1 56       2.5* 143 4.6 ___ \\nSource: Line-a line \\n___ 01:10    152*1 50*      2.1* 147* 4.2 ___ \\nSource: Line-arterial \\n___ 01:30    961 46*        1.7* 149* 4.1 110* 26 17 \\nSource: Line-art \\n___ 02:07    831 46*        1.7* 148* 4.1 ___ \\nSource: Line-A \\n___ 13:02    102*1 46*       1.6* 147* 3.9 ___ \\n___ 02:21    153*1 48*       1.5* 149* 3.4 108 32 12 \\nSource: Line-a line \\n___ 03:13    157*1 48*       1.3* 148* 3.6 ___ \\nSource: Line-a line \\n___ 04:29    112*1 46*       1.2 150* 3.6 113* 32 9 \\nSource: Line-art line \\n___ 20:00    175*1 47*      1.2 150* 4.2 111* 31 12 \\nSource: Line-art line \\n___ 05:31    199*1 47*      1.2 148* 3.6 106 34* 12 \\nSource: Line-PICC \\n___ 04:09    182*1 48*     1.2 149* 3.5 \\n\\n___ TTE\\nThe left atrium is moderately dilated. The estimated right \\natrial pressure is at least 15 mmHg. There is mild symmetric \\nleft ventricular hypertrophy with normal cavity size. Left \\nventricular systolic function is hyperdynamic (EF&gt;75%). Right \\nventricular chamber size and free wall motion are normal. The \\nright ventricular free wall is hypertrophied. A bioprosthetic \\naortic valve prosthesis is present. The aortic valve prosthesis \\nappears well seated, with normal leaflet/disc motion and \\ntransvalvular gradients. Trace aortic regurgitation is seen. The \\nmitral valve leaflets are mildly thickened. There is mild \\nposterior leaflet mitral valve prolapse. Moderate to severe (3+) \\nmitral regurgitation is seen. Moderate [2+] tricuspid \\nregurgitation is seen. There is moderate pulmonary artery \\nsystolic hypertension. There is no pericardial effusion. \\n\\nCompared with the prior study (images reviewed) of ___, a \\nwell seated aortic valve bioprosthesis with normal gradients and \\ntrace aortic regurgitation is seen. Mild posterior mitral valve \\nprolapse is now appreciated. There is significantly more mitral \\nand tricuspid regurgitation. Pulmonary pressures are higher\\n\\n___ Chest CT :\\n1.  Persistent left lower lobe consolidation with decrease in \\nsize of the \\nleft-sided pneumothorax with chest tube in situ.   \\n2.  Increase in size of a right pleural effusion, now moderate.  \\n \\n3.  New left mildly displaced rib fracture. \\n4.  Intra-abdominal findings are better detailed on the CT \\nabdomen and pelvis. \\n\\n___ Liver US :\\n1.  Normal hepatic echotexture.  No focal lesions.  No biliary \\nduct dilation. \\n2.  Small amount of abdominal ascites. \\n3.  Gallbladder sludge and gallbladder wall edema, which in the \\nsetting of acute liver disease and ascites, is nonspecific. \\n4.  Enlarging abdominal aortic aneurysm, which now measures 7.8 \\nx 6.3 cm. \\n\\n___ Video swallow :\\n\\nOropharyngeal swallowing video fluoroscopy was \\nperformed in conjunction with the speech and swallow division.  \\nMultiple \\nconsistencies of barium were administered.  There is pre-spill \\nof contrast \\nonto the vallecula with a large amount of residue on the \\nvallecula.  \\nPenetration is seen with nectar and thin liquids \\n\\n___ Abd CT :\\n1.  Removal of left pleural tube since ___ with \\npersistent left lower lobe consolidation and probably empyema.  \\nLarge amount of air is present in the left pleural cavity, \\nincluding a 3.9 cm pocket of air which could be pleural or \\nintraparenchymal, and could be further evaluated with a \\ndedicated chest CT.  Interval enlargement of now large right \\npleural effusion with adjacent atelectasis.   \\n  \\n2.  Large subcutaneous gas tracks from the left thoracic soft \\ntissues to the left inguinal region and is likely related to \\nprior pleural tube placement.   \\n  \\n3.  New PEG tube within the stomach.  Moderate pneumoperitoneum, \\nno free \\ncontrast in the abdomen. \\n  \\n4.  Stable size of infrarenal abdominal aortic aneurysm with \\neccentric mural thrombus.   \\n  \\n5.  Moderate amount of intra-abdominal ascites, increased since \\nthe prior \\nexam \\n\\n___ Left pigtail placement:\\n1. Successful drainage of left upper hydropneumothorax with 8 \\n___ catheter. \\nCatheter attached to a Pleuravac device on suction.  No \\nperiprocedural \\ncomplications. \\n  \\n2. Pleural thickening/fluid identified along the left lateral \\nchest wall, with \\nnumerous locules of air.  Large consolidation with air \\nbronchograms identified \\nat the left lower lobe.  Loculated pleural effusion in the left \\nlower lung \\nwith numerous air locules and pleural thickening.  \\n  \\n3. Moderate sized right pleural effusion. \\n  \\n4. Moderate perihepatic fluid. \\n  \\n5. Multiple nonenlarged lymph nodes in the left axilla.  \\nMultiple prominent \\nsubcentimeter mediastinal lymph nodes, predominantly in the \\nparatracheal and \\nprevascular regions, likely reactive.  \\n  \\n6.  A 6.8 cm loculated collection identified along the \\nsubcutaneous tissues of \\nleft posterolateral chest wall containing locules of air.  \\n  \\n___ Bilat ___ duplex :\\nNo evidence of DVT in either lower extremity to the level of the \\n\\nknee.  Calf vein thrombus cannot be completely excluded.  \\nPulsatile femoral waveforms indicate elevated central venous \\npressure. \\n\\n___ Bilat UE duplex scan:\\nNo evidence of DVT in either upper extremity.  There is \\nsuperficial phlebitis involving the left upper arm cephalic \\nvein. \\n\\n___ 10:18 am Mini-BAL      BRONCHIAL LAVAGE. \\n\\n                            **FINAL REPORT ___\\n\\n   GRAM STAIN (Final ___: \\n      2+   ___ per 1000X FIELD):   POLYMORPHONUCLEAR \\nLEUKOCYTES. \\n      NO MICROORGANISMS SEEN. \\n\\n   RESPIRATORY CULTURE (Final ___: \\n      Commensal Respiratory Flora Absent. \\n      NON-FERMENTER, NOT PSEUDOMONAS AERUGINOSA. \\n         10,000-100,000 ORGANISMS/ML.. \\n         sensitivity testing performed by Microscan. \\n         MEROPENEM (&lt;=1 MCG/ML). \\n\\n                              SENSITIVITIES: MIC expressed in \\nMCG/ML\\n                      \\n_________________________________________________________\\n                             NON-FERMENTER, NOT PSEUDOMONAS \\nAERUGINOSA\\n                             |   \\nAMIKACIN--------------  =&gt;64 R\\nCEFEPIME--------------    16 I\\nCEFTAZIDIME-----------     2 S\\nCEFTRIAXONE-----------    32 I\\nCIPROFLOXACIN---------     2 I\\nGENTAMICIN------------  =&gt;16 R\\nIMIPENEM--------------   &lt;=1 S\\nLEVOFLOXACIN----------   &lt;=1 S\\nMEROPENEM-------------       S\\nPIPERACILLIN/TAZO-----   &lt;=8 S\\nTOBRAMYCIN------------  =&gt;16 R\\nTRIMETHOPRIM/SULFA----   &lt;=2 S\\n\\n \\nBrief Hospital Course:\\nMr. ___ was admitted to the hospital and taken to the \\nOperating Room where he underwent a  total pulmonary \\ndecortication.  He tolerated the procedure well and returned to \\nthe PACU intubated in stable condition. He had an epidural \\ncatheter placed for pain but it was capped and eventually \\nremoved  as he remained intubated. His chest tubes remained in \\nplace and were draining sanguinous fluid. The remainder of this \\nsummary will be done as a systems review for completeness.\\n\\nResp:  He was finally extubated on ___ after multiple other \\nproblems but required reintubation on 2 more occasions and \\neventually underwent a tracheostomy on ___.  Currently he \\nis doing well on a 35% trach collar and has his PMV in place \\nwhen supervised.  His trach tube was downsized to a #6 cuffless \\nportex on ___ and he continues to do well.  he has been \\ntreated for pneumonia on 2 occasions but currently is afebrile \\nwith a normal WBC and minimal sputum production.\\n\\nCV: He had problems with hypotension and septic shock on post op \\nday # 3.  He was on multiple pressors. During this work up an \\nabdominal CT revealed an enlarging infrarenal AAA 7.9x7.4 cm.  \\nThe Vascular surgery service was consulted and due to his \\nunstable hemodynamics, surgery could not be considered.  His \\nblood pressure was controlled and the vascular surgeons \\nrecommended follow up after he recovered from this \\nhospitalization.  He also has had problems with RAF and required \\nrate control with lopressor and diltiazem but unfortunately his \\nblood pressure would not tolerate.  He was digitalized and has \\nmaintained controlled atrial fibrillation.  His dig level needs \\nto be followed at least 3 times a week as his renal function \\nchanges.  Today his dig level is 1.9 on digoxin 0.125 mg twice a \\nweek. His blood pressure is in the 110-130 range.\\n\\nGI; During his initial post op sepsis his liver enzymes rose and \\na RUQ US had non specific findings.  Currently his transaminase \\nare normal and his last T bili is 1.9.  His nutritional status \\nhas been supported with tube feedings and a PEG tube was placed \\non ___.  He has been seen by the speech and swallow \\ntherapist but is too weak for oral trials.  He will need to be \\nre evaluated at rehab because he feels hungry and would love the \\nopportunity to swallow ice cream!  \\n\\nGU: His urinary catheter has been removed twice and he has \\nfailed 2 voiding trials.  The GU service needed to replace the \\ncatheter both times.  They recommend giving him a chance after \\nhe becomes more mobile and hopefully that will be successful.  \\nHe needs to make an appointment in the ___ clinic in ___ \\nweeks and he will have a voiding trial and/or a catheter \\nexchange.  His urine culture has been negative on many \\noccasions.  From a renal standpoint, he developed ___ on \\n___ when his urine output decreased and his blood pressure \\nwas 90-100.  He was evaluated by the renal service and \\neventually required dialysis until a week ago.  His Dialysis \\ncatheter was removed on ___.  Currently he will need blood \\nwork 3 times a week.  His creatinine is 3.2 and he's making \\nabout 1400 mls of urine daily.\\n\\nHeme: During his hospitalization his platelet count decreased to \\nas low as 47 and the hematology service was asked to consult to \\nrule out HIT.  He had a positive HIT antibody with optical \\ndenisty &gt;1.0 indicating strong likelihood that result was a true \\npositve in the setting of therapeutic anticoagulation for afib \\nwith coumadin. However, his SRA came back negative.  In the \\ninterim he was treated with Coumadin alone but should his INR go \\n&lt; 1.8 he should be bridged with Argatroban.  The \\ngeneral consensus is that it is a true HIT.  Currently his \\nplatelet count is normal but should be followed along with his \\nINR.\\n\\nID: not currently on any antibiotics and his only positive \\nculture from this admission was a mini BAL on ___ which \\ngrew pseudomonas and was treated. He has been afebrile and his \\nWBC is8K.\\n\\nAfter a long hospital stay he will be teransferred to rehab for \\nfurther management of his pulmonary issues and physical therapy \\nwith the hope of getting him home soon.\\n\\n \\nMedications on Admission:\\nThe Preadmission Medication list is accurate and complete.\\n1. Metoprolol Tartrate 75 mg PO BID \\n2. Diltiazem 60 mg PO BID \\n3. Docusate Sodium 100 mg PO BID \\n4. Warfarin 1 mg PO DAILY16 \\n5. Ranitidine 150 mg PO BID \\n6. Atorvastatin 80 mg PO DAILY \\n7. Oxycodone-Acetaminophen (5mg-325mg) 1 TAB PO DAILY:PRN pain \\n8. Aspirin 81 mg PO DAILY \\n9. Hydrochlorothiazide 25 mg PO DAILY \\n\\n \\nDischarge Medications:\\n1. Aspirin 81 mg PO DAILY \\n2. Docusate Sodium 100 mg PO BID \\n3. Acetaminophen 325-650 mg PO Q6H:PRN pain \\n4. Albuterol Inhaler ___ PUFF IH Q4H:PRN Wheeze \\n5. Bisacodyl 10 mg PO/PR DAILY \\n6. Chlorhexidine Gluconate 0.12% Oral Rinse 15 mL ORAL BID \\n7. Digoxin 0.125 mg PO 2X/WEEK (MO,FR) \\n8. Famotidine 20 mg PO DAILY \\n9. OxycoDONE Liquid ___ mg PO Q4H:PRN pain \\n10. Polyethylene Glycol 17 g PO DAILY:PRN constipation \\n11. QUEtiapine Fumarate 50 mg PO QHS:PRN insomnia \\n12. Sodium Chloride 0.9%  Flush ___ mL IV DAILY and PRN, line \\nflush \\n13. Ursodiol 250 mg PO TID \\n14. Ranitidine 150 mg PO BID \\n15. ___  MD to order daily dose PO DAILY16 \\n\\n \\nDischarge Disposition:\\nExtended Care\\n \\nFacility:\\n___\\n \\nDischarge Diagnosis:\\nLeft fibrothorax\\nSeptic shock\\nAcute blood loss anemia\\n___\\nAtrial fibrillation\\nLiver failure\\nPneumonia\\nHIT\\n\\n \\nDischarge Condition:\\nMental Status: Clear and coherent.\\nLevel of Consciousness: Alert and interactive.\\nActivity Status: Out of Bed with assistance to chair or \\nwheelchair.\\n\\n \\nDischarge Instructions:\\n* You were admitted to the hospital for surgery to correct your \\ntrapped lung and you developed multiple post op complications \\nrequiring a long, difficult hoapitalization. You are improving \\ndaily and should continue to do so.  We are transferring you to \\nrehab so that you can work on increasing your mobility and \\nstrength.\\n* Your trach tube will remain in place and gradually be \\ndownsized again.  It will eventually be removed once we are sure \\nyour secretions are under control.\\n* The Speech and swallow team will follow you and hopefully when \\nyou get stronger, you will be able to eat and eventually the \\nfeeding tube will be removed.\\n* Your bladder catheter should stay in and hopefully once you \\nare up and walking a bit, you will be able to void.  In the \\nmeantime, the catheter stays in and you will come back to the \\n___ clinic for a catheter exchange in ___ weeks.\\n* You will continue to see Dr. ___ in the ___ in a few \\nweeks.\\n+ If you have any new problems or concerns please call Dr. ___ \\nat ___.\\n \\nFollowup Instructions:\\n___\\n</td>\n      <td>0</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>17007441</td>\n      <td>20790097</td>\n      <td>31504988</td>\n      <td>225798</td>\n      <td>225893</td>\n      <td>2138-06-12 00:00:00</td>\n      <td>28</td>\n      <td>\\nName:  ___                  Unit No:   ___\\n \\nAdmission Date:  ___              Discharge Date:   ___\\n \\nDate of Birth:  ___             Sex:   M\\n \\nService: MEDICINE\\n \\nAllergies: \\nNo Known Allergies / Adverse Drug Reactions\\n \\nAttending: ___.\\n \\nChief Complaint:\\nDOE \\n \\nMajor Surgical or Invasive Procedure:\\nIntubation\\nA-line \\nPICC line\\nTracheostomy\\nPEG\\n \\nHistory of Present Illness:\\n___ y/o M with h/o severe COPD, OSA and HTN who presented from \\n___ rehab with respiratory distress to ___ after \\ncomplaining of chest pain and dyspnea on exertion. Per notes, he \\nwas noted to have sudden onset SOB while walking in the hallway, \\nwent back to his room, put on his CPAP but this did not improve \\nhis breathing so went to ___. HR at ___ was 130s. \\nReceived nebs. At ___ he was wheezy, HR 120s (sinus), CXR \\nreportedly showed pulmonary edema and trop was indeterminate \\n(0.015, upper limit of normal 0.01), BNP 22. He was given lasix \\n40mg IV, SL NTG x3, solumedrol 125 IV, 25 PO metop and \\nlevalbuterol. ECG per per report with nonspecific ST changes. He \\nwas noted to become increasingly agitate and ABG showed CO2 of \\n82 so he was intubated at ___ for hypercarbic respiratory \\nfailure and started on a heparin gtt for ACS before transfer to \\n___. \\n\\nIn the ED here, initial vitals:  112 115/65 17 98% on unknown \\nvent settings, Exam showed wheezing, he was intubated, rate 18, \\nTV 400, PEEP 5 FiO2 60.  Initial ABG pH 7.17 / pCO2 112 /pO2 237 \\nHCO3 43. Additional labs showed PTT 61, WBC 13 ( 90% pmn, s/p \\nsolumedrol at OSH), Gluc 348, K 5.3 .  He continued sedation \\nwith versed/fentanyl, continued heparin gtt, and was given \\nazithromycin IV (no PO access), and CTA to rule out PE (read \\npending at time of arrival to MICU). \\n\\nRepeat ABG when RR increased to 25 pH 7.23 / pCO2 87 / pO2 78 / \\nHCO3 38 On transfer, vitals were:  114 121/63 22 92% vent \\n(unknown settings)\\n\\nOn arrival to the MICU, vitals are T:100.4 BP:102/54 P:117 R:19 \\nO2: 93% on pressure support ___ 60% FiO2, TV 500s. He is \\nintubated and sedated. \\n\\n \\nPast Medical History:\\nsevere COPD (AAT neg in the past) on home O2, FEV1 60%pred in \\n___  \\nStenotrophomonas colonization per AJ records (on ppx bactrim?)  \\nh/o pansens pseudomonas pneumonia  \\nHTN  \\nOSA uses CPAP  \\nObesity  \\nT2DM  \\n\\n \\nSocial History:\\n___\\nFamily History:\\nFather had COPD and died of an aneurysm. Mother died of a heart \\nattack in her ___. \\n \\nPhysical Exam:\\nADMISSION PHYSICAL EXAM:  \\nVitals- T:100.4 BP:102/54 P:117 R:19 O2: 93% on pressure support \\n___ 60% FiO2, TV 500s  \\nGENERAL: intubated sedated  \\nHEENT: Sclera anicteric, conjunctiva injectec, pupils 2mm \\nminimally reactive but equal,MMM, endotracheal tube and OGT in \\nplace  \\nNECK: supple, JVP not elevated, no LAD  \\nLUNGS: decreased air movement, expiratory wheezes difusely, \\nprolonged expiratory phase  \\nCV: tachycardic, regular normal S1 S2, no murmurs, rubs, gallops \\n \\nABD: MIldly distendedm, soft, +BS, no guarding or grimacing with \\ndeep palpation, no organomegaly  \\nEXT: Warm, well perfused, 2+ DP pulses, no clubbing, cyanosis or \\nedema  \\nSKIN: dry, warm, without rashes  \\nNEURO: sedated on fent/midaz, minimal spontaneous movement on \\narrival to ICU. \\n\\nDISCHARGE EXAM:\\nGen: eyes open, following commands, mouthing words\\n\\nHEENT: pupils small and reactive, equal, MMM, OP clear\\n\\nNECK: obese, trach in place\\n\\nCV: tachycardic, no MRG\\n\\nLUNGS: fair air movement, tachypneic, rare expiratory wheeze\\n\\nABD: soft and obese  + bowel sounds, mild RLQ tenderness\\n\\nGU: foley in place with light yellow urine\\n\\nGI: flexiseal out\\n\\nEXTR: warm, no edema, pitting edema in hands nearly resolved\\n\\nSKIN: R arm with several bullae ruptured and crusted over, mild \\nerythema but no pus or induration\\n\\n \\nPertinent Results:\\nADMISSION LABS:\\n========================\\n___ 11:30PM BLOOD WBC-13.8* RBC-4.37* Hgb-11.8* Hct-40.1 \\nMCV-92 MCH-27.0 MCHC-29.3* RDW-14.0 Plt ___\\n___ 11:30PM BLOOD Neuts-90.3* Lymphs-6.6* Monos-2.4 Eos-0.4 \\nBaso-0.3\\n___ 11:30PM BLOOD ___ PTT-61.7* ___\\n___ 11:30PM BLOOD Glucose-345* UreaN-23* Creat-1.1 Na-138 \\nK-5.5* Cl-93* HCO3-30 AnGap-21*\\n___ 11:30PM BLOOD cTropnT-0.02*\\n___ 11:30PM BLOOD CK-MB-4 proBNP-51\\n___ 03:45AM BLOOD Calcium-9.0 Phos-5.0* Mg-1.6\\n___ 11:16PM BLOOD Type-ART Rates-18/ Tidal V-400 PEEP-5 \\npO2-237* pCO2-112* pH-7.17* calTCO2-43* Base XS-8 -ASSIST/CON \\nIntubat-INTUBATED\\n___ 12:24AM BLOOD Lactate-2.3*\\n\\nIMAGING:\\n========================\\n___ TTE @AJ\\nThis is a technically difficult study. All cardiac chambers are \\nnormal in size.  Left ventricular systolic function is preserved \\nwith an estimated ejection fraction of 60%.  Abnormal septal \\nmotion is present. Right ventricular systolic  function is \\nnormal.  The aortic and mitral leaflets are minimally \\nthickenedwith no aortic and trace mitral regurgitation. There is \\ntrivial tricuspid regurgitation.  No pericardial effusion is \\nseen.  Compared to a prior study dated ___, there is no \\nsignificant change.   \\n       \\n\\n___ CTA chest\\nIMPRESSION: \\n1.  No pulmonary embolism. \\n2.  Faint ground-glass opacity in the right middle lobe and \\nlingula are non-specific, but could reflect infection or \\ninflammation. \\n3.  Background of centrilobular mild-to-moderate emphysema. \\n4.  Fatty liver. \\n\\n___ Upper extremity US w doppler\\nIMPRESSION:  No evidence of deep vein thrombosis in the right \\nupper extremity. \\n\\n___ Imaging PORTABLE ABDOMEN \\nThe enteric catheter passes below the level of the diaphragm, \\nending in the mid to upper stomach. The side-hole is near the \\nlevel of the gastroesophageal junction. There are no air-filled \\ndilated loops of bowel identified. The visualized aspects the \\nlungs are clear. IMPRESSION:    \\nEnteric catheter ends in the mid to upper stomach. The side-hole \\nis near the gastroesophageal junction. Advancement is \\nrecommended. \\n\\n___ Imaging LIVER OR GALLBLADDER US \\nThe study is severely limited secondary to poor acoustic windows \\nand overlying soft tissues.   \\nLIVER: The liver is severely echogenic resulting in poor \\nacoustic penetration. No focal lesions are identified in the \\nvisible portions of the liver parenchyma. Main portal vein and \\ncentral bile ducts cannot be assessed. There is no ascites.   \\nBILE DUCTS:  The common bile duct is not visualized.   \\nGALLBLADDER: Limited views of the gallbladder demonstrate no \\nevidence of \\nshadowing gallstones or gallbladder wall thickening.   \\nPANCREAS: The pancreas is not well visualized.  \\nSPLEEN: Normal echogenicity, measuring 11.8 cm.   \\nKIDNEYS: The right kidney is poorly assessed. The left kidney \\nmeasures 12.9 cm. Normal cortical echogenicity and \\ncorticomedullary differentiation is seen in the left kidney.  \\nThere is no evidence of masses, stones or hydronephrosis in the \\nleft kidney.   \\nRETROPERITONEUM: Visualized portions of aorta and IVC are within \\nnormal \\nlimits. IMPRESSION:  Severely echogenic liver consistent with \\nfatty infiltration, resulting in markedly decreased \\nvisualization of the majority of the liver including portal vein \\nand biliary structures. No definite evidence of gallstones or \\ngallbladder wall thickening.  Limited visualization of remaining \\nabdominal organs without focal abnormalities appreciated. \\n\\n___ Cardiovascular ECG \\nNormal sinus rhythm. Tracing is within normal limits. No \\ndiagnostic change \\nfrom ___. \\nIntervals Axes \\nRate PR QRS QT/QTc P QRS T \\n99  140 86 ___ 69\\n\\n___ Imaging CHEST (PORTABLE AP) \\nAs compared to the previous radiograph, the endotracheal tube \\nhas been removed and the patient has received an tracheostomy \\ntube. The left PICC line is in unchanged position.  Platelike \\natelectasis at the right lung bases is almost unchanged.  No new \\nfocal parenchymal opacities are visualized in the lung \\nparenchyma. Normal size of the cardiac silhouette. No \\npneumothorax. \\n\\nMICRO:\\n========================\\n___  BLOOD CULTURE ( MYCO/F LYTIC BOTTLE) PENDING _______\\n___  STOOL C. difficile DNA amplification assay-PENDING \\n_____\\n___  SPUTUM \\n   GRAM STAIN (Final ___: \\n      ___ PMNs and &gt;10 epithelial cells/100X field. \\n      Gram stain indicates extensive contamination with upper \\nrespiratory\\n      secretions. Bacterial culture results are invalid. \\n      PLEASE SUBMIT ANOTHER SPECIMEN. \\n\\n   RESPIRATORY CULTURE (Final ___: \\n      TEST CANCELLED, PATIENT CREDITED. \\n\\n___  URINE URINE CULTURE-No growth\\n___  BLOOD CULTURE Blood Culture, Routine-No growth \\n___  BLOOD CULTURE Blood Culture, Routine-No growth\\n___  BLOOD CULTURE Blood Culture, Routine-No growth \\n___  SPUTUM\\nGRAM STAIN (Final ___: \\n      ___ PMNs and &lt;10 epithelial cells/100X field. \\n      NO MICROORGANISMS SEEN. \\n\\n   RESPIRATORY CULTURE (Final ___: \\n      SPARSE GROWTH Commensal Respiratory Flora. \\n___  URINE URINE CULTURE-No growth\\n___  BLOOD CULTURE Blood Culture, Routine-No growth\\n___  BLOOD CULTURE Blood Culture, Routine-No growth\\n___  SPUTUM \\nGRAM STAIN (Final ___: \\n      &gt;25 PMNs and &lt;10 epithelial cells/100X field. \\n      3+  ___ per 1000X FIELD):   GRAM POSITIVE ROD(S). \\n      1+    (&lt;1 per 1000X FIELD):   BUDDING YEAST. \\n\\n   RESPIRATORY CULTURE (Final ___: \\n      MODERATE GROWTH Commensal Respiratory Flora. \\n\\n___  URINE URINE CULTURE-No growth\\n___  BLOOD CULTURE Blood Culture, Routine-No growth\\n___  URINE URINE CULTURE-No growth \\n___  BLOOD CULTURE Blood Culture, Routine-No growth\\n___  BLOOD CULTURE Blood Culture, Routine-No growth \\n___  STOOL C. difficile DNA amplification assay-NEGATIVE\\n___  BAL\\nRespiratory Viral Culture (Final ___: \\n      TEST CANCELLED, PATIENT CREDITED. \\n      Refer to respiratory viral antigen screen and respiratory \\nvirus\\n      identification test results for further information. \\n\\n   Respiratory Viral Antigen Screen (Final ___: \\n      Positive for Respiratory viral antigens. \\n      Specimen screened for: Adeno, Parainfluenza 1, 2, 3, \\nInfluenza A, B,\\n      and RSV by immunofluorescence. \\n      Refer to Respiratory Virus Identification for further \\ninformation. \\n\\n   Respiratory Virus Identification (Final ___: \\n      Reported to and read back by ___ (___) ON \\n___ @\\n      12:39PM. \\n      POSITIVE FOR RESPIRATORY SYNCYTIAL VIRUS (RSV). \\n         Viral antigen identified by immunofluorescence. \\n\\n___  BLOOD CULTURE Blood Culture, Routine-No growth \\n___  BLOOD CULTURE Blood Culture, Routine-No growth\\n___  URINE URINE CULTURE-No growth \\n___  BLOOD CULTURE Blood Culture, Routine-No growth \\n___  BLOOD CULTURE Blood Culture, Routine-No growth\\n___  URINE URINE CULTURE-No growth\\n___  SPUTUM    GRAM STAIN (Final ___: \\n      &gt;25 PMNs and &lt;10 epithelial cells/100X field. \\n      2+   ___ per 1000X FIELD):   MULTIPLE ORGANISMS \\nCONSISTENT WITH     \\n                                    OROPHARYNGEAL FLORA. \\n\\n   RESPIRATORY CULTURE (Final ___: \\n      MODERATE GROWTH Commensal Respiratory Flora. \\n\\n___ Rapid Respiratory Viral Screen &amp; Culture\\n___ 3:40 pm Rapid Respiratory Viral Screen &amp; Culture\\n   Respiratory Viral Culture (Final ___: \\n      TEST CANCELLED, PATIENT CREDITED. \\n      Refer to respiratory viral antigen screen and respiratory \\nvirus\\n      identification test results for further information. \\n\\n   Respiratory Viral Antigen Screen (Final ___: \\n      Positive for Respiratory viral antigens. \\n      Specimen screened for: Adeno, Parainfluenza 1, 2, 3, \\nInfluenza A, B,\\n      and RSV by immunofluorescence. \\n      Refer to Respiratory Virus Identification for further \\ninformation. \\n\\n   Respiratory Virus Identification (Final ___: \\n      Reported to and read back by ___ ___ 1005. \\n      POSITIVE FOR RESPIRATORY SYNCYTIAL VIRUS (RSV). \\n         Viral antigen identified by immunofluorescence. \\n___ BLOOD CULTURE Blood Culture, Routine-No growth\\n___ BLOOD CULTURE Blood Culture, Routine-No growth\\n___ MRSA SCREEN MRSA SCREEN-Negative\\n\\nDISCHARGE LABS:\\n\\n___ 04:33AM BLOOD WBC-8.8 RBC-3.18* Hgb-9.4* Hct-29.8* \\nMCV-94 MCH-29.4 MCHC-31.4 RDW-18.0* Plt ___\\n___ 04:33AM BLOOD Glucose-167* UreaN-38* Creat-0.6 Na-138 \\nK-4.9 Cl-96 HCO3-32 AnGap-___ntibiotics:\\nOseltamivir ___\\nAzithromycin ___\\nVanc/zosyn ___\\nVanc/cefepime ___\\nLevofloxacin ___\\nBactrim ___\\n\\nSteroids:\\nMethylpred ___\\nPred ___\\n\\n___ with COPD, OSA, HTN presenting from rehab with acute onset \\ndyspnea on exertion found to have hypercarbic respiratory \\nfailure, RSV infection with course complicated by prolonged \\nrespiratory failure s/p trach/PEG and intermittent fevers. \\n\\n# COPD/Hypercarbic respiratory failure due to RSV: Patient \\npresented with respiratory failure from rehab to ___ where \\nhe was found to be hypercarbic and became more agitated, \\nrequiring intubation and transfer to ___ MICU. Viral panel \\nrevealed positive RSV and patient had reported some sick \\ncontacts at rehab, so this was felt to be the most likely \\ntrigger for his respiratory failure, with concommitant COPD \\nexacerbation. He was treated with high dose steroids, \\nazithromycin, and high dose albuterol and ipratropium. He \\nrecieved 5 days of oseltamivir. Broad spectrum antibiotics were \\ninitially stopped after 48 hours of negative blood, urine, and \\nsputum cultures, but broad spectrum antibiotics were reinitiated \\nmultiple times throughout course as below. CTPA on admission was \\nnegative for embolism, and imaging and BNP levels not consistent \\nwith pulmonary edema. Course was complicated by prolonged \\nrespiratory failure due to global muscle weakness and underwent \\ntrach/PEG on ___. Pt recieved prolonged steroid taper from \\n___ until ___.  To optimize pulmonary status, pt was diuresed \\nusing IV lasix bolus dosing from ___, discontinued for ___ \\nas below. At the time of discharge he was stable on the trach \\ntolerating trach mask intermittently throughout the day for up \\nto 1.5 hours. Mask limited by pt reporting feeling tired, but \\nABG monitoring indicated he was maintaining his respiratory \\nfunction and would likely tolerate longer periods. Recommend \\ntrying ativan with trach mask trials to reduce anxiety.\\n\\n# Fevers: Pt intermittently febrile to 103 throughout admission. \\nWas repeatedly cultured (blood, urine, sputum) and received \\nantibiotics intermittently (see abx course above). Bronchoscopy \\nwith trach/PEG ___ showed no secretions. Other non-infectious \\netiologies also possible such as drug fever, atelectasis, PE, or \\npost-procedural fevers were considered.  C diff was negative. CT \\ntorso was considered and was not pursued because pt defervesced \\nabout a week prior to d/c. He spiked a low fever to 100.6 on \\n___. Repeat cultures were negative including PICC which was \\nremoved. He was not given any antibiotics for this and he did \\nnot have any further fevers. Mycolitic blood culture and fungal \\nmarkers were negative. \\n\\n# Right arm edema: likely related to infiltrated IVs. Resolved \\nwith IV relocation and elevation. US was negative for DVT. \\n\\n# Hypernatremia: Elevated Na in the context of tube feeds. Free \\nwater flushes increased ___, FW deficit calculated to be 4 \\nliters on ___. Recieved 1L D5W and Na normalized.\\n\\n# ___: Cr  1.4 peak  from baseline 0.7 in the setting of \\ndiuresis, high fevers, stool loss. Improved with IVF, discharged \\nCr 0.6.\\n\\n# Tachycardia: Baseline HR prior to admission 110s sinus tach. \\nHR 110s-140s throughout ICU admissin. Restarted Metoprolol; \\ndischarged on metoprolol 12.5mg po q6h with HR IN LOW 100s.\\n\\n# Hyperglycemia: H/o DM, on high dose steroids in the setting of \\nCOPD exacerbation. Held metformin, hyperglycemic on home \\nglargine and SSI. Transitioned to insulin gtt then long acting \\nbut back to insulin gtt for difficult to control sugars. ___ \\nwas consulted and recommended NPH 25mg BID - pt was transitioned \\nto this from insulin gtt and sugars were well-controlled on this \\nregimen with sliding scale.\\n\\n# Hypokalemia/Hyperkalemia: Labile potassium (low with diuresis, \\nhigh when hyperglycemic). Adjusted tube feeds. Treated with \\nsliding scale K repletion; hyperglycemia was managed as above. \\n\\n# Transaminitis: ALT/AST 100s, RUQ US showed fatty liver, no \\ngallbladder disease. Resolving, only mild elevation ___. Home \\nstatin was discontinued on ___.\\n\\nCHRONIC INACTIVE ISSUES:\\n# HTN: held lisinopril \\n# Chronic pain: unclear location, held oxycodone, lyrica\\n# Constipation: continued home bowel regimen\\n# Nutrition: held iron to decrease risk of constipation while \\nhospitalized, continued Vit D, initiated tube feeds after PEG \\nplacement\\n# OSA: will likely continued to need nocturnal CPAP after weaned \\nfrom ventilator\\n# HL:  Discontinued simvastatin\\n# GERD: continued PPI\\n\\nTRANSITIONAL ISSUES:\\nHCP is Son ___ ___ \\nFull code\\nLong term resident at ___ prior to admission\\n- Trach can be downsized 2 weeks after placement (___)\\n- Iron deficiency anemia: patient missed outpatient EGD and ___ \\nfor work up of this. Will need to be rescheduled on discharge.\\n \\nMedications on Admission:\\nThe Preadmission Medication list is accurate and complete.\\n1. Ipratropium Bromide MDI 2 PUFF IH QID \\n2. MetFORMIN (Glucophage) 1000 mg PO BID \\n3. Simvastatin 20 mg PO DAILY \\n4. Ferrous Sulfate 325 mg PO DAILY \\n5. Lisinopril 5 mg PO DAILY \\n6. OxycoDONE (Immediate Release)  2.5 mg PO Q6H:PRN pain \\n7. OxycoDONE (Immediate Release)  5 mg PO QHS \\n8. OxycoDONE (Immediate Release)  5 mg PO Q6H:PRN pain \\n9. Polyethylene Glycol 17 g PO DAILY \\n10. Fluticasone-Salmeterol Diskus (500/50)  1 INH IH BID \\n11. Vitamin D 1000 UNIT PO DAILY \\n12. Glargine 12 Units Bedtime\\nInsulin SC Sliding Scale using HUM Insulin\\n13. Senna 8.6 mg PO BID \\n14. Fluticasone Propionate NASAL 1 SPRY NU DAILY \\n15. Magnesium Oxide 200 mg PO EVERY OTHER DAY \\n16. Pregabalin 150 mg PO QHS \\n17. Pregabalin 75 mg PO QAM \\n18. Omeprazole 20 mg PO DAILY \\n19. Nystatin-Triamcinolone Ointment 1 Appl TP BID \\n20. Metoprolol Succinate XL 25 mg PO DAILY \\n\\n \\nDischarge Medications:\\n1. NPH 25 Units Breakfast\\nNPH 25 Units Dinner\\nInsulin SC Sliding Scale using REG Insulin\\n2. Ipratropium Bromide MDI 6 PUFF IH Q6H \\n3. Polyethylene Glycol 17 g PO DAILY:PRN contstipation \\n4. Senna 8.6 mg PO BID:PRN Constipation \\n5. Vitamin D 1000 UNIT PO DAILY \\n6. Acetaminophen 1000 mg PO Q8H:PRN fever or pain \\n7. Albuterol Inhaler ___ PUFF IH Q6H \\n8. Albuterol Inhaler ___ PUFF IH Q4H:PRN SOB/wheeze \\n9. Artificial Tears Preserv. Free ___ DROP BOTH EYES PRN dry \\neyes \\n10. Bisacodyl ___AILY:PRN constipation \\n11. Chlorhexidine Gluconate 0.12% Oral Rinse 15 mL ORAL BID \\n12. Docusate Sodium (Liquid) 100 mg PO TID:PRN constipation \\n13. Fluticasone Propionate 110mcg 6 PUFF IH BID \\n14. Heparin 5000 UNIT SC TID \\n15. Lansoprazole Oral Disintegrating Tab 30 mg PO DAILY \\n16. Lorazepam 0.5 mg IV BID:PRN anxiety on trach mask \\n17. Metoprolol Tartrate 12.5 mg PO Q6H \\n18. Ferrous Sulfate 325 mg PO DAILY \\n19. Magnesium Oxide 200 mg PO EVERY OTHER DAY \\n20. Simvastatin 20 mg PO DAILY \\n\\n \\nDischarge Disposition:\\nExtended Care\\n \\nFacility:\\n___\\n \\nDischarge Diagnosis:\\nhypercarbic respiratory failure\\nRSV infection\\nsevere COPD exacerbation\\nprolonged respiratory failure requiring trach and PEG\\n\\n \\nDischarge Condition:\\nLevel of Consciousness: Alert and nods to questions (unable to \\nspeak currently).\\nActivity Status: OOB to chair.\\n\\n \\nDischarge Instructions:\\nYou were admitted with respiratory failure and required \\nintubation. This was thought to be due to RSV viral infection. \\nYour course was complicated by exacerbation of your COPD, so you \\nwere treated with inhalers and steroids. You also developed \\nfevers and were treated with antibiotics and antivirals. You \\nwere unable to be extubated so a tracheostomy tube was placed so \\nyou could continue to receive mechanical ventilation and a PEG \\ntube was placed to give you tube feeds. You were then discharged \\nto rehab.\\n \\nFollowup Instructions:\\n___\\n</td>\n      <td>0</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>10118315</td>\n      <td>22138146</td>\n      <td>35949957</td>\n      <td>225798</td>\n      <td>225893</td>\n      <td>2111-06-24 12:15:00</td>\n      <td>10</td>\n      <td>\\nName:  ___                  Unit No:   ___\\n \\nAdmission Date:  ___              Discharge Date:   ___\\n \\nDate of Birth:  ___             Sex:   M\\n \\nService: CARDIOTHORACIC\\n \\nAllergies: \\nlatex / adhesive tape / IV Dye, Iodine Containing Contrast Media \\n/ morphine\\n \\nAttending: ___.\\n \\nChief Complaint:\\nSOB/tachypnea, increased WBC count, found to have new right \\npneumothorax, in context of minimally invasive esophagectomy on\\n___ \\n\\n \\nMajor Surgical or Invasive Procedure:\\n___\\n1. Esophagoscopy.\\n2. Bronchoscopy.\\n3. Right thoracotomy and partial decortication of lung.\\n4. Takedown of anastomosis and revision.\\n5. Repair of right mainstem bronchus.\\n6. Reinforcement of the bronchial suture line and the\\n    esophagogastric anastomosis with pleura.\\n\\n___\\n1. Esophagoscopy.\\n2. Flexible bronchoscopy.\\n \\nHistory of Present Illness:\\n___ s/p minimally invasive esophagectomy on ___, discharged \\nhome in good condition on ___, transferred from OSH today. \\nHe presented to OSH on\\n___ (POD#8) with complaint of increased SOB and tachypnea. \\nHe had been on tube feeds and taking clears PO, tolerating well. \\nHe had no vomiting or abdominal pain, no fevers or chills. CXR \\nat OSH showed 4-cm PTX on the R and a small pleural effusion. Of \\nnote, the patient was discharged with a known very small R PTX \\non ___. A CT was placed at OSH. He was also found to have \\nan\\nincreased WBC, but was afebrile, and hemodynamically stable. \\n\\nOf note, barium swallow study performed prior to discharge on \\n___ showed no leak. Upon transfer, he was hemodynamically \\nstable, not tachycardic\\nwith a normal blood pressure, with oxygen saturation of 98% on \\n4L NC. He had the chest tube in place. He denied any SOB/CP/N/V. \\nAn upper endoscopy was performed upon arrival in the ICU with \\nelective intubation, which revealed an approximately 3-4 cm \\nsegment of gastric tissue that appeared necrotic. The remainder \\nof the esophagus and stomach, including the anastamosis, \\nappeared\\nnormal. A bronchoscopy was also performed, which revealed a \\nsmall\\ndefect in the right mainstem bronchus.  \\n \\nPast Medical History:\\nHiatal hernia, PVD, h/o bronchitis, DJD, h/o bursitis, Barretts, \\nborderline DM, DVT, deviated septum, gastritis, allergic \\nrhinitis, asthma/COPD, hypercholesterolemia, HTN, depression, \\nanxiety, agoraphobia, LVH\\n\\n \\nSocial History:\\n___\\nFamily History:\\nMother\\nFather\\n___\\nOther: unknown cancer in both grandmothers\\n\\n \\nPhysical Exam:\\nUpon Discharge:\\n98.1  68  132/78 14 97%RA\\n\\nGENERAL        \\n[x] WN/WD  [x] NAD  [x] AAO  [ ] abnormal findings:\\n\\nHEENT          \\n[x] NC/AT   [x] EOMI   [x] PERRL/A   [x] Anicteric\\n[x] OP/NP mucosa normal     [x] Tongue midline\\n[x] Palate symmetric  [x] Neck supple/NT/without mass\\n[x] Trachea midline [x] Thyroid nl size/contour\\n[ ] Abnormal findings:\\n\\nRESPIRATORY    \\n[x] CTA/P     [x] Excursion normal     [x] No fremitus\\n[x] No egophony    [x] No spine/CVAT\\n[ ] Abnormal findings:\\n*incisions healing well, clean/dry/intact, steri strips in place \\n\\n\\nCARDIOVASCULAR \\n[x] RRR    [x] No m/r/g    [x] No JVD   [x] PMI nl  [x] No edema\\n[x] Peripheral pulses nl    [x] No abd/carotid bruit\\n[ ] Abnormal findings:\\n\\nGI             \\n[x] Soft    [x] NT   [x] ND  [x] No mass/HSM   [x] No hernia\\n[ ] Abnormal findings:\\n\\nGU             [x] Deferred  \\n[ ] Nl genitalia    [ ] Nl pelvic/testicular exam    [ ] Nl DRE\\n[ ] Abnormal findings:\\n\\nNEURO          \\n[x] Strength intact/symmetric    [x] Sensation intact/ symmetric\\n[x] Reflexes nl     [x] No facial asymmetry [x] Cognition intact\\n[x] Cranial nerves intact   [ ] Abnormal findings:\\n\\nMS         \\n[x] No clubbing   [x] No cyanosis   [x] No edema   [x] Gait nl\\n[x] No tenderness  [x] Tone/align/ROM nl   [x] Palpation nl\\n[x] Nails nl   [ ] Abnormal findings:\\n\\nLYMPH NODES   \\n[x] Cervical nl      [x] Supraclavicular nl     [ ] Axillary nl\\n[ ] Inguinal nl   [ ] Abnormal findings:\\n\\nSKIN           \\n[x] No rashes/lesions/ulcers\\n[x] No induration/nodules/tightening     [ ] Abnormal findings:\\n\\nPSYCHIATRIC    \\n[x] Nl judgment/insight    [x] Nl memory   [x] Nl mood/affect\\n[ ] Abnormal findings:\\n \\nPertinent Results:\\nCHEST X-RAY (___)\\n1.  Stable air-fluid level in the neo-esophagus. \\n2.  Stable right consolidation corresponding to the area of \\nmediastinal fat better evaluated on the recent CT. \\n3.  Improvement in right basilar atelectasis and edema. \\n4.  Stable small bilateral pleural effusions. \\n\\nCT TORSO (___):\\n1.  No evidence of anastomotic leak. \\n2.  8.1 cm collection of herniated mediastinal fat into the \\nright pleural \\nspace. \\n3.  Left upper and right middle lobe opacities compatible with \\npneumonia. \\n\\n___ 04:00AM BLOOD WBC-10.6 RBC-2.73* Hgb-8.2* Hct-26.3* \\nMCV-96 MCH-29.9 MCHC-31.1 RDW-15.7* Plt ___\\n___ 04:00AM BLOOD Plt ___\\n___ 04:00AM BLOOD Glucose-120* UreaN-16 Creat-1.0 Na-138 \\nK-4.6 Cl-99 HCO3-30 AnGap-14\\n___ 04:00AM BLOOD Calcium-8.7 Phos-3.8 Mg-2.2\\n \\nBrief Hospital Course:\\nMr. ___ was transferred to the Thoracic Surgery Service at \\n___ and underwent the following operation on ___: \\n1. Esophagoscopy.\\n2. Bronchoscopy.\\n3. Right thoracotomy and partial decortication of lung.\\n4. Takedown of anastomosis and revision.\\n5. Repair of right mainstem bronchus.\\n6. Reinforcement of the bronchial suture line and the\\n    esophagogastric anastomosis with pleura.\\n\\nPost-operatively, he was admitted to the ICU, where he was \\ninitially intubated, on antibiotics (vancomycin, zosyn, \\nfluconazole), with an NG tube, foley catheter, and 3 chest tubes \\nin place. On POD#2 he was successfully extubated. He was \\nmaintained on supplemental oxygen, with all tubes in place, and \\nantibiotics were continued. He was kept NPO, with tube feeds \\nrunning per his home regimen. Nutrition specialists were \\nconsulted and followed, along with Physical Therapists. \\n\\nUpon being deemed clinically stable and appropriate for transfer \\nto the general surgical floor, such was done. He remained NPO, \\nwith tube feeds, on IV pain medications, on antibiotics, being \\nseen by physical therapy, with regular daily chest x-ray and \\nlaboratory study check. \\n\\nOn ___ he underwent the following procedure:\\n1. Esophagoscopy.\\n2. Flexible bronchoscopy.\\nThe reader is referred to the Operative Note for details. In the \\nOR itself, his chest tubes were removed, with a confirmatory \\nchest x-ray thereafter. He was started on a clear liquid diet, \\nadvanced to full liquids as tolerated thereafter. All \\nantibiotics as above were continued in IV form through till the \\ntime of his discharge. He had good pain control with oral \\nmedications, was weaned off oxygen, and expressed feeling much \\nimproved in health. He was able to ambulate multiple times per \\nday independently. He continued on his tube feeds, in additional \\nto an improved oral intake daily. Once appropriate, he was \\nexplained and expressed agreement with the discharge plan, and \\ndischarged home in good condition. \\n \\nMedications on Admission:\\nThe Preadmission Medication list is accurate and complete.\\n1. Gabapentin 300 mg PO BID \\n2. Tiotropium Bromide 1 CAP IH DAILY \\n3. Clonazepam 0.5 mg PO BID \\n4. Verapamil SR 180 mg PO Q24H \\n5. Baclofen 10 mg PO TID \\n6. Omeprazole 20 mg PO DAILY \\n7. albuterol sulfate *NF* 90 mcg/actuation Inhalation q 4 hrs  \\nwheezing \\n8. Citalopram 40 mg PO DAILY \\n9. traZODONE 150 mg PO HS:PRN sleep \\n10. Acetaminophen 1000 mg PO Q6H \\n11. HYDROmorphone (Dilaudid) ___ mg PO Q4H:PRN pain \\n12. Docusate Sodium 100 mg PO BID \\n\\n \\nDischarge Medications:\\n1. Acetaminophen (Liquid) 650 mg PO Q6H \\nRX *acetaminophen 500 mg/5 mL 5 mL by mouth every six (6) hours \\nDisp #*1 Bottle Refills:*0\\n2. Citalopram 40 mg PO DAILY \\n3. Clonazepam 0.5 mg PO BID \\n4. Gabapentin 300 mg PO BID \\n5. HYDROmorphone (Dilaudid) ___ mg PO Q4H:PRN pain \\n6. traZODONE 150 mg PO HS:PRN sleep \\n7. albuterol sulfate *NF* 90 mcg/actuation Inhalation q 4 hrs  \\nwheezing \\n8. Baclofen 10 mg PO TID \\n9. Docusate Sodium 100 mg PO BID \\n10. Omeprazole 20 mg PO DAILY \\n11. Tiotropium Bromide 1 CAP IH DAILY \\n12. Verapamil SR 180 mg PO Q24H \\n13. TraMADOL (Ultram) 50 mg PO QID \\nRX *tramadol 50 mg 1 tablet(s) by mouth every six (6) hours Disp \\n#*40 Tablet Refills:*0\\n14. Metoprolol Tartrate 100 mg PO BID \\nRX *metoprolol tartrate 100 mg 1 tablet(s) by mouth twice a day \\nDisp #*40 Tablet Refills:*0\\n\\n \\nDischarge Disposition:\\nHome With Service\\n \\nFacility:\\n___\\n \\nDischarge Diagnosis:\\n1. Dehiscence of gastroesophageal anastomosis.\\n2. Fistula to right main stem bronchus.\\n\\n \\nDischarge Condition:\\nMental Status: Clear and coherent.\\nLevel of Consciousness: Alert and interactive.\\nActivity Status: Ambulatory - Independent.\\n\\n \\nDischarge Instructions:\\nCall Dr ___ ___ if you experience:\\n-Fevers greater than 101 or chills\\n-Increased shortness of breath, cough or chest pain\\n-Nausea, vomiting (take anti-nausea medication)\\n-Increased abdominal pain\\n-Incision develops drainage\\n\\nPain\\n-Dilaudid as needed for pain \\n-Take stool softners with narcotics\\n\\nActivity\\n-Shower daily. Wash incision with mild soap &amp; water, rinse, pat \\ndry\\n-No tub bathing, swimming or hot tub until incision healed\\n-No driving while taking narcotics\\n-No lifting greater than 10 pounds until seen\\n-Walk ___ times a day for ___ minutes increase to a Goal of 30 \\nminutes daily\\n\\nDiet:\\n\\nTube feeds: Replete Full Strength 75cc/hr x 18 hrs \\n\\nFlush J-tube with water every 8 hours with 10 cc's of water, \\nbefore and after starting tube feeds and giving medications \\nthrough tube\\n\\nFull liquid diet, may increase to soft solids over the next few \\ndays as tolerated.\\nEat small frequent meals. Sit up in chair for all meals and \\nremain sitting for ___ minutes after meals\\n\\nDaily weights: keep a log bring with you to your appointment\\n\\nNO CARBONATED DRINKS\\n\\nDanger signs\\n\\nFevers &gt; 101 or chills\\nIncreased shortness of breath, cough or chest pain\\nIncision develops drainage\\nNausea, vomiting (take anti-nausea medication)\\nIncreased abdominal pain\\n\\nCall if J-tube falls out (save the tube and bring with you to \\nthe hospital to be re-placed) or suture breaks\\n \\nFollowup Instructions:\\n___\\n</td>\n      <td>0</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>10267084</td>\n      <td>28933075</td>\n      <td>31922388</td>\n      <td>225798</td>\n      <td>225893</td>\n      <td>2147-12-03 04:10:00</td>\n      <td>4</td>\n      <td>\\nName:  ___                   Unit No:   ___\\n \\nAdmission Date:  ___              Discharge Date:   ___\\n \\nDate of Birth:  ___             Sex:   F\\n \\nService: CARDIOTHORACIC\\n \\nAllergies: \\nPercocet\\n \\nAttending: ___.\\n \\nChief Complaint:\\nDOE\\n \\nMajor Surgical or Invasive Procedure:\\n___\\nRight VATS RUL wedge\\n\\n \\nHistory of Present Illness:\\nMs ___ is a ___ with hep\\nC,cirrhosis and HCC had multiple lung nodules found on chest CT\\n___. The f/u CT ___ noted a new RUL 3.3mm nodule, while\\nall others were thought to be stable.Her PET ___ showed \\nmild\\nFDG avidity (SUV 1.4). ___ doesn't think ammenable to biopsy, so\\npt presents for eval for VATS wedge for biopsy. Pt reports\\noccasional DOE with usual activities, otherwise, denies\\nhemoptysis, cough, chest pain, HA, sweats, new bony pain.\\nShe presents now for biopsy.\\n \\nPast Medical History:\\nHep C\\ncirrhosis, decompensated\\nvarices\\n___ s/p RFA ___\\ns/p hyst\\ns/p cosmetic facial surg\\n\\n \\nSocial History:\\n___\\nFamily History:\\nson is deceased from ___ sarcoma.\\n\\n \\nPhysical Exam:\\nBP: 131/66. Heart Rate: 91. Weight: 134 (With Clothes; With\\nShoes). BMI: 25.3. Temperature: 98.1. O2 Saturation%: 99.\\n\\nGENERAL        \\n[x] WN/WD  [x] NAD  [x] AAO  [ ] abnormal findings:\\n\\nHEENT          \\n[x] NC/AT   [x] EOMI   [x] PERRL/A   [x] Anicteric\\n[x] OP/NP mucosa normal     [x] Tongue midline\\n[x] Palate symmetric  [x] Neck supple/NT/without mass\\n[x] Trachea midline [x] Thyroid nl size/contour\\n[ ] Abnormal findings:\\n\\nRESPIRATORY    \\n[x] CTA/P     [x] Excursion normal     [x] No fremitus\\n[x] No egophony    [x] No spine/CVAT\\n[ ] Abnormal findings:\\n\\nCARDIOVASCULAR \\n[x] RRR    [x] No m/r/g    [x] No JVD   [x] PMI nl  [x] No edema\\n[x] Peripheral pulses nl    [x] No abd/carotid bruit\\n[ ] Abnormal findings:\\n\\nGI             \\n[x] Soft    [] NT   [x] ND  [] No mass/HSM   [x] No hernia\\n[x ] Abnormal findings: tender RUQ w/ hepatomeg to ___ FB below\\nribs\\n\\nGU             [x] Deferred  \\n[ ] Nl genitalia    [ ] Nl pelvic/testicular exam    [ ] Nl DRE\\n[ ] Abnormal findings:\\n\\nNEURO          \\n[x] Strength intact/symmetric    [x] Sensation intact/ symmetric\\n[x] Reflexes nl     [x] No facial asymmetry [x] Cognition intact\\n[x] Cranial nerves intact   [ ] Abnormal findings:\\n\\nMS     \\n\\n        \\n[x] No clubbing   [x] No cyanosis   [x] No edema   [x] Gait nl\\n[x] No tenderness  [x] Tone/align/ROM nl   [x] Palpation nl\\n[x] Nails nl   [ ] Abnormal findings:\\n\\nLYMPH NODES   \\n[x] Cervical nl      [x] Supraclavicular nl     [x] Axillary nl\\n[x] Inguinal nl   [ ] Abnormal findings:\\n\\nSKIN           \\n[x] No rashes/lesions/ulcers\\n[x] No induration/nodules/tightening     [ ] Abnormal findings:\\n\\nPSYCHIATRIC    \\n[x] Nl judgment/insight    [x] Nl memory   [] Nl mood/affect\\n[x ] Abnormal findings: flat affect, very vague and slow to\\nprocess info\\n\\n \\nPertinent Results:\\n___ 05:34PM   HCT-34.2*\\n___ 05:34PM   PLT COUNT-88*\\n___ 05:34PM   ___\\n___ 07:05AM   GLUCOSE-89 UREA N-12 CREAT-0.9 SODIUM-135 \\nPOTASSIUM-4.3 CHLORIDE-104 TOTAL CO2-25 ANION GAP-10\\n\\n___ 9:57 pm Influenza A/B by ___\\n      Source: Nasopharyngeal swab. \\n\\n                            **FINAL REPORT ___\\n\\n   DIRECT INFLUENZA A ANTIGEN TEST (Final ___: \\n      Reported to and read back by ___ ___ ___. \\n      POSITIVE FOR INFLUENZA A VIRAL ANTIGEN. \\n\\n   DIRECT INFLUENZA B ANTIGEN TEST (Final ___: \\n      Negative for Influenza B. \\n\\n___ CT Torso :\\n1.  Large area of alveolar infiltrate which is patchy and \\nbilateral but \\ninvolving the right upper lobe more than the other lobes may \\nrepresent focal infectious process versus ARDS or drug reaction. \\n\\n2.  Right lower lobe airspace consolidation with air \\nbronchograms may also represent infectious process, small \\naspiration or atelectasis. \\n3.  Previously described lung nodules that were not resected are \\nnot seen and likely obscured by the ground-glass opacities. \\n4.  Cirrhotic morphology of the liver with evidence of portal \\nhypertension. \\n5.  Gallbladder sludge \\n\\n___ ___ scan :\\nNo sonographic evidence for right upper extremity deep vein \\nthrombosis.\\n\\n___ CXR :\\nAs compared to the previous radiograph from ___, \\nthere \\nis a mild decrease in severity and extent of the pre-existing \\nright upper lobe opacities.  Also improved is the retrocardiac \\natelectasis.  Otherwise, the radiograph is unchanged and the \\nappearance of the lung parenchyma is constant. \\nConstant size of the cardiac silhouette \\n\\n                    WBC RBC  Hgb   Hct  MCV MCH  MCHC  RDW Plt \\nCt \\n___ 06:30    4.6 3.31* 10.7* 31.8* 96 32.3* 33.6 14.5 94* \\n\\n\\n                 Glucose UreaN  Creat  Na   K    Cl  HCO3        \\n    \\n___ 07:15    94     15    0.8   136  3.8  105   25    \\n\\n \\nBrief Hospital Course:\\nMs. ___ was admitted to the hospital and taken to the \\nOperating Room where she underwent a right VATS RUL wedge \\nbiopsy.  She tolerated the procedure well and returned to the \\nPACU in stable condition.  She maintained stable hemodynamics \\nand had minimal chest tube drainage.\\n\\nFollowing transfer to the Surgical floor she had some problems \\nwith pain control and required vigorous pulmonary toilet to help \\nclear her secretions.  Following removal of her chest tube her \\npain lessened but she still required frequent Dilaudid to comply \\nwith incentive spirometry and chest ___.\\n\\nHer post pull CXR revealed a stable right apical space and her \\noxygen was weaned off without difficulty.  Her port sites were \\ndry.  She desaturated to the mid 70's on room air about 8 hours \\npost CT removal.  She was also tachycardic to 120 bpm.  Her ABG \\nwas 7.___.  Due to her hypoxia, she was transferred to \\nthe ICU for further management.  Her CXR revealed a RUL opacity \\nand she became more somnolent with an ABG of 7.___.  She \\nwas intubated, sedated and placed on full mechanical \\nventilation. Broad spectrum antibiotics were stared after she \\nwas pan cultured.  Her highest WBC was 12K.  Blood gases \\nimproved and bronchodilators were given on a standing basis.  \\nShe extubated herself the following day and was able to \\nventilate on her own and maintain adequate saturations. \\n\\nHer nasopharyngeal swab was positive for influenza A and she was \\nstarted on Tamiflu and her antibiotics were stopped.  She \\ncontinued to make good progress and was eventually transferred \\nback to the Surgical floor.  She initially was incontinent of \\nurine and stool and her lactulose was decreased to 15 ml BID.  \\nOnce her multiple bowel movements decreased she was continent \\nagain.  The lactulose was adjusted as needed based on her mental \\nstatus.  She had periods of confusion and some inattention and \\nthis resolved with lactulose 30 ml BID for her hepatic \\nencephalopathy.  \\n\\nShe still required oxygen at 2 liters to maintain an oxygen \\nsaturation of 94%.  She had periods where it was weaned down and \\noccasionally off but she couldn't sustain it with activity. She \\noccasionally has a productive cough and benefits from nebulizer \\ntherapy.  Her Tamiflu ends today after the last dose. \\n\\nThe Physical Therapy service worked with her and recommended a \\nshort term rehab placement prior to returning home to help \\nincrease her mobility, stamina and continue pulmonary toilet \\nwith the hope of sending her home off of oxygen.  She was \\ndischarged on ___ and will follow up in the Thoracic Clinic \\nin 2 weeks.\\n\\n \\nMedications on Admission:\\nThe Preadmission Medication list is accurate and complete.\\n1. Lactulose 30 mL PO TID \\n2. Zolpidem Tartrate 5 mg PO HS sleep \\n3. Furosemide 20 mg PO DAILY \\n4. Spironolactone 25 mg PO DAILY \\n5. Rifaximin 550 mg PO BID \\n6. Omeprazole 40 mg PO DAILY \\n7. albuterol sulfate *NF* 90 mcg/actuation Inhalation q 6 hrs \\nSOB \\n\\n \\nDischarge Medications:\\n1. Furosemide 20 mg PO DAILY \\n2. Omeprazole 40 mg PO DAILY \\n3. Rifaximin 550 mg PO BID \\n4. Spironolactone 25 mg PO DAILY \\n5. Zolpidem Tartrate 5 mg PO HS sleep \\n6. Calcium Carbonate 1250 mg PO BID \\n7. HYDROmorphone (Dilaudid) ___ mg PO Q4H:PRN pain \\nRX *hydromorphone 2 mg ___ tablet(s) by mouth every four (4) \\nhours Disp #*80 Tablet Refills:*0\\n8. albuterol sulfate *NF* 90 mcg/actuation INHALATION Q 6 HRS \\nSOB \\n9. Clonazepam 0.5 mg PO BID anxiety \\n10. Oseltamivir 75 mg PO Q12H \\nlast dose ___ \\n11. Ipratropium Bromide Neb 1 NEB IH Q6H \\n12. Senna 1 TAB PO BID constipation \\n13. Lactulose 30 mL PO BID \\n14. Guaifenesin ___ mL PO Q6H:PRN sputum \\n15. Heparin 5000 UNIT SC TID \\n\\n \\nDischarge Disposition:\\nExtended Care\\n \\nFacility:\\n___\\n \\n___ Diagnosis:\\nPulmonary nodule\\nInfluenza A\\nRespiratory insufficiency requiring re intubation\\n\\n \\nDischarge Condition:\\nMental Status: Clear and coherent.\\nLevel of Consciousness: Alert and interactive.\\nActivity Status: Ambulatory - Independent.\\n\\n \\nDischarge Instructions:\\n* You were admitted to the hospital for lung surgery and you've \\nrecovered well but still need some therapy prior to returning \\nhome. \\n* Continue to use your incentive spirometer 10 times an hour \\nwhile awake.\\n* Check your incisions daily and report any increased redness or \\ndrainage.   Cover the area with a gauze pad if it is draining.\\n* Your chest tube dressing may be removed in 48 hours.  \\n* You will continue to need pain medication once you are home \\nbut you can wean it over a few weeks as the discomfort resolves. \\n Make sure that you have regular bowel movements while on \\nnarcotic pain medications as they are constipating which can \\ncause more problems.  Use a stool softener or gentle laxative to \\nstay regular.\\n* No driving while taking narcotic pain medication.\\n* Take Tylenol  ___ mg every 6 hours in between your narcotic.  \\n* Continue to stay well hydrated and eat well to heal your \\nincisions\\n* Shower daily. Wash incision with mild soap &amp; water, rinse, pat \\ndry\\n* No tub bathing, swimming or hot tubs until incision healed\\n* No lotions or creams to incision site\\n* Walk ___ times a day and gradually increase your activity as \\nyou can tolerate.\\n\\nCall Dr. ___ ___ if you experience:\\n-Fevers &gt; 101 or chills\\n-Increased shortness of breath, chest pain or any other symptoms \\nthat concern you.\\n \\n \\n \\n \\nFollowup Instructions:\\n___\\n</td>\n      <td>0</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>10413295</td>\n      <td>22438881</td>\n      <td>37973258</td>\n      <td>225798</td>\n      <td>225893</td>\n      <td>2170-12-23 05:01:00</td>\n      <td>15</td>\n      <td>\\nName:  ___                  Unit No:   ___\\n \\nAdmission Date:  ___              Discharge Date:   ___\\n \\nDate of Birth:  ___             Sex:   M\\n \\nService: MEDICINE\\n \\nAllergies: \\nNo Known Allergies / Adverse Drug Reactions\\n \\nAttending: ___.\\n \\nChief Complaint:\\nUpper GI bleed\\n \\nMajor Surgical or Invasive Procedure:\\nnone\\n \\nHistory of Present Illness:\\nThis is a ___ gentleman with a pmhx. of alcohol \\ndependence who is transferred from ___ for \\nuncontrolled UGI bleed despite endoscopic intervention.  Per OSH \\nreport, patient was admitted on ___ for hematemesis and \\nmelanotic stools.  He underwent EGD on ___, which revealed \\nnon-bleeding grade II esophageal varicies and 2 duodenal ulcers, \\nwhich were thought to be the cause of patient's symptoms.  \\nUlcers were injected with epinepherine and patient remained \\nstable with hematocrits around 30 for about 72 hours.  On day of \\nadmission, hct dropped to 23 and patient had repeat endoscopy.  \\nDuodenal ulcers did not appear to be rebleeding, and five bands \\nwere placed around esophageal ulcers.  Patient was noted to have \\nBRBPR and colonoscopy was subsequently performed.  Scope was \\nadvanced to cecum however, only finding was copious bright red \\nblood.  Patient subsequently developed massive hematemesis and a \\nrepeat EGD was performed.  Four out of five bands were noted to \\nbe in place, but endoscopist did not advance further to avoid \\ndisloding bands or causing additional trauma.  Patient remained \\nintubated for airway protection.  There was question of \\naspiration during this episode of hematemesis.\\n.\\nOf note, patient was febrile to 103 on admission to OSH.  CXR \\nand urine cultures were reportedly unremarkable.  Patient was \\nstarted empirically on vanc/zosyn/flagyl for broad coverage.  \\nThere was also report of DTs during OSH admission.  Patient had \\nbeen placed on CIWA scale for withdrawal.  On ___ scored 20 \\nand 18, on ___ scored 7, 7, 5, and 4.\\n.\\nThe decision was made to transfer patient to facility with ___ \\ncapabilities.  Upon arrival to ___ MICU, HR was 80, BP 107/77, \\nSPO2 99% on CMV with FIO2 70%.  Patient was intubated and \\nsedated with propofol.  He has had no subsequent episodes of \\nhematemesis since EGD.\\n\\n \\nPast Medical History:\\n--Alcohol abuse\\n--HTN\\n \\nSocial History:\\n___\\nFamily History:\\nLung cancer in maternal uncle, mother with CHF.\\n \\nPhysical Exam:\\nUPON ADMISSION:\\nVS: Temp: BP: 92/68 / HR: 79 RR:  O2sat  \\nGEN: Intubated and sedated\\nHEENT: Pupils reactive, does not respond to commands\\nRESP: Coarse breath sounds throughout but with good air movement \\n\\nCV: RR, S1 and S2 wnl, no m/r/g  \\nABD: +BS, mildly distended, mild fluid wave\\nSKIN: Spider angiomas below neck and over clavicular area \\nNEURO: Sedated\\nRECTAL: Melena\\n.  \\nUPON DISCHARGE: pertinent changes only\\nOriented x3, no asterixis\\nAbdomen non-tender, no distention, no ascites\\nNo melena/hematochezia\\nNo wheezes/rhonchi/rales, respirations unlabored\\n \\nPertinent Results:\\nLabs upon admission:\\n\\n___ 08:54PM   PLT SMR-LOW PLT COUNT-81*\\n___ 08:54PM   HYPOCHROM-1+ ANISOCYT-2+ POIKILOCY-1+ \\nMACROCYT-3+ MICROCYT-NORMAL POLYCHROM-OCCASIONAL \\nOVALOCYT-OCCASIONAL TARGET-OCCASIONAL BURR-OCCASIONAL\\n___ 08:54PM   NEUTS-82* BANDS-0 LYMPHS-12* MONOS-5 EOS-0 \\nBASOS-0 ___ MYELOS-1*\\n___ 08:54PM   WBC-11.2* RBC-3.38* HGB-11.1* HCT-33.4* \\nMCV-99* MCH-32.7* MCHC-33.1 RDW-20.5*\\n___ 08:54PM   CALCIUM-7.0* PHOSPHATE-1.8* MAGNESIUM-1.9\\n___:54PM   CK-MB-2 cTropnT-&lt;0.01\\n___ 08:54PM   CK(CPK)-114\\n___ 08:54PM   estGFR-Using this\\n___ 08:54PM   GLUCOSE-111* UREA N-16 CREAT-0.7 SODIUM-137 \\nPOTASSIUM-3.8 CHLORIDE-110* TOTAL CO2-25 ANION GAP-6*\\n___ 09:00PM   ___ 09:00PM   ___ PTT-28.6 ___\\n___ 09:00PM   PLT SMR-VERY LOW PLT COUNT-79*\\n___ 09:00PM   HYPOCHROM-NORMAL ANISOCYT-2+ POIKILOCY-1+ \\nMACROCYT-3+ MICROCYT-NORMAL POLYCHROM-1+ OVALOCYT-OCCASIONAL \\nTARGET-OCCASIONAL BURR-1+\\n___ 09:00PM   NEUTS-76* BANDS-2 LYMPHS-13* MONOS-9 EOS-0 \\nBASOS-0 ___ MYELOS-0\\n___ 09:00PM   WBC-10.6 RBC-3.11* HGB-10.8* HCT-30.4* MCV-98 \\nMCH-34.6* MCHC-35.4* RDW-20.3*\\n___ 09:00PM   ALBUMIN-2.2* CALCIUM-7.0* PHOSPHATE-1.8* \\nMAGNESIUM-1.9\\n___ 09:00PM   CK-MB-2 cTropnT-&lt;0.01\\n___ 09:00PM   LIPASE-19\\n___ 09:00PM   ALT(SGPT)-31 AST(SGOT)-78* LD(LDH)-251* \\nCK(CPK)-110 ALK PHOS-74 TOT BILI-3.1*\\n___ 09:00PM   GLUCOSE-111* UREA N-15 CREAT-0.7 SODIUM-137 \\nPOTASSIUM-3.8 CHLORIDE-110* TOTAL CO2-25 ANION GAP-6*\\n___ 09:19PM   freeCa-0.96*\\n___ 09:19PM   ___ PH-7.44\\n___ 09:48PM URINE  ___ BACTERIA-OCC \\nYEAST-NONE ___ 09:48PM URINE  BLOOD-LG NITRITE-NEG PROTEIN-75 \\nGLUCOSE-NEG KETONE-TR BILIRUBIN-SM UROBILNGN-NEG PH-6.5 LEUK-SM\\n___ 09:48PM URINE  COLOR-Amber APPEAR-Hazy SP ___\\n.\\nLabs upon discharge: \\n.\\n___ 05:40AM BLOOD WBC-5.6 RBC-2.90* Hgb-9.5* Hct-29.2* \\nMCV-101* MCH-32.7* MCHC-32.4 RDW-18.4* Plt ___\\n___ 05:40AM BLOOD Neuts-54 Bands-0 ___ Monos-15* \\nEos-0 Baso-0 ___ Myelos-0\\n___ 05:40AM BLOOD ___\\n___ 05:40AM BLOOD Glucose-99 UreaN-20 Creat-0.7 Na-136 \\nK-3.9 Cl-105 HCO3-23 AnGap-12\\n___ 05:40AM BLOOD ALT-42* AST-84* AlkPhos-75 TotBili-0.9\\n___ 05:40AM BLOOD Calcium-9.4 Phos-3.0 Mg-1.8\\n___ 04:10AM BLOOD HBsAg-NEGATIVE HBsAb-POSITIVE \\nHBcAb-NEGATIVE HAV Ab-POSITIVE\\n___ 04:10AM BLOOD AFP-4.4\\n___ 04:10AM BLOOD HCV Ab-NEGATIVE\\n.\\nTTE:\\nThe left atrium is mildly dilated. No atrial septal defect is \\nseen by 2D or color Doppler. Left ventricular wall thickness, \\ncavity size and regional/global systolic function are normal \\n(LVEF &gt;55%). Doppler parameters are indeterminate for left \\nventricular diastolic function. There is no ventricular septal \\ndefect. Right ventricular chamber size and free wall motion are \\nnormal. The ascending aorta is mildly dilated. The aortic valve \\nleaflets (3) are mildly thickened but aortic stenosis is not \\npresent. No aortic regurgitation is seen. The mitral valve \\nleaflets are mildly thickened. There is no mitral valve \\nprolapse. Physiologic mitral regurgitation is seen (within \\nnormal limits). There is borderline pulmonary artery systolic \\nhypertension. There is no pericardial effusion. \\n\\nIMPRESSION: Normal regional and global biventricular systolic \\nfunction. Indeterminate indices for diastolic function \\nassessment. No intra-cardiac shunt seen - cannot excluded \\nPFO/small ASD as bubble study not performed adequately. \\nBorderline pulmonary artery systolic hypertension.\\n.\\nAbdominal ultrasound with dopplers\\n1. Patent hepatic vasculature. \\n2. Echogenic and nodular hepatic architecture. An ill-defined \\nhypoechoic \\nstructure seen adjacent to the main portal vein could represent \\nfatty sparing, \\nhowever a lesion at this location cannot be excluded. A CT or \\nMRI is \\nsuggested to further evaluate for possible lesions. \\n3. Small amount of sludge within the gallbladder. \\n4. Trace of ascites in the perihepatic space \\n.\\nCXR ___:  \\nPrevious areas of pulmonary opacity, in the left suprahilar and \\nright \\njuxtahilar lung have cleared. A relatively small region of \\nperibronchial \\nopacification persists in the right lower lobe medially, but \\nthis is not a new finding. There is no pleural effusion. Stomach \\nis distended with fluid and retained material. Heart size is \\nnormal. Azygos remains distended. \\n.\\nUS abd limited ___: no ascites\\n.\\n___: ___: No evidence of DVT in right or left lower \\nextremity.\\n.\\nMicrobiology:\\nBlood cultures: ___: negative\\nUrine cultures: ___: negative\\nPeritoneal cultures: ___: negative\\nStool cultures/Cdiff: ___: negative\\n  \\n\\n \\nBrief Hospital Course:\\nMr. ___ is a ___ year old gentleman with ETOH abuse admitted \\nfor an UGIB with hospital course complicated by newly diagnosed \\ncirrhosis and hypoxemic respiratory failure. \\n.\\n# Hypoxemic respiratory failure: Initially thought to be \\nsecondary to pulmonary edema, possible PNA, restriction from \\nabdominal distention.  Was intubated while receiving diuresis \\ninitially with lasix gtt and received 8 day course of \\nvancomycin/zosyn for potential VAP.  Found to have one day of \\nhypotension thought to be secondary to overdiuresis of 3L in 24 \\nhours; pressures stabilized with small fluid boluses and \\nadministration of albumin.  Extubated successfully on ___.  \\nRespiratory status continued to improve with diuresis on floor, \\noxygen weaned, and repeat CXR showed improvement in pleural \\neffusions and no new consolidation.  \\n.\\n#  UGI BLEED:  Likely due to duodenal ulcer (injected with epi \\non ___ and esophageal varicies (5 bands placed on ___.  \\nHct stable since transfer from OSH.  Patient found to be \\nH.pylori positive, treated for 10 days (___) with \\namoxicillin/clarithromycin/PPI.  He was continued on \\npantoprazole 40mg BID, sucralafate, and nadolol upon discharge.  \\nHis heart rate remained in the ___, but nadolol could not be \\nfurther uptitrated because of SBP 90-100.  He received EGD \\n___ which showed one varix band in place, no new varices, no \\nbleeding.  Counseled to avoid heavy lifting.  He will need \\nrepeat EGD in 6 months for varices surveillance.\\n.\\n# Alcoholic cirrhosis:  His hepatic vasculature was patent, he \\nwas started on lactulose, rifaximin, furosemide.  He has a \\nhypoechoic lesion noticed on RUQ US, likely focal fatty sparing. \\n AFP 4.4, making hepatoma less likely, however MRI of liver \\nshould be completed as an outpatient.\\n.\\n# Hepatic encephalopathy: Likely due to GI bleed and sedation.  \\nIntermittently required haldol and seroquel for agitation.  Did \\nnot exhibit signs of withdrawl on the floor.  Mental status \\ncleared when GI bleed resolved. \\n.\\n# Fever: unclear source, presumed to be due to intra-abdominal \\ntranslocation of bacteria during  \\n.\\nHe was full code for this admission.\\n \\nMedications on Admission:\\n--Atenolol\\n \\nDischarge Medications:\\n1. thiamine HCl 100 mg Tablet Sig: One (1) Tablet PO DAILY \\n(Daily).\\nDisp:*30 Tablet(s)* Refills:*2*\\n2. pantoprazole 40 mg Tablet, Delayed Release (E.C.) Sig: One \\n(1) Tablet, Delayed Release (E.C.) PO Q12H (every 12 hours).\\nDisp:*60 Tablet, Delayed Release (E.C.)(s)* Refills:*2*\\n3. sucralfate 100 mg/mL Suspension Sig: Ten (10) ml PO four \\ntimes a day.\\nDisp:*300 mL* Refills:*2*\\n4. lactulose 10 gram/15 mL Solution Sig: Fifteen (15) ML PO \\nthree times a day: titrate for 3 bowel movements daily.\\nDisp:*1 bottle (960 mL)* Refills:*2*\\n5. furosemide 40 mg Tablet Sig: One (1) Tablet PO DAILY (Daily).\\nDisp:*30 Tablet(s)* Refills:*2*\\n6. rifaximin 550 mg Tablet Sig: One (1) Tablet PO BID (2 times a \\nday).\\nDisp:*60 Tablet(s)* Refills:*2*\\n7. nadolol 20 mg Tablet Sig: Two (2) Tablet PO HS (at bedtime).\\nDisp:*60 Tablet(s)* Refills:*2*\\n8. nadolol 20 mg Tablet Sig: One (1) Tablet PO QAM (once a day \\n(in the morning)).\\nDisp:*30 Tablet(s)* Refills:*2*\\n\\n \\nDischarge Disposition:\\nHome\\n \\nDischarge Diagnosis:\\nDuodenal ulcer\\nEsophageal varices\\nAcute blood loss anemia\\nHypoxemic respiratory Failure \\nVentilator-associated pneumonia \\nH. pylori infection\\nAlcoholic cirrhosis\\nHepatic encephalopathy\\nHypertension\\n\\n \\nDischarge Condition:\\nLevel of Consciousness: Alert and interactive.\\nActivity Status: Ambulatory - Independent.\\nMental Status: Clear and coherent.\\n\\n \\nDischarge Instructions:\\nYou were admitted to the hospital with GI bleeding from an ulcer \\nin the small intestine and abnormal blood vessels (varices) in \\nthe esophagus. Your blood counts remained stable after transfer \\nto ___ from ___, and you did not require \\nadditional blood transfusions. \\n\\nYou were treated for pneumonia, as well as for an infection in \\nthe stomach called H. pylori.\\n\\nYou likely have cirrhosis, scarring of the liver due to \\nexcessive alcohol use.  This underlying liver problem almost \\ncertainly contributed to the episodes of bleeding. It is \\nabsolutely necessary that you never drink alcohol again to avoid \\nfurther damage to the liver. Please make sure that you attend \\nall of your outpatient alcohol rehabilitation sessions. \\n\\nPlease follow up with one of our liver specialists, Dr. ___, \\non \\n___ at 3:40 ___.\\n\\nThe following medication changes were recommended:\\n- STOP Atenolol\\n- START thiamine 100mg daily\\n- START pantoprazole 40mg twice daily\\n- START sucralafate 100 mL four times daily\\n- START lactulose 15mL three times daily - you can increase or \\ndecrease this as need to have 3 bowel movements daily\\n- START furosemide 40mg daily\\n- START rifaximin 550mg twice daily\\n- START nadolol 20mg every morning and 40mg every evening\\n\\n \\nFollowup Instructions:\\n___\\n</td>\n      <td>0</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>95</th>\n      <td>17745537</td>\n      <td>25137618</td>\n      <td>31986786</td>\n      <td>225798</td>\n      <td>225893</td>\n      <td>2119-11-28 23:29:00</td>\n      <td>4</td>\n      <td>\\nName:  ___                 Unit No:   ___\\n \\nAdmission Date:  ___              Discharge Date:   ___\\n \\nDate of Birth:  ___             Sex:   M\\n \\nService: MEDICINE\\n \\nAllergies: \\nheparin\\n \\nAttending: ___.\\n \\nChief Complaint:\\nhyperbilirubinemia, nausea, vomiting\\n \\nMajor Surgical or Invasive Procedure:\\n___: choledochoduodenostomy\\n \\nHistory of Present Illness:\\n___ year old M with mental retardation, s/p bioprosthetic MVR in \\n___ for mitral insufficiency, hypothyroidism, h/o PUD s/p \\nmassive bleed, and atrial fibrillation (not anticoagulated) who \\nwas recently diagnosed with pancreatic CA with liver mets. Pt \\nrecently discharged on ___ after undergoing EUS with FNA \\nconfirming diagnosis. Pt had some billiary obstruction from the \\nmass (Tbili 3.9 at discharge), but ERCP was unsuccessuful as the \\nscope could not be passed in the duodenum due to extrinsic \\ncompression. PTBD deferred as pt thought to be unlikely to \\ntolerate external drain maintenance. Pt seen in PCP's office \\nyesterday due to persistent nausea and vomiting. Labs show \\nrising bilirubin to 4.3, so admission has been arranged for \\nrepeat ERCP with rendezvous procedure. No fevers or chills. \\nNausea seems to have improved.  Prior to direct admission, \\npatient had persistent nausea and vomiting, so he was sent to \\nthe local hospital at ___, where a repeat CT scan \\nshowed enlarging liver lesions compared to prior CT scan at the \\nend of ___.  He was then transferred to the ___ ED.\\n\\nROS: unable to obtain\\n \\nPast Medical History:\\nMental retardation, moderate (I.Q. 35-49) \\nRectal prolapse / External hemorrhoids\\nMitral valve insufficiency, s/p bioprosthetic MVR ___\\nAnxiety\\nLumbar compression fracture\\natrial fibrillation\\nS/P colonoscopy \\nConstipation \\nHyperparathyroidism \\nPUD (peptic ulcer disease) \\nCerumen impaction\\nHeparin-induced thrombocytopenia\\nfibrous dysplasia\\nAspiration risk: mechanical soft ground diet with thin liquids.\\n\\nPAST MEDICAL HX REVIEW OF RECORDS-___ WEB:\\n___ valve prolapse with new regurgitation\\n___ valve prolapse with severe MR. ___ with LVH\\n___ with moderately dilated LV, LVEF 55-60%, Moderate LAE, \\nasymptomatic\\n___ echo with further dilated left ventricle (moderate \\nto severe) and preserved EF 55%. Severe mitral regurgitation and \\nmyxomatous degeneration of the bileaflets.\\nHx of rectal prolapse repair\\nObsessive-compulsive disorder with perservaration\\n___: mitral valve replacement with pericardial prosthesis \\nand ligation of left atrial appendage at Mass General: post op \\ncomplications included: atrial fibrillation requiring \\ncardioversion and amiodarone briefly\\nstarted on warfarin ___ after MVR x 6months more for HIT \\nthan for A. fib\\nAtrial fibrillation ___, on amiodarone briefly \\n___ sinus rhythm since cardioversion \\nin perioperative MVR period\\n\\nENDOCRINE:\\nOsteoporosis with a vertebral fracture of L1 in ___ and was \\nstarted on Fosamax in ___\\nHypercalcemia/Hyperparathyroidism with normal Sestamibi scan\\nElevated TSH in past with negative antibodies\\nHypothyroidism\\n \\nSocial History:\\n___\\nFamily History:\\nGiven his cognition the patient could not tell me what diseases \\nhis family members have or had.\\n\\n \\nPhysical Exam:\\nADMISSION PHYSICAL EXAM\\nVitals: 97.9 114/65 84 18 94%RA\\nGen: NAD, pleasant\\nHEENT: R facial droop/scarring, +icterus\\nCV: rrr, no r/m/g\\nPulm: clear b/l\\nAbd: soft, nontender, nondistended\\nExt: no edema\\nNeuro: alert, interactive, moves all extremities spontaneously, \\nconversant\\n \\nPertinent Results:\\nADMISSION LABS:\\n====================\\n___ 06:15AM BLOOD WBC-9.5 RBC-3.20* Hgb-11.5* Hct-35.1* \\nMCV-110* MCH-36.1* MCHC-32.8 RDW-14.7 Plt ___\\n___ 06:15AM BLOOD Glucose-118* UreaN-11 Creat-0.6 Na-143 \\nK-3.4 Cl-103 HCO3-34* AnGap-9\\n___ 06:15AM BLOOD Albumin-3.1*\\n___ 06:15AM BLOOD ALT-72* AST-101* AlkPhos-269* \\nTotBili-4.3*\\n___ 09:05AM BLOOD ___ PTT-31.7 ___\\n___ 06:33AM BLOOD Lactate-1.0\\n___ 03:30PM URINE Color-DkAmb Appear-Hazy Sp ___\\n___ 03:30PM URINE Blood-NEG Nitrite-NEG Protein-30 \\nGlucose-NEG Ketone-NEG Bilirub-SM  Urobiln-NEG pH-6.5 Leuks-NEG\\n___ 03:30PM URINE RBC-0 WBC-0 Bacteri-NONE Yeast-NONE Epi-0\\n\\nIMAGES\\n======\\n___: EUS and choledochoduodenostomy\\nImpression: EUS was performed using a linear echoendoscope at \\n___ MHz frequency: An ill-defined mass was noted in the head of \\nthe pancreas. The borders of the mass were irregular and poorly \\ndefined. CBD proximal to the mass was severely dilated At the \\nduodenum evaluation was made for a choledochoduodenostomy. The \\nextrahepatic bile duct was again visualized. A site for puncture \\nat D1/D2 was identified. \\nColor doppler was used to determine an avascular path for needle \\npuncture. \\nUnder EUS guidance, a 19-gauge needle was punctured through the \\nduodenal wall into CBD. \\nBilious fluid was aspirated confirming the location in CBD. \\nA cholangiogram was performed through the FNA needle revealing \\nmarked diffuse biliary dilation. \\nThere was no downstream drainage into the duodenum. \\nA 0.035 in guidewire was placed and reached the intrahepatic \\nducts. The needle was withdrawn. \\nAfter several methods were attempted to create a \\ncholedochoduodenostomy tract, an over the wire needle knife was \\nused to created a definitive tract under fluoroscopic \\nvisualization. \\nA hurricane balloon was then inserted to dilate the \\ncholedochoduodenostomy tract to 6 mm. \\nUpon attempting to advance the fully covered metal stent over \\nthe guidewire, the guidewire looped in the duodenum and wire \\naccess was temporarily lost. \\nThe EUS scope was then exchanged for a duodenoscope. Using a \\nsphincterotome, the guidewire was successfully advanced back \\ninto the CBD under fluoroscopic guidance. \\nA 10mm x 60mm WallFlex full-covered self expandable metal stent \\n(Ref: ___ ___: ___ was successfully placed in CBD \\nacross the duodenal wall, with resulting excellent bile flow. \\n \\nRecommendations: Return to ward for ongoing care. \\nIf any fever, worsening abdominal pain, or post procedure \\nsymptoms, please call the advanced endoscopy fellow on call \\n___/ pager ___. \\nNPO with IVF for hydration using RL. \\nCiprofloxacin and flagyl x 5 days\\n\\n___ KUB:\\nIMPRESSION: \\n1. No bowel obstruction or free air. \\n2. Bibasilar opacities incompletely characterized, likely \\natelectasis. \\n3. Mixed lytic and sclerotic left iliac lesion.  Comparison with \\nany older OSH studies recommended.\\n\\n___ PORTABLE CXR:\\nIMPRESSION:\\nNo previous images. Prosthetic valve is in place in a patient \\nwith intact \\nmidline sternal wires. There is enlargement cardiac silhouette \\nwith layering effusions, compressive basilar atelectasis, and \\ndiffuse parenchymal opacification consistent with pulmonary \\nedema. The possibility of superimposed pneumonia or even ARDS. \\nIV considered in the appropriate clinical setting. No evidence \\nof free intraperitoneal gas. However, this is not a true upright \\nview is rotated free air is AC is clinical concern, CT could be \\nobtained. \\n\\n \\n\\n \\n\\n \\nBrief Hospital Course:\\n___ year old male with PMH of mental retardation, bioprosthetic \\nMVR, A-fib and recently diagnosed metastatic pancreatic cancer \\npresenting with worsening biliary obstruction.\\n\\n1. Onc: Metastatic pancreatic cancer with worsening biliary \\nobstruction.  He underwent choledochoduodenostomy on ___.  \\nPlaced on ciprofloxacin and flagyl after the procedure.  \\nInitially tolerated a regular diet, had mild leukocytosis to 14 \\nthat resolved, bilirubin downtrending.  Developed bilious \\nvomiting on ___, KUB showed no evidence of free air or \\nobstruction.  Had increased abdominal distention on ___, CT \\nA/P orderered, while drinking contrast for CT scan developed \\nvomiting, worsening pain and distention, fevers and hypotension. \\n Transferred to ___ for further management. \\n\\n2. CV: Bioprosthetic MVR, atrial fibrillation not on \\nanticoagulation, hyperlipidemia. \\n-His home Toprol XL and lisinopril were held when he became \\nhypotensive.\\n-Continued simvastatin\\n\\n3. Thrombocytosis: Continue hydroxyurea\\n\\n4. History of HIT: Continue fondoparinux for DVT ppx\\n\\n5. Hypothyroidism: Continue Synthroid\\n\\n6. FEN/PPX: NPO, fondoparinux, PPI\\n\\nGuardian ___ ___ (all decisions made by\\nguardian)\\nFather: ___\\n___ (group home nurse) ___ with recently diagnosed pancreatic adenocarcinoma that \\npresented to the ___ with septic shock following recent GI \\nprocedure.\\n\\n#Septic shock: Patient with ___ SIRS criteria in setting of \\nlikely GI source of infection with hypotension unresponsive to \\nmultiple boluses of IVF consistent with septic shock. Given \\nperitoneal signs on exam there was concern that there might have \\nbeen leakage from perforation of small bowel in the setting of \\nrecent choledochoduodenostomy stent migration. Unfortunately, he \\nwas not a candidate for surgery or further endoscopic \\ninterventions with underlying co-morbidities and ongoing \\ncritical illness. Started vanc/zosyn and continue cipro/flagyl \\nfor double Pseudomonal and GNR, VRE, and C. diff coverage. \\nBolused with IVF PRN until CVP ___, maintained MAP &gt;65 with \\nlevophed followed by vaso and epi, trended sVO2, lactate, and \\nABG q6h to help with hemodynamic monitoring. We were unable to \\nplace NGT ___ facial scarring and planned for CT w/contrast to \\nconfirm perforation if stabilized. \\n\\n#Hypoxic respiratory distress: Bilateral fluffy infiltrates on \\nCXR and new O2 requirement concerning for aspiration pneumonitis \\nvs. PNA vs. early ARDS. Initially satting well on ___ mask. \\nContinued to monitor oxygenation with IVF and titrated \\nsupplemental O2 to maintain SaO2 &gt;90% Treatment of PNA with \\nabove abx\\n\\n#GOC: There was no chance of a meaningful recovery despite \\nmaximum medical therapy in the setting of abdominal perforation \\nwith no surgical option; as such, CPR was not indicated. His \\n___ agreed with this, and neither the medical \\nteam, nor ___ wished to intubate Mr. ___ as it would only \\nprolong suffering without offering a chance of survival. She \\nwanted to focus on comfort.\\n\\n#Metastatic pancreatic adenocarcinoma: Not a candidate for \\nchemo/XRT at time of presentation given critical illness. \\nInitial plan was that if the patient were to improve, we would \\nt/b with onc to discuss further management.\\n\\n#ET: Thrombocytopenic. Held hydroxyurea in setting of critical \\nillness.\\n\\n#Atrial fibrillation: Rate  well controlled. Held nodal agents \\nin setting of septic shock\\n\\n#Hypothyroidism: Continued synthroid\\n\\n#HTN: Held lisinopril in setting of shock\\n\\nUnfortunately, Mr. ___ began to deteriorate clinically \\nwith respect to increasing confusion and worsening mental \\nstatus. He was also somewhat more hypotensive, and given his \\ngoals of care, medical management was not to be escalated. This \\nincluded interventions like adding on pressors and intubation. \\nHe died suddenly in the setting of an arrhythmia, Torsades de \\npointes. He was DNR/DNI at that time, consistent with goals of \\ncare, and no resuscitation was attempted. \\n \\nMedications on Admission:\\nThe Preadmission Medication list is accurate and complete.\\n1. Zenpep (lipase-protease-amylase) 20,000-68,000 -109,000 unit \\noral tid \\n2. Ascorbic Acid ___ mg PO BID \\n3. Simvastatin 20 mg PO DAILY \\n4. Omeprazole 20 mg PO BID \\n5. Multivitamins 1 TAB PO DAILY \\n6. Polyethylene Glycol 17 g PO DAILY:PRN constipation \\n7. Metoprolol Succinate XL 25 mg PO DAILY \\n8. Psyllium 1 PKT PO TID:PRN constipation \\n9. Lisinopril 2.5 mg PO DAILY \\n10. Levothyroxine Sodium 50 mcg PO DAILY \\n11. Hydroxyurea 1000 mg PO DAILY \\n12. Docusate Sodium 100 mg PO BID \\n13. Fish Oil (Omega 3) 1000 mg PO BID \\n14. Citalopram 20 mg PO DAILY \\n15. Acidophilus (L.acidoph &amp; \\n___ acidophilus) 175 mg oral \\nbid \\n16. Aspirin 81 mg PO DAILY \\n17. Acetaminophen 650 mg PO Q6H:PRN pain \\n\\n \\nDischarge Medications:\\nPatient passed away during hospitalization. \\n \\nDischarge Disposition:\\nExpired\\n \\nDischarge Diagnosis:\\nPancreatic adenocarcinoma with liver metastases\\nBile duct obstruction\\n\\n \\nDischarge Condition:\\nLevel of Consciousness: Alert and interactive.\\nActivity Status: Ambulatory - Independent.\\n\\n \\nDischarge Instructions:\\nThe patient expired during this hospitalization.\\n \\nFollowup Instructions:\\n___\\n</td>\n      <td>0</td>\n    </tr>\n    <tr>\n      <th>96</th>\n      <td>17862236</td>\n      <td>26604678</td>\n      <td>30586056</td>\n      <td>225798</td>\n      <td>225893</td>\n      <td>2127-09-29 15:30:00</td>\n      <td>4</td>\n      <td>\\nName:  ___               Unit No:   ___\\n \\nAdmission Date:  ___              Discharge Date:   ___\\n \\nDate of Birth:  ___             Sex:   M\\n \\nService: MEDICINE\\n \\nAllergies: \\nSulfa (Sulfonamide Antibiotics) / ketamine\\n \\nAttending: ___.\\n \\nChief Complaint:\\nChest pain\\n \\nMajor Surgical or Invasive Procedure:\\nCardiac catheterization ___\\nCardiac catheterization ___ with drug eluting stent\\n\\n \\nHistory of Present Illness:\\nMr. ___ is a ___ y/o man with a PMH of CAD s/p \\nmultiple PCI, PVD s/p R BKA/L ___ toe amputation, stroke, HTN, \\nHLD, T2DM, chronic pain, who presents with chest pain. He \\npresented to the ED yesterday evening with three hours of \\ncrushing substernal chest pain, without radiation. He reported \\nthat it was similar to his prior MI pain but more sever. It was \\nworse with lying down and better when sitting up. Of note, he \\nhad also been experiencing erythema and pain of his left foot \\nand was febrile to ___ shortnly before arrival. \\n \\nIn the ED initial vitals were: T 99.8F BP 113/59 mmHg P ___ RR \\n20 O2 98% NC  \\nEKG: NSR, rate of 105, ST depressions in V4/V5, with TWI in \\nV1/V2, Q-wave in III\\nExam was notable for diaphoresis, tachycardia, and skin findings \\nconsistent with L foot cellulitis.\\nLabs/studies notable for normal Chem 7, including Cr of 1.2 \\n(though from a baseline of ~0.9), WBC 15,700, with 89.6%N, no \\nbands, H/H 13.9/42.9, PLT 273, trop-T of 0.02 rising to 0.40, \\nlactate 2.3, bland UA. CXR was notable for stable \\ncardiomediastinal silhouette, without evidence of pneumonia, \\nlarge effusion, or pneumothorax. A foot radiograph demonstrated \\nno evidence of erosion or radiographic evidence of \\nosteomyelitis.\\n\\nCardiology was consulted. He was treated with aspirin 243 mg, \\nvancomycin/Zosyn, heparin gtt, and nitroglycerin infusion. His \\nchest pain persisted, and therefore he was urgently taken to the \\ncardiac catheterization laboratory. Vitals on transfer: T 103.8F \\nBP 152/66 mmHg P ___ RR 18 O2 99% RA\\n\\nIn the cath lab, radial access was obtained, and he was found to \\nhave diffuse three vessel disease in a left dominant system with \\ncomplex lesions in the proximal LAD (bifurcation lesion with a \\ndiffusely disease restenotic diagonal), distal LAD, ostial ramus \\nintermedius and moderate disease in the dominant AV groove Cx \\ninto the LPDA. He was noted to have moderate-severe LV diastolic \\nheart failure, with an LVEDP of 23 mmHg. He continued to have \\nongoing chest pain despite IV NTG, heparin, and a high grade \\nfever, concerning for active infection with bacteremia/sepsis. \\nOverall, given his ongoing infection, the decision was made to \\ntreat the ongoing NSTEMI medically without PCI, with the option \\nto return for proximal LAD bifurcation stenting and distal LAD \\nstenting with PCI of the ramus intermedius after clearance of \\nthe infection. \\n\\nOn arrival to the CCU, he reported that he was continuing to \\nhave 4 of 10 chest pressure, though much improved from prior. He \\nactually reported that this pain is distinct from his prior \\nanginal pain. He also reported a headache; in fact, the headache \\nis bothering him more than the chest pain currently. He did \\nreport fevers, which started essentially shortly prior to his \\narrival in the ED. He reports pain and rash in his left foot, \\nwhich has improved since he arrived. Otherwise, he denied \\nnausea, vomiting, abdominal pain, dysuria, dyspnea, orthopnea, \\nedema, syncope, hematuria, hematochezia. \\n \\nREVIEW OF SYSTEMS:  \\n- as above, otherwise negative\\n \\nPast Medical History:\\n- CAD s/p PCIx8 reportedly (stents implanted at ___ in \\n___ info available. Last cath done at ___ in ___: nl LM. \\n80% mid LAD between prior stents, 70% apic LAD, D1 occluded at \\nprior stent, OM1 ___ 89%, 70% distal ramus at site of stent. \\nNondom small RCA. No intervention then)\\n- PVD s/p R BKA, L ___ toe amputation\\n- HTN\\n- T2DM c/b peripheral neuropathy\\n- HLD\\n- chronic pain\\n- stroke c/b L hemiparesis, now improved\\n- L sided humeral fracture (___), L patellar fracture, L \\ntibial plateau fracture\\n- depression\\n- pituitary adenoma \\n- laparoscopic appendectomy (___)\\n- angioplasty of LLE ___ ___ w/ Dr. ___\\n- multiple R heel debridement, free tissue transfer to R thigh \\nto R heel now s/p R BKA\\n\\n \\nSocial History:\\n___\\nFamily History:\\nFather died of esophageal cancer, was heavy smoker. Mother died \\nof unknown cancer type.\\n \\nPhysical Exam:\\nAdmission exam: \\nVS: T 98.0F BP 109/63 mmHg P 91 RR 14 O2 100%\\nGeneral: Uncomfortable appearing man, appearing his stated age.\\nHEENT: Anicteric sclerae, EOMs intact.\\nNeck: Supple, no JVD.\\nCV: RRR, no MRGs; normal S1/S2.\\nPulm: CTA b/l; no wheezes, rhonchi, or rales.\\nAbd: Soft, non-tender, non-distended, NABS.\\nExt: s/p R BKA. L toe lesions with mild erythema/tenderness, no \\nevidence ulceration or erosion. s/p L toe amputation. \\nDopplerable DP pulse.\\nNeuro: A&amp;Ox3; CNs II-XII grossly intact. \\n\\nDischarge exam:\\nGeneral: Alert, awake, no acute distress\\nHEENT: anicteric sclera, MMM\\nNeck: No JVD appreciated\\nLungs: clear to auscultation bilaterally with good symmetric\\nairflow\\nCV: RRR with S1/S2, no murmurs, rubs, or gallops\\nAbdomen: soft, nontender\\nExtremities: warm, 2+ DP pulses, no edema\\n \\nPertinent Results:\\nAdmission and notable labs:\\n___ 06:00PM BLOOD WBC-15.7*# RBC-4.95 Hgb-13.9 Hct-42.9 \\nMCV-87 MCH-28.1 MCHC-32.4 RDW-13.3 RDWSD-42.1 Plt ___\\n___ 06:00PM BLOOD Neuts-89.6* Lymphs-3.9* Monos-5.4 \\nEos-0.2* Baso-0.2 Im ___ AbsNeut-14.08*# AbsLymp-0.61* \\nAbsMono-0.85* AbsEos-0.03* AbsBaso-0.03\\n___ 02:30AM BLOOD ___ PTT-49.2* ___\\n___ 06:00PM BLOOD Glucose-152* UreaN-17 Creat-1.2 Na-137 \\nK-4.6 Cl-101 HCO3-23 AnGap-18\\n___ 12:25PM BLOOD ALT-19 AST-45* LD(LDH)-162 AlkPhos-114 \\nTotBili-0.6\\n___ 06:00PM BLOOD cTropnT-0.02*\\n___ 09:26PM BLOOD cTropnT-0.06*\\n___ 12:54AM BLOOD cTropnT-0.13*\\n___ 04:15AM BLOOD cTropnT-0.21*\\n___ 08:00AM BLOOD CK-MB-21* cTropnT-0.40*\\n___ 12:25PM BLOOD CK-MB-21* cTropnT-0.48*\\n___ 06:09PM BLOOD CK-MB-20* cTropnT-0.52*\\n___ 04:30AM BLOOD CK-MB-22* cTropnT-0.72*\\n___ 06:00PM BLOOD Calcium-9.7 Phos-2.3* Mg-2.0\\n___ 12:25PM BLOOD Calcium-8.3* Phos-2.6* Mg-1.6 Cholest-103\\n___ 04:30AM BLOOD Calcium-8.7 Phos-2.8 Mg-1.9\\n___ 12:25PM BLOOD %HbA1c-7.7* eAG-174*\\n___ 12:25PM BLOOD Triglyc-85 HDL-33 CHOL/HD-3.1 LDLcalc-53\\n___ 06:21PM BLOOD Lactate-2.3*\\n___ 03:55AM URINE Blood-NEG Nitrite-NEG Protein-TR \\nGlucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-7.0 Leuks-NEG\\n___ 03:55AM URINE RBC-1 WBC-&lt;1 Bacteri-NONE Yeast-NONE \\nEpi-0\\n___ 03:55AM URINE Color-Yellow Appear-Clear Sp ___\\n\\nMICROBIOLOGY\\n\\nIMAGING:\\nTTE ___\\nThe left atrium and right atrium are normal in cavity size. Left \\nventricular wall thicknesses are normal. The left ventricular \\ncavity size is normal. There is mild regional left ventricular \\nsystolic dysfunction with distal ___ of the LV showing \\nhypo-/akinesis. Doppler parameters are most consistent with \\nGrade I (mild) left ventricular diastolic dysfunction. Right \\nventricular chamber size and free wall motion are normal. The \\naortic root is mildly dilated at the sinus level. The ascending \\naorta is mildly dilated. The aortic valve leaflets (3) appear \\nstructurally normal with good leaflet excursion and no aortic \\nstenosis or aortic regurgitation. The mitral valve appears \\nstructurally normal with trivial mitral regurgitation. The \\nestimated pulmonary artery systolic pressure is normal. There is \\nan anterior space which most likely represents a prominent fat \\npad. \\n\\nIMPRESSION: Suboptimal image quality despite use of IV U/S \\ncontrast. \\n1) Mild regional left ventricular systolic dysfunction c/w CAD \\nin mid to distal LAD territory. \\n\\nCompared with the prior study (images reviewed) of ___, \\nregional wall motion abnormalities are new.\\n\\nCARDIAC CATH ___\\nDominance: Left\\nLMCA: The LMCA was short.\\nLAD: The proximal LAD had diffuse plaquing to 25% leading to an \\n85% bifurcation lesion extending to 75% at the ostium of the \\npreviously stented D1. D1 had diffuse in-stent and distal stent \\nedge restenosis to 80%. The mid LAD may have been \\nintramyocardial. The stent in the mid-distal LAD had hazy mild \\nin-stent restenosis. The distal LAD beyond the stent was of \\nsmall caliber and diffusely diseased to 85% before the\\nLAD wrapped well around the apex to the mid inferior septum. \\nFlow in the LAD was TIMI 2. \\nRamus intermedius: The stented ramus intermedius had a proximal \\nedge 70% stenosis at its ostium. There was also distal stent \\nedge restenosis to 80% in the lower basal pole of the ramus with \\nTIMI 2 flow beyond.\\nLCX: The CX supplied a tiny OM1. The large branching OM2/LPL1 \\nhad an origin 50% stenosis with more distal diffuse mild \\nplaquing to 40%. The distal AV groove CX had a 60% stenosis \\nbefore the prior stent. The other LPLs and the LPDA were all \\nsmall with diffuse disease to 45% in the mid LPDA. Flow in the \\nAV groove CX was pulsatile and delayed, consistent with \\nmicrovascular dysfunction.\\nRCA: The RCA was previously documented as non-dominant, small \\nand diffusely diseased and was not imaged today.\\nImpressions:\\n1. Diffuse three vessel disease in a left dominant system with \\ncomplex lesions in the proximal LAD (bifurcation lesion with a \\ndiffusely diseased restenotic diagonal), distal LAD, ostial \\nramus intermedius and moderate disease in the dominant AV groove \\nCX into the LPDA.\\n2. Moderate-severe left ventricular diastolic heart failure.\\n3. Ongoing chest pain despite IV TNG, IV heparin (with ACT only \\n181 secs), HR 95 and SBP &lt;100 mm Hg.\\n4. High grade fever concerning for active infection with \\nbacteremia/sepsis.\\n\\nCXR ___\\nFINDINGS:    \\nAP portable upright view of the chest.  Mild linear atelectasis \\nin the lower lungs noted.  No focal consolidation is seen \\nconcerning for pneumonia.  No large effusion or pneumothorax \\nseen.  The left CP angle is partially excluded. \\nCardiomediastinal silhouette appears stable.  Bony structures \\nare intact. \\n\\n \\nBrief Hospital Course:\\nMr. ___ is a ___ y/o man with a PMH of CAD s/p \\nmultiple PCI, PVD s/p R BKA/L ___ toe amputation, stroke, HTN, \\nHLD, T2DM, chronic pain who has been admitted with NSTEMI in the \\nsetting of sepsis from skin and soft tissue infection. \\n\\n# CORONARIES: Diffuse 3VD, L dominant, complex lesions in ___ \\nLAD\\n(bifurcation lesion with a diffusely diseased restenotic diag), \\ndistal LAD, ostial ramus intermedius and moderate disease in the \\ndominant AV groove CX into the LPDA. Underwent PCA to LAD this \\nadmission (see below)\\n# PUMP: LVEF &gt;55%\\n# RHYTHM: NSR\\n\\n# NSTEMI: Patient presented with chest pain in the setting of \\nsepsis. EKG showed NSR, rate of 105, ST depressions in V4/V5, \\nwith TWI in V1/V2, Q-wave in III. Trops initially 0.13 with CKMB \\n21. Patient initially underwent cardiac catheterization on \\nhospital day 1 which showed diffuse multivessel CAD. No \\nintervention was performed due to diffuse disease and ongoing \\nfevers (see below). He was planned for medical management with \\nnitro gtt for chest pain symptom relief as well as Plavix, \\nmetoprolol, aspirin 81, atorvastatin 80 mg qHS. ACEi was \\ninitially held due to hypotension (although ultimately resumed \\nover hospital course). However, troponins continued to rise and \\npatient again developed chest pain on ___ that was responsive \\nto SL nitro. He was placed on heparin gtt and isordil for chest \\npain control. He was taken back to the cath lab on ___, and \\nreceived a drug-eluting stent to proximal LAD, and balloon \\nangioplasty of D1 ostium and lower pole branch of ramus \\nintermedius. Please review OMR for the catheterization reports. \\n\\n# Severe sepsis secondary to cellulitis: Patient initially \\nfebrile, with leukocytosis, borderline hypotension and \\ntachycardia. Source appears to be left foot with warmth and \\nerythema. No evident ulceration or erosion. Dopplerable DP \\npulses. No evidence of trauma, though neuropathy and severe \\nperipheral vascular disease does place him at high risk for \\nSSTI. Given his recent hospitalizations and diabetes, patient \\nwas initially covered broadly, including with MRSA and \\nPseudomonal coverage. He does not have any cough or evidence of \\nPNA on CXR or evidence of UTI. He was initiated on vancomycin \\n1000 mg IV q8h and zosyn with panculture. Given concern for \\nosteomyelitis of foot, case discussed with vascular, podiatry, \\nand infectious diseases and decision was made that there was low \\nsuspicion for osteomyelitis, and no MRI was necessary. \\nUltimately, he defervesced and improved clinically in &lt;24 hours \\nand it was felt that the source of infection was cellulitis. He \\nwas narrowed to cephalexin and will complete a course ending \\n___.\\n\\n#HEART FAILURE WITH PRESERVED EJECTION FRACTION. Noted to have \\nelevated LVEDP on catheterization. No dyspnea, PND, orthopnea at \\nthis time to suggest significant decompensation. Given concern \\nfor sepsis, he did not undergo diuresis initially. TTE this \\nadmission showed mild regional left ventricular systolic \\ndysfunction c/w CAD in mid to distal LAD territory. EF 45-50%.\\n\\nChronic issues:\\n# T2DM. Home glipizide and metformin were held, and he was \\nplaced on sliding scale insulin. \\n# CHRONIC PAIN. He was continued on home oxycodone 5 mg BID PRN \\nand breakthrough morphine ___ mg IV q4h PRN severe pain.\\n# PVD. He was continued on home aspirin, clopidogrel, and \\natorvastatin as above.\\n# DIABETIC NEUROPATHY. He was continued on home gabapentin 300 \\nmg TID.\\n# HLD. His home gemfibrozil was held, given interaction with \\natorvastatin 80 mg.\\n# ANXIETY. He was continued on home lorazepam 0.5 mg BID. \\n# DEPRESSION. He was continued on home sertraline 100 mg daily. \\n# IRON DEFICIENCY ANEMIA. He was continued on home ferrous \\nsulfate 325 mg daily.\\n# GERD. He was continued on home pantoprazole 40 mg q24h. \\n\\nTRANSITIONAL ISSUES:\\n- Given DES placed ___, patient should continue Plavix for \\nat least ___ year but likely lifelong given significant \\nmultivessel CAD and PVD\\n- Patient placed on long abx course for cellulitis with \\ncephalexin and should continue for 1 week after discharge \\n(started ___. \\n- home metoprolol tartrate 25mg was uptitrated to metoprolol \\ntartrate 50mg TID. ___ need to consider long acting metoprolol \\nsuccinate as HR and BP allows.\\n- Held home gemfibrozil during hospital course and discharge due \\nto interaction with atorvastatin 80 mg qHS.\\n- Please discuss cardiac clearance at upcoming cardiology \\nappointment so that patient can resume home ___\\n \\nMedications on Admission:\\nThe Preadmission Medication list is accurate and complete.\\n1. Ascorbic Acid ___ mg PO BID \\n2. Atorvastatin 80 mg PO QPM \\n3. Calcium Carbonate 500 mg PO BID \\n4. Clopidogrel 75 mg PO DAILY \\n5. Ferrous Sulfate 325 mg PO DAILY \\n6. GlipiZIDE 10 mg PO DAILY \\n7. Gemfibrozil 600 mg PO BID \\n8. Multivitamins 1 TAB PO DAILY \\n9. Senna 8.6 mg PO BID:PRN constipation \\n10. Sertraline 100 mg PO DAILY \\n11. Lisinopril 5 mg PO DAILY \\n12. LORazepam 0.5 mg PO Q12H:PRN anxiety \\n13. Zinc Sulfate 220 mg PO DAILY \\n14. MetFORMIN XR (Glucophage XR) 1000 mg PO BID \\n15. Vitamin D2 (ergocalciferol (vitamin D2)) 50,000 unit oral \\n1X/WEEK \\n16. Pantoprazole 40 mg PO Q24H \\n17. Polyethylene Glycol 17 g PO DAILY:PRN Constipation  \\n18. Sarna Lotion 1 Appl TP BID:PRN pruritis over back  \\n19. Gabapentin 300 mg PO TID \\n20. Docusate Sodium 100 mg PO BID \\n21. Aspirin 81 mg PO DAILY \\n22. OxyCODONE (Immediate Release) 5 mg PO BID:PRN Pain - \\nModerate \\n  Reason for PRN duplicate override: changing frequency of drug\\n23. Metoprolol Tartrate 25 mg PO DAILY \\n24. Nitroglycerin SL 0.3 mg SL Q5MIN:PRN chest pain \\n\\n \\nDischarge Medications:\\n1.  Cephalexin 500 mg PO Q6H \\nRX *cephalexin 500 mg 1 capsule(s) by mouth every six (6) hours \\nDisp #*28 Capsule Refills:*0 \\n2.  Metoprolol Tartrate 50 mg PO TID \\nRX *metoprolol tartrate 50 mg 1 tablet(s) by mouth three times a \\nday Disp #*28 Tablet Refills:*0 \\n3.  Ascorbic Acid ___ mg PO BID  \\n4.  Aspirin 81 mg PO DAILY  \\n5.  Atorvastatin 80 mg PO QPM  \\n6.  Calcium Carbonate 500 mg PO BID  \\n7.  Clopidogrel 75 mg PO DAILY  \\n8.  Docusate Sodium 100 mg PO BID  \\n9.  Ferrous Sulfate 325 mg PO DAILY  \\n10.  Gabapentin 300 mg PO TID  \\n11.  GlipiZIDE 10 mg PO DAILY  \\n12.  Lisinopril 5 mg PO DAILY  \\n13.  LORazepam 0.5 mg PO Q12H:PRN anxiety  \\n14.  MetFORMIN XR (Glucophage XR) 1000 mg PO BID  \\n15.  Multivitamins 1 TAB PO DAILY  \\n16.  Nitroglycerin SL 0.3 mg SL Q5MIN:PRN chest pain  \\n17.  OxyCODONE (Immediate Release) 5 mg PO BID:PRN Pain - \\nModerate \\n  Reason for PRN duplicate override: changing frequency of drug \\n18.  Pantoprazole 40 mg PO Q24H  \\n19.  Polyethylene Glycol 17 g PO DAILY:PRN Constipation   \\n20.  Sarna Lotion 1 Appl TP BID:PRN pruritis over back   \\n21.  Senna 8.6 mg PO BID:PRN constipation  \\n22.  Sertraline 100 mg PO DAILY  \\n23.  Vitamin D2 (ergocalciferol (vitamin D2)) 50,000 unit oral \\n1X/WEEK  \\n24.  Zinc Sulfate 220 mg PO DAILY  \\n25. HELD- Gemfibrozil 600 mg PO BID  This medication was held. \\nDo not restart Gemfibrozil until told to do so by your doctor\\n\\n \\nDischarge Disposition:\\nHome\\n \\nDischarge Diagnosis:\\nPrimary:\\nNon-ST elevation myocardial infarction requiring stent placement\\nSevere sepsis secondary to cellulitis\\n\\nSecondary:\\nCoronary artery disease\\nPeripheral vascular disease\\nDiabetes mellitus\\nHypertension\\nHyperlipidemia\\nChronic pain\\n\\n \\nDischarge Condition:\\nMental Status: Clear and coherent.\\nLevel of Consciousness: Alert and interactive.\\nActivity Status: Ambulatory - Independent.\\n\\n \\nDischarge Instructions:\\nDear Mr. ___,\\n\\nYou were seen at ___ for fevers \\nand for chest pain. Your fevers were ultimately felt to be due \\nto an infection of your skin/fat tissue (called \"cellulitis\"). \\nYou were initially treated with broad IV antibiotics but these \\nwere adjusted to oral antibiotics with the input of infectious \\ndisease. You will continue these antibiotics (cephalexin) for 7 \\ndays after you are discharged (end ___. \\n\\nFor your chest pain, you underwent a cardiac catheterization \\nearly in your admission to determine if there was a blockage in \\nthe arteries to your heart.\\n\\nWhat should you do when you leave the hospital?\\n- Please follow up with the appointments we have arranged.\\n- Please continue cephalexin (an antibiotic) until ___.\\n- Please discontinue your gemfibrozil due to the \\ndrug-interaction with atorvastatin. \\n- There were no other major medication changes. Please continue \\ntaking your Plavix.\\n\\nIt was a pleasure taking care of you at ___.\\n\\nSincerely, \\nYour ___ care team\\n \\nFollowup Instructions:\\n___\\n</td>\n      <td>0</td>\n    </tr>\n    <tr>\n      <th>97</th>\n      <td>18017363</td>\n      <td>28138354</td>\n      <td>37413388</td>\n      <td>225798</td>\n      <td>225893</td>\n      <td>2117-04-05 18:23:00</td>\n      <td>1</td>\n      <td>\\nName:  ___                   Unit No:   ___\\n \\nAdmission Date:  ___              Discharge Date:   ___\\n \\nDate of Birth:  ___             Sex:   F\\n \\nService: SURGERY\\n \\nAllergies: \\nPatient recorded as having No Known Allergies to Drugs\\n \\nAttending: ___.\\n \\nChief Complaint:\\n- colon cancer\\n \\nMajor Surgical or Invasive Procedure:\\n- exploratory laparotomy\\n- ileocecectomy\\n\\n \\nHistory of Present Illness:\\nOn admission:\\n___ yo female with history of iron deficiency anemia who was \\nevaluated by her primary care physician and found to have colon \\ncancer on colonoscopy. She now presents for ileocecectomy.  \\n \\nPast Medical History:\\n- paroxysmal atrial fibrillation\\n- hypertension\\n- hyperlipidemia\\n- arthritis\\n- vertigo\\n- spinal stenosis\\n- diabetes mellitus, type II\\n- anemia\\n.\\n- hysterectomy\\n- breast reduction\\n- repair for pelvic organ prolapse\\n- right rotator cuff repair\\n \\nSocial History:\\n___\\nFamily History:\\n- non-contributory\\n \\nPhysical Exam:\\nDay of Discharge:\\nVitals -  T:98.0  BP:141/60  HR:74  RR:16  O2sat:98% RA\\nGen: NAD, A&amp;O x 3\\nCV: irregular, normal rate, no M/R/G\\nResp: CTAB, no respiratory distress\\nAbd: soft, not distended, no TTP, no rebound/guarding\\nIncision: C/D/I, no erythema or induration\\nExt: no C/C/E\\n \\nPertinent Results:\\n___ WBC-7.1 Hgb-9.5 Hct-29.6 Plt ___\\n___ WBC-11.2 Hgb-10.0 Hct-32.5 Plt ___\\n.\\n___ ___ PTT-25.5 ___\\n___ ___ PTT-19.4 ___\\n.\\n___ Glucose-118 UreaN-17 Creat-0.8 Na-141 K-4.2 Cl-104 \\nHCO3-27 \\n___ Glucose-105 UreaN-19 Creat-0.8 Na-137 K-4.8 Cl-102 \\nHCO3-25 \\n___ Albumin-3.2 Calcium-8.5 Phos-2.2 Mg-2.0\\n___ Calcium-9.0 Phos-3.7 Mg-2.0\\n.\\n___ ALT-17 AST-26 LD(LDH)-212 AlkPhos-49 TotBili-0.7\\n.\\n___ CK(CPK)-215\\n.\\n___ TSH-1.2\\n.\\n___ Digoxin-2.5\\n.\\nRAPID PLASMA REAGIN TEST (Final ___: NONREACTIVE. \\n.\\nUCX negative x ___\\nMRSA negative\\nBCX negative\\n.\\n___: CTA - No PE\\n___: LENIs - no DVT\\n___: ECHO - LVEF &gt;55%, trace AR, mod MR\\n\\n      \\n\\n \\nBrief Hospital Course:\\n*)Colon Cancer\\nShe was taken to the operating room and underwent ileocecectomy; \\nplease see the operative report for full details. On POD#1 she \\ndeveloped intermittently low urine output and received \\nadditional IV fluids. Early in the morning on POD#2 she \\ndeveloped mild respiratory distress with a CXR consistent with \\nfluid overload. IV fluids were stopped and she was given Lasix \\nand nebulizer treatments, to which she responded. However, over \\nthe course of the day and into POD#3 she continued to have \\nissues with low urine output and respiratory distress, and was \\ntransferred to the MICU for closer monitoring.\\n.\\n*)MICU Course\\nMs. ___ was transferred to the medical ICU from the surgical \\nteam for hypoxia believed to be pulmonary edema.  On transfer \\nshe was fluid overloaded with evidence of pulmonary edema.  She \\nwas diuresed serially with lasix and her symptoms resolved.  She \\nwas transitioned from a high flow mask to decreasing oxygen \\nlevels, then finally to a nasal cannula. \\nHer ICU course was complicated by delirium on the night of \\nadmission that was controlled with IV haldol. In addition, while \\ndelerious she began to pass bright red bloody stools. Surgery \\nwas made aware and determined this to be consistent with her \\nsurgery. She was transfused one unit of pRBCs for a falling \\nhematocrit.  \\nThe patient's ICU course was prolonged by atrial fibrillation \\nwith a rapid rate that was difficult to control.  She was \\nstarted on metoprolol IV, trialed unsuccessfully on diltiazem \\nand amiodarone drips.  When her delirium resolved and she was \\nable to take PO medications, her home regimen with verapamil and \\nmetoprolol was adjusted with the assistance of cardiology to \\ncontrol her rate.\\n.\\n*)Post-operative Course (s/p MICU)\\nShe was transferred back to the floor and closely monitored, \\nwith no further episodes of respiratory distress. Her diet was \\nslowly advanced with the return of her bowel function, and on \\ndischarge she was tolerating a regular diet and her pain was \\nwell controlled on oral medications. \\n.\\n*)Atrial Fibrillation\\nHer heart rate was somewhat difficult to control initially, and \\nshe had some episodes of tachycardia after her return to the \\nfloor. Cardiology continued to follow her for the duration of \\nher hospital course. Medications were adjusted, with better \\ncontrol after the addition of digoxin. On discharge, her heart \\nrate was well controlled on digoxin and verapamil, and she was \\nto resume her home regimen of atenolol. Follow up with her \\nPCP/cardiologist was scheduled. Her Coumadin was held during her \\npost-operative recovery and was to be re-started on discharge. \\n \\nMedications on Admission:\\n- Tylenol\\n- warfarin (stopped ___\\n- vaginal cream\\n- simvastatin \\n- atenolol  \\n- verapamil \\n- alprazolam prn\\n- iron \\n- citracal\\n- MVI\\n- metformin \\n \\nDischarge Medications:\\n1. Atenolol 50 mg Tablet Sig: One (1) Tablet PO DAILY (Daily).  \\n2. Verapamil 120 mg Tablet Sig: One (1) Tablet PO Q12H (every 12 \\nhours).  \\n3. Percocet ___ mg Tablet Sig: ___ Tablets PO every six (6) \\nhours as needed for pain.\\nDisp:*40 Tablet(s)* Refills:*0*\\n4. Docusate Sodium 100 mg Capsule Sig: One (1) Capsule PO BID (2 \\ntimes a day) for 1 months: Take with pain meds.\\nDisp:*60 Capsule(s)* Refills:*0*\\n5. Metformin 500 mg Tablet Sig: One (1) Tablet PO BID (2 times a \\nday).  \\n6. Digoxin 250 mcg Tablet Sig: One (1) Tablet PO DAILY (Daily).\\nDisp:*30 Tablet(s)* Refills:*2*\\n7. Verapamil 120 mg Tablet Sig: One (1) Tablet PO Q12H (every 12 \\nhours).  \\n8. Atenolol 50 mg Tablet Sig: One (1) Tablet PO twice a day.  \\n9. Coumadin 5 mg Tablet Sig: One (1) Tablet PO once a day: \\nPlease take at 4pm.  \\n\\n \\nDischarge Disposition:\\nHome With Service\\n \\nFacility:\\n___ \\nhome\\n \\nDischarge Diagnosis:\\n- colon cancer\\n.\\n- paroxysmal atrial fibrillation\\n- hypertension\\n- arthritis\\n- hyperlipidemia\\n\\n \\nDischarge Condition:\\n- stable\\n- tolerating a regular diet\\n- pain controlled on oral medications\\n\\n \\nDischarge Instructions:\\nGeneral Instructions:\\nPlease call your doctor or return to the ER for any of the \\nfollowing:\\n* You experience new chest pain, pressure, squeezing or \\ntightness.\\n* New or worsening cough or wheezing.\\n* If you are vomiting and cannot keep in fluids or your \\nmedications.\\n* You are getting dehydrated due to continued vomiting, diarrhea \\nor other reasons. Signs of dehydration include dry mouth, rapid \\nheartbeat or feeling dizzy or faint when standing.\\n* You see blood or dark/black material when you vomit or have a \\nbowel movement.\\n* Your pain is not improving within ___ hours or not gone \\nwithin 24 hours. Call or return immediately if your pain is \\ngetting worse or is changing location or moving to your chest or \\nback.\\n*Avoid lifting objects &gt; 5lbs until your follow-up appointment \\nwith the surgeon.\\n*Avoid driving or operating heavy machinery while taking pain \\nmedications.\\n* You have shaking chills, or a fever greater than 101.5 (F) \\ndegrees or 38(C) degrees.\\n* Any serious change in your symptoms, or any new symptoms that \\nconcern you. \\n* Please resume all regular home medications and take any new \\nmeds \\nas ordered. \\n* Continue to ambulate several times per day.\\n.\\nIncision Care:\\n-Your steri-strips will fall off on their own. Please remove any \\nremaining strips ___ days after surgery.\\n-You may shower, and wash surgical incisions.\\n-Avoid swimming and baths until your follow-up appointment.\\n-Please call the doctor if you have increased pain, swelling, \\nredness, or drainage from the incision sites.\\n.\\nMedications: \\n1. Coumadin: please restart your home does of coumadin 5 mg \\ndaily.\\n-You need to have lab work done on ___ and have the \\nresults faxed to your cardiologist. \\n2. Digoxin 0.25 mg by mouth daily. Please hold for HR ___ \\n-You should take this medication once a day.\\n-A handout was provided regarding this medication. \\n\\n \\nFollowup Instructions:\\n___\\n</td>\n      <td>0</td>\n    </tr>\n    <tr>\n      <th>98</th>\n      <td>18455402</td>\n      <td>26039491</td>\n      <td>34320919</td>\n      <td>225798</td>\n      <td>225893</td>\n      <td>2193-08-17 10:06:00</td>\n      <td>8</td>\n      <td>\\nName:  ___                 Unit No:   ___\\n \\nAdmission Date:  ___              Discharge Date:   ___\\n \\nDate of Birth:  ___             Sex:   M\\n \\nService: CARDIOTHORACIC\\n \\nAllergies: \\nAmiodarone / Monosodium Glutamate\\n \\nAttending: ___.\\n \\nChief Complaint:\\nAsymptomatic ascending aortic aneurysm\\n \\nMajor Surgical or Invasive Procedure:\\n___ - Redo Sternotomy, Replacement of ascending aorta and \\ntotal arch. \\ntracheostomy ___\\ngastrojejunostomy ___\\n\\n \\nHistory of Present Illness:\\nThis ___ year old white male underwent repair of a Type A aortic \\ndissection and coronary artery bypass in ___. The aorta was \\nnoted to be dissected to both iliacs at that time and he \\nsubsequently had coil embolization of left\\ninternal iliac aneurysm ___. Recent CTA shows increase in \\nascending aortic diameter to 6.3 cm. He was referred for \\nsurgical evaluation.\\n\\n \\nPast Medical History:\\nPeripheral vascular disease\\nascending aortic aneurysm\\nType A aortic dissection\\nHypertension\\nCongestive heart failure\\nAtrial fibrillation s/p ablation ___\\nTachybrady syndrome s/p pacemaker\\nVentral Hernia\\nCholelithiasis\\nDiverticulosis\\nBenign Prostatic Hypertrophy\\nSpinal stenosis \\ns/p Replacement of Ascending aorta (26mm Gelweave \\ngraft)/resuspension of Aortic Valve /Coronary Artery Bypass \\nGraft x1 (SVG to ___\\ns/p Coil embolization of left internal iliac ___\\ns/p Tonsillectomy\\ns/p left trigger finger release\\nhyperlipidemia\\n \\nSocial History:\\n___\\nFamily History:\\nnoncontributory\\n \\nPhysical Exam:\\nAdmission:\\n\\nPulse:  Resp:  O2 sat: \\nB/P  Right: 132/76  Left: 128/80\\nHeight: ___    Weight: 203 lbs\\n\\nGeneral:\\nSkin: Dry [X] intact [X]\\nHEENT: PERRLA [X] EOMI [X]\\nNeck:  Supple [X] Full ROM [X]\\nChest: Lungs clear bilaterally [X]\\nHeart: RRR [X]  Irregular []  Murmur\\nAbdomen: Soft [X] non-distended [X] non-tender [X] bowel sounds \\n+\\n[X] ventral hernia\\nExtremities: Warm [X], well-perfused [X]  Edema Varicosities:\\nNone [X] left thigh saph. vein harvest site incision well-healed\\nNeuro: Grossly intact [X],nonfocal exam, MAE ___ strengths\\nPulses:\\nFemoral      Right/Left: 2+\\nDP           Right/Left: 2+\\n___           Right/Left: 2+\\nRadial       Right/Left: 2+\\n\\nCarotid Bruit    Right/Left: none\\n\\n \\nPertinent Results:\\n___ Head CT\\nThere is no evidence of hemorrhage, edema, mass or mass effect.  \\n\\nThere is no evidence of acute vascular territorial infarct. The \\npreviously \\nseen hypoattenuating focus within the left frontal lobe is again \\ndemonstrated, most likely representing partial volume-averaging \\neffect.The ventricles and sulci are normal in caliber and \\nconfiguration, unchanged in size in comparison to prior studies. \\nNo fracture identified. \\n  \\n___ Chest CT without contrast\\nThere is complete resolution of the pre-existing left \\npneumothorax with \\ncomplete reexpansion of the left lung. \\nIn the mediastinum, the aortic graft continues to be barely \\nvisualized. The parts of the superior pericardial recess that \\nbulge into the aortopulmonary window are of unchanged \\n___. Also unchanged are the diffuse calcifications of the \\naortic valve and the coronary arteries. The pre-described \\nretrosternal fluid collection is of unchanged apical basal \\nextent, however, its overall thickness has minimally decreased. \\nIn unchanged manner, the fluid collection does not contain gas \\nand shows as far as an assessment without contrast is possible. \\nUnchanged moderate cardiomegaly. Minimal increase of the \\npre-existing bilateral pleural effusions. Newly occurred \\nbilateral dependent areas of atelectasis with air bronchograms. \\nThe symmetry and the bilateral nature of the changes favor \\natelectasis over pneumonia. Newly appeared are minimal \\nuncharacteristic peribronchial nodular opacities in the right \\nlower lung that are too small to represent substantial \\ninfectious changes that could cause the clinical symptoms of the \\npatient. Unchanged suspicion of bronchomalacia. No atrial septal \\ndefect is seen by 2D or color Doppler. Overall left ventricular \\nsystolic function is normal (LVEF&gt;55%). Right ventricular \\nchamber size and free wall motion are normal. A mobile density \\nis seen in the descending aorta consistent with an intimal \\nflap/aortic dissection with likely thrombus. The aortic valve \\nleaflets (3) are mildly thickened. No masses or vegetations are \\nseen on the aortic valve. Mild (1+) aortic regurgitation is \\nseen. The mitral valve leaflets are mildly thickened. No mass or \\nvegetation is seen on the mitral valve. Trivial mitral \\nregurgitation is seen. No masses or vegetations are seen on the \\npulmonic valve, but cannot be fully excluded due to suboptimal \\nimage quality. There is no pericardial effusion. \\n\\n___ Echo:\\nIMPRESSION: No evidence of endocarditis. Normal bi-ventricular \\nfunction. Mild aortic regurgitation. Extensive descending aortic \\ndissection with thrombus in the false lumen.   \\n\\nHematology \\nCOMPLETE BLOOD COUNT WBC RBC Hgb Hct MCV MCH MCHC RDW Plt Ct \\n___  6.0 3.34* 10.1* 31.2* 93 30.2 32.4 17.0* \\n224 \\nSource: Line-PICC \\nBASIC COAGULATION ___, PTT, PLT, INR) ___ PTT Plt Smr Plt Ct \\n___ \\n___          224   \\nSource: Line-PICC \\n___ 15.4* 26.8     1.3* \\nChemistry \\nRENAL &amp; GLUCOSE    Glucose UreaN Creat Na K Cl HCO3 AnGap \\n___  95    42*    1.1 145 4.2 109* 27 13 \\nSource: Line-PICC \\nENZYMES &amp; BILIRUBIN ALT AST LD(LDH) CK(CPK) AlkPhos Amylase \\nTotBili DirBili \\n___    65* 44* 265*   88 18 0.6   \\n \\nOTHER ENZYMES &amp; BILIRUBINS Lipase \\n___         179* \\n \\nCHEMISTRY TotProt Albumin Globuln Calcium Phos Mg UricAcd Iron \\n___                   8.7 3.5 2.3     \\n\\nNEUROPSYCHIATRIC     Phenoba Phenyto Valproa Phenyfr %Phenyf \\n___    12.2         \\n   \\n___  ART 37.1  CPAP  40   86 33* 7.49* 26 \\n \\n \\n  \\n\\n \\nBrief Hospital Course:\\nMr. ___ was admitted to the ___ on ___ for surgical \\nmanagement of his ascending aortic aneurysm. He was taken to the \\noperating room where he underwent a redo sternotomy with \\nreplacement of his ascending aorta and arch. Please see \\noperative note for details. Postoperatively he was taken to the \\nintensive care unit for monitoring. He remained intubated and \\nsedated following surgery. \\n\\nLeft shoulder and right thigh twitching was noted and a \\nneurology consult was obtained. A head CT was performed which \\nwas negative. Repeat scan 2 days later also negative. He \\ncontinued to have seizure activity and was started on dilantin, \\nKeppra, and ultimately phenobarbital over more than a week with \\ncontinued frequent seizures whenever Propofol was off. Propofol \\nwas turned off to continue to evaluate his neurological status \\nwith continued neurology evaluations and continuous EEG \\nmonitoring. He had persistent fevers with no source for many \\ndays.  Eventually he developed a LLL pneumonia with enterococcus \\nin his sputum and positive blood cultures. Ampicillin and \\ngentamicin were started and he defervesced.\\n\\nHe eventually was off Propofol without seizures (although still \\nunresponsive) and the phenobarbital was weaned by levels.  He re \\nspiked fevers and cultures of sputum on ___ grew Serratia for \\nwhich a two week course of Cipro and Vancomycin were given. \\nLines were changed multiple times during these times. Of note, \\nthe patient has a right IJ thrombosis discovered during a line \\nplacement. \\n\\nNeurology continued to follow the patient with multiple EEG's \\nperformed to evaluate seizure activity.  He was weaned off of \\ndilantin, briefly taken off phenobarbital and then restarted on \\na standing dose. He was weaned down on Keppra with improving \\nmental status but EEG performed on ___ showed increased \\nseizure activity.  His Keppra was increased to 750 mg nightly \\nand he was kept on his maintenance phenobarbital dose per \\nneurology recommendations. CT of the head on ___ showed \\nhypodensity of the right frontal lobe. Repeat head CT on ___ \\nshowed no acute process. The patient's mental status improved \\ngradually and he was following simple commands, answering \\nquestions and moving all extremities at the time of discharge.  \\nPer neurology, the patient is to maintain his standing doses of \\nphenobarbital and Keppra and follow up with neurology after \\ndischarge from rehab. Multiple discussions were had with his \\nwife and family throughout the course.\\n\\nThe patient developed atrial fibrillation during his hospital \\ncourse and was started on Lopressor for rate control. He was on \\nand off Neo-Synephrine intermittently.  He was anticoagulated \\nwith Coumadin for afib (which was briefly held due to \\nhematuria).  At the time of discharge, he had restarted Coumadin \\nand INR was slowly increasing.  He was no longer in atrial \\nfibrillation but being paced with his intrinsic permanent \\npacemaker at a rate in the 60's alternating with sinus rhythm in \\nthe 70's.  He was on a maintenance dose of beta blockers.\\n\\nThe patient was slowly weaned on the ventilator and on ___ he \\nunderwent a percutaneous tracheostomy at the bedside.  See \\noperative note for full details.  He was treated for a full two \\nweek course for enterococcus pneumonia.  He was thought to be \\ncolonized with serratia and required no further antibiotic \\ntreatment.  He did have a left sided chest tube placed for \\neffusion. CXR on ___ showed small left effusion, left \\nbasilar atelectasis.  He was tolerating CPAP with a pressure \\nsupport of 10, becoming tachypneic with lower pressure support \\ntrials.  CXR on ___ showed small left effusion and left \\nbasilar atelectasis. He was restarted on a 7 day course of Lasix \\nfor the effusion.\\n\\nMr. ___ underwent a minilaparotomy and transgastric jejunal \\ntube placement on ___.  See operative report for full \\ndetails.  He was tolerating tube feeds at goal.  Stools were \\nbeing guiaced and were negative.\\n\\nThe patient had hypernatremia and increased BUN throughout his \\nhospital course.  He was thought to be intravascularly dry and \\nLasix was discontinued.  He was given free water and sodium \\nreturned to a normal range.  Creatinine peaked at 1.9 but was \\nback to baseline (1.1) at the time of discharge.  He did have \\nhematuria after foley trauma while on Coumadin.  He was seen by \\nurology and started on continuous bladder irrigation.  His urine \\nbecame clear and foley was pulled ___. He failed to void and \\nfoley was reinserted later that night with small old blood clots \\nevacuated.  He was able to be easily manually irrigated and \\nurine was clear at discharge.  Per urology recommendations, the \\npatient was started on Flomax and he is to have a repeat voiding \\ntrial in 2 weeks.  No further urology follow up is needed unless \\nhematuria recurs.\\n\\nInterventional pulmonology was consulted for a question of \\nbronchomalacia after a bronchoscopy. They determined he needed \\nno intervention at this time.\\n\\nMr ___ received multiple units of red blood cells throughout \\nhis hospital course.  He had iron studies done which showed \\nnormal iron levels, low TIBC and low transferrin levels.  It was \\ndetermined that the patient has anemia of chronic disease.  He \\nwas restarted on Coumadin on ___ and had a goal INR ___ for \\natrial fibrillation and right internal jugular thrombosis.  \\nLength of anticoagulation to be determined by the patient's \\ncardiologist and neurologist.\\n\\nAt the time of discharge, Mr. ___ was afebrile, white blood \\ncount was normal, he was being Hoyer lifted into a chair and \\ntolerating the settings of CPAP 40% PEEP 5 PS 12.  His mental \\nstatus continued to improve. It was felt that he was safe for \\ntransfer to a rehabilitation facility at this time. \\n\\n \\nMedications on Admission:\\nNorvasc 5', Lipitor 20', Lasix 20', Lopressor 150\", KCl 20', \\nFlomax 0.4', ASA 81', Colace 200', MVI, Multag 400', Lorazepam \\n0.5', Naproxen prn \\n \\nDischarge Medications:\\n1. Acetaminophen 650 mg Tablet Sig: ___ Tablets PO Q4H (every 4 \\nhours) as needed for temperature &gt;38.0.  \\n2. Aspirin 81 mg Tablet, Chewable Sig: One (1) Tablet, Chewable \\nPO DAILY (Daily).  \\n3. Docusate Sodium 50 mg/5 mL Liquid Sig: 10 ml  PO BID (2 times \\na day).  \\n4. Magnesium Hydroxide 400 mg/5 mL Suspension Sig: Thirty (30) \\nML PO DAILY (Daily) as needed for constipation.  \\n5. Dronedarone  Oral\\n6. Ranitidine HCl 15 mg/mL Syrup Sig: 10 ml  PO DAILY (Daily).  \\n7. Bisacodyl 10 mg Suppository Sig: One (1) Suppository Rectal \\nDAILY (Daily) as needed for constipation.  \\n8. Polyvinyl Alcohol-Povidone 1.4-0.6 % Dropperette Sig: ___ \\nDrops Ophthalmic Q6H (every 6 hours).  \\n9. Ipratropium-Albuterol ___ mcg/Actuation Aerosol Sig: ___ \\nPuffs Inhalation Q6H (every 6 hours).  \\n10. Simvastatin 10 mg Tablet Sig: Two (2) Tablet PO DAILY \\n(Daily).  \\n11. Phenobarbital 20 mg/5 mL Elixir Sig: 7.5 ml  PO TID (3 times \\na day).  \\n12. Metoprolol Tartrate 25 mg Tablet Sig: 0.5 Tablet PO TID (3 \\ntimes a day).  \\n13. Senna 8.6 mg Tablet Sig: One (1) Tablet PO BID (2 times a \\nday).  \\n14. Nystatin 100,000 unit/mL Suspension Sig: Five (5) ML PO QID \\n(4 times a day).  \\n15. Levetiracetam 100 mg/mL Solution Sig: Five (5) ML PO QAM \\n(once a day (in the morning)).  \\n16. Levetiracetam 100 mg/mL Solution Sig: 7.5 ML PO QPM (once a \\nday (in the evening)).  \\n17. Tamsulosin 0.4 mg Capsule, Sust. Release 24 hr Sig: One (1) \\nCapsule, Sust. Release 24 hr PO HS (at bedtime).  \\n18. Warfarin 2.5 mg Tablet Sig: One (1) Tablet PO ONCE (Once): \\nDose for Goal INR ___ ___.  \\n19. Sodium Chloride 0.9%  Flush 10 mL IV PRN line flush \\nTemporary Central Access-ICU: Flush with 10mL Normal Saline \\ndaily and PRN. \\n20. Potassium Chloride 10 mEq Capsule, Sustained Release Sig: \\nTwo (2) Capsule, Sustained Release PO twice a day for 7 days.  \\n21. Lasix 40 mg Tablet Sig: One (1) Tablet PO twice a day for 7 \\ndays.  \\n\\n \\nDischarge Disposition:\\nExtended Care\\n \\nFacility:\\n___\\n \\nDischarge Diagnosis:\\nDilated ascending aorta\\ns/p replacement of ascending aorta and arch\\npostoperative seizures\\nPeripheral vascular disease\\ns/p Type A aortic dissection\\nHypertension\\nCongestive heart failure\\nAtrial fibrillation s/p ablation ___\\nTachybrady syndrome s/p pacemaker\\nVentral Hernia\\nCholelithiasis\\nDiverticulosis\\nBenign Prostatic Hypertrophy\\nSpinal stenosis \\ns/p Replacement of Ascending aorta (26mm Gelweave \\ngraft)/resuspension\\nof Aortic Valve /Coronary Artery Bypass Graft x1 (SVG to PDA)\\n___\\ns/p Coil embolization of left internal iliac ___\\ns/p Tonsillectomy\\ns/p left trigger finger release\\ns/p tracheostomy\\ns/p gastrojejunostomy\\n\\n \\nDischarge Condition:\\ngood\\n\\n \\nDischarge Instructions:\\n1) Monitor wounds for signs of infection. These include redness, \\ndrainage or increased pain. Please contact you surgeon at ___ with all wound issues. \\n2) Report any fever greater then 100.5\\n3) Flush double lumen PICC with 10 cc NS q shift\\n3) Report any weight gain of 2 pounds in 24 hours or 5 pounds in \\n1 week.\\n4) Wash incision daily with soap and water. No lotions, creams \\nor powders to incision until it has healed (6 weeks).\\n5) No lifting greater then 10 pounds for 10 weeks from date of \\nsurgery.\\n6) No driving for 1 month.\\n7) Check lytes, BUN/Cre, Hct, coags daily until stable - Goal \\nINR ___ Call with any questions or concerns.\\n \\nFollowup Instructions:\\n___\\n</td>\n      <td>0</td>\n    </tr>\n    <tr>\n      <th>99</th>\n      <td>18761260</td>\n      <td>26980143</td>\n      <td>31681715</td>\n      <td>225798</td>\n      <td>225893</td>\n      <td>2144-10-10 08:00:00</td>\n      <td>19</td>\n      <td>\\nName:  ___                    Unit No:   ___\\n \\nAdmission Date:  ___              Discharge Date:   ___\\n \\nDate of Birth:  ___             Sex:   M\\n \\nService: SURGERY\\n \\nAllergies: \\nNo Known Allergies / Adverse Drug Reactions\\n \\nAttending: ___.\\n \\nChief Complaint:\\nMVC, b/l ankle fractures\\n \\nMajor Surgical or Invasive Procedure:\\n___ - ex-fix L ankle; closure scalp lac\\n___ - ORIF R ankle, washout L ankle\\n___ - Trach\\n___ - PEG\\n___ - Debridement L foot/heel. Longer trach \\n \\nHistory of Present Illness:\\n___ s/p MVC vs guard rail as unrestrained driver, swerved with \\nsignificant intrusion and prolonged extrication of 45-minutes. \\nPatient was GCS at scene with significant bleeding from scalp \\nnoted and large blood loss at scene. Patient was brought to \\n___ by medflight with ancef given en route, hemodynamically \\nstable. GCS was 15 on arrival to ED. Surveys and radiographic \\nworkup revealed a right closed ankle fracture, left open ankle \\nfracture\\nwith significant deformity, and large scalp laceration actively \\nbleeding. Patient's left foot was mildly cooler than the right \\nwith only a DP doppler signal (baseline exam unknown).\\n \\nPast Medical History:\\nPMH: HTN, HL, ? OSA\\nPSH: Umbilical hernia repair\\n\\n \\nSocial History:\\n___\\nFamily History:\\nNC\\n \\nPhysical Exam:\\nAdmission Physical:\\nT 99.1  P 98  BP 118/44  RR 18  O2 94% 4L\\nanxious, in pain, AOx3\\nairway intact, breathing stable, HD stable\\nsuperficial scalp laceration\\ntrachea midline without crepitus\\nchest wall stable, no crepitus\\nabdomen soft/nontender/nondistended\\npelvis stable\\nno gross deformity upper extremities\\n\\nSevere deformity of left ankle, with foot angled ~90 degrees\\nmedially with respect to leg. Extensive open area on lateral\\naspect with exposed muscles and tendons. DP by Doppler. Unable \\nto\\nassess ___ due to deformity.  Deformity of right ankle, closed. \\nDP\\nand ___ by Doppler.  Remainder of extremities nontender and with\\nfull ROM.\\n\\nDischarge Physical:\\nInteractive, usually following commands\\ntracheostomy in place, on trach mask\\nlungs CTAB\\nRRR, no r/m/g\\nabd \\n \\nPertinent Results:\\nImaging:\\n-___ Trauma CXR and Pelvic XR: No abn  \\n-___ Bilateral ankle fx: Dislocation of the right ankle with \\nlateral displacement of the talus in relation to the tibia. \\nThere is a distal fibular fracture with a distal fragment \\ndisplaced posteriorly. There is a talonavicular dislocation and \\nmild widening at the calcaneocuboid joint. There is also likely \\na medial malleolus fracture. There is a displaced proximal fifth \\nmetatarsal fracture. The left ankle is dislocated with the talus \\ndisplaced medially compared to the tibia. There is also \\ndisplaced fracture of the medial malleolus. There is likely \\nless-well visualized fracture of the lateral malleolus as well \\nas the distal fibula. There are proximal and distal fifth \\nmetatarsal fractures.  \\n-___ CT Head: Small right vertex subgaleal hematoma  \\n-___ CT Cspine: No fracture  \\n-___ CTA chest/abd/pelvis: no PE, no obvious abnormality  \\n-___ TTE: unremarkable, LVEF&gt;55%, RV wnl  \\n-___ CXR: Lsided opacities  \\n-___ CT Head: No acute intracranial process  \\n-___ MRI/MRA: 1. Few small white matter infarcts seen \\nbilaterally, suggestive of embolic disease. No evidence of \\nanoxic brain injury. 2. Patent carotid and vertebral arteries.  \\n-___. Multiple peripheral pulmonary opacities could \\nrepresent septic emboli. Aggressive search for a source of \\ninfection is recommended. 2. Increased bibasilar consolidation \\nof the dependent lungs, most likely representing atelectasis, \\nthough an infectious process is possible. 3. New small bilateral \\npleural effusions.  \\n-___ TEE: No valvular vegetation, abscess, or intracardiac \\nmass/thrombus visualized  \\n-___ ___: negative for DVT  \\n-___ Bilateral ankle xrays: Hardware well aligned, no \\ndislocations  \\n-___ Overall appearance is similar. Possible very slight \\ninterval improvement in the CHF findings.  \\n\\nAdmission Labs - \\n___ 12:55PM   WBC-23.0* RBC-3.91* HGB-11.9* HCT-36.3* \\nMCV-93 MCH-30.5 MCHC-32.9 RDW-13.0\\n___ 06:00PM   GLUCOSE-192* UREA N-27* CREAT-1.5* SODIUM-143 \\nPOTASSIUM-4.2 CHLORIDE-109* TOTAL CO2-20* ANION GAP-18\\n___ 12:55PM   LIPASE-___ M s/p MCV with bilateral ankle fractures admitted to the TICU \\nintubated. In brief, he made steady improvements over his 24 day \\nstay and was discharged to a ventilator rehabilitation on \\n___. Below is his hospital course through his stay in the \\nTrauma ICU:\\n\\nHe was taken emergently to the OR for wash out and splinting of \\nhis fractures and repair of his scalp laceration. Intraop, he \\nrequired phenylephrine with 3L crystalloid and 3U PRBC given to \\nwean off. In PACU, he was noted to be very agitated with mild \\nhypotension. On arrival to ___, he was hemodynamically stable \\nbut confused. Subsequently, had hypoxic event leading to PEA s/p \\nCPR and epi x 2, difficult intubation. \\n\\nN:  Following intubation the pt was kept sedated on fentanyl and \\npropofol. He was administered PRN haldol due to agitation. It \\nwas difficult to establish an adequate neuro exam because of \\nsedation and agitation and on HD 4 a continuous EEG was ordered. \\nThe EEG was significant for periodic epileptiform discharges, \\nconcernign for seizure activity. A neurology consult was \\nobtained and the patient was started on keppra. An MRI was \\nobtained which was significant for a few small white matter \\ninfarcts seen bilaterally, suggestive of embolic disease. There \\nwas no evidence of anoxic brain injury and the carotid and \\nvertebral arteries were patent. Final read on EEG was \\nencephalopathy with no focal or epileptiform features. It was \\nfelt that the Keppra was adequately treating previously recorded \\nepileptiform activity and it was recommended he stay on Keppra \\nuntil follow-up in one month with Dr ___. He continued to \\nbe agitated and over the course of the remaider of his ICU stay \\nhe was tried on various regimens of haldol, ativan, precedex, \\nativan, clonidine, and seroquel for his agitation. Ultimately \\nthe patient's mental improved by the end of his first week and \\nhe was kept on a stable dose of seroquel and clonidine for \\nintermitent agitation. He continued to improve and by discharge \\nwas interactive, following commands though still mildly \\nagitated. He requires Trazodone to sleep some nights. \\n\\nCV: He had a brief PEA arrest post-op. Due to continued fevers a \\nCTA Chest was done on HD 9. The read was concerning for septic \\nemboli. A formal TEE was obtained and was significant for no \\nvalvular vegetation, abscess, or intracardiac mass/thrombus \\nvisualized. He otherwise had no cardiovascular issues.\\n\\nPulm: Following PEA arrest immediately post op the patient was \\nintubated. The patient was initially weaned to CPAP but due to \\nrespiratory distress he was placed on APRV and CMV through \\nvarious portions of his initial hospitalization. He was placed \\non a prolonged course of vancomycin and inhaled tobramycin. \\nGiven his inability to wean from the vent he had a tracheostomy \\nperformed on ___. Following the procedure he was slowly \\nweaned to CPAP and then to trach color which he was tolerating \\nwell at the time of discharge. \\n\\nGI: On HD 5 tube feeds were initiated through an OGT. The \\npatient was able to tolerate full feeds and they were only \\ndiscontinued prior to procedures. On ___ the patient \\nunderwent a percutaneous gastrostomy tube placement as a more \\npermanent solution to long term feeding. He was able to tolerate \\nfull feeds via the PEG through the rest of his hopitalization. \\nHe will be discharged on Isosource 1.5 Cal Full strength; \\nAdditives: Beneprotein, 35 gm/day, Goal rate: 45 ml/hr.\\n\\nGU: No active issues. His urine output was adequate throughout \\nhospitalization. He was on a Lasix drip HD ___ as he mobilized \\nthe fluid from his admission resuscitation. He then was given \\nintermittent lasix for several days and transitioned to \\nlisinopril. His Foley catheter was removed ___.  \\n\\nHeme: He had a persistent mild anemia. This was believed to be \\ndue to anemia of chronic disease. He was transfused a total of \\n14 units PRBC: 11 units ___, and a subsequent 3 \\nunits over the following 3 weeks. He was started on iron \\nsupplementation.\\n\\nID: He was treated for two weeks with broad spectrum antibiotics \\nas he was spiking fevers and had a rising WBC. His BAL from \\n___ showed \\nESCHERICHIA COLI.    10,000-100,000 ORGANISMS/ML.\\nMORGANELLA ___. 10,000-100,000 ORGANISMS/ML.\\nIt was unclear if he was spiking fevers from this pneumonia or \\nfrom his left leg, which had shown signs of worsening necrosis. \\nFollowing debridement of his left leg on ___, his fevers \\nsubsided and he was narrowed to Ancef for coverage. \\n\\nExtrem:\\nHe presented with bilateral lower extremity fractures. His right \\nlower extremity underwent ORIF on admission and has done well. \\nHis left leg had significantly more soft tissue damage and a \\nmore impressive fracture pattern. He was placed in an an \\nexternal fixator on that side and underwent several debridements \\nduring his stay. His final debridement was ___ by Dr ___ at \\nwhich time he was left with an exposed gastroc tendon and \\ncalcaneous. The prospect of a BKA was discussed with his family, \\nand the decision was made to continue dressing changes and have \\nhim see Dr ___ in follow-up for consideration of flap coverage. \\nPer orthopedic surgery, he is to be non-weight bearing on both \\nlower extremities.  \\n \\nMedications on Admission:\\nLisinopril 40', Simvastatin 20' HS, Metoprolol tartrate 150'', \\nDiltiazem ER 240\\n\\n \\nDischarge Medications:\\n1. bisacodyl 5 mg Tablet, Delayed Release (E.C.) Sig: Two (2) \\nTablet, Delayed Release (E.C.) PO DAILY (Daily) as needed for \\nConstipation.  \\n2. senna 8.8 mg/5 mL Syrup Sig: One (1) Tablet PO BID (2 times a \\nday).  \\n3. insulin regular human 100 unit/mL Solution Sig: One (1)  \\nInjection ASDIR (AS DIRECTED).  \\n4. heparin (porcine) 5,000 unit/mL Solution Sig: One (1)  \\nInjection TID (3 times a day).  \\n5. albuterol sulfate 90 mcg/actuation HFA Aerosol Inhaler Sig: \\nSix (6) Puff Inhalation Q4H (every 4 hours) as needed for \\nwheezing.  \\n6. ipratropium bromide 17 mcg/actuation HFA Aerosol Inhaler Sig: \\nSix (6) Puff Inhalation QID (4 times a day).  \\n7. acetaminophen 650 mg/20.3 mL Solution Sig: One (1)  PO Q6H \\n(every 6 hours) as needed for pain/fever.  \\n8. miconazole nitrate 2 % Powder Sig: One (1) Appl Topical BID \\n(2 times a day) as needed for rash.  \\n9. docusate sodium 50 mg/5 mL Liquid Sig: One (1)  PO BID (2 \\ntimes a day).  \\n10. camphor-menthol 0.5-0.5 % Lotion Sig: One (1) Appl Topical \\nQID (4 times a day) as needed for itching.  \\n11. diltiazem HCl 60 mg Tablet Sig: One (1) Tablet PO QID (4 \\ntimes a day).  \\n12. levetiracetam 100 mg/mL Solution Sig: One (1)  PO BID (2 \\ntimes a day): Continue until follow-up with neurology.  \\n13. metoprolol tartrate 50 mg Tablet Sig: Three (3) Tablet PO \\nTID (3 times a day).  \\n14. trazodone 50 mg Tablet Sig: 0.5 Tablet PO HS (at bedtime) as \\nneeded for insomnia .  \\n15. lisinopril 20 mg Tablet Sig: One (1) Tablet PO DAILY \\n(Daily).  \\n16. clonidine 0.2 mg Tablet Sig: One (1) Tablet PO TID (3 times \\na day).  \\n17. ferrous sulfate 300 mg (60 mg iron)/5 mL Liquid Sig: One (1) \\n PO DAILY (Daily).  \\n18. cefazolin 10 gram Recon Soln Sig: One (1) Recon Soln \\nInjection Q8H (every 8 hours).  \\n\\n \\nDischarge Disposition:\\nExtended Care\\n \\nFacility:\\n___\\n \\nDischarge Diagnosis:\\nRespiratory failure\\nTraumatic brain injury with delerium\\nBilateral lower extremity fractures\\n\\n \\nDischarge Condition:\\nMental Status: Confused - sometimes.\\nLevel of Consciousness: Alert and interactive.\\nActivity Status: Out of bed with assistance. NWB bilateral lower \\nextremities.\\n\\n \\nDischarge Instructions:\\nPlease call your doctor or nurse practitioner if you experience \\nthe following:\\n*New chest pain, pressure, squeezing or tightness.\\n*New or worsening cough, shortness of breath, or wheeze.\\n*Vomiting and cannot keep down fluids or your medications.\\n*Dehydration due to continued vomiting, diarrhea, or other \\nreasons. Signs of dehydration include dry mouth, rapid \\nheartbeat, or feeling dizzy or faint when standing.\\n*Blood or dark/black material when you vomit or have a bowel \\nmovement.\\n*Burning when you urinate, blood in your urine, or urinary \\ndischarge.\\n*Your pain doesn't improve in ___ hours or is not gone within \\n24 hours. Call or return immediately if your pain becomes \\nsevere, changes location or moves to your chest or back.\\n*Shaking chills or fever greater than 101.5F or 38C.\\n*An acute change in your symptoms, or new symptoms that concern \\nyou.\\n*Increased pain, swelling, redness, or drainage from any \\nincisions you may have.\\n*Any of the warning signs listed below.\\n\\n \\nFollowup Instructions:\\n___\\n</td>\n      <td>0</td>\n    </tr>\n  </tbody>\n</table>\n<p>100 rows × 9 columns</p>\n</div>"
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from detectdd.serializer import Serializer\n",
    "from detectdd.auth_bigquery import BigQueryClient\n",
    "serializer = Serializer()\n",
    "total_drug_interactions = serializer.read_total_drug_interactions()\n",
    "#dropping duplicate rows based on hadm_id and subject_id\n",
    "df_unique_rows = total_drug_interactions.drop_duplicates(subset=['hadm_id', 'subject_id'])\n",
    "\n",
    "#reaching the clinical notes, it's one clinical note per hadm_id\n",
    "clinical_notes_path = '../data/nlp_model_training/clinical-notes-filtered.csv'\n",
    "discharge_df = pd.read_csv(clinical_notes_path)\n",
    "\n",
    "clinical_notes_df = discharge_df[['subject_id', 'hadm_id', 'text']]\n",
    "\n",
    "cohort_for_nlp = pd.merge(df_unique_rows, clinical_notes_df, on=['subject_id', 'hadm_id'], how='inner') #does this cohort have the same number of rows as df_unique_rows?\n",
    "\n",
    "cohort_with_nlp = cohort_for_nlp.copy()\n",
    "text_vectors = count_vectorizer.transform(cohort_with_nlp.text)\n",
    "cohort_with_nlp['nlp_result'] = rfc.predict(text_vectors)\n",
    "cohort_with_nlp.head(100)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-10-31T12:49:56.052777900Z",
     "start_time": "2023-10-31T12:49:13.511934Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "outputs": [
    {
     "data": {
      "text/plain": "<10581x11029 sparse matrix of type '<class 'numpy.int64'>'\n\twith 6629596 stored elements in Compressed Sparse Row format>"
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "text_vectors"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-10-31T12:51:30.094832400Z",
     "start_time": "2023-10-31T12:51:29.977803100Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "outputs": [
    {
     "data": {
      "text/plain": "0"
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sum(cohort_with_nlp['nlp_result'])"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-10-31T12:50:17.313705900Z",
     "start_time": "2023-10-31T12:50:17.294716200Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "outputs": [
    {
     "data": {
      "text/plain": "   Unnamed: 0         note_id  subject_id   hadm_id note_type  note_seq  \\\n0          60  10001884-DS-38    10001884  26184834        DS        38   \n1          89  10002428-DS-18    10002428  23473524        DS        18   \n2         146  10003400-DS-18    10003400  20214994        DS        18   \n3         147  10003400-DS-19    10003400  23559586        DS        19   \n4         163  10004235-DS-21    10004235  24181354        DS        21   \n\n             charttime            storetime  \\\n0  2131-01-20 00:00:00  2131-01-20 09:41:00   \n1  2156-05-22 00:00:00  2156-05-23 13:10:00   \n2  2137-03-19 00:00:00  2137-03-19 13:50:00   \n3  2137-09-02 00:00:00  2137-09-02 17:38:00   \n4  2196-03-04 00:00:00  2196-03-06 10:57:00   \n\n                                                text  \n0   \\nName:  ___             Unit No:   ___\\n \\nA...  \n1   \\nName:  ___               ___ No:   ___\\n \\n...  \n2   \\nName:  ___                 Unit No:   ___\\n...  \n3   \\nName:  ___                 Unit No:   ___\\n...  \n4   \\nName:  ___                  Unit No:   ___\\...  ",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Unnamed: 0</th>\n      <th>note_id</th>\n      <th>subject_id</th>\n      <th>hadm_id</th>\n      <th>note_type</th>\n      <th>note_seq</th>\n      <th>charttime</th>\n      <th>storetime</th>\n      <th>text</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>60</td>\n      <td>10001884-DS-38</td>\n      <td>10001884</td>\n      <td>26184834</td>\n      <td>DS</td>\n      <td>38</td>\n      <td>2131-01-20 00:00:00</td>\n      <td>2131-01-20 09:41:00</td>\n      <td>\\nName:  ___             Unit No:   ___\\n \\nA...</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>89</td>\n      <td>10002428-DS-18</td>\n      <td>10002428</td>\n      <td>23473524</td>\n      <td>DS</td>\n      <td>18</td>\n      <td>2156-05-22 00:00:00</td>\n      <td>2156-05-23 13:10:00</td>\n      <td>\\nName:  ___               ___ No:   ___\\n \\n...</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>146</td>\n      <td>10003400-DS-18</td>\n      <td>10003400</td>\n      <td>20214994</td>\n      <td>DS</td>\n      <td>18</td>\n      <td>2137-03-19 00:00:00</td>\n      <td>2137-03-19 13:50:00</td>\n      <td>\\nName:  ___                 Unit No:   ___\\n...</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>147</td>\n      <td>10003400-DS-19</td>\n      <td>10003400</td>\n      <td>23559586</td>\n      <td>DS</td>\n      <td>19</td>\n      <td>2137-09-02 00:00:00</td>\n      <td>2137-09-02 17:38:00</td>\n      <td>\\nName:  ___                 Unit No:   ___\\n...</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>163</td>\n      <td>10004235-DS-21</td>\n      <td>10004235</td>\n      <td>24181354</td>\n      <td>DS</td>\n      <td>21</td>\n      <td>2196-03-04 00:00:00</td>\n      <td>2196-03-06 10:57:00</td>\n      <td>\\nName:  ___                  Unit No:   ___\\...</td>\n    </tr>\n  </tbody>\n</table>\n</div>"
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "discharge_df.head()"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-10-31T12:29:31.519304500Z",
     "start_time": "2023-10-31T12:29:31.452502Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "outputs": [],
   "source": [
    "k = rfc.predict_proba(text_vectors)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-10-31T13:07:35.432528300Z",
     "start_time": "2023-10-31T13:07:06.602036700Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "outputs": [
    {
     "data": {
      "text/plain": "array([0.62269226, 0.37730774])"
     },
     "execution_count": 33,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import seaborn\n",
    "k[0]\n"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-10-31T13:07:35.449105600Z",
     "start_time": "2023-10-31T13:07:35.438633Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "outputs": [
    {
     "data": {
      "text/plain": "<Axes: ylabel='Density'>"
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": "<Figure size 640x480 with 1 Axes>",
      "image/png": "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"
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "seaborn.distplot(k)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-10-31T13:08:07.512758200Z",
     "start_time": "2023-10-31T13:08:06.212934800Z"
    }
   }
  }
 ]
}
